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ABSTRACT
Sequence analysis of human antiphospholipid antibodies (aPL) has shown that their binding 
properties are derived from the accumulation of replacement mutations and basic residues 
in their complementarity determining regions (CDRs). This thesis describes the effects of 
particular CDR motifs, often sites of somatic mutation and/or containing arginine residues, 
on the binding to cardiolipin (CL) of two human IgG monoclonal aPL, IS4 and CL24.
Following sequence analysis of IS4 and CL24 a transient expression system was used to 
express whole IgG containing variants of IS4 and CL24 produced by chain shuffling 
experiments with three other monoclonal antibodies, UK4, B3 and 33H11. The light chain 
sequences ( V l )  of four of these five mAbs were encoded by the same germline V l  gene and 
hence differed only in their pattern of somatic mutations. The heavy chain (V h )  of IS4 was 
dominant in conferring the ability to bind CL in a direct ELISA, whilst the identity of the 
paired Vl was important in determining the strength of CL binding. Computer-generated 
models revealed surface exposed arginine residues in the CDRs of IS4VH and those VL 
sequences that were particularly favourable for binding to CL.
Seven new Vl sequences and six new Vh sequences were produced by using CDR 
exchange and site-directed mutagenesis to alter the patterns of somatic mutation and 
arginine residues in the wild-type VL and Vh sequences of these antibodies. Alteration of 
specific arginine residues in B3Vl CDR1 and IS4VH CDR3 led to a significant reduction in 
CL binding. It was concluded that it is not just the presence but precise locations of specific 
arginine residues in the CDRs of pathogenic aPL, which are important in determining 
binding affinity for CL.
In order to produce larger quantities of these expressed Vh/Vl combinations, a stable 
expression system was developed. Three stable cell lines were produced, expressing IS4Vh 
with three different Vl sequences. The IgG produced showed the same CL binding 
characteristics as those produced in the transient system.
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CHAPTER ONE 
INTRODUCTION
1.1 FROM IMMUNITY TO AUTOIMMUNITY
1.1.1 The normal immune response
The normal immune system protects an individual from foreign organisms or substances, 
called antigens (Ag), and has two functional components which act in concert. Innate 
immunity, the first line of defence, mounts an immediate response with disease resistance 
mechanisms that are not specific to a particular pathogen. This component has the 
advantage of speed but lacks specificity and may cause host damage. Innate immunity 
comprises four types of defensive barriers: anatomical, e.g. skin and mucous membranes; 
physiological, e.g. temperature, low pH and chemical mediators including lysosyme, 
interferon and complement; phagocytic e.g. neutrophils, monocytes and macrophages; and 
inflammatory, e.g. vasodilation, increased capillary permeability leading to an influx of 
phagocytes (Goldsby et al., 2000).
If these primary defences are breached specific or adaptive immunity is activated. Unlike 
innate immunity, adaptive immune responses are specific to a particular antigen and display 
four characteristic attributes: antigenic specificity; diversity; immunological memory; and 
self/non-self recognition. Antigenic specificity allows the immune system to recognise even 
single amino acid differences between antigens. A tremendous diversity is generated in the 
recognition molecules of the immune system such that billions of different antigens may be 
recognised. After initial exposure to an antigen immunological memory occurs and re­
exposure to the same antigen results in a memory response which is quicker and stronger 
than the first conferring life long immunity to many infectious agents. Lastly, the normal 
functioning of the immune system is reliant upon its ability to respond only to foreign 
antigens as opposed to self molecules. The major cells involved in adaptive immunity are 
lymphocytes and antigen presenting cells (Goldsby et al., 2000).
1.1.2 Cells of the immune system
There are two major populations of lymphocytes -  B lymphocytes (B cells) and T 
lymphocytes (T cells).
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1.1.2.1 B lymphocytes
B cells comprise approximately 25% of the lymphocyte population. They mature within the 
bone marrow and, by the time they leave, express a unique antigen-binding receptor on 
their surface. This receptor is a membrane bound antibody (Ab) molecule described in 
detail later. Upon initial antigen encounter, a naive B cell expressing a matching membrane 
bound antibody will bind to the antigen. In the presence of cytokines and B cell growth 
factors, the cell is activated and rapidly divides into memory B cells and plasma cells. 
Memory B cells have a longer life span than naive B cells and continue to express 
membrane bound antibody with the same specificity as their parent B cell. Plasma cells, 
however, live for only a few days and do not express membrane bound antibody; instead 
they produce enormous amounts of the antibody in a secreted form. These secreted 
antibodies are the major effector molecules of humoral immunity (Morrow et al., 1999; 
Goldsby et al., 2000).
1.1.2.2 T lymphocytes
T cells also arise in the bone marrow and then, unlike B cells, migrate to the thymus gland 
to mature. During its maturation the T cell comes to express a unique antigen binding 
molecule called the T cell receptor on its membrane. Unlike B cell receptors (membrane 
bound antibody), T cell receptors can only recognise antigen that is bound to cell 
membrane proteins called major histocompatibility complex (MHC) molecules, which are 
polymorphic glycoproteins found on cell membranes. There are two major types of MHC 
molecules called class I and class II. Class I MHC molecules are expressed by nearly all 
nucleated cells and consist of a heavy chain linked to a small invariant protein called p2- 
microglobulin. Class II MHC molecules, which consist of an a and a p glycoprotein chain, 
are expressed only by antigen presenting cells. When a nai've T cell encounters its specific 
antigen combined with an MHC molecule on a cell the T cell proliferates and differentiates 
into memory T cells and various effector T cells (Goldsby et al., 2000).
T cells have two principal functions and are divided into two groups, T helper (Th) cells 
and T cytotoxic (Tc) cells. These cells can be distinguished by the presence of either CD4 
or CD8 membrane glycoproteins on their surface. T cells displaying CD4 generally 
function as Th cells which have a variety of functions in controlling immune responses.
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Once a Th cell recognises and interacts with an antigen-MHC class II molecule the cell is 
activated to secrete various growth factors known as cytokines. Different cytokines activate 
B cells, Tc cells, macrophages and various other cells that participate in the immune 
response and Th cells may be subdivided according to their cytokine secretion profile. Thl 
cells secrete interleukin (IL)-2, IL-3 and gamma interferon (IFN)-y which play a central 
part in cell mediated immunity and acute allograft rejection. Th2 cells secrete IL-4, IL-5, 
IL-6, IL-9 and IL-10 which enhance antibody production and humoral immunity. Cytokines 
also affect the differentiation of T cells into these two subsets. IFNy and IL-12 promote Thl 
differentiation and IL-4 is a potent inducer of Th2 cells. IL-10 however decreases the 
synthesis of Thl cytokines. Immune responses are modulated by cytokines that affect cell 
proliferation, survival, differentiation, antigen presentation and trafficking (Morrow et al., 
1999).
T cells displaying surface CD8 molecules generally function as Tc cells. Under the 
influence of Th derived cytokines a Tc cell bound to antigen presented by MHC class I 
molecules will proliferate and differentiate into a cytotoxic lymphocyte (CTL) which 
secretes fewer cytokines. They have a vital function in dealing with virus infections and 
cancer cells (Morrow et al., 1999).
1.1.2.3 Antigen presenting cells
Cytokines produced by Th cells are important in the activation of both the humoral and cell 
mediated branches of the immune system. Careful regulation of the Th cell response is 
ensured by virtue of the fact that these cells can only recognise antigen that is displayed in 
conjunction with MHC class II molecules on the surface of antigen presenting cells (APCs). 
These specialised cells include macrophages, B cells and dendritic cells. They express 
MHC class II molecules on their membranes and deliver a costimulatory signal necessary 
for T cell activation.
1.1.3 The role of antibodies in the immune system
Emil von Behring and Shibasaburo Kitasato in 1890 first demonstrated that a serum 
component could transfer immunity and in 1939 A. Tiselius and E. Kabat showed that a 
fraction of serum first called gamma-globulin, now immunoglobulin (Ig), was responsible
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for this activity (Goldsby et al., 2000). The active molecules in the Ig fraction are 
antibodies, the antigen binding proteins present on the surface of B cells and secreted by 
plasma cells.
Antibodies recognise and bind to antigens upon foreign cells or molecules that have entered 
the body and then either neutralize or facilitate the elimination of the foreign substance. 
Each antibody binds to a discrete site on the antigen. These sites are called antigenic 
determinants or epitopes. Once an antigen is coated with antibody, it can be eliminated in 
several ways. Antibody can cross-link several antigens forming clusters that are more 
readily ingested by phagocytic cells than a single Ab-Ag complex. Binding of antibody to 
antigen on a microorganism can also activate the complement system leading to lysis of the 
foreign organism. Toxins and viral particles coated with antibody are prevented from 
binding to other cells and thus neutralized.
The antigenic specificity of each B cell is determined by the membrane bound antibody 
molecule expressed by the cell. Antibodies can differentiate between protein antigens that 
differ by only a single amino acid. The generation of such antibody specificity and diversity 
is described in section 1.7.3. Antigen presented to B cells is degraded or processed and 
presented, in a MHC restricted manner, to T cells as well. Thus Th cells are generated 
which enhance the antibody (humoral) response made by B cells and also serve to regulate 
the cell mediated response in conjunction with CTLs and various phagocytic cells.
1.1.4 Antibody structure
An antibody molecule shown in Figure 1, is composed of two identical heavy (H) chains 
(MW 50,000 -  70,000) and two identical light (L) chains (MW 25,000). Each heavy and 
light chain contains intra-chain disulphide bonds and the heavy and light chains are linked 
to each other by disulphide bonds and noncovalent interactions.
Sequencing analysis of antibodies first became feasible with the discovery of multiple 
myeloma, a cancer of antibody producing plasma cells. These unregulated cancer cells 
escape the normal controls on their life span and continue to proliferate producing specific 
antibody (called myeloma protein) indefinitely. Excessive amount of myeloma derived 
antibody is produced compared to the amounts of antibody produced by other plasma cells.
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Figure 1.1 Schematic diagram of immunoglobulin structure
Abbreviations Vh -  heavy chain variable region; Vl -  light chain variable region; Ch - 
heavy chain constant region; Cl -  light chain constant region; NH3+ - amino terminal; 
COO- - carboxyl terminus; S -  sulphide group; CHO -  carbohydrate moiety.
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Myeloma protein produced from a particular myeloma clone is a huge source of 
homogenous antibody protein. Sequence analysis of myeloma proteins has revealed striking 
patterns within both the heavy and light chains (Wu and Kabat, 1970).
The carboxyl terminal domains of both the heavy and light chains are highly conserved and 
are called the constant (C) regions. These constant regions subserve effector functions, such 
as complement fixation, which are common to all antibodies of a given isotype. Light chain 
constant regions ( C l )  exist in two forms (or isotypes), kappa ( k )  or lambda (Z ). In humans 
60% of the light chains are k  (Schable and Zachau, 1993) and 40% are X (Williams et al., 
1996). In contrast, in mice 95% of the light chains are k  and only 5% X (Kofler et al., 
1992). An antibody molecule contains only one of these isotypes, never both. Amino acid 
differences in the X light chains means they are further classified into subtypes. Mice have 
three (X\,X2 and X3) and humans have four subtypes.
Heavy chain constant regions (C h )  exist in five distinct forms (p, 5, y, 8  and a) called 
isotypes. The heavy chains of a given antibody determine the class of that antibody: 
IgM(p), IgG(y), IgA(a), IgD(8 ) and IgE(£). Each class can have either k  or X light chains. 
As in the light chains sequence differences exist in the IgA and IgG heavy chains, hence 
there are two IgA subclasses (al and a2) and four IgG subclasses (yl, y2, y3 and y4).
The amino terminal domains, comprising half of each light chain and one quarter of each 
heavy chain, are much more variable (V) in sequence and are responsible for binding 
antigen. These domains are known as the heavy chain variable region (VH) and light chain 
variable region ( V l ) .  Antigen binding sites usually comprise three polypeptide loops from 
the Vh domain and three polypeptide loops from the VL domain (Chothia et al., 1989). 
These six polypeptide loops, regions of high variability (in both sequence and length), are 
known as the complementarity determining regions (CDRs). The CDRs are separated by 
more conserved regions which perform a structural role and are hence called the framework 
regions (FRs) (Wu and Kabat, 1970).
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1.1.5 Antigenic determinants on antibodies
Antibodies themselves may function as antigens and provoke an immune response. 
Antigenic determinants upon antibodies fall into three categories: isotypic, allotypic and 
idiotypic determinants and are all located in characteristic portions of the molecule.
Isotypic determinants are found in the constant region and determine the heavy chain class 
and light chain type within a species. Each isotype is encoded by a separate constant region 
gene. A normal individual will possess all isotypes in their bloodstream. Anti-isotype 
antibodies are useful in the identification of the class or sub-class of an antibody produced 
in an immune response either in the serum or membrane bound to a B cell.
Allotypic determinants are amino acid changes encoded by different alleles of the isotype 
genes that occur in some but not all members of a species. In humans allotypes exist for all 
four IgG subclasses, for one IgA subclass and for the k  light chain.
Antigenic determinants also reside within the amino acid sequence of the VH and VL 
domains of any given antibody. Idiotypic determinants are generated by the conformation 
of the Vh/Vl domains and each individual antigenic determinant of the variable region is 
called an idiotope. Idiotypes are usually specific for individual B cells (private idiotypes) 
but are sometimes shared between different B cell clones (cross-reacting, public or 
recurrent idiotypes).
1.1.6 Role of T helper cells in the production of antibodies
Once a naive B cell, which has not previously encountered antigen, first encounters the 
antigen for which its membrane bound Ig (mlg) is specific, the B cell will bind to the 
antigen. Before the B cell can become activated (i.e. proliferate and differentiate) however, 
additional interactions with molecules on the surface of activated CD4+ Th cells and the 
cytokines they produce are required (Goldsby et al., 2000).
After binding of antigen by mlg on B cells the antigen is internalized by receptor mediated 
endocytosis and processed into peptides. This event causes levels of MHC class II 
molecules and co-stimulatory molecule, B7 (the ligand for T cell CD28) to be upregulated 
on the surface of the B cell. The internalised peptides associate with MHC class II
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molecules and are presented on the B cell surface to a Th cell. Once a Th cell recognises a 
processed peptide for which it is specific in the presence of MHC class II, the B cell surface 
molecule B7 simultaneously contacts its ligand on the T cell surface, CD28. This process 
leads to the upregulation of CD40L on the Th cell surface which binds with CD40 on the B 
cell. Thus B cells are stimulated to upregulate the expression of cytokine receptors so that 
they may interact with cytokines produced by the activated Th cell. The signals produced 
by these cytokine receptor interactions support B cell proliferation and can induce 
differentiation events which include formation of plasma and memory B cells (described 
earlier); class switching and affinity maturation (described later).
1.1.7 Autoantibodies and autoimmunity
Several different mechanisms of self tolerance exist to protect an individual from 
potentially self reactive lymphocytes. Failure of these mechanisms leads to an inappropriate 
response of the immune system against self components, called autoimmunity. Antibodies 
that bind to self-antigens are termed autoantibodies
Even in healthy individuals however, low titres of low affinity autoantibodies are part of 
the normal B cell repertoire (Peeva et al., 2002). These natural autoantibodies resemble the 
antibodies of a primary immune response in that they are primarily IgM and display 
polyreactive binding to a wide variety of both autoantigens and foreign antigens. Sequence 
analysis has revealed that they are mainly germline encoded i.e. unmutated compared to the 
chromosomal DNA in the B cell from which they arose (Peeva et al., 2002).
Natural autoantibodies are not unique to patients with autoimmune disease and do not 
appear to be pathogenic (Peeva et al., 2002). Their precise function however, is unknown 
and some authors have speculated that they are the precursors to pathogenic autoantibodies 
(Dersimonian et al., 1987). Others have suggested that these two classes of autoantibodies 
arise from distinct B cell populations and that pathogenic autoantibodies arise by the 
somatic mutation of genes that encode protective autoantibodies (Shlomchik et al., 1987).
Despite the fact that the formation of autoantibodies may be a normal physiological 
process, production of certain autoantibodies can cause serious damage to cells and organs 
sometimes with fatal consequences. Damage to the body’s tissues may arise in a number of
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different ways. Autoantibodies may react directly with a tissue specific antigen, resulting in 
inflammation and tissue damage. For example, anti-glomerular basement membrane 
antibodies in Goodpastures syndrome cause progressive kidney failure. Alternatively, if 
circulating immune complexes are not cleared and large amounts remain they often deposit 
in tissues such as the kidney, skin, joint or nervous system and lead to tissue damaging type 
III hypersensitivity reactions. This damage occurs as a result of complement activation, 
accumulation and activation of neutrophils with the release of proteolytic enzymes and 
further damage. T cells are also routinely observed as infiltrates in inflammatory lesions 
and thought to contribute to tissue destruction, particularly in diseases such as insulin 
dependent diabetes mellitus and multiple sclerosis (Goldsby et al., 2000).
Autoimmune disease in humans can be divided into two broad categories; organ specific or 
systemic autoimmune disease. In an organ specific disease the immune response is directed 
to a target antigen unique to a single organ or gland so that the effects are largely localized 
to that organ, such as occurs in insulin dependent diabetes mellitus. In systemic 
autoimmune disease however, the immune response is directed to target antigens present in 
many tissues and organs. Systemic lupus erythematosus (SLE) and the Antiphospholipid 
Syndrome (APS) are both examples of systemic autoimmune disease and will be discussed 
later in this chapter.
1.1.8 Pathogenic autoantibodies
Autoantibodies found in SLE and APS patients tend to differ from natural autoantibodies 
found in healthy individuals in that they are generally IgG isotype and have a high affinity 
for a particular autoantigen. Certain of these autoantibodies - in particular antibodies to 
double stranded DNA (dsDNA) (Isenberg et al., 1997) and antiphospholipid antibodies 
(aPL) (Alarcon-Segovia et al., 1989) - have been implicated in disease pathogenesis. To 
study the sequence and structural properties of individual autoantibodies in more detail 
those derived from a single clone in which every cell has the same genomic DNA 
rearrangement and secretes the same Ig are required. These are called monoclonal 
antibodies.
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1.1.9 Monoclonal antibodies
The preparation of homogenous antibodies with a defined specificity was achieved with the 
development of hybridoma technology. In 1975 a method was devised that allowed 
antibody secreting cells isolated from an immunised mouse to be fused with a myeloma cell 
(Kohler and Milstein, 1975). These hybrid cells (called hybridomas) have the immortal 
growth properties of the myeloma cell and the antibody producing properties of the B cell. 
The resultant cell lines can be maintained in-vitro indefinitely and will continue to secerete 
antibodies with a defined specificity. This method was later adapted to produce human 
monoclonal antibodies (Olsson and Kaplan, 1980; Teng et al., 1983).
Sequence analysis of the antigen combining sites of monoclonal Abs is a powerful tool to 
gain greater understanding of features at the molecular level which distinguish natural (non- 
pathogenic) autoantibodies found in healthy individuals from pathogenic autoantibodies 
found in patients with autoimmune disease. The work described in this thesis investigates 
the sequence and structure of aPL found in patients with APS or SLE. The features and 
aetiopathogenesis of these conditions are described in the next sections.
1.2 THE ANTIPHOSPHOLIPID SYNDROME (APS) 
1.2.1 Definition of the APS
The APS is a multi-system disease characterised by arterial and venous thrombosis, 
recurrent pregnancy loss, livedo reticularis or thrombocytopenia in association with a 
spectrum of autoantibodies, known as aPL which are directed against phospholipids (PL) 
and plasma PL binding proteins (Harris et al., 1983; Hughes, 1983; Asherson et a l , 1989; 
Levine and Brey, 1996). In clinical practice these antibodies are recognised by 
anticardiolipin (aCL) enzyme linked immunosorbent assays (ELISA) and the lupus 
anticoagulant (LA) assay (which detects an inhibitor of coagulation subsequently found to 
belong to the family of aPL). The concept of these clinical and serological disorders as a 
full-blown “syndrome” has only really evolved within the last twenty years. Clinical 
observations by earlier workers had already laid the foundation for future research.
1.2.2 The discovery of aPL and recognition of the APS
In 1906 the reagin test for the detection of a reaction between a lipoid tissue antigen and an 
autoantibody in syphilitic sera was developed (Wasserman et al., 1906). Initially human
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organs derived from patients with syphilis were used as the antigen but the test was later 
modified, when it was discovered that the antigen could be obtained from normal human or 
animal organs (Landsteiner et al., 1907). The antigen used in the majority of reagin tests 
was an alcoholic extract from beef heart and in 1941 this extract was found to contain a 
phospholipid later named cardiolipin (CL) (Pangbom, 1941; Pangbom, 1942).
During mass screening for syphilis in certain population groups in America in 1952, it was 
noted that large numbers of people had positive reactions to reagin tests but no clinical 
features of syphilis, hence the term biologically false positive serological tests for syphilis 
(BFP-STS) was coined (Moore and Mohr, 1952). Further testing of sub groups of these 
patients with chronic BFP-STS using more specific tests for syphilis (the Treponema 
Pallidum Immobilisation and Fluorescent Treponemal Antibody Absorption tests) gave 
negative results and interestingly a high incidence of autoimmune disorders, mainly SLE 
was found in this group of patients (Moore and Mohr, 1952).
In 1952 a circulating inhibitor of coagulation was first described in two patients with SLE 
and BFP-STS (Conley and Hartmann, 1952). Later work confirmed that this inhibitor was 
frequently associated with BFP-STS (Laurell and Nilsson, 1957). Bowie and colleagues in 
1963, first described the paradoxical occurrence of thrombotic lesions in SLE patients with 
a circulating anticoagulant (Bowie et al., 1963) closely followed by another group in 1965 
who also noted the association of a circulating anticoagulant, thrombosis and a BFP-STS in 
SLE patients (Alarcon-Segovia and Osmundson, 1965). Despite these early reports of 
association of the circulating anticoagulant with thrombotic events, the term LA was coined 
in 1972 (Feinstein and Rapaport, 1972). Subsequently it was confirmed that the LA assay 
detects aPL (Thiagarajan et al., 1980) which interfere with in-vitro PL dependent 
coagulation tests. These antibodies are not specific to patients with SLE and, paradoxically, 
they are associated with thrombotic events in-vivo (Mueh et al., 1980; Boey et al., 1983).
It was not until the early 1980's that the triple association of recurrent fetal losses, 
thrombosis and LA was made .(Soulier and Boffa, 1980; Carreras et al., 1981a; Carreras et 
al., 1981b). Subsequently, an editorial in 1983 linked major cerebral disease as well as 
thrombosis and abortions with the LA in SLE patients and suggested the presence of a 
syndrome (Hughes, 1983). The subsequent development of solid phase immunoassays with
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CL as the target antigen to detect aPL, initially by radioimmunoassay (Harris et al., 1983) 
and later by ELISA (Loizou et al., 1985) led to the recognition of the role of aCL in this 
disorder. Hence the term aCL syndrome was introduced in 1985 (Hughes et al., 1986) and 
then superseded by the APS in 1987 (Harris et al., 1987). Approximately 60% of patients 
with aPL have both aCL and LA whilst the remaining 40% have only one (Triplett et al.,
1988). Therefore both tests are necessary in order to establish the presence of aPL.
Early studies on the assays of aCL demonstrated the need for bovine serum as a diluent and 
that this seemed to enhance the binding of aCL to the target antigen. In 1990 three groups 
independently identified a cofactor for the binding of autoimmune aCL to antigen (Galli et 
al., 1990; Matsuura et al., 1990; McNeil et al., 1990). This cofactor was shown to be p2 - 
Glycoprotein I (P2 GPI), a 50kD plasma protein that binds negatively charged PL and is 
described in detail later in section 1.6. In fact autoimmune aPL have been shown to be 
directed against a variety of other phospholipid binding serum proteins which include 
protein C (Oosting et al., 1993), protein S (Oosting et al., 1993) and prothrombin (PT) 
(Bevers et al., 1991). 6 2 GPI however, is the most extensively studied of these protein 
cofactors and appears to be the most relevant clinically (McNally et al., 1995; Tsutsumi et 
al., 1996; Kandiah et al., 1998).
1.2.3 Classification of the APS
APS may be diagnosed where a positive test for either aPL or LA occurs in a patient with 
the clinical features noted above. The presence of LA in “non-lupus patients” has been 
noted since the early 1980's (Hughes, 1983). It was not until the end of that decade 
however that the existence of a primary syndrome was recognized and classification criteria 
proposed in 1988 (Asherson, 1988). One year later several larger series of patients with 
primary APS (PAPS) were described (Alarcon-Segovia and Sanchez-Guerrero, 1989; 
Asherson et al., 1989; Mackworth-Young et al., 1989) and it is now clear that PAPS 
accounts for more than 50% of APS patients (Cervera et al., 2002). In the presence of 
another autoimmune rheumatic disease (ARD), most commonly SLE, the APS is 
considered to be secondary (SAPS).
Despite several earlier proposals for APS criteria in the 1990s (Hughes et al., 1986; Harris, 
1987; Alarcon-Segovia et al., 1992; Alarcon-Segovia and Cabral, 1994; Wilson et al.,
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1999) there was no attempt at a consensus until preliminary classification criteria were 
proposed in 1998 (Wilson et al., 1999), shown in Table 1. These criteria include two 
clinical outcomes vascular (arterial, venous or small vessel) thrombosis and pregnancy 
morbidity, either recurrent early ( < 1 0  week) losses or preterm birth due to severe placental 
insufficiency or pre-eclampsia. Laboratory criteria require the presence of a LA and/or 
moderate to high titre IgG or IgM aCL on two or more occasions at least six weeks apart. 
Evaluation of these criteria against APS diagnosed by experienced clinicians with a special 
interest in the syndrome showed acceptable sensitivity and specificity in a recent validation 
study (Lockshin et al., 2000). The criteria have helped to focus research but do have their 
limitations and were not intended to guide clinical diagnosis or treatment. In particular they 
make no mention of non-thrombotic manifestations of APS and do not include in the 
laboratory criteria any of the more recent and more specifc tests such as identification of 
an ti^G PI antibodies. These issues should be addressed in future consensus meetings.
1.2.4 Epidemiology of the APS
The prevalence of APS is unknown. aPL however are found among young, apparently 
healthy control subjects at a prevalence of 1.5% to 5% for both aCL and LA, which 
increases with age (Petri, 2000). In patients with SLE the prevalence of aPL is higher, with 
figures quoted of 24-39% for aCL (Alarcon-Segovia et al., 1989; Cervera et al., 1993) and 
15-30% for the LA (Cervera et al., 1990; Cervera et al., 1993).
The presence of aPL, however, does not always correlate with clinical consequences. In 
otherwise healthy subjects, there are insufficient data to determine what percentage of those 
with aPL will eventually develop a manifestation of the APS (Levine et al., 2002). In 
contrast, the APS has been shown to develop in up to 50 to 70% of patients with SLE who 
are aPL positive (Alarcon-Segovia et al., 1992; Petri, 2000).
It is widely accepted that an association exists between aPL and vascular thrombosis, 
although there are some discrepancies in published reports due to their heterogeneity in 
terms of study design, enrollment criteria, associated conditions, clinical end points and 
laboratory tests for aPL, including isotypes measured and cutoffs taken for a positive result.
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Clinical criteria
1. Vascular thrombosis: One or more clinical episodes of arterial, venous or small 
vessel thrombosis in any tissue or organ. Thrombosis must be confirmed by imaging 
or Doppler studies or histopathology, with the exception of superficial venous 
thrombosis. For histopathological confirmation, thrombosis should be present 
without significant evidence of inflammation in the vessel wall.
2. Pregnancy morbidity
a) One or more unexplained deaths of a morphologically normal fetus at or beyond the 
tenth week of gestation with normal fetal morphology documented by ultrasound or 
by direct examination of the fetus, or
b) One or more premature births of a morphologically normal neonate at or before the 
34th week of gestation because of severe pre-eclampsia or severe placental 
insufficiency, or
c) Three or more unexplained consecutive spontaneous abortions before the 10th week 
of gestation with maternal anatomic or hormonal abnormalities and paternal and 
maternal chromosomal causes excluded.
Laboratory criteria
1. Anticardiolipin antibody of IgG and/or IgM isotype in blood present in medium or 
high titre, on two or more occasions at least six weeks apart measured by a standard 
ELISA for P2 GPI dependent aCL.
2. Lupus anticoagulant present in plasma on two or more occasions at least six weeks 
apart detected according to the guidelines of the International Society on 
Thrombosis and Haemostasis.
Table 1.1 Preliminary criteria for classification of definite APS
Definite APS is considered to be present if at least one of the clinical and one of the
laboratory criteria are met. Abbreviations: - ELISA -  Enzyme linked immunosorbent assay;
P2 GPI - P2 Glycoprotein I; aCL -  anticardiolipin antibody.
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A lack of standardisation of the aCL test, and the cutoff point at which a result is regarded 
as abnormal, is still a major problem in the study of aPL. Values for the IgG and IgM aCL 
tests are expressed in international units of GPLU and MPLU respectively. These units are 
derived from international standardised IgG and IgM calibrators (containing a defined 
concentration of aCL) distributed from the aPL standardisation laboratory which are then 
used as a standard in each ELISA (Harris and Pierangeli, 2002). Despite these efforts in 
standardisation which includes numerous workshops a considerable degree of 
interlaboratory variability still exists between laboratories, even those with extensive 
experience in the detection of aPL (Harris and Pierangeli, 2002).
Evidence of an association between aPL and venous thromboembolism (VTE) in patients 
who do not have SLE comes from various studies. A case control sub-study of 190 patients 
from the Physicians Health Study of healthy adult men found titres of aCL to be 
significantly higher in patients with VTE compared to controls although the relative risk of 
VTE was only statistically significant in patients with titres of aCL greater than 33GPLU 
(Ginsburg et al., 1992). Unfortunately the LA was not measured in this study and the 
methods of diagnosing VTE were not stated. A later study examined 244 unselected 
patients with suspected VTE and found a significant association between proven deep vein 
thrombosis (DVT) and pulmonary embolus (PE) with the presence of LA but not aCL 
(Ginsberg et al., 1995). These authors only considered an aCL >30GPLU as abnormal, 
whilst other authors and laboratories will accept >5GPLU as abnormal. Hence the 
importance of aCL <30GPLU was not assessed in this study. Another cross sectional study 
of 293 unselected patients with DVT or PE also failed to show a statistically significant 
association between VTE and aPL and tests for LA were not performed (Bongard et al., 
1992). This study considered values of above 5 for IgG and 3 for IgM aPL to be positive, 
and did not exclude low positive titers of aCL (<20GPLU). The significance of low positive 
values is uncertain and has not been validated (Lockshin et al., 2000), which may in part 
explain the negative finding in Bongard's study. Prospective studies however have shown 
that aPL are predictive of recurrent VTE and death (Finazzi et al., 1996; Schulman et al., 
1998) as well as myocardial infarction (Vaarala et al., 1995; Brey et a l, 2001).
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Studies of all strokes have revealed conflicting results with some case control studies 
showing a strong association between aCL and stroke (Tuhrim et al., 1999) and recurrent 
stroke (Levine et al., 1992) whilst others have found no association between ischaemic 
stroke and aCL (Ginsburg et al., 1992). These differences may in part be explained by the 
use of different aCL assays and methodological differences between studies. For example, 
in the study of Ginsburg et al. (1992) cerebral infarctions occurred an average of three 
years after samples for aCL were obtained and assays were performed after an average of 
eight years of frozen storage which may have affected the chance of obtaining a positive 
aCL. A large prospective nested case control study has clearly demonstrated an association 
of aPL, particularly P2 GPI dependent aPL, with stroke (Brey et al., 2001).
The strongest association of aPL with pregnancy morbidity is with late fetal loss beyond 10 
weeks or more of gestation (Lockshin et al., 1985; Oshiro et al., 1996). In contrast, fetal 
losses due to other causes (e.g. chromosomal abnormalities) usually occur within the first 
nine weeks of pregnancy (Levine et al., 2002).
1.2.5 Risk factors for thrombosis in aPL positive patients
Various studies have tried to assess which factors in aPL positive patients are associated 
with an increased risk for a thrombosis. A four year, randomised, multicentre, prospective 
study of unselected patients, comparing different durations of oral anticoagulation, 
measured IgG aCL six months after a first or second episode of VTE (Schulman et al.,
1998). Among 412 patients with a first episode of VTE the risk of recurrence was found to 
be 29% in patients with aPL and 14% in those without aPL, a statistically significant 
difference. This risk was increased during the first six months after cessation of 
anticoagulation and with moderate or high titers of IgG aCL, >35GPLU although this 
association was not described statistically (Schulman et al., 1998). A weakness of this 
study is that the presence and titer of aPL at the time or prior to VTE was not examined 
hence it could be argued that the aPL may be an epiphenomenon post VTE. This 
explanation is unlikely however because similar results have been obtained from 
prospective studies which measured aPL before or at the time of VTE. One four year 
multicentre study, prospectively followed 360 consecutive unselected cases of aPL positive 
patients (Finazzi et al., 1996). In this study the total incidence of thrombosis was 2.5% per 
year and a history of thrombosis and IgG aCL titer > 40GPLU were the most statistically
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significant predictors for thrombosis. Other prospective studies have also demonstrated a 
statistically significant association between an elevated level of IgG aCL and thrombosis 
(Alarcon-Segovia et al., 1989), pregnancy morbidity (Lynch et al., 1994) and myocardial 
infarction (Vaarala et al., 1995).
A systematic review and meta-analysis of 26 articles examining the association between 
aPL and VTE found that SLE patients with the LA compared to those lacking LA had 
approximately a six fold greater risk for VTE (Wahl et al., 1997). The risk of VTE in 
patients with SLE who were aCL positive was approximately twice that of patients lacking 
aCL (Wahl et al., 1997). There are methodological limitations to this analysis since it 
combined studies of differing quality and design. Nonetheless, their finding of LA being 
the strongest risk factor for VTE in SLE patients has been confirmed in a retrospective 
study (Horbach et al., 1996). In fact a recent systematic review of 25 studies on more than 
7000 patients and controls found that LA were statistically stronger risk factors for 
thrombosis than aCL regardless of the site (arterial or venous) or type (first event or 
recurrence) of thrombosis and the presence of SLE (Galli et al., 2003b).
Of the various cofactors that have been identified, antibodies against B2 GPI have been 
shown in several case control studies to have a statistically significant association with 
VTE in patients with either PAPS or SLE/APS (Martinuzzo et al., 1995; McNally et al., 
1995) and have been reported to be more specific than aCL in detecting manifestations of 
the APS (Roubey et al., 1996). A recent systematic review of 28 mainly retrospective 
studies found a statistically significant association between anti-l^GPI antibodies and 
thrombosis in 34 (57%) of 60 associations (mostly venous thrombosis) examined, 
particularly with IgG and IgA antibodies (Galli et al., 2003a). Overall this association was 
not as strong as for the LA and thrombosis. Laboratory studies have also shown that 
binding to B2 GPI is not an absolute requirement in determining the pathogenicity of aPL as 
human monoclonal IgG aPL that bind PL in the absence of B2 GPI have been isolated and 
shown to be highly pathogenic in-vivo (Ikematsu et al., 1998; di Simone et al., 2000).
37
1.2.6 Clinical Manifestations of the APS
1.2.6.1 Thrombotic manifestations
Thrombosis within the venous or arterial circulation is a major clinical feature of this 
syndrome, see Table 1.2. Any size of vessel may be affected. Venous thrombosis, 
especially deep venous thrombosis of the legs, is the most common manifestation, 
occurring in 29-55% of APS patients during an average follow up of less than six years 
(Asherson et al., 1989; Alarcon-Segovia et al., 1992; Vianna et al., 1994). PE are also 
frequent occurring in up to half of these patients (Asherson et a l, 1989; Alarcon-Segovia et 
al., 1992; Vianna et al., 1994). Arterial thromboses are less common and most frequently 
affect the brain with transient ischaemic attacks and strokes accounting for 50% of arterial 
occlusions (Asherson et al., 1989). A further 23% of arterial occlusions occur in coronary 
arteries with the remainder involving diverse areas including subclavian, renal, retinal and 
pedal arteries (Asherson et al., 1989). Arterial emboli, particularly from mitral or aortic 
valve vegetations found in 4% of APS patients (Vianna et al., 1994) may also lead to 
cerebral events. Thrombotic microangiopathy may occur as a result of microvascular 
involvement either acutely, resulting in a clinical picture similar to the haemolytic uraemic 
syndrome and thrombotic thrombocytopenic purpura, or as a more chronic process leading 
to a slow progressive loss of organ function.
Other prominent manifestations of the APS include thrombocytopenia (40-50% of 
patients), haemolytic anaemia (14-23% patients) and livedo reticularis (11-22% patients) 
(Asherson et al., 1989; Alarcon-Segovia et al., 1992; Vianna et al., 1994).
1.2.6.2 Obstetric manifestations
The other major clinical feature of the APS is pregnancy morbidity, shown in Table 1.2, 
and the recent classification criteria (described in section 1.2.3) now recognise that other 
adverse pregnancy outcomes as well as late fetal loss, may also occur in pregnant women 
who are aPL positive (Wilson et al., 1999). These adverse outcomes include premature 
delivery due to pregnancy associated hypertensive disease and uteroplacental insufficiency 
(Branch et al., 1992) and recurrent (three or more) consecutive spontaneous abortions 
before the 10th week of gestation with other medical causes excluded (Kutteh, 1996; Rai et 
al., 1997).
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Organ system Clinical manifestations of the APS
Cardiac
Cutaneous
Endocrine
Gastrointestinal
Haematologic
Limb vessels
Miscellaneous
Neurologic
Obstetrical
Ophthalmologic
Pulmonary
Renal
Angina, myocardial infarction, cardiac valvular 
vegetations, valvular abnormalities, intracardiac thrombi, 
nonbacterial thrombotic endocarditis, peripheral 
embolisation or atherosclerosis
Livedo reticularis, superficial thrombophlebitis, splinter 
haemorrhages, leg ulcers, distal cutaneous ischaemia, 
infarcts of the skin,
Adrenal infarction, adrenal failure, testicular infarction, 
prostate infarction, pituitary gland necrosis or failure 
Budd-Chiari syndrome, hepatic infarction, intestinal 
infarction, splenic infarction, oesophageal perforation, 
ischaemic colitis, pancreatitis or ascites 
Thrombocytopenia, haemolytic anaemia or haemolytic 
uraemic syndrome and thrombotic thrombocytopenic 
purpura
Deep vein thrombosis, claudication, ischaemia, gangrene 
Perforation of the nasal septum or avascular necrosis 
Transient ischaemic attack, cerebrovascular accident, 
chorea, seizures, mulit-infarct dementia, transverse 
myelitis, encephalopathy, migraines, pseudotumour 
cerebri,cerebral sinus thrombosis, mononeuritis multiplex 
or amaurosis fugax
Pregnancy loss, intrauterine growth retardation, HELLP 
syndrome (haemolysis, elevated liver enzymes and a low 
platelet count in association with preeclampsia), 
oligohydramnios, uteroplacental insufficiency or 
preeclampsia
Retinal artery or vein thrombosis
Pulmonary emboli, pulmonary hypertension, pulmonary
arterial thrombosis or alveolar haemorrhage
Renal vein thrombosis, thrombosis of the renal artery,
renal infarction, hypetension, acute renal failure, chronic
renal failure, proteinuria, haematuria or the nephrotic
syndrome________________________________
Table 1.2 Clinical manifestations of the antiphospholipid syndrome
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1.2.6.3 The catastrophic APS
Less than 1% of APS patients present with an acute and devastating syndrome 
characterised by multiple simultaneous vascular occlusions throughout the body, often 
resulting in death (Erkan et al., 2003). This syndrome, called the catastrophic APS (CAPS) 
differs from classic APS in several ways. Vascular involvement of large vessels is less 
common in patients with CAPS who tend to present with severe multiple organ dysfunction 
characterised by rapid, diffuse small vessel ischaemia and thromboses predominantly 
affecting the parenchymal organs (Erkan et al., 2003). The clinical characteristics and 
outcomes of 130 reported CAPS patients have been reviewed in two different series 
(Asherson et al., 1998; Asherson et al., 2001) and an international registry for these patients 
has now been created (Erkan et al., 2003). Based on these series, 63 of 130 CAPS patients 
(43%) died at the time of the reported event. Older age and a higher number of involved 
organs particularly the spleen, heart and intestine were associated with mortality (Erkan et 
al., 2003).
1.2.6.4 Non-thrombotic manifestations o f aPL
Although thrombosis underlies many complications of the APS some manifestations 
especially those affecting the nervous system are difficult to explain solely on the basis of a 
hypercoagulable state. Support for a direct antibody mediated interaction comes from both 
animal and human data. Animal work has shown aPL to bind directly to cat brain (Kent et 
al., 1997), whilst in snails aPL reduce a GABA receptor mediated current in snail neurons 
(Liou et al., 1994). Thus aPL may directly and reversibly lower seizure threshold by 
binding to brain PL. In APS patients with reversible chorea it has been postulated that the 
underlying mechanism may be related to striatal binding of aPL rather than aPL associated 
striatal ischaemia. Two case reports of aPL associated chorea using serial PET scans have 
shown transient hypermetabolism in the contralateral basal ganglia of both patients studied 
(Furie et al., 1994; Sunden-Cullberg et al., 1998) suggesting an underlying excitatory rather 
than ischaemic pathophysiologic mechanism.
Pregnancy morbidity in APS patients may result from poor placental perfusion (De Wolf et 
al., 1982) due to localised thrombosis, possibly by interference with trophoblastic annexin 
V that is mediated by aPL (Rand et al., 1997). It has also been proposed however that aPL 
may also impair trophoblast invasion and hormone production, thereby promoting not only
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pre-embryonic and embryonic loss but also fetal loss and uteroplacental insufficiency (di 
Simone et al., 2000).
1.2.7 Is it important to differentiate between primary and secondary APS?
The question of whether the presence of SLE modifies in any way the clinical or 
serological expression of the APS was first addressed by Vianna and colleagues (Vianna et 
al., 1994). They compared 56 SLE/APS patients with 58 PAPS patients and found similar 
clinical and laboratory profiles in both groups, with the exception of autoimmune 
haemolytic anaemia, endocardial valve disease, neutropenia and low C4 levels which were 
all more common in SLE/APS patients. More recently a pan-European study of 1,000 
unselected patients with definite APS, according to the preliminary classification criteria 
(Wilson et al., 1999), analysed the prevalence and characteristics of the main clinical and 
immunological manifestations of both PAPS and SAPS at disease onset and during its 
evolution to define patterns of disease expression (Cervera et al., 2002). APS was primary 
in 53.1% of the patients and associated with SLE in 36.2%. A wide variety of thrombotic 
manifestations were recorded during the evolution of the disease in vessels of almost all 
organ systems. Patients with APS associated with SLE had more episodes of arthritis, 
livedo reticularis, thrombocytopenia and leucopenia. There were also differences related to 
sex as all female patients had a higher frequency of arthritis, livedo reticularis, and 
migraine. Male patients had a higher frequency of myocardial infarction, epilepsy, and 
arterial thrombosis in the lower legs and feet. Patients in whom APS occurred before the 
age of 15 had more episodes of chorea and jugular vein thrombosis whilst those with 
disease onset after the age of 50 had a higher frequency of stroke and angina pectoris, but a 
lower frequency of livedo reticularis, than the remaining patients (Cervera et al., 2002).
This study is important because it is the largest cohort of patients described to date with 
definite APS identified by the current classification criteria and thus truly representative of 
what are currently accepted as patients with the syndrome. It allows a more precise estimate 
of the prevalence of both major and minor features compared to previous studies, as well as 
the analysis of the pattern of disease expression in specific APS groups. Factors 
independent of coexistent SLE were found to modify APS expression and define specific 
subsets of the disease. The fascinating question of whether the APS patients with different
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patterns of disease expression also have a different prognosis will be assessed during the 
next ten years of follow up of this cohort.
1.2.8 Prognosis in APS
Elevated titers of aPL six months after an episode of VTE, in unselected patients, increases 
the risk of recurrence to 29% and four year mortality to 15%, compared with recurrence 
rates of 14% and 6 % mortality in aPL negative patients, regardless of the duration of 
warfarin treatment (Schulman et al., 1998). Other studies have also shown that APS carries 
a heavy disease burden with recurrence rates of up to 29% for thrombosis and mortality of 
up to 1 0 % over a follow-up period of ten years, despite the currently best available 
treatment of life long anticoagulation (Shah et al., 1998).
1.2.9 Management of APS patients
Treatment of the APS falls into four main categories: - prophylaxis; prevention of further 
thrombosis of large vessels; treatment of acute thrombotic microangiopathy; and 
management of pregnancy in aPL positive patients.
1.2.9.1 Prophylaxis
Aspirin (325mg/day) was not protective against the occurrence of DVT and PE in 190 
healthy male physicians, followed for 60 months, found to be aCL positive (Ginsburg et al., 
1992). In contrast aspirin (81 -  325mg) did reduce the incidence of subsequent thrombosis 
in a subgroup of 65 APS patients with pregnancy morbidity and no previous thrombosis, 
followed for on average eight years (Erkan et al., 2001). Hydroxychloroquine may be 
protective against thrombosis in SLE patients with APS (Petri, 1996). Any other risk 
factors for thrombosis should be identified and treated such as defects in coagulation 
factors and homocystinaemia. In addition, modification of any secondary risk factors for 
athersclerosis (AS) such as smoking, hypercholesterolaemia, hypertension, and diabetes is 
advisable given the putative role of aPL in AS (see section 1.5.4). Hormone replacement 
therapy should be avoided in view of its prothrombotic potential.
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1.2.9.2 Treatment after a thrombotic event
Anticoagulation after a thrombotic event is the only treatment which has been shown to 
reduce the rate of further thrombosis in both retrospective (Derksen et al., 1993) and 
prospective studies (Rosove and Brewer, 1992; Khamashta et al., 1995). The exact level of 
anticoagulation however remains less clear. A retrospective study of 19 primary and 
secondary APS patients found that patients treated with oral anticoagulants at an 
international normalized ratio (INR) of 2.5 -  4.0 had a 100% probability of survival free 
from VTE at 8  years of follow up (Derksen et al., 1993). By comparison among patients 
whose anticoagulation was stopped the rate of recurrence was 50% at two years and 78% at 
eight years of follow up (Derksen et al., 1993). In two larger series which were both 
retrospective the level of protection against arterial and VTE correlated directly with the 
intensity of anticoagulation (Rosove and Brewer, 1992; Khamashta et al., 1995). One study 
of 70 primary and secondary APS patients found recurrent events in 53% of patients and 
that the site of the first event (arterial or venous) tended to predict the site of subsequent 
events (Rosove and Brewer, 1992). In this study there were fewer recurrent thrombotic 
events in patients treated with warfarin as opposed to those patients who received no 
treatment or aspirin alone. In the warfarin treated patients there were nine thrombotic 
recurrences in seven patients, six of which occurred during low intensity treatment (INR < 
2.0) and three during intermediate intensity treatment (INR 2.1 -  2.9). There were no 
recurrent thrombotic events in patients who received high intensity warfarin treatment (INR 
> 3.0) during 110.2 patient years of follow up (Rosove and Brewer, 1992). Similar results 
were found in a series of 147 APS patients (Khamashta et al., 1995). In both of these 
studies aspirin alone was ineffective in reducing the rate of recurrent thrombosis (Rosove 
and Brewer, 1992; Khamashta et al., 1995).
Results from these retrospective studies (Rosove and Brewer, 1992; Khamashta et al., 
1995) showed a clear benefit of anticoagulation in preventing recurrent thrombosis which 
was greater at a higher intensity of anticoagulation (INR > 3.0). In view of the retrospective 
nature of these studies however, and conflicting results from other studies in which 
intermediate intensity warfarin has appeared to be effective in suppressing recurrent 
thrombosis (Ginsberg et al., 1995), the benefits of high intensity coagulation remain unclear 
given its higher risk of haemorrhagic complications.
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A recent randomized double blind trial has attempted to address the question of whether 
APS patients should be treated with high versus medium intensity warfarin (Crowther et al., 
2003). This study recruited 114 primary and secondary APS patients and followed them for 
a mean of 2.7 years. There were six recurrent thrombotic events among the 56 patients in 
the high intensity warfarin group (INR 3.1 -  4.0) compared with two in 58 patients in the 
medium intensity warfarin group (INR 2.0 -  3.0). The incidence of major bleeding was 
similar in both groups. Therefore the conclusion from this study was that high intensity 
warfarin was not superior to moderate intensity warfarin for thromboprophylaxis in APS 
patients with prior thrombotic events. A closer inspection of the results however reveals 
that although the average INR values in the moderate and high intensity warfarin groups 
were within their target range 2.3 and 3.3 respectively, the INR was kept within its target 
range 71% of the time in the moderate intensity group and in only 40% of the time in the 
high intensity group. In this latter group the target INR was sub-therapeutic (i.e. < 3.0) 43% 
of the time. The two recurrent thrombotic events in the moderate intensity group occurred 
at INRs of 1.6 and 2.8 and, of those six events which took place in the high intensity group, 
one occurred in a patient who had discontinued warfarin 137 days previously and the 
remaining five at INRs of 3.1, 1.0, 0.9, 1.9, and 3.9. Therefore of the nine recurrent 
thrombotic events seen in this study only two occurred at an INR >3.1 and seven occurred 
in patients with an INR of < 2.8. Therefore I believe that further studies are required with 
tighter control of the INR in different intensity of treatment warfarin groups to decide 
whether patients should receive high or medium intensity warfarin treatment.
1.2.9.3 Management o f pregnancy in aPL positive patients
Studies of treatment of pregnancy morbidity in patients with APS have mainly centred 
upon the prevention of fetal loss. Early studies using high doses of Prednisolone (> 60mg 
daily) reported improved fetal survival (Lubbe et al., 1983; Kwak et al., 1994). Later 
studies however have demonstrated that aspirin and heparin gave equivalent fetal outcomes 
when compared with aspirin and steroids with significantly less fetal morbidity (Cowchock 
et al., 1992). Therefore the use of steroids in APS pregnancies has been abandoned. Two 
prospective randomised studies .have shown that heparin plus low dose aspirin provides a 
significantly better outcome than low dose aspirin alone (Kutteh, 1996; Rai et al., 1997). A 
more recent study however failed to demonstrate any additional efficacy with low
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molecular weight heparin plus aspirin compared to aspirin alone in APS patients with 
recurrent miscarriage and no thrombotic events (Farquharson et al., 2002). In practice, 
heparin is offered in addition to aspirin to APS patients with no thrombotic events who 
have had one or more second trimester loss or three or more first trimester losses.
In APS patients with a previous history of thromboembolism it is common practice to 
administer low molecular weight heparin throughout pregnancy as well as aspirin 
(Lakasing et al., 2000). If a thrombotic event occurs during an APS pregnancy despite 
heparin thromboprophylaxis, or in patients with a history of previous cerebrovascular 
thromboses, the risk of recurrence is sufficiently high to consider antenatal administration 
of warfarin (Hunt et al., 1998). In practice the use of warfarin is avoided in the first 
trimester of pregnancy because of its potential for teratogenicity and is switched to heparin 
two weeks prior to planned delivery to allow clearance of warfarin by both mother and 
fetus.
Immunosuppression with azathioprine, intravenous Ig, plasma exchange and IL-3 therapy 
has all been tried in APS pregnancies (reviewed in (Lakasing et al., 2000)). Due to the 
variable course of the disease and small numbers of patients involved however any 
potential benefits remain unproven.
1.2.9.4 Treatment o f catastrophic APS
Early diagnosis and aggressive treatment are crucial in the management of CAPS patients. 
A high index of clinical suspicion and careful investigation are required. A recent review of 
data from the CAPS registry recommends that as soon as the diagnosis of CAPS is 
suspected, anticoagulation and corticosteroids should be commenced (first line treatment). 
Furthermore, intensive care therapy, haemodialysis for renal failure, mechanical ventilation 
for respiratory failure or inotropic drugs for cardiogenic shock also play an important role 
in the management of CAPS patients (Erkan et al., 2003).
Treatment or elimination of possible precipitating factors - such as infections, tissue 
necrosis, drugs (mostly oral contraceptives), or surgical procedures - is also very important. 
Medical management is centered on anticoagulation (usually intravenous heparin followed 
by a warfarin derivative), corticosteroids, plasmapheresis and intravenous gammaglobulins
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are the most commonly prescribed medications for CAPS patients and seem to be the most 
useful (Erkan et al., 2003). A variety of other management options have been reported for 
CAPS patients where either no benefit was found e.g. with the addition of 
cyclophosphamide or they were only used in single cases e.g. defibrotide, hence their 
benefit is doubtful (Erkan et al., 2003).
1.3 SYSTEMIC LUPUS ERYTHEMATOSUS
SLE is a complex clinical syndrome of multifactorial aetiology, which I shall describe in 
brief since this thesis is primarily about aPL and the APS. SLE is characterised by 
widespread inflammation, most commonly affecting women during the child bearing years. 
It is characterised by periods of relative quiescence and periods of exacerbations, which 
may involve any organ or system in various combinations (Isenberg and Horsfall, 1998). 
Because of its multisystem involvement and protean manifestations, the
diagnosis of SLE may be difficult. The American College of Rheumatology have published 
criteria for the classification of patients as having SLE (Tan et al., 1982) which were 
revised in 1997 (Hochberg, 1997) to include “positive finding of aPL” in the
immunological disorder criterion, shown in Table 1.3. Although these criteria were 
designed primarily as a research rather than diagnostic tool they are useful in evaluating 
individual patients and it is widely accepted that if a patient has, at any time in their 
medical history at least four of the 11 criteria documented, the diagnosis of SLE can be 
made.
1.3.1 Aetiology of SLE
The precise aetiology of SLE remains unclear. However the cardinal features of the
abnormal immune response: - defects in B cell hyperactivity, contributing to
hypergammaglobulinaemia and pathogenic autoantibody production; impaired cell 
mediated immunity; a predominance of Th2 cytokines; dysfunction of apoptosis or in the 
clearance of apoptotic material; and upregulation of adhesion molecules are well described, 
for review see (Mason and Isenberg, 1998). The marked diversity seen in the
immunological abnormalities undoubtedly has a genetic predisposition and in general terms 
SLE occurs in an individual when the appropriate stimulus is delivered to a genetically and 
probably hormonally susceptible person.
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Item Definition
Malar rash Fixed erythema, flat or raised, over the malar eminences, sparing the 
nasolabial folds
Discoid rash Erythematosus raised patches with adherent keratotic scaling and 
follicular plugging: atrophic scarring may occur in older lesions
Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or 
physician observation
Oral ulcers Oral or nasopharyngeal ulceration, usually painless observed by a 
physician
Nonerosive
arthritis
Involving 2 or more peripheral joints, charatcerised by tenderness, 
swelling or effusion
Pleuritis or 
pericarditis
a. Pleuritis - convinving history of pleuritic pain or rub heard by a 
physician or evidence of pleural effusion
OR
b. Pericarditis - documented by electrocardiogram or rub or evidence of 
pericardial effusion
Renal disorder a. Persistent proteinuria > 0.5gm per day or >3+ if quantitation not 
performed
OR
b. Cellular casts - may be red cell, haemoglobin, granular, tubular or 
mixed
Neurologic
disorder
a. Seizures OR b. Psychosis - in the absence of offending drugs or 
known metabolic derangement e.g. uraemia, ketoacidosis or electrolyte 
imbalance
Haematologic
disorder
a. Haemolytic anaemia with reticulocytosis 
OR
b. Leucopenia- <4,000/mm3 on > 2 occasions 
OR
c. Lymphopenia- < 1,500/mm3 on > 2 occasions 
OR a
d. Thrombocytopenia- <100,000 mm in the absence of offending drugs
Immunologic
disorder
a. Anti-DNA: antibody to native DNA in abnormal titre 
OR
b. Anti-Sm: presence of antibody to Sm nuclear antigen 
OR
c. Positive finding of aPL based on : 1) an abnormal serum level of IgG 
or IgM aCL, 2) a positive test result for LA using a standard method, or 
3) a false positive test result for syphilis sustained for at least 6  months 
and confirmed by Treponema pallidum immobilisation or fluorescent 
treponemal antibody absorption test
Anti-nuclear
antibody
An abnormal titre of ANA by immunofluorescence or an equivalent 
assay at any point in time in the absence of drug
Table 1.3 1997 update of the 1982 American College of Rheumatology classification
criteria for systemic lupus erythematosus
Adapted from Tan et al. (1982) and Hochberg (1997).
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1.3.2 Epidemiology and natural history of SLE
SLE is found worldwide with racial and geographic variation; hence it is much more 
common among black females in the United Kingdom (UK), the West Indies and the 
United States of America (Morrow et al., 1999). A UK study has recorded prevalence rates 
of 36.2, 90.6 and 206 per 100,000 among women of Caucasian, Asian and Afro-Caribbean 
origin respectively (Johnson et al., 1995).
Women are affected with SLE between 1 0 - 2 0  times more frequently than men and the 
overwhelming majority of patients will develop their disease between the ages of 15 and 40 
years. It is now recognised that in 10 -  15% of patients the disease will begin after the age 
of 50 and in this subgroup the female to male ratio falls to around 4:1 (Morrow et al.,
1999).
The prognosis of SLE has improved dramatically in the last 40 years with survival rates 
quoted of -90% at 10 years after diagnosis and -70% at 20 years (Rus and Hochberg, 
2002). Deaths early in the course of SLE are usually attributed to active disease and 
infections, but deaths that occur later in the disease course are often due to atherosclerotic 
vascular disease (Esdaile et al., 2001; Roman et al., 2003). Despite the marked 
improvement in survival SLE remains a disease with the potential to cause considerable 
morbidity and increased mortality in a young age group.
1.3.3 Clinical features
The musculoskeletal system and skin are organ systems most frequently affected. Non­
specific features such as severe fatigue, fever, anorexia, weight loss and lymphadenopathy 
are commonly found in the presence of active disease. Arthralgia occurs in about 90% of 
SLE patients and is usually polyarticular, symmetrical, episodic and may be flitting in 
nature. Clinical evidence of erosive arthritis however is only found in 5% of patients. 
Similarly although myalgia is reported in up to 50% of patients a true myositis is found in 
only 5% of these patients (Isenberg and Horsfall, 1998).
A variety of skin lesions are seen in SLE patients including alopecia , the classic butterfly 
rash, maculopapular and discoid lesions, splinter haemorrhages, dilated nailfold capillaries,
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bullous lesions, angioneurotic oedema as well as buccal and nasal ulceration are all widely 
recognised (Isenberg and Horsfall, 1998). Many of these skin lesions are photosensitive 
thus sun protection forms an important part of management of SLE. A variant of SLE 
known as subacute cutaneous lupus erythematosus is well recognised and associated with 
anti-Ro antibodies. Immunoglobulin deposition at the dermal/epidermal junction may be 
found in lesional and non-lesional areas of skin.
A normochromic, normocytic anaemia is present in up to 70% of SLE patients and a 
Coombs' positive haemolytic anaemia in 10% of all patients. Leucopenia and lymphopenia 
are the most frequent abnormalities of the white blood cell count found in SLE patients. 
Thrombocytopenia may present in one of three ways; a chronic form which is rarely 
associated with bleeding episodes; acutely where the fall in the platelet count may be both 
dramatic and life threatening; or as what initially appears to be an idiopathic 
thrombocytopenia which is treated but other manifestations of SLE later develop (Morrow 
etal., 1999).
Despite the high incidence of abnormal pulmonary function tests reported in 85% of SLE 
patients the commonest clinical features of pulmonary disease, dyspnoea and pain due to 
pleurisy (often associated with an effusion) are seen in only about 40% of patients. 
Parenchymal involvement due to SLE is found less commonly in 18% of patients and true 
SLE pneumonitis is rare in less than 2% of patients (Morrow et al., 1999). Many pulmonary 
lesions are the result of concomitant infection, congestive cardiac failure or drug toxicity. 
The presence of pulmonary thromboembolic disease should prompt the clinician to search 
for the presence of aPL. These antibodies should also be sought in the small numbers of 
SLE patients who develop pulmonary hypertension (D’Cruz et al., 2002).
The pericardium, myocardium and endocardium may all be affected by SLE. 
Electrocardiographic and echocardiographic studies have all shown that involvement of 
these structures is more common than is suspected on clinical examination. Although, up to 
30% of SLE patients approximately may have clinical evidence of pericardial disease, large 
pericardial effusions are rare. Clinical myocarditis occurs in up to 15% of patients but 
valvular lesions rarely cause significant lesions (Morrow et al., 1999).
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Significant renal disease will develop in approximately 30% of SLE patients. Clinical 
symptoms suggesting renal involvement rarely become evident until substantial damage has 
been done. Thus careful monitoring of the blood pressure for hypertension, the urine for 
protein, red cells or casts, and the plasma for raised plasma creatinine and urea levels is 
mandatory. The World Health Organisation has classified SLE renal disease into five major 
categories according to information derived from renal biopsy (Isenberg and Horsfall, 
1998). This classification however is constantly being revised and the exact role of renal 
biopsy in SLE remains a matter of debate.
Virtually every feature of central nervous system disease has been described in SLE 
patients, from the common migraine through to less common features such as major 
psychotic episodes, grand mal seizures and rarely movement disorders. The neurological 
manifestations of SLE may be peripheral and psychiatric as well as central. In fact up to 
70% of SLE patients have been reported to suffer from some sort of neurological or 
psychiatric abnormality (Isenberg and Horsfall, 1998).
Vascular lesions particularly Raynaud's phenomenon which occurs in a third of patients, as 
well as cutaneous vasculitis, ulcers and digital gangrene are also well recognised in SLE 
patients (Isenberg and Horsfall, 1998). Abdominal pain is found in 10 -  20% of the 
patients, the causes of which range from mild non-specific gastroenteritis to life threatening 
mesenteric vasculitis. Hepatomegaly and/or persistent liver function test abnormalities as 
well as splenomegaly are found in up to 1 0 % of patients but pancreatitis is less common 
(Morrow et al., 1999).
There has been a marked improvement in the five year survival of this disease over the last 
2 0  years but it still remains a disabling and potentially fatal disease that tends to affect 
women in the prime years of their lives. Current treatments available are limited, especially 
in view of potentially severe side effects and more targeted therapies are needed. Therefore 
much research has tried to gain a greater understanding of the pathogenesis of this disease 
and autoantibodies are among the main areas of interest.
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1.3.4 Autoantibodies in SLE
A variety of autoantibodies are found in SLE patients, see Table 1.4. Given the vast number 
of targets available within the cell (around 2 0 0 0 ) however, the diversity of autoantibodies 
produced in lupus patients is actually rather restricted. These autoantibodies may be 
directed against: cell nucleus components e.g. antinuclear antibodies (ANA) and anti- 
dsDNA antibodies; cytoplasmic antigens e.g. heat shock proteins; cell membranes e.g. anti­
platelet antibodies and aPL; and serum components e.g. Clq.
Screening for ANA is an important primary step in the diagnosis of lupus. Detection of 
specific autoantibodies is then required by more specific tests and even then not all 
autoantibodies can identify a specific disorder (Smeenk et al., 1985). Consideration of 
autoantibody profiles however increase diagnostic predictive value without loss of 
specificity or sensitivity for example in identifying SLE (by the presence of antibodies to 
dsDNA and/or Sm) from other ARD, such as Sjogren's syndrome (associated with anti-Ro 
and/or anti-La) or systemic sclerosis (anticentromere and/or Scl 70 antibodies) (Juby et al., 
1991). The same autoantibody profiles may also be used to identify disease subsets in SLE 
patients. Thus patients with antibodies to dsDNA and/or Sm have a significant increase in 
malar rash, hypocomplentaemia, renal and haematological involvement whilst patients with 
anti-Ro and/or anti-La antibodies have a worse lupus rash and photosensitivity (Thompson 
et al., 1993). aPL are found in 20-50% of lupus patients and LA in 15-35% and are 
associated with the manifestations of the APS. Therefore more diagnostic and prognostic 
power is conferred when autoantibody profiles are considered as a whole in each patient.
1.3.5 Anti-dsDNA antibodies
Of the disease specific antibodies in patients with SLE those targeting dsDNA carry the 
most diagnostic power and clinical application. Between 60-83% of lupus patients are 
found to have anti-dsDNA antibodies and in some patients the titre of these antibodies is an 
excellent measure of disease activity (Hahn, 1998). These antibodies are almost specific to 
patients with SLE and are rarely seen in patients with other diseases or in healthy people 
(Isenberg et al., 1985). Levels of IgG anti-dsDNA antibodies, in particular, are closely 
correlated with the degree of renal damage in lupus nephritis and have been shown to 
deposit in the kidneys of SLE patients (Hahn, 1998). Only a subset of anti-dsDNA 
antibodies appears to be pathogenic however, because not all patients with high serum
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Antibody
specificity
Literature (%) CFR (%)
ANA >90 95
dsDNA 40-90 61
ssDNA Up to 70 -
Histone 30-80 -
Sm 5-30 1 0
RNP 20-35 2 2
Ro 30-40 33
La 10-15 1 2
CL 20-50 23(IgG) 10(IgM)
LA 1 0 - 2 0 13
Fc IgG (RF) 25 23
Thyroid Ags Up to 35 1 1
Table 1.4 Approximate prevalence of antibodies detectable in the serum of SLE 
patients
The literature column refers to an approximate range from several published studies. The 
CFR column is based on the first 388 patients with SLE under long term follow up at the 
Centre for Rheumatology (CFR), Middlesex Hospital, London.
ANA (substrate rat liver) > 1:80 positive result. RF > 1:80 positive result.
Abbreviations: ANA -  Anti-nuclear antibody; ds -  double stranded; ss -  single stranded; 
CL -  cardiolipin; LA -  lupus anticoagulant; RF -  rheumatoid factor.
Adapted from Table 4.10, Morrow et al. (1999) with personal communication from 
Professor D. Isenberg.
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levels of these antibodies have high disease activity. Similarly, not all anti-dsDNA 
antibodies tested in experimental models can cause tissue damage (Ehrenstein et al., 1995). 
Sequence analysis of monoclonal anti-dsDNA antibodies has proved invaluable in 
determining the molecular features which distinguish potentially pathogenic antibodies 
from those which are less likely to be pathogenic.
1.3.6 Management of SLE
All SLE patients need education, counseling and support due to the complexity and 
unpredictability of the disease process. General measures include advice to minimise any 
factors that may precipitate a disease flare such as: sun exposure; undue stress; and 
infection where possible. Preventative measures to avoid infection include influenza and 
pneumococcal vaccination; live vaccines however should be avoided in patients taking 
immunosuppression or >10mg prednisolone/day. Adequate contraception is vital 
particularly when lupus is active and the patient is taking cytotoxic drugs. Since 
cardiovascular disease is a major cause of long term morbidity and mortality among SLE 
patients (Esdaile et al., 2001; Roman et al., 2003), strategies to identify and treat 
cardiovascular risk factors are also very important.
The degree of further treatment required in each SLE patient depends upon the range of 
disease manifestations present. SLE patients with mild disease (fatigue, fever, rash, 
arthralgia and mild serositis) can usually be managed with a combination of topical high 
factor sunscreens, glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs) and 
antimalarials such as hydroxychloroquine or mepacrine (Morrow et al., 1999).
Oral corticosteroids are required when NSAIDs and antimalarials have failed to control the 
disease or there is major organ involvement. Low dose prednisolone (<0.5mg/kg/day) is 
often sufficient to gain disease control. Severe organ involvement, such as nephritis or 
vasculitis, requires systemic treatment with a combination of high dose glucocorticoids and 
other immunosuppressive agents most commonly either azathioprine or cyclophosphamide 
(Morrow et al., 1999).
Cyclophosphamide, mycophenolate, azathioprine and methotrexate may be used to treat 
major organ manifestations in SLE. However, they inhibit the inflammatory immune
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response nonspecifically and are therefore associated with a host of side effects that 
frequently require further therapeutic intervention e.g. corticosteroid induced osteoporosis. 
Furthermore the management of several manifestations of severe SLE remains 
controversial. For instance in the treatment of lupus nephritis early studies showed benefit 
with cyclophosphamide given as intravenous boluses at monthly intervals (for six months 
then three monthly for two years) added to daily oral prednisolone (Boumpas et al., 1992). 
This regimen however is associated with infertility (especially in women >30 years) and 
infection. More recent studies have shown benefit and reduced toxicity with low dose 
regimens of intravenous cyclophosphamide (500mg monthly for three months) followed by 
early introduction of azathioprine (Houssiau et al., 2002).
1.3.7 Inadequacies of current treatments in SLE and APS and the need for novel 
therapies
Despite attempts to improve the side effect profile of cyclophosphamide it is not always 
effective. A number of novel therapies with improved side effect profiles and/or more 
specific targeting of the immune system, such as B cell depletion and B cell tolerisation are 
being developed (reviewed in (Gescuk and Davis, 2002)). Similarly in the treatment of the 
APS the mainstay of both prophylaxis and active treatment regimes for thrombosis and 
pregnancy loss is aspirin and anticoagulation. Both of these treatments have potential side 
effects particularly the risk of haemorrhagic complications with warfarin which is increased 
when aspirin is taken concomitantly.
It is therefore important to develop new treatments which are both more effective and more 
accurately targeted to the disease process in APS and SLE. Considerable evidence exists 
that aPL play a major role in causing the clinical features of APS (reviewed in section 
1.2.4). A greater understanding of the structural properties of aPL that determine how they 
bind to their target antigen may allow the development of new therapies, with hopefully 
better efficacy and/or better side effect profiles, to block or manipulate interactions between 
aPL and their major epitopes leading to an amelioration of disease features in the APS.
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1.4 ANTIPHOSPHOLIPID ANTIBODIES
1.4.1 Aetiology of aPL
The precise aetiology of aPL remains unclear. A genetic predisposition to aPL production 
has been described in both family and population studies. The first report suggesting a 
familial association of the LA described two pairs of siblings with clear evidence of LA 
(Exner et al., 1980). Subsequent studies have reported that first degree relatives of patients 
with SLE or PAPS had a higher incidence of aCL (Mackworth-Young et al., 1987; 
Radway-Bright et al., 2000). Further evidence of a familial form of APS has come from the 
identification of several kindreds with an increased frequency of aPL and the associated 
clinical manifestations (Mackie et al., 1987; Matthey et al., 1989; Ford et al., 1990; 
Dagenais et al., 1992; Bansal et al., 1996).
Various studies have proposed that a genetic predisposition to APS is at least in part to be 
accounted for by the human leucocyte antigen (HLA) locus. A variety of different HLA 
class II alleles have been identified. In northern Italian patients with SLE, aCL were found 
to be significantly associated with HLA DR7 (Savi et al., 1988) whilst in English patients 
with SLE, HLA DR4 was significantly associated with aCL (McHugh and Maddison,
1989). In neither of these studies was it clear whether any of the patients examined had 
manifestations of the APS. Two studies of PAPS patients however have also indicated an 
increased frequency of DR-4 and DR-7 specifically DRw53 (Trabace et al., 1991; Asherson 
et al., 1992; Camps Garcia et al., 1994) as well as DQw7 (Arnett et al., 1991; Camps 
Garcia et al., 1994). A recent U.K. study of 83 British Caucasoid APS patients found the 
DQBl*0604/5/6/7/9-DQAl*0102-DRB 1*1302 haplotypes to be significantly correlated 
with anti-l^GPI antibodies in the subset of PAPS patients (Caliz et al., 2001). They also 
found the presence of the DQB 1*0303-DQA1 *0201-DRB 1*0701 haplotype to be 
associated with APS in all patients (Caliz et al., 2001).
In contrast several large studies have not found an association with DRw53 (Arnett et al., 
1999; Galeazzi et al., 2000). Arnett et al. (1999) analysed the association of anti-^GPI 
antibodies in a multiethnic group of 262 patients with SLE, PAPS or another ARD. They 
found that HLA-DR4 haploytpes especially those carrying HLA-DQ8  (DQB 1*0302) were 
associated with an ti^G P I antibodies in Mexican Americans and to a lesser extent in
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whites. In addition they found that the HLA-DRB1*1302;DQB 1*0604/0605 haplotype was 
associated with anti-p2 GPI antibodies primarily in black patients (Arnett et al., 1999). A 
large European study of 600 SLE patients found that aCL were positively associated with 
HLA-DRB1*04, -DRB1*07, -DQA1*0201, -DQA1*0301, -DQB1*0302, -DRB3*0301 
and that anti-f^GPI antibodies have a positive association with DQB 1*0302 (Galeazzi et 
al., 2 0 0 0 ).
A further layer of complexity is added when other studies are considered which have failed 
to find an association with HLA antigens at all. Goel et al. (1999) studied seven families 
with 101 family members 30 of whom met their own diagnostic criteria for APS and failed 
to find linkage in the APS families with HLA or markers for several other candidate genes. 
Their results were consistent with a genetic basis for disease in APS families which 
appeared to be inherited in an autosomal dominant pattern (Goel et al., 1999). Close 
inspection however, of the results of this study reveals that the seven probands were 
diagnosed with at least one major clinical manifestation (vascular thrombosis and/or 
recurrent fetal loss) of APS and medium positive titres of aCL or positive LA. In contrast, 
family members with a medium positive titre aCL or positive LA and minor or no clinical 
manifestations were diagnosed with APS. Major manifestations of the APS occurred in 
only six of the 23 “affected” family members. Therefore this study is really an examination 
of the genetics of aPL rather than the APS.
Many of these apparently conflicting studies are difficult to interpret due to small patient 
numbers and the use of ethnically diverse patient groups. Further confounding factors from 
some studies are likely to be the study of aPL positive patients who do not have the APS; 
the use of different classification criteria to identify APS patients; a lack of patient 
stratification (primary versus secondary APS) and variation in the measurement of aPL. 
Overall genetic factors appear to be important in the development of APS and HLA alleles 
appear to account for only part of this susceptibility. In fact HLA alleles may only 
determine the susceptibility to produce aPL that are then responsible for the clinical 
manifestations of APS. The alleles identified thus far may only be apparent because of their 
linkage disequilibrium with an as yet unidentified primarily involved HLA locus or they
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could act in cooperation with other genes residing outside the MHC. The search for a more 
strongly associated polymorphism continues.
A number of different infections and drugs have been implicated as precipitating factors in 
the generation of aPL. These precipitants however are mostly associated with the formation 
of cofactor independent IgM aPL. Notable exceptions are findings of B2 GPI dependent 
antibodies in patients infected with parvovirus B19 (Loizou et al., 1997) and patients taking 
procainamide (Merrill et al., 1997).
1.4.2 The nature of pathogenic aPL
Not all aPL are associated with pathogenicity. aPL can occur in 1.5-5% of healthy people 
and may also occur in various medical conditions without causing clinical features of APS 
(Greaves et al., 2000). The aPL which are found in patients with APS, whether primary or 
secondary to an ARD differ from those found in healthy people in that they target 
predominantly negatively charged PL and are directed against a variety of phospholipid 
binding serum proteins, of which 6 2 GPI is the most extensively studied and appears to be 
the most relevant clinically. It has been suggested that the properties of IgG isotype, 
specificity for negatively charged PL and ability to bind 8 2 GPI may define a population of 
pathogenic aPL which are particularly likely to cause the effects on thrombosis that lead to 
APS (described in section 1.2.5).
1.4.3 The causative role of pathogenic aPL in APS
The most convincing evidence of the pathogenic nature of aPL comes from the induction of 
typical APS features in nai've mice by both the passive transfer of aPL and active 
immunization with aPL or B2 GPI (reviewed in (Radway-Bright et al., 1999)). The full range 
of clinical manifestations seen in human APS however has proved difficult to reproduce in 
any one single animal model of APS.
There are few models of the thrombosis found in patients with APS. Pierangeli et al. 
(Pierangeli and Harris, 1994; Pierangeli et al., 1996) have shown that when the femoral 
vein of a mouse is subjected to a pinch stimulus, the size and longevity of the thrombus 
produced can be enhanced in the presence of aPL which has been passively infused or 
produced by immunization with I^GPI/aCL compared to a control IgG antibody.
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Intraperitoneal injection of affinity purified IgG aPL (isolated from APS patients) led to 
endothelial cell (EC) activation by significantly increasing leucocyte adhesion in-vivo and 
the expression of adhesion molecules in-vitro (Pierangeli et al., 1999). Monoclonal aPL, 
induced in mice by immunization with a 15 amino acid (AA) synthetic peptide (called 
GDKV) that contains the major PL binding region of B2 GPI, have also been shown to 
enhance thrombus formation and increase leucocyte adherence to EC in a mouse model 
(Gharavi et al., 1999). A later study of seven maPL derived from two APS patients, found 
four to be thrombogenic in the pinch stimulus model and three caused more in-vivo 
leucocyte adhesion compared with control IgG mAbs and enhanced adhesion molecule 
molecule expression in-vitro (Pierangeli et al., 2000). These findings provide direct 
evidence that aPL are pro-thrombotic but also clearly demonstrate the heterogeneity of 
these antibodies.
Other models of APS exist, mainly in mice prone to spontaneously develop autoimmune 
disease. NZWxBXSB Fj mice produce high titres of aCL and develop degenerative 
coronary vascular disease with myocardial infarction and thrombocytopenia (Hashimoto et 
al., 1992). MRL/lpr mice are a lupus-prone strain with a recessive lymphoproliferation gene 
(lpr) encoding a defective Fas molecule, leading to defective Fas mediated apoptosis. These 
mice spontaneously develop some features similar to human APS such as high levels of 
IgG aCL, thrombocytopenia and poor pregnancy outcome (Gharavi et al., 1989) and have 
histological evidence of thrombosis in the brain (Smith et al., 1990).
More direct evidence of a pathogenic role of aPL in obstetric manifestations of APS comes 
from the models of passive and actively induced APS. Passive induction entails the 
intravenous infusion of monoclonal and/or polyclonal aPL into mice to create disease 
manifestations. Blank et al. (1991) infused murine monoclonal aPL and human polyclonal 
IgG aPL and monoclonal IgM aPL from a patient with PAPS into pregnant ICR mice. They 
found a lower fecundity rate, increased resorptions index of embryos, lower numbers of 
embryos per pregnancy and lower weights of embryos and placentae compared to mice 
infused with murine or human control Ig lacking aCL binding (Blank et al., 1991). 
Similarly, a significantly higher rate of fetal resorptions with a significant reduction in fetal 
and placental weight was found in pregnant BALB/c mice passively infused with human
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monoclonal IgG aPL from a PAPS patient compared to mice infused with a control human 
monoclonal IgG Ab lacking aPL activity (Ikematsu et al., 1998).
Active induction of APS entails administration of aPL or generation of this Ab in response 
to an autoantigen, followed by stimulation of the immune system by one of its idiotypes to 
produce an Ab against it. Consequently Ab directed against the anti-idiotypic Ab may be 
generated which has the binding characteristics of the original Ab. Following intradermal 
immunisation of naive BALB/c mice with human IgM and IgG aPL, the mice have been 
shown to develop high titres of aPL, prolongation of the activated partial thromboplastin 
time (aPTT), thrombocytopenia and pregnancy morbidity compared to mice immunised 
with control Ig lacking aPL activity (Bakimer et al., 1992; Cohen et al., 1993). Bakimer et 
al. (1992) used a human monoclonal IgM aPL generated from a healthy subject following 
immunisation with diphtheria and tetanus hence the relevance of this study to the APS is 
less certain. Cohen et al. (1993) however used polyclonal aPL purified from a PAPS 
patient. They found that mice immunised with purified IgG aPL showed low fecundity, 
increased fetal resorptions with reduced fetal and placental weights compared to controls 
whilst mice immunised with purified IgM aPL showed only a reduced fecundity and 
slightly increased fetal resorption rate. Immunisation of naive BALB/c mice with 6 2 GPI has 
also been shown to induce the above features compared to mice immunised with CL (Blank 
et al., 1994).
1.5 MECHANISMS OF PATHOGENESIS OF THE APS
A satisfactory unifying explanation for the association between aPL and all thrombotic 
events in APS patients has yet to be defined. The frequent and variable manifestations of 
thrombosis in APS patients may, in part, be explained by the heterogeneous population of 
aPL which depending upon their specificity can interfere with different pro-coagulant 
reactions. Various mechanisms have been proposed and the most consistent and 
reproducible data suggest that the major mechanisms of hypercoagulability in APS involve 
up-regulation of the tissue factor (TF) pathway, inhibition of the protein C pathway and the 
interaction of aPL with the endothelium.
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1.5.1 Tissue factor pathway
TF, an inducible cell glycoprotein, is the major initiator of coagulation in-vivo. It is 
expressed in a variety of cells (e.g. EC and monocytes) in response to various stimuli 
including bacterial lipopolysaccharide (LPS), IL-1 and tumour necrosis factor (TNF). 
Expression of TF results in formation of a complex between TF and coagulation factor VII 
on the cell surface, which activates factors IX and X. Activated factor X, in conjunction 
with activated factor V, then converts prothrombin to thrombin which leads to fibrin 
formation and platelet activation (Cuadrado et al., 1997).
In-vitro studies have shown that sera from SLE patients with LA induce TF activity in 
cultured EC (Tannenbaum et al., 1986). A number of other studies have shown that serum, 
plasma, purified total IgG and anti-p2GPI antibodies from APS patients enhance TF 
expression and procoagulant activity on normal monocytes (Komberg et al., 1994; Reverter 
et al., 1998). Additionally, using preserved ex-vivo monocytes thawed and grown in tissue 
culture, TF expression was found to be increased in APS patients with a history of 
thrombosis compared to APS patients without thrombosis; patients with thrombosis and no 
aPL; and a group of healthy controls (Cuadrado et al., 1997). To clarify the effects of 
thawing and cell adhesion on monocyte activation the same group have used uncultured 
fresh mononuclear blood cells and shown that mean levels of TF mRNA were statistically 
increased in monocytes from PAPS patients with thrombosis compared to six healthy 
controls (Dobado-Berrios et al., 1999).
The TF/VIIa activity is regulated by tissue factor pathway inhibitor (TFPI) complexed with 
factor Xa. Up-regulation of the TF pathway could potentially be caused by decreased TFPI 
activity. Functional anti-TFPI activity has been detected in a subset of PAPS patients 
(Adams et al., 2001). Furthermore increased factor Xa generation in normal plasma, 
indicating suppression of TFPI activity, stimulated by aPL isolated from six PAPS patients 
was lost when patients' IgG was depleted of anti-p2GPI Ab or when normal plasma was 
depleted of (32GPI or TFPI (Salemink et al., 2000). Thus anti-|32GPI antibodies have been 
implicated in anti-TFPI activity.
An additional mechanism by which monocyte TF activity may be increased in APS 
involves the cellular immune response to p2 GPI. It has been shown that CD4+ T cells
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specific for P2 GPI from APS patients can induce monocyte TF upregulation when cultured 
in the presence of P2 GPI (Visvanathan et al., 2000).
1.5.2 The protein C pathway
The protein C pathway is an important endogenous antithrombotic mechanism which is 
initiated when thrombin binds to thrombomodulin on EC (Esmon et al., 1997). Thrombin 
then loses its procoagulant activity and its ability to activate protein C is markedly 
enhanced. Activated protein C (APC) acts as an anticoagulant by proteolytically 
inactivating factors Va and Villa with its cofactor protein S, thus limiting the rate of 
thrombin generation. Various studies have shown that aPL may interfere with the protein C 
pathway in many different ways with the most convincing evidence indicating inhibition of 
protein C activation and function by aPL.
A number of publications have observed the inhibition of both protein C activation and 
function in association with aPL (Marciniak and Romond, 1989; Malia et al., 1990; Borrell 
et al., 1992). Marciniak and Romond (1989) reported a decreased rate of factor Va 
degradation in the plasma of 15 patients with LA. Borrell et al. (1992) found that IgG 
fractions from almost all of 21 aPL positive patients with APS, SLE and one asymptomatic 
donor, showed an inhibitory effect on factor Va degradation by APC when compared with 
control IgG from normal subjects. Similar results were obtained by Oosting et al. (1993) 
studying purified IgG from 30 patients, of whom 26 had aPL and 23 had thrombosis. They 
also showed that the antibodies responsible for inhibiting Va degradation were directed 
against PL bound protein C or protein S (Oosting et al., 1993). Plasma and purified IgG 
fractions from APS patients may reduce the effect of activated protein C in functional 
assays for APC resistance leading to an acquired protein C resistance (Male et al., 2001). 
This anti-APC activity was found to be dependant upon the phospholipid 
phosphatidylethanolamine (PE) in one study (Smirnov et al., 1995). Even a partial 
reduction of APC anticoagulant activity is known to be a major thrombotic risk factor 
(Esmon etal., 1997).
Anti- P2 GPI Ab have been shown to interfere with the protein C pathway although some 
data are equivocal. P2 GPI itself can inhibit protein C activation by 
thrombin/thrombomodulin. This was shown using P2 GPI incubated with CL vesicles
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(Keeling et al., 1993). Other studies have shown that the binding of protein C to PL is 
inhibited by purified P2 GPI (Mori et al., 1996) and that aPL recognise protein C only in the 
presence of P2 GPI (Atsumi et al., 1998). In contrast, another study found p2GPI to have 
little or no effect on protein C activation on endothelial cells, in the presence or absence of 
anti^G PI Ab (Oosting et al., 1991). Whilst the APC resistance of aPL has been shown to 
be strictly P2 GPI dependent by others (Galli et al., 1998).
There are a number of conflicting reports regarding the presence of aPL directed against 
thrombomodulin. Several studies using IgG isolated from LA positive plasma found that 
the Abs were directed against thrombomodulin (Freyssinet et al., 1986; Cariou et al., 
1988), whilst other groups have failed to support these observations at all (Watson and 
Schorer, 1991; Keeling et al., 1993) and one study of IgG from 46 different patients with 
LA found only two cases with reduced rate of APC formation (Potzsch et al., 1995). 
Therefore although some aPL may be directed against thrombomodulin their functional 
effects are unknown and their frequency in the population tested was so low that they 
cannot be the mechanism that explains the majority of aPL mediated thrombotic events.
There are case reports of acquired protein C or S deficiencies in isolated APS patients 
P2 GPI (Parke et al., 1992). In general, however, studies in larger populations of patients 
with APS have failed to show a correlation between decreased protein C levels and the 
presence of aPL (Hasselaar et al., 1989).
1.5.3 Effects of aPL on vascular EC
Recent work has focused on the aPL-EC interaction. Several different groups have shown 
aPL to stimulate cultured EC leading to increased expression of adhesion molecules (Del 
Papa et al., 1995; Simantov et al., 1995; Pierangeli et al., 1999; Pierangeli et al., 2000). In 
the in-vitro studies aPL binding to EC was dependent upon the presence of P2 GPI (Del 
Papa et al., 1995) and these effects were mediated through the F(ab) ' 2  fragment of the Ab 
(Simantov et al., 1995). Using murine in-vivo models of microcirculation Pierangeli et al.
(2000) demonstrated, by direct visualisation, an increased adhesiveness of leucocytes to EC 
of vessels in the cremaster muscle of mice infused with aPL. They also found the same aPL 
to enhance thrombus formation in-vivo and upregulate the expression of adhesion 
molecules on cultured human umbilical vein ECs (HUVECs). The importance of certain
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adhesion molecules -  intercellular adhesion molecule 1 (ICAM-1) and P-selectin - was 
indicated when the same in-vivo models of microcirculation and thrombosis were studied 
using adhesion molecule knockout mice (Pierangeli et al., 2001). In both ICAM-17" mice 
and ICAM-l^/P-selectin7' mice, IgG aPL affinity purified from an APS patient did not 
increase leucocyte adhesion to ECs nor did these Ab enhance thrombus formation 
(Pierangeli et al., 2001). Thus aPL appear to induce a proadhesive and proinflammatory 
phenotype. Interestingly fluvastatin, a fully synthetic hydroxymethylglutaryl coenzyme A 
reductase inhibitor, has been shown to inhibit EC adhesion molecule expression on cultured 
HUVECs induced by human aPL (Meroni et al., 2001). More recently, fluvastatin has been 
shown to significantly diminish aPL mediated thrombosis and EC activation in the in-vivo 
models of microcirculation and thrombosis described above (Ferrara et al., 2003).
E-selectin up regulation in ECs activated by aPL binding to fcGPI has been shown to be 
dependant on translocation of a transcription factor, nuclear factor kB (NF-kB) in a manner 
comparable to that induced by proinflammatory cytokines (IL-1 p and TNFa) or by bacterial 
LPS (Meroni et al., 2001). It is known that LPS and IL-1 interact with membrane proteins, 
namely toll-like receptors (TLRs) and IL-1 receptors, which share a homologous 
cytoplasmic signalling domain, the toll/IL-1 receptor (TIR) domain and use the same 
intracellular mediators in their activation pathway. The adapter molecule myeloid 
differentiation protein (MyD8 8 ) is the first protein that associates with both the TLRs and 
IL-1R through its TIR domain. Recently, Raschi et a l (2003) have proposed that aPL 
activate EC through a TLR and the MyD8 8  pathway after experiments in which they co­
transfected immortalised human microvascular EC with dominant negative constructs of 
different components of the TLR signalling pathway. They also found EC activation by 
human anti-p2 GPI Ab produced a signalling cascade comparable to that induced by 
bacterial LPS which is known to act via TLR4 (Raschi et al., 2003).
1.5.4 aPL and the development of atherosclerosis
An emerging concept is that aPL have an effect on the development of AS. Low density 
lipoprotein receptor deficient (Lf)L-RD) mice fed a high cholesterol diet develop AS and 
apo-E deficient mice develop spontaneous AS. Immunisation of either of these mouse 
strains with 6 2 GPI leads to the production of high titers of anti-I^GPI antibodies, whilst
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controls of non-immunised mice or mice immunised against ovalbumin do not develop 
these antibodies (George et al., 1998a; George et al., 1999). As well as a raised titer of anti- 
8 2GPI antibodies, larger AS lesions were found in the immunised animals which contained 
abundant CD4 cells also (George et al., 1998a; George et al., 1999). Similarly when LDL- 
RD mice were immunised with aCL they developed high titers of anti-anti-aCL, that had 
the same binding characteristics as the original antibody used for manipulation, and had 
increased AS compared with control mice immunised with normal human IgG (George et 
al., 1997). Further evidence of the association of aPL and AS in mice comes from 
experiments in which lymphocytes transferred from ft2GPI immunised LDL-RD mice by 
intraperitoneal injection into syngenic LDL-RD mice led to enhanced AS in the recipients 
(George et al., 2000).
In the presence of aPL, 6 2GPI increases the uptake of oxidised LDL by macrophages, 
which is an important step in the formation of AS (for review see (Petri, 1998)). It has been 
suggested that 8 2GPI dependent aPL may cause AS by direct activation of the vascular 
endothelium (Simantov et al., 1995; Del Papa et al., 1997; Pierangeli et al., 1999), 
increased clearance of oxidised LDL (Hasunuma et al., 1997), or by reduced paraoxonase 
activity (Delgado Alves et al., 2002). Paraoxonase is a circulating anti-oxidant, levels of 
which are reduced in APS. This reduction may lead to increased oxidation of LDL.
Despite this experimental evidence, the findings from clinical studies of a link between the 
presence of carotid AS and aPL are conflicting. One study found a statistically significant 
association (Ames et al., 2002) between IgG aCL titre and the intima media thickness 
(IMT) of carotid arteries and another found a trend towards a higher prevalence of carotid 
plaque in aPL positive patients (Roman et al., 2001). Several groups however, have not 
found any association between aPL and carotid or coronary AS (Asanuma et al., 2003; 
Roman et al., 2003; Vlachoyiannopoulos et al., 2003). Notably of those studies which did 
support an association between aPL and AS, Ames et al. (2002) did not use a control group 
and the other was a pilot study (Roman et al., 2001) which subsequently did not support the 
trend towards a positive association in a larger group of patients (Roman et al., 2003). Thus 
a clinical association between the presence of carotid AS and aPL has not yet been 
conclusively proven and requires further clinical studies.
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1.5.5 Other pathogenic mechanisms of aPL
Other hypotheses for pathogenic mechanisms of aPL have been postulated. aPL have been 
shown to interfere with the production and release of prostacyclin by endothelial cells, 
disrupt the Annexin V anticoagulant shield, both inhibit and induce platelet activation, 
impair fibrinolytic mechanisms and interfere with antithrombin III activity (for reviews see 
(Santoro, 1994) and (Rand, 2002)).
1.5.6 The role of T cells and cytokines in the APS
Given the importance of T cells and cytokines in the humoral immune response, explained 
in section 1 . 1 .6 , it is not surprising that evidence is emerging which implicates these 
molecules in the pathogenesis of the APS.
Cytokine abnormalities have been implicated in the pathogenesis of fetal loss, one of the 
major manifestations of the APS. In normal pregnancies IL-3 and granulocyte macrophage 
colony stimulating factor (GM-CSF) have been shown to promote placental development 
and fetal growth (Wegmann, 1989) and the concentration of IL-3 rises, to peak at delivery 
(Fishman et al., 1992b). Low levels of IL-3 have been found both in APS patients 
(Shoenfeld et al., 1998b) and in BALB/c mice with high titers of aPL and pregnancy 
morbidity following active immunisation with a human maPL (Fishman et al., 1992a). 
Furthermore administration of murine recombinant IL-3 to pregnant ICR mice which had 
been passively injected with aPL led to a dramatic reduction in the fetal resorptions rate and 
reduction in severity of thrombocytopenia (Fishman et al., 1993). It has also been suggested 
that the beneficial effect of low dose aspirin in preventing the clinical manifestations of 
APS may in part be mediated by its ability to stimulate IL-3 production (Fishman et al., 
1996). Similarly, Ciprofloxacin (a broad spectrum quinolone antibiotic) has been shown to 
decrease pregnancy loss in association with an increase in IL-3 and GM-CSF production 
(Riesbeck et al., 1994). However the exact role of IL-3 in the pathogenesis of the APS 
remains unclear.
Since autoantibody production by B cells generally requires T cell help, it is not surprising 
that T cells appear to have a prominent part in the pathogenesis of APS. High titers of aPL 
and pregnancy morbidity have been shown to be induced in total body irradiated naive 
BALB/c recipient mice following infusion of T cells originating from naive mice that were
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actively immunised with a murine maPL (Blank et al., 1995). Similar features of the APS 
were not seen when T cells were taken from donor mice immunised with a control IgG aPL 
which lacks CL binding (Blank et al., 1995). Anti-CD4 mAbs, given before or after 
induction of experimental SLE and APS in BALB/c mice, can prevent the development of 
autoantibody production, including aPL as well as the clinical manifestations of the disease 
(Tomer et al., 1994).
Circulating B2GPI specific CD4+ T cells have been demonstrated in 8  out of 18 patients 
with APS studied but not found in healthy individuals or patients with other ARD or aPL 
positive patients who did not have the APS (Visvanathan and McNeil, 1999). T cells that 
are autoreactive to B2GPI have been found in APS patients and healthy individuals (Hattori 
et al., 2000). Native B2GPI however, did not induce a proliferative response in peripheral 
blood T cells which were only stimulated by a reduced form of 6 2 GPI. This discrepancy 
was thought to have occurred because T cell tolerance to peptides generated through 
normal processing of B2GPI is induced because of the abundance of B2GPI in the 
circulation. Thus it was considered likely that the reduced form of B2GPI expresses cryptic 
peptides that are able to stimulate T cells. How much, if any of this reduced form of B2GPI 
is found in-vivo is unknown, thus the relevance of these findings to patients with APS is 
uncertain. Furthermore the authors admit, that the mechanism by which exposure to cryptic 
peptides may result in the activation of 6 2GPI reactive T cells in APS patients is unknown 
(Hattori et al., 2000).
To examine antigen recognition profiles and Th cell activity in B2GPI reactive T cells 
further, the same group generated 14 CD4+ T cell clones specific to B2GPI from three 
patients with APS (Arai et al., 2001). At least four distinct T cell epitopes were identified, 
but the majority of the B2GPI specific T cell clones responded to a peptide encompassing 
AA residues 276 to 290 of B2GPI containing the major PL binding site. Ten of 12 B2GPI 
specific T cell clones stimulated peripheral blood B cells that produced anti-B2GPI Ab in 
the presence of recombinant B2 GPI. Th cell activity was found exclusively in T cell clones 
capable of producing IL-6 .In-vitro anti-B2GPI Ab production induced by T cell clones was 
inhibited by either anti-IL- 6  or by the anti-CD40 ligand monoclonal antibody. In addition, 
exogenous IL- 6  augmented anti-B2GPI Ab production in cultures of B cells with T cell 
clones lacking IL- 6  expression. The results of this study indicate that B2GPI specific CD4+
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T cells in APS patients preferentially recognise the antigenic peptide containing the major 
PL binding site and have the capability to stimulate B cells to produce anti-p2GPI Ab via 
expression of IL- 6  (Arai et al., 2001).
In contrast, another group generated CD4+ T cell lines reactive with B2GPI peptides from 
three of 18 ARD patients (five with APS) who were all carrying anti-B2GPI Ab. They found 
the major T cell epitope to reside in a fragment containing codons 244-264 and a leucine at 
position 247. This epitope however was also found in a CD4+ T cell line derived from one 
of two healthy control subjects who did not have anti-l^GPI Ab (Ito et al., 2000).
Evidence of T cells in the lesions of AS (George et a l, 1999; George et a l, 2000) and 
increased monocyte TF activity found in the APS (Visvanathan et al., 2000) has previously 
been described in sections 1.5.4 and 1.5.1 respectively.
1.6 THE IMPORTANCE OF p2GPI IN APS
Although B2GPI is a major target antigen in the pathogenesis of the APS (described in 
section 1.2.5), the exact nature of the aPL-I^GPI interaction remains a matter of some 
debate. Opinion is divided as to whether pathogenic aPL are directed against the B2 GPI-PL 
complex (Shoenfeld et al., 1998a), a cryptic epitope revealed on B2GPI by binding to PL (or 
certain synthetic surfaces) (Koike et al., 1998), or whether they bind directly to an 
increased density of B2GPI immobilised upon PL or gamma irradiated plates (Roubey et al., 
1995), see Figure 1.2. The location of the major epitopes on B2GPI is also unclear and 
evidence has been published supporting the existence of epitopes in various different 
regions of B2 GPI.
1.6.1 B2GPI -  Molecular structure and function
B2 GPI is a 50kDa (Schultze et al., 1961) single chain polypeptide, 326 amino acid residues 
long with five oligosaccharide attachment points (Lozier et al., 1984; Steinkasserer et al., 
1991). The protein is composed of five common structurally related repeats known as 
domains which are classed as members of the short consensus repeat or complement 
control protein (CCP) super family (Reid and Day, 1989). Each domain is approximately 
60 amino acid residues in length with two intra-domain disulphide bonds. The first four 
domains are typical CCP domains but domain V is aberrant, containing 82 amino acids and
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A) aPL
Native P2 GPI 
PL
B)
/ / \
Cryptic epitope 
On P2 GPI
C)
Figure 1.2 Schematic representations of various hypotheses regarding aPL-p2 GPI 
interaction
Pathogenic aPL are depicted binding to: - A) the 6 2 GPI-PL complex; B) a cryptic epitope 
revealed on 6 2 GPI by binding to PL (or certain synthetic surfaces); C) an increased density 
of l^GPI immobilised upon PL (or certain synthetic surfaces).
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a long carboxyl terminal tail which is cross linked by an additional disulphide bond. The 
crystal structure of B2 GPI has been described by two independent groups (Bouma et al., 
1999; Schwarzenbacher et al., 1999).
The precise physiological function of human B2 GPI remains unclear. In-vitro, B2 GPI binds 
to negatively charged phospholipids (such as CL and phosphatidylserine (PS)), inhibits 
contact activation of the intrinsic coagulation pathway (Schousboe, 1985), platelet 
prothombinase activity (Nimpf et al., 1986), adenosine diphosphate (ADP) mediated 
platelet aggregation (Nimpf et al., 1987) and aids clearance of oxidised LDL, (Hasunuma et 
al., 1997). In-vivo, B2 GPI is involved in the clearance of apoptotic bodies (Pittoni et al., 
2000) and liposomes (Chonn et al., 1995) as well as interfering with the protein C pathway 
(Roubey, 1996). B2 GPI adheres to resting human EC. Subsequent binding of circulating 
aPL led to EC activation (Del Papa et al., 1997) (for review see (Meroni et al., 1998)). Thus 
8 2 GPI appears to promote clearance of certain products of oxidation and prevent thrombus 
formation (for review see (Inane et al., 1997)). Binding of aPL to epitopes on B2 GPI may 
interfere with these functions, and therefore promote thrombosis. The possible role of 
B2 GPI on the development of AS has been discussed in section 1.5.6.
1.6.2 Evidence in favour of a cryptic epitope upon B2 GPI
Several groups have found monoclonal (Matsuura et al., 1994) and polyclonal aPL 
(Chamley et al., 1999) bind directly to B2 GPI coated on irradiated, but not plain, 
polystyrene ELISA plates in the absence of CL, even when the concentration of B2 GPI on 
the plain plates was higher. Thus these authors felt that a conformational change in B2GPI 
was required to explain the increased binding of aPL to irradiated plates.
Indirect methods using infrared spectroscopy (Borchman et al., 1995), spectrophotometry 
to produce a circular dichroism spectrum (Subang et al., 2000) and microcalorimetry 
(Hammel et al., 2001) have all been used to infer an alteration in the structure of B2 GPI 
upon binding to PL. Subang et al. (2000) demonstrated a conformational change in B2 GPI 
upon binding to CL but not other anionic PL such as phosphatidylglycerol (PG) and PS. 
Despite this, B2 GPI complexes with PG and PS were still found to be immunogenic, leading 
to the production of aPL and LA in BALB/c mice.
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Matsuura et al. (2000) showed no binding of polyclonal or monoclonal human aPL or 
monoclonal murine aPL to plasmin cleaved B2 GPI on polyoxygenated plates. Binding of 
B2 GPI to the plates was unaffected by plasmin cleavage, as measured by binding to murine 
anti-human B2 GPI. Since this experiment measured binding of aPL to B2 GPI in the absence 
of PL, these results were taken as evidence that proteolytic cleavage of B2 GPI between Lys- 
317 and Thr-318 does not simply reduce binding to PL but also prevents exposure of 
cryptic epitopes for aPL (Matsuura et al., 2000).
1.6.3 Evidence against a cryptic epitope
Roubey et al. (1995) compared the binding of aPL to 6 2 GPI bound to plain and irradiated 
plates and found that aPL binding was detected only when the amount of B2 GPI coated on 
the high binding plates exceeded that which could be coated to the plain plates. Inhibition 
experiments demonstrated little detectable binding of aPL to physiologic concentrations of 
fluid phase B2 GPI or a low density of immobilised B2 GPI. Binding of monovalent Fab' 
fragments of aPL to B2 GPI on irradiated plates was substantially less than that of bivalent 
F(ab' ) 2  fragments (Roubey et al., 1995). Thus they argued that aPL which bind to B2 GPI are 
of low affinity, requiring bivalent binding which only occurs when B2 GPI is “clustered” 
upon an irradiated plate or anionic PL surface and does not require the exposure of a cryptic 
epitope on B2 G PI.
The striking differences between the results obtained by Roubey et al. (1995) and Chamley 
et al. (1999) may be explained in a number of ways. Firstly, the two groups used different 
techniques to quantify the amount of B2 GPI bound to the plates and carried out their 
experiments at significantly different coating concentrations. Secondly, different antibodies 
were tested in the two experiments. It is possible that some aPL require the presence of a 
cryptic epitope for binding to B2 GPI, whereas others do not.
An insect expression system was used to produce a variant of B2 GPI, which dimerises 
spontaneously (Sheng et al., 1998). This variant bound polyclonal human aPL better than 
wild-type B2 GPI on non-irradiated plates, irradiated plates and in the fluid phase. Bivalent 
F(ab')2 , but not monovalent Fab', fragments could bind the dimerising variant (Sheng et al., 
1998). These experiments again suggested the importance of bivalent binding of low
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affinity aPL to clustered B2 GPI. It is possible, however, that the process of dimerisation 
itself might lead to exposure of a cryptic epitope.
Using surface plasmon resonance (SPR) the interactions of five monoclonal murine aPL 
with B2 GPI have been studied (Regnault et al., 1999). Molar ratios of the monoclonal aPL 
binding to B2 GPI immobilised upon sensor chips were approximately 0.5, indicating 
bivalent binding.
1.6.4 Conclusion - is the epitope cryptic?
The binding of aPL to B2 GPI upon certain synthetic surfaces in the absence of PL can be 
interpreted both for and against a cryptic epitope for aPL upon B2 GPI. Increased binding of 
aPL to mutant forms of “dimerised” B2 GPI, plus a lack of binding of monovalent aPL Fab' 
fragments, confirm that many aPL are intrinsically low affinity antibodies for which 
bivalent binding is required upon clustered B2 GPI.
It is important to recognise that the ideas of cryptic epitopes and high-density binding are 
not mutually exclusive. A particular aPL may bind preferentially to a cryptic epitope 
exposed when B2 GPI binds to an irradiated plate but may also be capable of binding to 
native B2 GPI when presented at sufficiently high density. Overall, however, the evidence in 
favour of the importance of binding to non-cryptic epitopes currently seems to be the most 
persuasive, because it has been obtained using a wider range of techniques and antibodies.
1.6.5 Which domains of 6 2 GPI contain major epitopes for aPL?
During the last eight years evidence has been published demonstrating specificity of aPL 
for epitopes on all five domains of B2 GPI which is summarised in Table 1.5 and discussed 
in light of the recently discovered three-dimensional crystal structure of B2 GPI. Lack of 
patient stratification and control groups plus limited statistical power is commonplace 
amongst these studies, making it difficult to decide whether the conclusions are likely to be 
applicable to the majority of patients with APS.
1.6.5.1 Domain V
It is now generally accepted that domain V contains the major site of binding to PL, but it is 
much less clear whether that domain interacts with aPL .
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Author (reference) Method Origin o f  aJPL Original conclusion Reassessment
Hunt et al. (1993) 
Hunt & Krillis (1994)
Wang et al. (1995)
Sheng et al. (1996)
Igarashi et al. (1996)
George et al. (1998c)
Blank et al. (1999a)
Iverson et al. (1998) 
McNeeley et al.
(2001)
Guerin et al. (2000) 
Sheng et al. (2001) 
Reddel et al. (2000)
Plasmin cleaved 132GPI 
D V peptides
D V peptides
Mutagenesis Lys - 284, 286,
287
DM
DM
Hexapeptide phage display
DM -  glyhis6 tag 
SPR, DM
Elastase & Protease 
cleavage B2GPI
LA activity domain specific 
aPL
mutagenesis D I B2GPI
PAPSJ sera 
SLE & PAPS* sera
PAPS* maPL
APS*§ sera
PAPS* maPL & Murine 
maPL
PAPS & SAPS*f sera, 
murine maPL 
PAPS* & normal sera
PAPS & SAPS*t sera 
APS*§ sera
APSJ§ sera 
murine maPL
APS*§ & aPL +ve sera, 
murine maPL
D V -  PL binding & cofactor activity 
D V -  PL binding (CKNKEKKC) & 
aPL binding (intact Lys 317-Thr 318)
D V -  PL binding (CKNKEKKC) & 
aPL binding (? exact site)
Lys - 284, 286, 287 critical for PL 
binding
D V -  PL binding 
D I-IV, favoured D IV aPL binding 
D V -  PL binding 
D I-IV aPL binding 
D I-II interlinker, D III, D IV contain 
epitopes for aPL binding 
D I binds aPL 
D I binding in 80% sera
D V cleavage lost aPL binding 91% sera 
D I cleavage 50% reduction in aPL 
binding 81% sera
D I binding aPL prolong dRVVT & KCT 
> than -
D II binding aPL prolong KCT 
D 1 binds aPL
Crystal structure reveals D V to be 
intimately involved in PL binding
D V deleted mutants do bind aPL
Crystal structure reveals domain III and 
IV to be heavily glycosylated.
D IV produced from insect cells may be 
less glycosylated than human B2GPI
Crystal structure reveals D I and II to be 
the most accessible domains for aPL 
binding.
Most persuasive evidence for D I
Pathogenic aPL contain clusters o f  
positively charged residues. In D 1 there 
is a surface exposed pocket o f  negative 
charge
Table 1.5 Summary of experimental data linking various domains of B2GPI with aPL binding
Abbreviations:- maPL -  monoclonal aPL; D -  Domain; KCT -  kaolin cephalin clotting time; SPR -  surface plasmon resonance; for others see text. 
Symbols:- * - APS classification criteria not applied; f - APS secondary to SLE; J - APS classification criteria applied; § - no distinction primary or 
secondary APS.
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The lysine-rich sequence Cys 281-Lys-Asn-Lys-Glu-Lys-Lys-Cys-288 (CKNKEKKC) is 
particularly crucial in binding to PL. B2GPI loses its ability to bind PL, or to act as a 
cofactor for aPL/PL binding, when the number of lysines in this region is reduced by 
mutagenesis (Sheng et al., 1996). Peptides containing the CKNKEKKC sequence inhibit 
binding of purified aPL in a CL-ELISA. The importance of domain V in binding to PL is 
underlined by the finding that a preparation of B2GPI cleaved between residues Lys-317 
and Thr-318 in domain V completely lost its ability to bind negatively charged PL and to 
act as a cofactor for affinity purified aPL from “autoimmune patients” (Hunt et al., 1993). It 
was suggested that this cleavage also reduced the binding of B2GPI to polyclonal human 
aPL (Hunt and Krilis, 1994), but mutations in the CKNKEKKC sequence did not affect this 
binding (Sheng et al., 1996). These data gave conflicting messages as to whether domain V 
is important in the interaction between B2GPI and aPL.
Gharavi and colleagues demonstrated that immunisation of mice with purified whole 
human or bovine B2GPI induced aPL production (Gharavi et al., 1992). Sub sequent work by 
the same group has implicated the domain V CKNKEKKC sequence in this process. aPL 
were induced in mice by immunisation with a synthetic peptide (called GDKV) spanning 
Gly274-Cys288 of domain V in B2 GPI. Mice immunised with the peptide and carrier 
protein complexes produced significantly higher levels of aPL than those mice immunised 
with either the peptide or carrier protein alone. The GDKV induced maPL were shown to 
enhance thrombus formation and increase leucocyte adherence to EC in a mouse model 
(Gharavi et al., 1999). Furthermore, this group have recently shown that pathogenic aPL 
can be generated by immunising mice with a peptide, derived from human 
cytomegalovirus, that resembles the GDKV peptide (Gharavi et al., 2002).
However, consideration of the crystal structure of B2GPI reveals that the sequence Ser-311 - 
Lys-317 forms a hydrophobic loop acting as a membrane stabiliser for the positively 
charged CKNKEKKC PL binding region. This region is so closely apposed to the PL 
membrane that it is unlikely to be a major epitope for binding to aPL under physiological 
conditions. Although previous studies suggested that regions of domain V outside 
CKNKEKKC might be responsible for binding of aPL (Hunt and Krilis, 1994; Wang et al., 
1995), this now seems unlikely. Those regions would be sterically hindered from 
interaction with aPL, because they are not surface-exposed, or because they are in close
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proximity to the PL membrane bound to domain V. In light of the crystal structure it would 
seem more likely for the aPL binding site to be contained in another domain.
1.6.5.2 Domain IV
Two groups have studied mutant forms of B2 GPI in which various domains were deleted 
and expressed in insect cells (Igarashi et al., 1996; George et al., 1998c). Both groups 
confirmed that domain (D) V was essential for binding to CL whilst binding to human or 
murine monoclonal aPL took place in the absence of DV. The mutant DI-IV bound the 
murine antibody WB-CAL-1 better than either whole B2 GPI or mutant DI-III. Unusually, 
WB CAL-1 was able to bind to DI-IV upon plain polystyrene plates so this mutant was 
thought to have undergone a conformational change following the deletion of domain V 
thus exposing an epitope for aPL. It was concluded that domain IV contains a major epitope 
for binding of these aPL. Interestingly the authors did not demonstrate binding of WB 
CAL-1 to any domain deleted mutant (DM) lacking DI and conversely DM peptides 
containing only DI or DI-II were not made or tested. They concluded that autoimmune aPL 
recognise an epitope in domain IV of B2 GPI (George et al., 1998c). This conclusion would 
have been more compelling if DII-V, DIII-V and DIV-V had been shown to support aPL 
binding.
Pursuing this hypothesis, another group produced four mutant forms of B2 GPI in which 
point mutations were made in domain IV (Koike et al., 2000). The binding of human maPL 
and polyclonal sera from 30 anti-l^GPI antibody positive APS serum samples to these 
mutant forms of B2 GPI immobilised upon microtitre plates was greatly reduced in 
comparison to wild-type B2 GPI. However, it has subsequently been shown (Iverson et al., 
2002) that these mutant forms of B2 GPI do bind aPL in the fluid phase and that the results 
are critically dependent upon the type of ELISA plate used. Therefore the mutations in 
domain IV alter the interaction of B2 GPI with particular ELISA plates rather than affecting 
an epitope for binding of aPL. Thus, like domain V, experimental evidence currently does 
not favour the idea that domain IV contains the major epitopes for the interaction between 
B2 GPI and aPL
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1.6.5.3 Domain III and Domain I-II linker region
Using a phage display library three peptides were identified that react specifically with the 
three human IgM B2 GPI dependent maPL ILA-1, ILA-3 and H3 (Blank et al., 1999a). 
These aPL were isolated from a patient with APS and had previously been shown to cause 
EC activation and induce increased fetal resorption, thrombocytopenia and prolonged aPTT 
in pregnant BALB/c mice (George et al., 1998b). The peptides bore sequence homology to 
regions of B2 GPI in the interlinker of domain I-II, domain IV and domain III respectively. 
All three peptides specifically inhibited in-vitro and in-vivo biological functions of the 
corresponding maPL. Exposure of EC to ILA-1, ILA-3 and H3 in the presence of their 
corresponding peptides inhibited in-vitro EC activation. In-vivo, the ability of each 
antibody to induce features of APS in pregnant BALB/c mice was reduced if the 
corresponding specific peptide was administered post mAb (Blank et al., 1999a).
When affinity purified polyclonal B2 GPI dependent aPL isolated from patients with APS 
were examined, different fractions of antibodies were identified that specifically recognise 
each peptide. Sera from only 10 of 43 patients, however, were found to contain Abs to one, 
two or all three of the peptides. The amounts of the peptide specific anti-l^GPI fractions 
varied between 0.4 and 43% of the total anti-l^GPI Abs identified in each of these 10 
patients. The majority of the human anti-l^GPI must therefore bind to epitopes other than 
these peptides (Blank et al., 1999a).
The crystal structure shows that domains III and IV are both heavily glycosylated in native 
B2 GPI. Insect cells however, do not glycosylate proteins the same way as mammalian cells. 
Recombinant whole B2 GPI expressed in insect cells has an estimated molecular mass of 
43kD as opposed to 50kD for native B2 GPI purified from human serum, presumably due to 
differences in the oligosaccharide chains attached by glycosylation (Igarashi et al., 1996; 
George et al., 1998c). Hence domain IV in B2GPI produced from insect cells may be more 
accessible for binding to aPL than domain IV in human B2 GPI in vivo. This is an important 
caveat in interpreting data on domains III and IV derived from experiments using the insect 
expression system.
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1.6.5.4 Domain I
Iverson et al. (1998) studied binding of DMs to affinity purified polyclonal human aPL 
from 11 patients (9 of whom had APS). All 11 aPL bound strongly to DI-IV with 
significant but more variable binding to other DMs containing domain I. In contrast the 
DMs in which domain I had been deleted showed little or no specific binding to aPL. In 
the fluid phase, binding of aPL from all 11 patients to B2GPI plates was inhibited by DMs 
containing domain I, but not by DMs which lacked domain I (Iverson et al., 1998). These 
results support the presence of an epitope for aPL residing in a surface exposed region of 
domain I, which does not need to be revealed by a conformational change.
Iverson et al. (1998), Igarashi et al. (1996) and George et al. (1998b) all studied similar 
DMs produced from the same insect expression system. Each showed that the DI-IV mutant 
bound aPL better than any other DM containing DIV. Binding to the DI-III mutant was 
shown by Iverson et al. (1998) and Igarashi et al. (1996), but not by George et al. (1998b). 
If domain IV does contain the major epitope for aPL then the mutants DII-V, DIII-V, and 
DIV-V would be expected to bind aPL to variable degrees. These mutants were either not 
examined (Igarashi et al., 1996; George et al., 1998c), or found not to bind aPL (Iverson et 
al., 1998). Thus the data of Iverson et al. (1998) complements and extends that of the other 
two groups and clearly implicates domain I in the binding of aPL particularly as they found 
that the DI-II and DI mutants both bound aPL.
DM may be subject to misfolding; hence failure of an aPL to bind to a DM may occur 
because an epitope has been hidden rather than deleted. Single point mutations of specific 
nucleotides in the DNA encoding B2 GPI may be less likely to alter protein structure. Reddel 
et al. (2000) have studied DMs and whole l^GPI with single point mutations in domain I. 
They demonstrated that monoclonal murine 132GPI-dependent aPL and polyclonal aPL from 
18 out of 21 human sera did not bind to DMs lacking domain I. In addition charge altering 
mutations in domain I of Gly to Glu at position 40 and Arg to Gly at position 43 both lead 
to a decreased binding to the majority of sera tested. The charge conserving mutation Thr to 
Ala at position 50 did not show a consistent pattern of altered binding to these sera (Reddel 
et al., 2 0 0 0 ).
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Subsequently the Arg to Gly mutation at position 43 has been shown to lead to a reduction 
in binding to maPL derived from patients with APS (Iverson et al., 2002). These results 
were reproduced in the solid and fluid phase regardless of the type of ELISA plate used, 
implying that this mutation is really altering an epitope bound by these maPL. In contrast 
reduced binding with DIV point mutants was only seen when they were coated on certain 
types of plate.
Serum samples from a large cohort of 106 patients with APS have been tested for binding 
to 8 2 GPI by SPR. These samples revealed a significantly greater interaction with 
immobilised native 6 2 GPI in comparison with a DII-V mutant, lacking domain I. Eighty 
percent of the patient samples exhibited a marked preference for whole 8 2 GPI containing 
domain I with almost half of the total patient samples showing an almost complete lack of 
binding to the DII-V mutant (McNeeley et al., 2001).
Overall, evidence that domain I contains the major epitopes is more robust and more 
convincing than that for the other domains. This evidence is supported by consideration of 
the crystal structure.
1.6.6 Consideration of the crystal structure of B2 GPI
The crystal structure (Bouma et al., 1999; Schwarzenbacher et al., 1999) shows a J shaped 
molecule, with domain V interacting with PL. The solution structure of 8 2GPI (Hammel et 
al., 2002) however, reveals an S-shaped model of human B2 GPI, in which additional 
carbohydrate residues missing from the crystal structure were modelled and the angle 
between domain I and domain II was rotated. The corrections evident in the solution 
structure do not alter the conclusions described below.
Domain V is seen to be intimately involved in binding anionic PL or certain synthetic 
surfaces and domain IV and III are both heavily glycosylated so even surface exposed 
residues are shielded by the glycan moieties. Thus the most easily accessible domains for 
aPL binding would appear to be domain I and II. A detailed examination of surface exposed 
residues in domain I reveals a region that is rich in negatively charged residues. This region 
contains two Asp residues at positions 8  and 9 and three Glu residues at positions 23, 26 
and 27, which are in close approximation to each other upon the surface of the molecule
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with only one salt bridge being formed from Glu 26 to a Lys at position 19. Such a pocket 
of negative charge may be of significance because sequence analysis of pathogenic aPL has 
shown a clustering of positively charged arginine and lysine residues in their antigen 
binding regions (Giles et al., 2003b).
1.7 ORGANISATION AND EXPRESSION OF IMMUNOGLOBULIN GENES 
Consideration of how aPL may cause the APS, therefore shows that there are a number of 
possible mechanisms, described in section 1.5. Not all aPL however, are equally capable of 
causing pathogenesis by these mechanisms. Evidence from clinical and laboratory studies 
identifies those antibodies which bind negatively charged PL and l^GPI as being 
particularly important in pathogenesis of APS. Within I^GPI domain I is a site of 
particularly important epitopes of which the surface exposed pocket of negative charge, 
described in section 1 .6 .6 , may be one.
The work described in this thesis aims to investigate the structural characteristics of aPL 
which confer these important binding properties. To do this, it is first necessary to consider 
the basic structure of the genes encoding the antibody binding site
1.7.1 Immunoglobulin gene rearrangement in B cells
In the mammalian immune system the total number of antibody specificities (known as the 
repertoire) available to an individual is approximately 108 to 1011 (Berek and Milstein, 
1988). Before sequence analysis of Ig genes was possible there were two main theories as 
to the origin of Ig diversity. The germline theory held that there is a separate gene for each 
different Ig chain and that the antibody repertoire is largely inherited. In contrast somatic 
diversification theories proposed that the observed repertoire is generated from a limited 
number of inherited V region sequences that undergo alteration within a B cell during the 
individual’s lifetime. In 1965 elements of both theories were combined (Dreyer and 
Bennett, 1965) and it was proposed that each chain of the Ig molecule would be encoded by 
combining one of a small group of C region genes with a V region gene chosen from a 
much larger and more diverse population.
Sequence analysis of cloned mouse Wx (Tonegawa et al., 1977; Tonegawa et al., 1978), VK 
(Sakano et al., 1979; Schilling et al., 1980) and Vr (Schilling et al., 1980) showed that the
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variable region of the H chain is encoded by three segments in the order V-D-J (variable- 
diversity-joining) whilst the L chain is encoded by two fused gene segments in the order V- 
J (variable-joining).
In L chains the V gene segment encodes most of the V domain apart from most of FR4 (up 
to 13 amino acids) which is encoded by the J gene segment. Similarly in H chains most of 
the V domain is encoded by the V gene segment apart from most of CDR3 which is 
encoded by the D and the J segments and therefore has the potential to be more variable 
than the other regions. The J segment of the H chain also encodes FR4. The entire C region 
of each chain is encoded by the C gene (Tonegawa, 1983).
These Ig gene segments undergo a process of rearrangement in pre-B cells (early B cell 
precursors that do not express functional membrane bound Ig) to produce complete Ig H 
and L chains as described above. DNA rearrangements are guided by conserved noncoding 
DNA sequences which consist of a conserved palindromic heptamer (5'CACTGTG3') 
which is always contiguous with the coding sequence and a conserved nonamer 
(5'GGTTTTTGT3'). Separating the heptamer and nonamer is a nonconserved region 
known as the spacer which is either 12 or 23 nucleotides long. One heptamer-spacer- 
nonamer unit is located 3' to each V gene segment, 5' to each J gene segment and on both 
sides of the D gene segment (Tonegawa, 1983). The spacer varies in sequence but its 
conserved length corresponds to one or two turns of the DNA double helix (Early et al., 
1980). The heptamer-nonamer sequences are called recombination signal sequences (RSS) 
since they directly flank each germline V, D and J segment and seem to signal exactly 
where the germline DNA should be broken during rearrangement.
All VK, h  (Sakano et al., 1979; Tonegawa, 1983) and D (Kurosawa and Tonegawa, 1982) 
spacers are 1 2 bp long whilst almost all V*., JK, Vh and Jh spacers are 23bp long (Sakano et 
al., 1979; Tonegawa, 1983). Recombination only occurs between gene segments located on 
the same chromosome and generally follows the rule that only a gene segment flanked by a 
RSS with a 12bp spacer can be.joined to one flanked by a 23bp spacer. This phenomenon is 
known as the 12/23 rule and explains why some arrangements are allowed (e.g. V-D, D-J, 
V ;Ja.) whilst others are not (e.g. V - V  or V h J h ) (Early et al., 1980). This process o f
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rearrangement was first described in mice and subsequently confirmed in humans when the 
first sequences of Vh (Matthyssens and Rabbitts, 1980) Dh (Siebenlist et al., 1981), JH 
(Ravetch et al., 1981), VK (Bentley and Rabbits, 1980), V*, (Brockly et al., 1989), 
(Vasicek and Leder, 1990) and JK (Hieter et al., 1980) were cloned.
1.7.2 The mechanism of immunoglobulin variable region DNA rearrangements
V(D)J recombination is a multi-step process involving a complex of enzymes termed V(D)J 
recombinase as well as the products of two lymphoid specific genes RAG-1 and RAG-2 
(recombination activating genes) and the enzyme terminal deoxynucleotidyl transferase 
(Tdt) (Alt et al., 1987). In brief V(D)J recombinases in conjunction with RAG proteins 
recognise the RSS and catalyse the formation of double strand breaks between both of the 
coding region/heptamer junctions. The DNA ends are held tightly in a complex by the RAG 
proteins and other associated DNA repair enzymes until the ligation of the coding 
sequences with each other and signal sequences with each other takes place. The two RSS 
are precisely joined to form the signal joint. Coding joint formation however, is more 
complex and contributes to antibody diversity. This junctional diversity at V-J and V-D-J 
coding joints is generated by a number of mechanisms including the removal of nucleotides 
(by exonuclease activity) and the addition of template encoded P-region nucleotides by 
DNA repair enzymes and, in the H chain only, non-template encoded N-region nucleotides 
(by TdT) (Alt et al., 1987).
As well as contributing to antibody diversity, imprecision in the joining of signal sequences 
may give rise to non-productive rearrangements whereby the triplet reading frame for 
translation is disrupted. The resulting VJ or VDJ unit will contain stop codons which 
interrupt translation. Gene segments which are joined in phase maintain triplet reading 
frames thus leading to productive rearrangements of VJ or VDJ units that can be translated 
into a complete region polypeptide. If in-phase rearrangements for both H and L chains are 
not produced the B cell will die by apoptosis (Schatz et al., 1992). Even though B cells are 
diploid they will only express the rearranged H and L chain genes from one chromosome. 
This process is called allelic exclusion and ensures that functional B cells never contain 
more than one functional V h D h J h  and one V l J l-  The recombination machinery is thought
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to be turned off once productive VhDhJh and VlJl units have been produced to ensure that 
the H and L chain genes on the homologous chromosomes are not expressed.
One model to account for allelic exclusion suggests that once a productive rearrangement is 
attained its encoded protein is expressed and acts as a signal for the recombination 
machinery to be turned off (Alt et al., 1987). The presence of the H chain signals for H 
chain recombination to stop and for k  chain recombination to start. If a productive k  
rearrangement is made, a k  chain is produced and serves to switch off L chain 
recombination. If the k  rearrangement is non-productive for both k  alleles, rearrangement 
of the X chain begins. If neither X allele rearranges productively, the B cell dies by 
apoptosis (Alt et al., 1987). Some B cells which have made productive H and L chain 
rearrangements will nevertheless rearrange a second light chain locus or make a second 
rearrangement of the active light chain locus such that the previously productive genes are 
deleted (Prak and Weigert, 1995). This process is called receptor editing (the receptors 
being the surface IgG molecules on the B cell surface which bind to antigen) and allows a 
B cell to quickly change the sequence hence binding properties of an antibody. The H chain 
of an antibody may be replaced by a process analogous to receptor editing called receptor 
revision (Nemazee and Weigert, 2000).
After antigenic stimulation of a B cell, the H chain DNA can undergo a further process of 
rearrangement in which the VhDhJh unit can combine with any CH gene segment. The CH 
gene segments are organised into a series of coding exons and non-coding introns. Each 
exon encodes a separate domain of the H chain constant region. Conservation of important 
biological effector functions is maintained by the limited numbers of Ch gene segments. 
The germline gene segments are arranged in order p, 5, y, 8  and a. In an antibody the Cp is 
the first constant region gene to be expressed (as IgM) but can be replaced by class 
switching to downstream constant regions (e.g. IgG, IgD, IgE or IgA) (Goldsby et al., 
2000). This phenomenon allows clonally derived B cells to maintain the same V region 
specificity in association with different H chain constant regions specifying different 
effector functions (Alt et al., 1987).
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1.7.3 The generation of diversity in immunoglobulins
The availability of a relatively large number of potentially functional variable region genes 
for recombination contributes to the diversity of possible antibody sequences (and therefore 
possible antigen binding sites) that can be produced. Diversity is amplified by imprecision 
at the joining of Vl-Jl, Vh-Dh and Dh-Jh segments with deletion or insertion of nucleotides 
(Tonegawa, 1983). After rearrangement of Vh, Dh and Jh genes to produce a functional 
heavy chain and of either VK and JK or V*. and J?, genes to produce a functional light chain, 
a B lymphocyte begins to secrete IgM antibody. By entering a germinal centre and 
recruiting T cell help, the B cell may then alter the isotype of the antibody produced by 
class switching and alter the sequence of the Vh and Vl domains by somatic 
hypermutation.
1.7.4 Rearranged V genes are further diversified by somatic mutation
During an immune response, B cells migrate to the germinal centres where antigen is 
presented to them in the presence of Th cells. Presentation of antigen specific to a B cell 
receptor will lead to proliferation (clonal expansion) and differentiation into plasma cells 
and memory B cells. Within the germinal centres B cells undergo somatic hypermutation, 
which leads to the alteration of a rearranged Vh or Vl sequence by introduction of 
nucleotide changes during the lifetime of a B cell which are subsequently passed on to all 
clonal descendants of that B cell. This process operates only in B lymphocytes and has been 
shown to be largely confined to the V domain, rarely being found in the C domain (Berek 
and Milstein, 1988; Storb, 1996). The observed mutation rate in these V regions is 10' 3 to 
1 0 ' 4  per nucleotide per cell division.
Each mutation may be either silent ((S) leading to no change in amino acid sequence) or 
replacement ((R) leading to a change in amino acid sequence). R mutations may increase, 
decrease or fail to alter affinity of the antibody for antigen. Those somatic mutations that 
increase this affinity play a key role in the production of the secondary repertoire. B cells 
expressing higher affinity IgG on their surface will be selected by limited amounts of 
antigen and stimulated to divide faster hence leading to clonal expansion of these 
somatically mutated B cells (Wagner and Neuberger, 1996). The presence of antigen leads 
to a selective pressure that favours the accumulation of particular R mutations in the CDRs, 
because these are the areas of the sequence where such mutations can exert the greatest
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positive effects on binding affinity (Shlomchik et al., 1987). Thus R:S ratios tend to be 
higher in CDRs than in FRs for antibodies which have been subject to this antigen driven 
process (Shlomchik et al., 1987).
A number of authors have noted, however, that codon usage is different in CDRs and FRs 
and this means that the inherent tendency for a mutation to be R rather than S is higher in 
CDRs (Chang and Casali, 1994). Statistical methods have been designed which enable the 
distribution of R and S mutations to be analysed in a way which allows for this inherent 
difference between CDRs and FRs. The binomial method of Chang and Casali (1994) has 
been used widely, but has been superseded by a more accurate cumulative multinomial 
method. This new statistical method (Lossos et al., 2000) is more accurate since, unlike the 
binomial method, it takes into account all four possible outcomes of a particular mutation 
i.e. R and S mutations in the CDRs and/or FRs of the gene. Calculations using the 
multinomial method can be made using the JAVA applet provided by Lossos et al. at 
http://www-stat.stanford.edu/immunoglobin. For instance, a low p value (p<0.05) obtained 
by the multinomial method suggests that the observed distribution of R and S mutations is 
very unlikely to have arisen by chance alone and is likely to have arisen as a result of 
antigen selection of mutations. In practice antigen drive favours an excess of R mutations in 
the CDRs but an excess of S mutations and scarcity of R mutations in FRs. Therefore low p 
values may be obtained for FRs as well as CDRs.
The mutations introduced by somatic hypermutation of variable region sequences are 
predominantly single nucleotide substitutions (Ignatovich et al., 1997).Somatic insertions 
and deletions occur to a lesser degree and would appear to be closely linked to nucleotide 
substitutions and probably created by the same enzymatic machinery (de Wildt et al., 
1999b). Somatic mutations are limited to the V region of the Ig gene and its proximate 
flanks covering a variable stretch of 1-2 Kb from the 5' end of the transcribed region 
(Storb, 1996). Activation of V region mutations generally requires T cell help, is restricted 
to a brief period in B cell development and targeted to specific residues (hot spots) with 
characteristic motifs such as RGYW (R = purine, Y — pyrimidine, W = A/T). Such motifs 
have an intrinsic mutability which does not depend upon antigen selection, have no strand 
bias and are concentrated within the CDR's (Domer et al., 1998). Somatic mutations spread 
diversity to regions at the periphery of the antigen binding site that are conserved in the
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primary repertoire so the pattern of sequence diversity of the mature (secondary) repertoire 
is more evenly distributed across the entire antigen binding site (Tomlinson et al., 1996a).
The precise molecular mechanism responsible for somatic hypermutation is not fully 
understood. In order to undergo somatic mutation the Ig gene must be transcriptionally 
active ((Peters and Storb, 1996; Fukita et a l, 1998; Neuberger et al., 1998; Storb, 1998). 
The DNA mismatch repair system, as well as a newly described DNA polymerase (pol p), 
has been implicated in somatic mutation (Cascalho et al., 1998; Wiesendanger et al., 1998; 
Dominguez et al., 2000). More recently a novel cytidine deaminase, expressed only in 
germinal centre B cells, has been shown to play a crucial role in both somatic mutation and 
class switch recombination (Muramatsu et al., 2000; Revy et al., 2000). DNA double strand 
breaks have also been proposed as the initiating event and thence the focus for error prone 
DNA repair in creating somatic mutations (Papavasiliou and Schatz, 2000).
1.7.5 Human V region gene repertoire
By comparing the Vh and Vl sequences of an antibody with those of the germline genes 
from which they were derived, the positions and nature (R or S) of the somatic mutations 
can be identified. To do this accurately, one must be confident that the assignment of 
germline genes is correct. Such confident assignment is now feasible for human antibodies, 
because all the genes in the human heavy, k  and X loci have been identified and mapped 
(Matsuda et al., 1993; Schable and Zachau, 1993; Cook et al., 1994; Williams et al., 1996). 
Furthermore, although allelic polymorphism occurs in some VH, VK and V^ genes, it can be 
excluded as a cause for most differences between antibody sequences and germline genes, 
because it is possible to use specialist software to screen databases of all known alleles to 
find the closest possible germline match for any antibody. It is unlikely that large numbers 
of undiscovered alleles exist. New polymorphisms have been reported for only 
approximately 15% of all Vh, Vk and V  ^genes over the past five years and most of these 
are single nucleotide changes only (Tomlinson personal communication).
1.7.6 Genetics of the Ig V germline gene repertoire
In humans, functional immunoglobulin heavy, kappa, and lambda genes are found on 
chromosomes 14, 2 and 22 respectively. All functional V genes have now been mapped to
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these three chromosomes (Schable and Zachau, 1993; Cook et al., 1994; Williams et al., 
1996).
1.7.7 Human heavy chain Ig germline gene locus
Each heavy chain locus contains approximately 50 functional VH (Matsuda et al., 1993; 
Cook et al., 1994), 30 Dh (Corbett et al., 1997) and 6  Jh genes (Ravetch et al., 1981). The 
genes in each locus are grouped in families on the basis of sequence homology.
1.7.7.1 Human Vh locus
Analysis of the human Ig Vh locus at chromosome 14q23.3 was completed in 1994 (Cook 
et al., 1994). The human germline VH repertoire consists of approximately 50 functional VH 
gene segments spanning 1 lOOkb upstream of the Jh segments. By definition, functional VH 
segments must contain an open reading frame (ORF) and must have been observed in 
functional VDJ rearrangements. They are interspersed among an equivalent number of 
pseudogenes (Tomlinson et al., 1992), which are nucleotide sequences that are stable 
components of the genome but are incapable of being expressed. Human Vh segments can 
be divided into seven families, Vh 1-7 on the basis of sequence homology, which are 
interspersed throughout the locus. Each family member shares 80% homology at the 
nucleotide sequence level and some families are more highly related (VH4) than others, 
which are more divergent (VH5). Some Vh families are larger than others, with the largest 
contribution made by the Vh3, Vh4 and VH1 families (Cook and Tomlinson, 1995).
Twenty four human VH segments have also been mapped to chromosomes 15 and 16. 
However, since these chromosomes lack Dh, Jh and Ch segments they are unlikely to be 
functional. Expression of Vh segments on chromosomes 15 and 16 would require 
interchromosomal recombination, which has not been demonstrated in B cells (Matsuda et 
al., 1993).
The exact dimensions of the Vh locus and number of functional segments vary between 
individuals. Two types of polymorphism affect the germline repertoire: the insertion or 
deletion of Vh segments and the occurrence of different alleles of the same segment. Allelic 
polymorphism is limited. Insertion/deletion polymorphism however, is fairly common and 
75% of people have an extra group of genes located between segments 3-30 and 4-31
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which are listed in VBASE, a sequence directory containing the complete human Ig gene 
repertoire that is constantly being updated with new alleles (Tomlinson et al., 1996b).
1.7.7.2 Human Dh locus
The complete nucleotide sequence of the human Ig D segment locus on chromosome 
14q32.3 was determined by Corbett et al. (1997). They identified a total of 27 D segments 
which could be grouped into seven families based on sequence homology. Previously, 
conventional VDJ recombination alone had not been thought sufficient to explain the 
extreme diversity found in VHCDR3. Various hypotheses had been proposed to explain this 
extensive versatility such as the DD recombination (regardless of the 12/23 rule) (Sanz, 
1991), occurrence of DIR segments (longer sequences interspersed amongst the functional 
Dh segments) (Ichihara et al., 1988), inverted D segments, or the use of minor D segments 
found on chromosome 15 (Cook and Tomlinson, 1995). A systematic analysis however to 
compare the complete sequence of the human Ig D segment locus with a database of 
rearranged sequences to identify all the germline D segments and any other sequences that 
contribute to the extreme diversity of VhCDR3 found no evidence to suggest that any of the 
above mechanisms took place (Corbett et al., 1997). The authors felt that conventional VDJ 
recombination which obeys the 12/23 rule was sufficient to explain the wealth of lengths 
and sequences of VhCDR3. The fact that they found no sequences that matched DIR genes 
or DD fusions may have arisen due to the stringent criteria applied whereby at least ten 
consecutive nucleotides of identity were generally required to confidently assign a D 
segment to its germline match, depending upon the length of CDR3. Previous studies have 
taken only five nucleotides of identity with one mismatch as their minimum cut off for 
identifying a germline sequence (Brezinschek et al., 1995).
1.7.7.3 Human Jh locus
The human JH locus contains nine J-like gene segments, six of which appear to be 
functional and account for most of the known human H chain amino acid sequences whilst 
three are pseudogenes (Ravetch et al., 1981).
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1.7.8 Human light chain immunoglobulin germline genes
1.7.8.1 Human kappa locus
The kappa locus has been mapped to chromosome 2p 11-12 and contains approximately 40 
functional VK (Schable and Zachau, 1993) and five JK genes with no D gene segments
(Schable and Zachau, 1993). There are seven VK families, the members of which are
interspersed throughout the locus amongst 36 pseudogenes. Additional VK genes are located 
upon chromosomes 1 and 22 but these are pseudogenes. Allelic polymorphism is rare and 
where present, alleles differ by only one or two nucleotides (Schable and Zachau, 1993). 
There is only one CK gene segment so no alternative isotypes of the k  chain exist.
1.7.8.2 Human lambda locus
Sequence analysis of the human lambda locus on chromosome 22q 11.2 has identified 30 
functional V*, (Williams et al., 1996) and four functional H genes (Vasicek and Leder, 
1990). Ten families exist, spread amongst three distinct gene clusters. Some families 
are larger than others and the larger V^l, 2 and 3 families are more commonly expressed in 
humans. Similarly to the human Vh and VK loci, allelic polymorphism is relatively rare and 
where present, alleles differ by only one or two nucleotides (Williams et al., 1996).
The Cx locus, also located upon chromosome 22, contains seven different genes of which 
four are functional and three are pseudogenes. As a result X chains like heavy chains have 
several isotypes. Each of the four functional genes is preceded by a single Ja. gene 
segment of which J* 2  and J^3 are identical therefore mAb sequences can include only one 
of three different Ja. sequences (Vasicek and Leder, 1990).
1.8 SEQUENCE ANALYSIS OF MONOCLONAL ANTIBODIES
1.8.1 Interpretation of antibody sequences analysis
An understanding of the genetic origin of Ig sequences as determined in the previous 
sections, enable us to analyse the sequence of any antibody molecules by asking the 
following questions. Which were the genes of origin? What is the extent of somatic 
hypermutation and is it likely to have been driven by antigen? Are there sequence motifs 
common to antibodies which share particular binding properties? Do these sequence motifs
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correspond with sites of somatic hypermutation and with the predicted contact sites of the 
antibody?
Which were the genes of origin? In analysing the sequences of the VH and VL domains of 
a particular antibody, therefore, it is possible to deduce which of the available genes in the 
repertoire have been used to encode these domains and the extent to which somatic 
mutations and modification at the junctions has occurred. By repeating this analysis for a 
large number of different Ab such as aPL, it would theoretically be possible to deduce 
whether particular genes are preferentially rearranged to create PL binding sites. To reach 
this conclusion, however, it is vital to recognise that each locus shows an intrinsic bias 
towards the rearrangement of certain genes. In other words, some Vh, Vk and V*, genes are 
more likely to be used to encode antibodies than others, regardless of the specificities of the 
antibodies produced. This bias is shaped by intrinsic genetic factors as it is seen in both 
productive and non-productive gene rearrangements (Brezinschek et al., 1997; Ignatovich 
et a l, 1997; Ignatovich et al., 1999). Measurement of the frequency of expression of 
different Vh/Vl pairs has demonstrated that preferential pairing of specific genes or 
families does not occur. The most likely finding in a single B cell is the expression of a 
commonly rearranged Vh gene together with a commonly rearranged VL gene (Brezinschek 
et al., 1998; de Wildt et al., 1999a). The pattern of VH/VL gene usage and pairing in 
peripheral blood lymphocytes (PBL) is not significantly different in patients with SLE 
compared to healthy people (de Wildt et al., 2000). Investigations of Vh/Vl pairing in 
patients with primary APS have not been reported.
What is the extent of somatic hypermutation and is it likely to have been driven by 
antigen? Having identified the positions of R and S mutations within the VH and Vl 
sequences, it is possible to analyse the distribution of these mutations using the 
mulitinomial method (Lossos et al., 2000).
Are there sequence motifs common to antibodies which share particular binding 
properties? In antibodies which seem likely to have been modified by antigen driven 
selection of mutations, it is possible to identify particular sequence features which result 
from these modifications and which may therefore enhance binding to the driving antigen.
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Do these sequence motifs correspond with sites of somatic hypermutation and with the 
predicted contact sites of the antibody? Analysis of the known crystal structures of 26 
different Ag-Ab complexes has shown that certain residues within CDRs of the H and L 
chains are more likely than others to contact antigens (MacCallum et al., 1996). For 
example, antigens are much more likely to contact residues towards the beginning of heavy 
chain CDR2 than those towards the end of that CDR. These authors suggested that analyses 
of CDR AA composition could be much more informative when the likelihood that an AA 
at a particular position will be involved in antigen contact is taken into account.
1.8.2 Sequence analysis of anti-DNA antibodies
Sequence analysis of the antigen combining sites of monoclonal Ab serves as a powerful 
tool to gain greater understanding of features at the molecular level which serve to 
distinguish pathogenic from non-pathogenic Ab. This form of analysis has been applied to 
sequences of both murine and human anti-DNA Ab. An extensive review of the sequences 
of over 300 murine monoclonal anti-DNA Abs from many different models of SLE, 
revealed that certain Vh and VK genes were used preferentially, and some pairings of these 
genes were more common than others (Radic and Weigert, 1994).
The antigen driven accumulation of somatic mutations has also been found to be important 
in determining the ability of murine anti-DNA Ab to bind dsDNA. Marion et al. (1992) 
analysed the sequences of 117 monoclonal anti-DNA antibodies from 11 different (NZB x 
NZW)Fi mice. In some cases, IgG produced by a single mouse were derived from the same 
expanded B cell clone whereas the majority of IgM were not. Clonally related IgM and IgG 
hybridomas were obtained from two individual mice. Within a single clone, more mutations 
were found in the IgG than the IgM, particularly in the CDRs. This increase in mutations 
was associated with increased ability to bind dsDNA (Marion et al., 1992).
Somatic mutations creating arginine (Arg), lysine (Lys) and asparagine (Asn) residues in 
the CDRs were also found to occur very commonly by Radic and Weigert (1994). All of 
these amino acids may promote binding to the negatively charged DNA double helix by 
charge interactions (Arg and Lys) or hydrogen bond formation (Asn). Computer modelling 
programs, which predict the three dimensional structures of antibodies from their amino 
acid sequences (Martin et al., 1991; Chothia et a l , 1998), have been used to predict sites of
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contact between the dsDNA molecule and arginine residues in the CDRs (Radic and 
Weigert, 1994). These predictions were subsequently tested by altering Arg residues at 
those sites by mutagenesis and demonstrating that this altered DNA-binding affinity in the 
way predicted by the model (Radic et al., 1993).
In conclusion, sequence analysis of murine monoclonal anti-DNA antibodies has shown 
that there is preferential use of Vh and VK genes to encode these antibodies and that there is 
antigen-driven accumulation of somatic mutations in the CDRs leading to the prevalence of 
certain amino acid residues, in particular Arg, in the CDRs.
Human monoclonal Ab are difficult to produce, hence far fewer human than murine 
monoclonal Ab have been sequenced. Despite the relative lack of human data it is 
important to discover whether the conclusions derived from studying murine Ab are equally 
applicable to human Ab for a number of reasons. Firstly there are major differences 
between the available Ig gene repertoires in humans and mice. For instance, there are only 
about 50 functional human VH genes (Cook et al., 1994) and up to about 1 0 0 0  in the mouse 
(Kofler et al., 1992). Secondly, because the entire human V region gene repertoire has been 
characterised, it is possible to identify sites and types of somatic mutation with an accuracy 
that may not be possible for all murine Ab. Lastly, approximately 40% of human Ab but 
only 5% of murine Ab carry X chains which means it is impossible to make deductions 
about utilisation and mutation of X genes in anti-DNA Ab found in SLE by studying murine 
Ab.
A recent review (Rahman et al., 2002a), identified published reports of 6 6  human anti-DNA 
Ab which included sequence data. Systematic analysis of the human sequences found no 
evidence for a preferential usage of particular human Vh or Vl genes. Somatic mutations 
commonly occurred in IgG and IgA Ab and were clustered in the CDRs. Statistical analysis 
using the method of Lossos et al. (2000) strongly supported the idea that antigen drive was 
responsible for this pattern of mutation in the majority of cases. Furthermore an 
accumulation of Arg, Asn and Lys at sites of antigen contact, as defined by MacCallum et 
al. (1996), were found in the IgG and IgA Ab largely as a result of somatic mutations. 
Similarly to murine Ab, computer modelling programs have been used to show that Arg
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residues in some human anti-DNA Ab are also important sites of contact with dsDNA 
(Kalsi et al., 1996; Rahman et al., 2001).
Overall, other than the differences in Ig gene utilisation, sequence analysis of both human 
and murine anti-dsDNA Ab has revealed similar findings. Therefore a large body of 
evidence now exists which suggests that the amino acids Arg, Lys and Asn are important in 
conferring the ability to bind dsDNA, especially where they are derived from antigen- 
driven accumulation of somatic mutations in the CDRs of IgG and IgA Abs. The same 
principles of sequence analysis may be applied to human and murine monoclonal aPL.
1.9 SEQUENCE ANALYSIS OF aPL
1.9.1 Previous evidence from sequence analysis of aPL
1.9.1.1 Animal Studies
Unlike murine anti-dsDNA Ab relatively little has been published on murine aPL. One 
reason for this is that the full range of clinical manifestations seen in the human syndrome 
is not found in any one animal model of APS. Thus far aPL have been produced from 
animal models which show consistent serological features of the syndrome but which 
generally show either the obstetric or thrombotic clinical features but not both (Radway- 
Bright et al., 1999). Studies of aPL derived from MRL lpr/lpr mice (Kita et al., 1993) and 
NZW x BXSB FI mice (Kita et al., 1994; Monestier et al., 1996) do not reveal convincing 
evidence of any particular gene preference, somatic mutations or specific residues in CDRs 
which are important for binding. The most commonly expressed VH genes in these murine 
aPL were members of the J558 murine VH family, but almost 50% of all spontaneously 
activated B cells in MRL lpr/lpr mice express J558 genes regardless of antigen specificity 
(Foster et al., 1991). Despite some evidence of clonal expansion in development of aPL and 
some clustering of replacement mutations in Vh CDRs found in one study (Monestier et al., 
1996), the extent to which antigen driven somatic mutations and the presence of certain 
residues in CDRs are important in murine aPL remains uncertain (Rahman et al., 1996).
1.9.1.2 Human Studies
Previous sequence analysis of human monoclonal aPL antibodies showed that IgG, but not 
IgM, aPL often contain large numbers of somatic mutations in their variable regions. In 
many cases R:S ratios were particularly high in the CDRs, particularly in IgG antibodies
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and those derived from patients with APS (Rahman et al., 1996). This pattern of mutation is 
characteristic of antigen driven clonal expansion to create high affinity antibodies 
(Shlomchik et al., 1987). These monoclonal aPL tended to have an accumulation of certain 
residues such as Arg and Asn in their CDRs, but the evidence for this was not as strong as 
for anti-DNA antibodies (Radic and Weigert, 1994; Isenberg et al., 1997).
1.9.1.3 Conclusions and limitations o f previous aPL sequence analysis
Conclusions from previous aPL sequence analysis postulated a link between specificity for 
negatively charged PL and the presence of accumulations of Arg or Asn residues in CDRs. 
In IgG (but not IgM) aPL these residues probably arose due to antigen driven somatic 
mutation (Rahman et al., 1996; Rahman et al., 1998). Limitations of these previous 
analyses include: the small numbers of published IgG aPL; no consideration of the 
relevance of ability to bind B2 GPI; an incomplete knowledge of the human V gene 
repertoire; and less advanced statistical methods for analysing the pattern of mutations.
In recent years, more human IgG aPL have been derived from patients with APS (rather 
than those with SLE alone), many of these have been tested for ability to bind B2 GPI, and 
the first sequences of human monoclonal IgG anti-B2GPI Ab fragments derived by phage 
display have been reported (Chukwuocha et al., 1999). Thus, more sequence information 
relating to clinically relevant antibodies is now available and it is now clear that a large 
proportion of pathogenic antibodies in APS probably bind epitopes on B2 GPI. Furthermore, 
it is now possible to be more confident in predicting which residues within a particular 
antibody sequence are most likely to form close contacts with antigen (MacCallum et al., 
1996). These predictions may be strengthened by the use of computer modelling programs 
to show the probable shape of the antigen binding site encoded by a particular antibody 
sequence. I therefore performed a new analysis of published human aPL and anti- B2GPI 
antibody sequences with colleagues (Giles et al., 2003b).
1.9.2 Updated aPL sequence analysis
All published human and murine monoclonal aPL and anti-B2 GPI sequences were identified 
by a PubMed search using the keywords - monoclonal, antiphospholipid antibodies. The 
original papers describing the V region DNA sequences of these antibodies were obtained 
and the sequences analysed. Sequences were compared to all the alleles of human Ig genes
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in the VBASE database using DNAPLOT software. Both the alignment program and the 
database are available at http://www.mrc-cpe.cam.ac.uk/imt-doc/vbase-home-page.html. 
Any differences between the germline and expressed antibody sequences were considered 
to be somatic mutations unless they were at sites of junctional diversity or could be shown 
to arise from PCR primers used to clone the antibody cDNA in the original experiment.
Statistical analysis, using the multinomial method (Lossos et al., 2000), of the distribution 
of R and S mutations was carried out for all the Vh or VL sequences where homology to the 
germline gene was less than 98%. It was assumed that sequences with homologies greater 
than this contained too few mutations for statistical analysis to be informative (Schroeder 
and Dighiero, 1994). The sequences of the monoclonal antibodies were aligned and the 
amino acid residues most likely to contact antigen were determined according to the paper 
of MacCallum et al. (1996)
1.9.3 Results of aPL sequence analysis
Thirty six human aPL were identified, 22 of these were of IgM isotype and were derived 
from lymphocytes immortalized by Epstein Barr transformation or by fusion with immortal 
cells to form hybridomas. The genes of origin, homology values and binding characteristics 
of these antibodies are shown in Tables 1.6 and 1.7.
As noted previously, these IgM antibodies can be divided into two groups (Rahman et al., 
1996; Rahman et al., 1998). These are shown as groups A and B in Table 1.6. The first 
group (A) of 15 antibodies are polyreactive and were not selected for specific binding to PL 
or for relevance to APS (Dersimonian et al., 1987; Hoch and Schwaber, 1987; Cairns et al., 
1989; Logtenberg et al., 1989; Siminovitch et al., 1989; Hohmann et al., 1995; Rioux et al., 
1995). Most of these mAb were actually selected for binding to DNA and were incidentally 
found to bind PL (often with low affinity) on panel Ag testing. Most of the antibodies in 
group A were derived from PBL of healthy individuals. Only four (18/2, 1/17, Cl 19 and 
C471) of the 15 aPL identified in this group were derived from patients with SLE, none of 
whom had features of the APS. Binding to B2GPI was not reported for any of these Ab.
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References for mAb Tables 1.6 and 1.7
Table 1.6 Table 1.7
1) Dersimonian et al. (1987) 1) Van Es et al. (1992)
2) Hochetal. (1987) 2) Menon et al. (1997)
3) Siminovitch et al. (1989) 3) Ikematsu et al. (1998)
4) Cairns et al. (1989) 4) Lai et al. (1998)
5) Logtenberg et al. (1989) 5) von Landenberg et al. (1999)
6) Rioux et al. (1995) 6) Chukwuocha et al. (1999)
7) Homann et al. (1995)
8) Siminovitch et al. (1990)
9) Mariette et al. (1993)
10) Harmer et al. (1995)
11) Denomme et al. (1994)
12) Demaison et al. (1995)
13) Lai etal. (1998)
Abbreviations for Tables 1.6 and 1.7
The symbols f  denote binding to B2GPI and * lupus anticoagulant activity. 
Abbreviations: - NM -  No Match; NP -  Not Published; SLE -  Systemic Lupus 
Erythematosus; PBL -  Peripheral Blood Lymphocyte; PD -  Phage display; CLL -  
Chronic Lymphocytic Leukaemia; ss/ds DNA -  single/double stranded DNA; Poly I -  
Polyinosinic acid; Poly G -  Polyguanolic acid; Poly U -  Polyuracil; Poly dA-dT -  
Polydeoxyadenylate-thymidylate sodium salt; Poly dG-Poly dC -  Polydeoxyguanylate- 
polydeoxycytidylate; Pit -  Platelet; CL -  Cardiolipin; Hel -  Hen egg lysozyme; Cyt c - 
Cytochrome c; DOPE -dioleoylphosphatidylethanolamine; RE -  Rheumatoid Factor; PT 
-  Prothrombin; OVA -  Chicken ovalbumin; BSA -  Bovine Serum Albumin.
In Table 1.7 only binding to antigens other than anionic PL is indicated.
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Nucleotide Nucleotide
mAb origin VH gene Homology Dh Jh VL family VL gene Homology J l Binding Reference
Group A
m18/2 SLE PBL V3-23 100 NM NM NP NP NP NP ssDNA, poly-l, poly-dT, Pit 1
m1/17 SLE PBL V3-23 100 NM NM NP NP NP NP ssDNA, Pit, Vimentin 1
C6B2 Sickle cell 
spleen
V4-61 97.5 D3-10 J H3b NP NP NP NP Poly-G/I/U, ss/dsDNA 
Poly-dAdT-PolydAdT 
PA, CL, PI, PG
2
Kim4.6 Healthy Tonsil V3-30 100 D3-10 J H6a V J 1b 100 NM ss/dsDNA, poly-dAdT 
poly-dG-Poly-dC, RNA, CL
3,4
A10 Healthy PBL V6-01 99 NM J H6a NP NP NP NP ss/dsDNA, CL, PdT, Hel 5
A431 Healthy PBL V6-01 98 NM JH6a NP NP NP NP ss/dsDNA, CL, PdT, Cyt c 5
L16 Fetal Liver V6-01 100 NM J H6a NP NP NP NP ssDNA, CL, PdT 5
C119 * SLE, PBL V3-23 95.5 NM NM Vk3 L6 100 J*4 ssDNA, Pit, CL, DOPE 6
B122 Healthy PBL V1-18 97 NM NM V J L12a 98.3 NM ssDNA, Pit, CL, DOPE 6
B6204 Healthy PBL V3-23 97 NM NM Vk3 A27 99.6 NM ssDNA, Pit, CL, DOPE, RF 6
C471 SLE, PBL V3-64 99.6 NM NM Vk3 L2 100 Jk2 ssDNA, Pit, DOPE 6
H3 Healthy PBL V1-46 97 D6-13 J h4 Vk3 31 97 Jx2/3a CL, PS, PE, DT, TT 7
H5 Healthy PBL V4-30 96 DIRL J h 4 NP NP NP NP CL, DT, TT 7
A5 Healthy PBL V3-23 100 DHF16 J h 6 V*3 3p 97 J„2/3a CL, DT, TT, ssDNA 7
Bou 53.6 Healthy Tonsil V3-23 100 D4 J h 6 VK1 L12 99 Jk2 CL, polyreactive 7
Group B
Kim 13.1 Healthy Tonsil 1-e 100 NM J h 5b Vk3 L6 100 J r4 CL, RF 8
REN t CLL V4-61 100 NM JH 3b Vx8 8a 99.7 Jx3b CL, ssDNA 9
BH1 * | PAPS PBL V3-30 100 NM NM Vx3 3r 97.5 J.3b anionic PL 10
STO 103 Healthy Tonsil V4-61 100 D3-03 J h 4a VJV B3 100 Jk2 Pit, anionic PL 11
RSP 4 SLE PBL V3-30 96 D4-23 Jh 4b V J le 98.3 J J CL 12
B9421* SLE/APS PBL V3-72 100 D21-9 J H 3 Vx2 2a2 99.3 Jx3b LA 13
B9427 * t SLE/APS PBL V3-15 100 D21-9 J h 4 Vk2 A17 100 Jk3 LA 13
Table 1.6 Sequence Features of Polyreactive IgM, group A and More Specific IgM, group B aPL
VO
Nucleotide Nucleotide
mAb origin VH gene Homology Dh J h VL family VL gene Homology J l Binding to  o ther Ag Reference
R149 SLE PBL V1-69 96.6 NM JH6a Vk2 A19 99.3 Jk2 ssDNA 1
LJ-1 SLE PBL NP NP NP NP V*3 3h 98.6 Jx2/Jx3a histone 2
AH-2 SLE PBL V5-51 94.9 D4-23 JH 6b V J le 99 J*3b no 2
DA-3 SLE PBL V5-51 95.2 D3-09 J h 6a V J le 98.3 Jx3b histone 2
UK-4 SLE PBL V3-74 95 NM J h 4b Vx2 2a2 94 Jx2/Jx3a No 2
516 PAPS PBL V1-69 97.3 D3-10 J H 6b VK1 L19 96.9 Jk4 ssDNA, recombinant 3
human insulin, tetanus 
toxoid, human 
thyroglobulin, BSA
519 Healthy PBL V4-34 97.9 NM J h 5a Vk3 L2 98.9 Jk4 No 3
B9416 * SLE/APS PBL V3-23 98 NM J h 4b VK1 012/02 98.6 J J no 4
HL-5B * PAPS PBL V3-53 89 NM NM NP NP NP NP oxLDL 5
RR-7F SLE PBL V3-24 86.1 NM NM NP NP NP NP oxLDL 5
B14 t Healthy PD V3-23 91.9 D2-15 J h 4b V J A20 97.6 Jk2 no 6
B22 t Healthy PD V6-01 93.7 NM J h 4b V J A20 98.1 Jk3 no 6
B27 f Healthy PD V6-01 93.7 NM J h 4b VK1 L15 95.8 Jk4 no 6
P11 t Healthy PD V4-30 92.7 D3-03 J h 4b V J L8 96 Jk3 PT, OVA, ssDNA 6
Table 1.7 Sequence Features o f IgG aPL
vo
O n
Although the antibodies in Group A seem likely to have limited relevance to the 
pathogenesis of APS, they are included in this analysis to ensure a comprehensive analysis 
of all human aPL sequences. The group A antibodies are likely to be representative of non- 
pathogenic natural autoantibodies and thus their sequence characteristics serve as a useful 
comparison with those of the more specific and probably more pathogenic IgM aPL in 
group B and of the IgG aPL.
Members of the second group B of seven IgM antibodies are likely to be more relevant to 
the pathogenesis of APS (Siminovitch et a l, 1990; Mariette et al., 1993; Denomme et al., 
1994; Demaison et al., 1995; Harmer et al., 1995; Lai et al., 1998). Most of these 
antibodies showed specific binding to PL alone despite testing against a range of other 
antigens. The exception was REN, which also binds ssDNA. Three antibodies in group B 
showed LA activity (BH1, B9421 and B9427). B9427 bound B2 GPI, REN showed 6 2 GPI 
dependent binding to PL and BH1 showed serum dependent binding to PL (the effect of 
B2 GPI was not tested formally). Three antibodies (BH1, B9427 and B9421) were produced 
from the lymphocytes of APS patients and another one (RSP4,) from a patient with SLE 
and serum aPL, who did not have clinical features of APS.
The other 14 aPL identified were IgG antibodies.(Van Es et al., 1992; Menon et a l, 1997; 
Ikematsu et al., 1998; Chukwuocha et a l, 1999; von Landenberg et al., 1999) The genes of 
origin, homology values and binding characteristics of these antibodies are shown in Table 
1.7. Ten of these IgG antibodies were derived from immortalised lymphocytes and four 
(PI 1, B22, B27 and B14) by repertoire cloning using the phage display method 
(Chukwuocha et al., 1999). These four antibodies were produced from cDNA derived from 
lymphocytes of a patient who had circulating anti-l^GPI antibodies, although he did not 
have APS. The cDNA was cloned into phage display vectors which allowed the production 
of a library of phages carrying surface Fab derived from heavy and light chain sequences 
expressed in that patient's lymphocytes although the Vh/Vl gene combinations are artificial 
and not all may have been expressed in patient serum. Phages carrying anti-l^GPI Fab were 
selected by binding to plates carrying B2 GPI. Thus the heavy and light chain gene 
combinations of the aPL selected by phage display may not be representative of naturally 
occurring aPL. Such a discrepancy does not occur in monoclonal aPL that are derived from
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immortalised B cells in which the VH /VL gene combination is definitely expressed by at 
least one B cell in the individual from which it was produced.
Of the other 10 IgG aPL, seven were derived from patients with SLE (one of whom had 
APS) whilst two were produced from patients with PAPS. Most of the monoclonal IgG aPL 
showed specificity for PL or 132GPI, as shown in Table 1.7. The only monoclonal aPL 
shown to be pathogenic in the papers studied were the IgG aPL 516 and 519 derived from a 
PAPS patient and healthy subject respectively. Both of these monoclonal aPL induced a 
significantly higher rate of fetal resorption and a significant reduction in fetal and placental 
weight following intravenous injection into mated BALB/c mice (Ikematsu et al., 1998).
1.9.4 Which were the genes of Origin?
The frequency of use of V, D and J genes to encode monoclonal aPL was compared with 
that which would be expected from the intrinsic bias of the Ig gene recombination process.
1.9.4.1 Heavy chain genes
Twelve of the 15 polyreactive aPL in group A, all seven of the more specific IgM aPL in 
group B and 9 of 13 published IgG aPL used genes from the Vh 1,3? or 4 families. These 
are the largest and most commonly expressed Vh families in both normal donors and 
patients with SLE (de Wildt et al., 2000). The other three polyreactive antibodies used the 
V h 6  gene V6 -0 1 , but were derived from an experiment which set out specifically to 
produce monoclonal Ab encoded by that gene (Logtenberg et al., 1989). The apparently 
high prevalence of polyreactive aPL encoded by V6-01 is therefore misleading.
The most commonly used gene amongst polyreactive IgM aPL and IgG aPL is V3-23 
which is the most commonly rearranged VH gene in IgM secreting B cells regardless of Ag 
specificity (Brezinschek et al., 1997). A group of Vh genes that are particularly likely to be 
rearranged due to the intrinsic bias in the recombination process has been identified by 
single cell PCR in peripheral B cells (Brezinschek et al., 1997; de Wildt et al., 2000). This 
group includes V3-23, V3-30, V3-07, V4-34, V4-39, V4-59, Vl-18, Vl-69 and V5-51. 
Members of this group of genes encode VH sequences in 8  of the 15 polyreactive IgM 
antibodies, 7 of the 13 published IgG aPL, but only two of the seven more specific IgM 
antibodies.
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For a number of the antibodies studied, it was not possible to match the heavy chain CDR3 
sequence to any known Dh gene. The reason for this is that the DNAPLOT software used 
very stringent criteria, described in section 1.7.7.2, for aligning Ab sequences to germline 
D segments (Corbett et al., 1997). Six of the 15 IgM sequences in group A, four of the 
seven in group B and five of the 13 IgG sequences could be matched to known D genes. 
The majority of the D segments matched were from the D2 and D3 families which have 
previously been shown to dominate the expressed repertoire (Brezinschek et al., 1997; 
Corbett et al., 1997; de Wildt et al., 2000).
Jh genes of origin could be identified for nine IgM antibodies in group A, six in group B 
and 11 IgG antibodies. Where no match could be made, this was usually because the 
published sequence did not extend as far as the J region. The majority of the sequences 
matched the Jh3, Jh4 or JH6 genes, which are the most commonly rearranged Jh genes in 
peripheral B cells (de Wildt et al., 2000).
1.9.4.2 Light chain genes
Information from single cell PCR experiments (Brezinschek et al., 1998) and from analysis 
of human VL cDNA libraries (Ignatovich et al., 1997) has allowed the identification of VK 
and Wx genes which account for most of the expressed repertoire. Of the light chain 
sequences of these aPL, all polyreactive IgM, all IgG and five of seven more specific IgM 
aPL used genes which are members of the three largest and most commonly expressed VK 
(I-III) or (1-3) families. Six of the 8  published VL sequences of IgM in Group A, six of 
seven sequences in Group B and 9 of 12 published IgG aPL sequences utilised VK or 
VX genes which are known to be commonly rearranged and expressed (Cox et al., 1994; 
Ignatovich et al., 1997). The most commonly rearranged VK genes include A3, A17, A20, 
02/12, L8 , L12, L6 , A27, L2, and B3 while commonly rearranged Vx genes include 
lb,lc,le, 2a2,2b2,2c, 3h and 3r.
In the cases where assignment to a Jl gene could be made, it was found that X encoded 
sequences always used J^ 2  or J^3 genes, whereas the k  encoded sequences were split 
evenly between JK2, JK3 and JK4. There was no difference between IgM and IgG
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antibodies. These results mirror the known usage of these genes in peripheral lymphocytes 
(Domer et al., 1999; de Wildt et al., 2000), though the low rate of use of the JK1 gene 
amongst aPL is a little surprising.
In summary, therefore, the pattern of gene usage in these aPL antibodies is generally that 
which would be expected from the intrinsic bias of the recombination mechanism. Genes 
that are commonly rearranged by that mechanism are also commonly used to encode both 
IgM and IgG aPL. The only exception is in the group of more specific IgM aPL, where five 
of seven antibodies use Vh genes which are not commonly rearranged in other antibodies. 
These genes include Vl-e, V3-15, V3-72 and V4-61, which are not used to encode either 
polyreactive IgM aPL or IgG aPL. Each of these genes is used in its germline 
configuration. One might therefore suspect that the germline sequences of these genes 
could contain motifs which were beneficial in binding to PL or P2 GPI. However, on 
comparing the sequences of these germline genes, no common motif in either CDR1 or 
CDR2 is evident. The genes are derived from three different families (VH 1, Vh 3 and VH 4) 
and each has a different three dimensional fold structure (predictable from the amino acid 
sequence). Therefore, there is no evidence to support the idea that these genes confer any 
common structural property which promotes formation of a PL binding site. The number of 
antibodies in Group B is small, and none of these genes is used to encode more than one of 
these antibodies. It is therefore not possible to conclude that these results represent 
preferential use of these particular genes to encode a PL binding site in specific IgM aPL.
1.9.5 What is the extent of somatic hypermutation?
Overall, IgG aPL carried more somatic mutations than IgM aPL, and this difference was 
most pronounced when considering the heavy chains. All 13 published IgG VH sequences 
but only five of 12 published IgG VL sequences showed homology of 98% or less to the 
corresponding germline gene (see Table 1.7). The high degree of somatic mutation in IgG 
antibodies was expected, since class switching and somatic hypermutation are closely 
linked processes in the B lymphocyte. They appear to occur at similar times in B cell 
development within germinal centres and some important effector molecules may play 
major roles in both processes (Muramatsu et al., 2000).
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Nevertheless, somatic hypermutation can take place in the absence of class switching, 
leading to the production of IgM antibodies carrying many mutations. A number of such 
antibodies were seen in Group A, where seven of 15 VH sequences and two of eight 
published VL sequences had homology values less than or equal to 98%.
The more specific IgM aPL in Group B, however, contained very few somatic mutations 
with one Vh chain having 96% nucleotide homology and the other six Vh chains having 
100% homology. Five of the seven VL chains showed greater than 99% homology to 
germline genes with only one Vl chain having less than 98% nucleotide homology.
1.9.6 Are the somatic mutations antigen driven?
Results of statistical analysis of the distribution of R and S mutations in the CDR and FR 
regions of the VH and Vl sequences by the multinomial (Pm) method (Lossos et al., 2000) 
are shown in Table 1.8. A Pm value of less than 0.05 for either FRs or CDRs in the heavy 
or light chain is taken as representing strong evidence of antigen drive. Eight of the 14 IgG 
aPL analysed fulfil this criterion.
The six IgG aPL which do not have Pm values of less than 0.05 in either chain are LJ-1, 
AH-2, DA-3, 519, RR-7F and PI 1. No conclusion can be made as to whether antigen drive 
plays a role in the development of LJ-1 and RR-7F, because the sequences of LJ-1 Vh and 
RR-7F VL are unpublished. There is good evidence that AH-2 and DA-3 are derived from a 
clone of B cells which has been subject to antigen driven expansion, despite the non­
significant Pm values. AH-2 and DA-3 are distinct monoclonal antibodies derived from 
descendants of the same B lymphocyte clone in a single patient. This is evident because 
they share exactly the same Vh and VL sequences, except at a few sites of somatic 
mutation. The fact that the same clone has given rise to two distinct monoclonal antibodies 
implies that it is a highly expanded clone, and the fact that the sequences contain multiple 
somatic mutations implies that this has been driven by antigen. Thus, in only two IgG 
antibodies (PI 1 and 519) was the evidence clearly against the influence of antigen drive.
It is therefore apparent that most of the IgG aPL have been subject to antigen driven 
expansion and accumulation of somatic mutations. Since these antibodies showed 
specificity for either PL or P2 GPI, these seem likely to have been the driving antigens.
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Antibody Heavy chain 
Pm
Light chain 
Pm
C6B2 FR 0.0186 NP
CDR 0.882 NP
Cl 19 FR 0.00031 ND
CDR 0.0271 ND
B122 FR 0.137 ND
CDR 0.899 ND
B6204 FR 0.0142 ND
CDR 0.0645 ND
BH1 FR ND 0.560
CDR ND 0.908
RSP4 FR 0.422 ND
CDR 0.942 ND
R149 FR 0.00009 ND
CDR 0.00177 ND
AH-2 FR 0.435 ND
CDR 0.152 ND
DA-3 FR 0.349 ND
CDR 0 . 1 2 2 ND
UK-4 FR 0.150 0.035
CDR 0.622 0.016
516 FR 0.0376 0 . 1 0 1
CDR 0.286 0.433
519 FR 0.982 ND
CDR 0.844 ND
B9416 FR 0.0029 ND
CDR 0.484 ND
HL-5B FR < lx l 0 ' 6 NP
CDR 0.0213 NP
RR-7F FR 0.0739 NP
CDR 0.0645 NP
B14 FR 0.317 0.041
CDR 0.104 0.873
B22 FR 0 . 0 1 1 ND
CDR 0.0911 ND
B27 FR 0 . 0 1 1 < lx l 0 ' 6
CDR 0.0911 0.0367
P ll FR 0.0820 0.175
CDR 0.641 0.229
Table 1.8 Statistical analysis of aPL with < 98% nucleotide homology to germline 
genes
For origin, sequence features and binding characteristics of each mAb see Tables 1.6 and
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It must be stressed however, that all statistical models for determining the influence of 
antigen drive have drawbacks. For example, they do not take into account the fact that 
some FR residues contact the antigen while some CDR residues do not. Antigen drive 
might select for mutations at such FR residues and against mutation at such CDR residues. 
The statistical model would interpret such selection as evidence against antigen drive. In 
addition, the specification of p=0.05 as the threshold for significance is somewhat arbitrary 
in this context.
The results for the more specific IgM aPL in Group B are completely different from those 
of the IgG aPL. Most have very few mutations, and even the two sequences which are 
significantly mutated (RSP-4 VH and BH1 VL) do not show any evidence of antigen drive 
on statistical analysis and did not demonstrate specificity for PL or (32 GPI. Indeed, the 
majority of the more specific IgM aPL had very few somatic mutations. This suggests that 
these IgM attain specificity due to features inherent in their germline sequence or produced 
at the Vh-Dh, Dh-Jh or Vl-Jl junctions. Antigen drive would then tend to select against 
somatic mutations because mutations would tend to alter the favourable germline sequence. 
Conversely, IgG aPL would attain specificity and high affinity for PL or p2GPI due to 
accumulation of somatic mutations.
Seven of the polyreactive IgM aPL could potentially have been subjected to statistical 
analysis, since either their Vh or Vl sequences showed less than 98% homology to 
germline genes. However, for three of these antibodies (H3, H5 and A5) nucleotide 
sequences were not published and therefore could not be analysed (Hohmann et al., 1995). 
Of the remaining four antibodies (C6B2, Cl 19, B122 and B6204), statistical analysis gave 
Pm values of less than 0.05 in three cases. This shows that antigen driven accumulation of 
mutations in IgM antibodies is not always associated with the loss of polyreactivity. 
However, extensive somatic mutation was the exception rather than the rule in polyreactive 
IgM antibodies, in contrast to the IgG aPL discussed above.
1.9.7 Are particular residues, important in CDRs and contact regions?
The sequences of the Vh regions of the more specific IgM and IgG aPL are shown in 
Figure 1.3 whilst the sequences of the VL regions of these aPL are shown in Figure 1.4.
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FR1 CDR1
ab
FR2 CDR2
abc
IgM 1 10 20 30 31 35 36 47 5052 58 65
BH1 QVQLVESGGGVVQPGGSLRLSCAASGFTFS S--YGMH WVRQAPGKGLEWVA FIRY--DGSNKYYADSVKG
RSP4 QVQLVESGGGVVQPGRSLRLSCAASGFTFS S--YGMH WVRQAPGKGLEWAA VISY— DGSNKYYADSVKG
REN QVQLQESGPGLVKPSQTLSLTCTVSGGSIS SGSYSWS WIRQPAGKGLEWIG RIY-- TSGSTNYNPSLKS
Kim QVQLVQSGAEVKKPGSSVKVSCKASGGTFS S--YAIS WVRQAPGQGLEWMG GIIP--IFGTANYAQKFQG
STO QVQLQESGPGLVKPSETLSLTCTVSGGSVS SGSYYWS WIRQPPGKGLEWIG YIY-- YSGSTNYNPSLKS
9421 EVQLVESGGGLVQPGGSLRLSCAASGFTFS D--HYMD WVRQAPGKGLEWVG RTRNKANSYTTEYAASVKG
9427
IgG
516
EVQLVESGGGLVKPGGSLRLSCAASGFTFS N— AWMS WVRQAPGKGLEWVG RIKSKTDGGTTDYAAPVKG
QVQLVQSGAEVKKPGSSVKVSCKTSGGTFS S— YAIN WVRQAPGQGLEWMG GIIP--IYGTANYAQKFQG
519 QVQLQQWGAGLLKPSETLSLTCAVYGGSFR G— YYWS WIRQPPGKGLEWIG EIN-- HSGSTNYNPSLKS
R149 QVQLVQSGAEVKKPGSSVKVSCKASGGTFS S--YSVS WVRQAPGQGLEWMG RIIP— VLTLANYAQKFQG
B22 LESGPGLLKPSQTLSLTCVISGDNVS RNSVGWN WLRQSPSRGLEWLG RTYYR-SKWYNDYAAFVRS
Pll LESGPGLVKPSQTLSLTCTVSGDSIS SGGYYWS WVRQHPGKGLDWIG YIY-- YSGKRYYNPSLKS
B14 LESGEGVVQPGRSLRLSCAASGFTFR S— YAMH WFRQTPGRGLEWVS GISG— TGGSTDYANSVRG
RR7F GGLVQPGGSLRLSCAASGFSFS S--YVMS WVRQAPGKGLEWVS TISG— SGASTYYADSVKG
HL5B GDLIQPGGSLRLSCAASGFTVT D— THMN WVRQAPGKGLEWVS VIY-- KGGRSDYADSVKG
9416 EVQLLESGGGLVQPGGSLRLSCAASGFTFS S--YVMS WVRQAPGKGLEWVS AISG— SGGSTYYADSVKG
AH 2 EVQLLQSGAEVKKPGESLKISCQASGYSFA T— YWIG WVRQMPGKGLECMG MVFP— GDSDTRYSPSFQG
DA 3 EVQLLQSGAEVKKPGESLKISCQASGYSFA T--YWIG WVRQMPGKGLECMG MVFP— GDSDTRYSPSFQG
UK4 EVQLVESGGGLVQPGGSLRLSCVASGFTFS G— YWMH WVRQVPGKGLVWVS RINS— DGRSTSYADSVKG
CONTACT HI CONTACT H2
FR3
abc
IgM 66 82 90 93
BH1 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAN 
RS P 4 RFTISRDNAKNSLSLQMNS LRAE DTAMYYCAR 
REN RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR 
Kim RVTITADKSTSTAYMELSSLRSEDTAVYYCAR 
S TO RVTISVDTSKNQFSLKLSSVTAADTAVYYCAR 
9421 RFTISRDDSKNSLYLQMNSLKTEDTAVYYCAR 
9427 RFTISRDDSKNTLYLQMNSLKTEDTAVYYCTT 
IgG
516 RVTITADESTSTAYMELSSLRSGDTAVYYCAR 
519 RVTISVDTSKNQFSLNLRSVTAADTAIYFCAR 
R149 RVTITADKSTSTAYMELSSLRSEDTAVYYCAR 
B22 RITINPDTSKNQFSLHLNSVTPEDTAVYYCAR 
Pll RVTILLDLSKNQFSLKLNSVTAADTAVYYCAR 
B14 RFTISRDNSKDTLYLQMNNLRVEDTAVYYCSK 
RR7F RFTISRDNSKNTLYLQMNSLRADDTAVYYCAK 
HL5B RFTISRENSRNTLYLQMNSLRVDDTAVYYCAR 
9416 RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK 
AH2 QVTISADKSLSTAYLQWSSLKASDTAIYLCAR 
DA3 QVTISADKSLS TAYLQWS S LKASDTAlYFCAR 
UK4 RFTISRDNSKNTLVLQMNSLRADDTAVYYCAR
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NNGQQLVYS------ YMDV WGKGTTVTVSS
NRWEPLN------------  WGQGTLVTVSS
DKGGFWSGYYTRNSRAAFDI WGQGTMVTVSS
ARIAARLPGSN---- WFDP WGQGTLVTVSS
VGTRGLWLFY-------- Y WGQGTLVTVSS
VPPYYYDSSGYYPD AFDI WGQGTMVTVSS
DYSGYYFW------- YFDY WGQGTLVTVSS
GGRFIRGLT FMDV WGQGTTVTVSS
GRIAVTSQPRP FDS WGQGILVTVSS
GSIRRERFLDRIQTRESEGSYYAMDVWGQGTTVTVSS
GAGAAPH DY WGQGTLVTVSS
GPYALFGWI PH YFDN WGQGALVTVSS
QVFF GGQGALVTVSS
EAPAGGGEY 
LGTGAPLTAFFTP 
LGTGEPLTANFTPY 
DLGAVTAY------
WGQGTLVTVSS 
YYYSRMDVWGQGTTVTVSS 
YYSRMEVWGQGT TVTVS S 
-YFDY WGQGALVTVSS
CONTACT H3
Figure 1.3 Sequence alignment of more specific IgM and all IgG aPL heavy chains
The positions of CDRs and FRs are as defined by Wu and Kabat (1970). Positions of the contact 
regions HI, H2, H3, LI, L2 and L3 are as defined by MacCallum et al. (1996). The underlined 
amino acids are somatically mutated and those shown in bold are at sites that contact antigens.
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RASQSVS------ SYLA WYQQKPGQAPRLLIY DASNRAT GIPARFSGSGSGTDFTLTISSLEPEDFAVYYC QQRSNWPL-T FGGGTKVEIK
RSSQSLVYSDGN-TYLN WFQQRPGQSPRRLIY KVSNRDS GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQGTHWPF-T FGPGTKVDIK 
KSSQSVLYSSNNKNYLA WYQQKPGQPPKLLIY WASTRES GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQYYSTPPGT FGQGTKLEIK
RASQGIS------ NWLA WYQQKPGKAPKLLIY AASSLQS GVPLRFSGSGSGTDFTLTISNLQPEDSATYYC QQAKSFPPVT FGGGTKVEIK
RASQSVS SNLA WYQQKPGQAPRLLIY GASTRAT GIPARFTGSGSGTEFTLTISSLQSEDFAVYYC QQYNKWPL-A FGGGTKVEIK
RASQGIS TYLV WYQQKPEKAPKSLIY AASNLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQYNSYPF-T FGGGTKVEIK
RASQGIS NYLA WYQQKPGKVPKLLIY AASTLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYSTPR-T FGQGTKVDIK
RASQGIS SALA WYQQKPGKAPKFLMY AASTLQS GVPSRFSGSGSGTEFTLTISSLQPEDFGTYYC QQFNAYPL-T FGPGTKVEIK
RASQGIS NYLA WYQQKPGKVPNLLIY GASTLQS GVPSRFSGSGSGTDFTLTISSLQPEDVATYYC QKYDSAPR-T FGPGTKVDIK
RASQSIS SYLN WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQSYSTPPWT FGQGTKVEIK
RSSQSLLHRYGY-NYLD WYLQKPGQSPQLLIY LGSNRAS GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQALQTPY-T FGQGTKLEIK
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SALTQPASVSGSPGQSITISC TGTSNDVGSYNYVS WYQLHPGEAPKLLIY DAIKRPS GVSNRFSGSESGNTASLTISGLQAEDEGDYYC
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Figure 1.4 Sequence alignment of IgM and IgG aPL light chains
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The figures show the positions of the CDRs and FRs identified by the Kabat system (Wu 
and Kabat, 1970) and contact sites as defined by MacCallum et al. (1996). Most of these 
contact sites are within the CDRs but it is important to note that not all CDR residues are 
contact sites and that some FR residues can be contact sites.
On considering the figures, it is apparent that somatic mutations occur frequently in the 
contact HI and H2 regions of the IgG antibodies, less commonly in LI, L2 and L3 of the 
IgG antibodies, and are very rare in the IgM antibodies. None of the residues in H3 have 
been assigned as somatic mutations since it is very difficult to be sure where somatic 
mutations occur in H3, due to the contribution of junctional diversity and the large number 
of cases in which germline D genes of origin cannot be identified.
The hypothesis that somatic mutation to create Arg, Lys and Asn residues in the contact 
regions may play a major role in IgG aPL is examined in Table 1.9. The proportion of 
somatic mutations in the contact regions which give rise to these amino acids is compared 
with the proportion of mutations in the same regions which give rise to aspartic acid (Asp) 
or glutamic acid (Glu). These residues were chosen for comparison because thay are acidic 
and negatively charged as opposed to the basic, positively charged Arg and Lys.
Table 1.9 clearly shows an excess of mutation to Arg, Lys and Asn in the contact sites of 
the IgG aPL in comparison to Asp and Glu. This is particularly striking in VHCDR1 and 
VhCDR2. In Table 1.10, the total numbers of Arg, Asn and Lys residues in the contact 
regions of both the IgG aPL and the more specific IgM aPL are compared with the numbers 
of Asp and Glu residues in those regions. This Table includes both germline encoded 
residues and those derived by somatic mutation. This comparison is particularly important 
for the IgM antibodies, where somatic mutation plays no major role. In general, there is an 
excess of Arg, Lys and Asn residues over Asp and Glu residues in the contact regions of the 
VH and VK, but not the Vx sequences. Interestingly, this does not hold true for the H3 
regions of the IgG antibodies. Accumulation of basic residues (particularly Arg) in H3 has 
been noted to be a common feature of human and murine IgG anti-DNA antibodies (Radic 
and Weigert, 1994; Rahman et al., 1998), but does not seem to be an important feature in 
the IgG aPL considered here.
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V Region Number of 
antibodies
Number of somatically 
mutated contact residues that 
are Arg, Asn or Lys / number 
of contact residues that are 
somatic mutations
Number of somatically mutated 
contact residues that are Asp or 
Glu / number of contact residues 
that are somatic mutations
Contact 
Region 1
Contact 
Region 2
Contact 
Region 3
Contact 
Region 1
Contact 
Region 2
Contact 
Region 3
IgG VH 1 2 5 / 20 4 / 22 - 1 / 2 0 2 / 2 2 -
IgG VK 8 2 / 7 1 / 3 2 / 5 0 / 7 0 / 3 1 / 5
IgGVx 4 1 / 1 1 /5 2 / 2 0 / 1 2 /5 0 / 2
Table 1.9 Analysis of somatic mutations at contact residues
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VRegion
Number of 
antibodies
Total Arg, Asn or Lys residues present 
at contact sites (in brackets; total not 
including somatically mutated residues)
Total Asp or Glu residues present at 
contact sites (in brackets; total not 
including somatically mutated residues)
Contact 
Region 1
Contact 
Region 2
Contact 
Region 3
Contact 
Region 1
Contact 
Region 2
Contact 
Region 3
IgG VH 1 2 6 ( 1 ) 15(11) 9(-) 1 (0 ) 9(7) 1 2  (-)
IgG VK 8 7(5) 2 ( 1 ) 5(3) 1 ( 1 ) 0 (0 ) 1 (0 )
IgGV^ 4 3(2) 3(2) 2 (0 ) 2 (2 ) 2 ( 1 ) 2 (2 )
IgM VH 7 1 ( 1 ) 13(13) H O 2 (2 ) 5(5) 8(-)
IgM VK 3 H 5(5) 4(4) 2 (2 ) K D 3(3) 0 (0 )
IgM V* 4 2 (2 ) 5(4) 1 ( 1 ) 2 (2 ) 2 (0 ) 2 (2 )
Table 1.10 Analysis of all amino acids present at sites of contact
The number of Arg, Lys and Asn is compared to the number of Asp and Glu.
Thus, whereas both the Group B IgM aPL and the IgG aPL show some evidence of 
accumulation of Asn, Arg and Lys at the contact sites, these are mostly encoded in the 
germline in IgM and derived from somatic mutation in IgG. The presence of CDRs and 
contact regions which are rich in Arg, Asn and Lys residues in both the more specific IgM 
aPL and IgG aPL is relevant to the nature of the epitope bound by these antibodies. It has 
already been discussed how pathogenic aPL have a predilection for negatively charged PL 
and B2 GPI (section 1.2.5) which has a potential epitope rich in negatively charged residues 
within domain I (section 1.6 .6 ). Therefore aPL containing Arg, Asn, and Lys residues in the 
contact regions may increase the affinity of binding via electrostatic interactions and 
hydrogen bonds with negatively charged epitopes upon PL and domain I of B2 GPI.
1.9.8 Are there differences between antibodies which bind P2 GPI and those which do 
not?
Eight antibodies were either known to bind P2 GPI or there was strong evidence to suggest 
that P2 GPI was required for them to bind phospholipids. Three of these antibodies (BH1, 
REN and B9427) were IgM antibodies from group B while the other 5 (516, B 14, B22, B27 
and Pl l )  were IgG antibodies. When these antibodies are considered as one group, the 
results are similar to those noted for the whole set of aPL. Thus the five IgG antibodies 
which bound P2 GPI all had many somatic mutations and Pm values suggested antigen drive 
in four cases (Pl l  was the exception). The three IgM antibodies had few or no mutations 
with no evidence of antigen drive. All the IgG antibodies except P ll contained somatic 
mutations to Arg, Asn or Lys in their contact regions whereas none of the IgM antibodies 
had mutations to those residues in their contact regions.
Since this updated aPL sequence analysis was completed, the sequences of seven further 
IgG aPL (four of which were P2 GPI dependent) have been published (Chukwuocha et al., 
2002). Five of the antibodies had previously been shown to be thrombogenic whilst two 
were not, in a mouse model (Pierangeli et al., 2000). The pattern of gene usage in these aPL 
did not reveal any bias, consistent with the above findings. Thirteen out of the 14 Ab 
heavy/light chains contained somatic mutations with 84 -97% homology. In six of the 
seven aPL statistical analysis using the multinomial method (Lossos et al., 2000) showed 
evidence of antigen drive in the FRs and/or CDRs. The presence of antigen driven somatic
109
mutations was found in both pathogenic and non-pathogenic aPL. An accumulation of Arg 
residues however, was found in the Vh CDR3 of pathogenic compared to non-pathogenic 
aPL (Chukwuocha et al., 2002). Thus the findings from sequence analysis of these 
additional aPL was consistent with those described above.
1.9.9 Computer modelling of aPL
Computer models of the specific IgM aPL RSP4 and the IgG aPL UK-4 are shown in 
Figure 1.5. These models support the idea that Arg and Asn residues are important at the 
binding sites of these antibodies. In RSP4, Arg and Asn 
residues from a number of different CDRs form ridges on the surface of the 
molecule. In UK-4, Arg and Asn residues from LI, H2 and L3 are exposed at 
the surface. Two of these Asn residues are derived from somatic mutations 
in the light chain.
Once computer models such as these have been used to identify particular amino acids that 
potentially affect the aPL- I^GPI-PL interaction, further experiments are needed to produce 
variant forms of aPL in which these key residues are altered to test the effect this has upon 
binding and/or pathogenic properties of the antibody. Of course this is only possible if the 
wild type and variant antibodies can be expressed as whole antibody molecules and their 
properties compared. A number of different systems to express antibody sequences exist.
1.10 EXPRESSION SYSTEMS FOR ANTIBODIES
Compared to monoclonal Ab produced from PBL or splenic lymphocytes from humans or 
mice the in-vitro expression of cloned Ab cDNA produces a poor yield of Ig. A powerful 
advantage of expression systems, however, is that the sequence of the DNA being 
expressed can be controlled. It is possible to determine the importance of particular residues 
in antigen binding by expressing cDNA encoding the H and L chains of a particular Ab in- 
vitro and then using a technique such as site-directed mutagenesis to create altered forms of 
the sequence in which Arg, Asn or Lys residues of interest had been altered. For instance, if 
an aPL were altered in this way the binding properties of these altered forms could then be 
tested to see whether affinity for PL and/or 6 2GPI had changed in the way predicted by the 
hypothesis. Similar experiments have shown the importance of Arg residues in human and
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A ) RSP4
B) UK4
Figure 1.5 Com puter generated models o f the three dimensional structures o f RSP4 and UK4
The three dim ensional orientation o f  UK.4 is exactly like that o f  RSP4 so location o f  the contact 
regions can be directly cross-compared.
Colour code:- Green -  V L; Light Blue -  V H; Magenta -  Asn residues; Purple -  Arg residues
1 1 1
murine anti-DNA antibodies (Radic et al., 1993; Radic and Weigert, 1994; Rahman et al., 
2001).
All expression systems involve cloning VH and/or VL sequences of a selected antibody into 
an expression vector containing the appropriate amount of CH and/or CL as well as the 
components required to enable the plasmid vector to express Ig protein once transfected 
into either a bacterial or eukaryotic cell. In this way, either part or the whole Ig molecule is 
expressed containing a functional binding site. Several different types of expression system 
have been used for this purpose and they will be described below.
1.10.1 Bacterial expression systems
A major disadvantage of bacterial expression of eukaryotic proteins is that post 
translational modifications such as glycosylation are absent and that the molecules may not 
fold properly. Consequently it has not been possible to express a stable, functional whole Ig 
molecule in bacteria (Rahman et al., 2002b). Since binding properties of an Ab depend only 
on the V regions however, it has proved possible to express smaller fragments of Ab which 
contain a functional binding site.
The simplest expression products are single chain fused variable region (scFv) molecules. 
In scFv expression plasmids Vh and Vl sequences are cloned either side of a sequence 
encoding a short flexible linker fragment, see Figure 1.6 A). When expressed from bacterial 
cells the flexibility of the linker, typically rich in glycine and serine residues, allows the Vh 
and Vl to interact with each other and produce an antigen binding site (Bird et al., 1988).
In some scFv expression systems the VH and VL DNA are ligated into phagemids rather 
than plasmid vectors. This system enables scFv to be expressed as a fusion protein 
connected covalently to a surface protein of the phage particle and is called phage display. 
If a library of VH and VL sequences is cloned into a phagemid a library of different phage 
particles that display a repertoire of different VH/VL combinations is produced. This process 
is called repertoire cloning (McCafferty et al., 1990). By panning phages against surfaces 
carrying antigens of interest (e.g DNA or PL) under gradually more stringent washing 
conditions in each round of exposure to antigen it is possible to select from a large 
repertoire of combinations those with a high affinity for a particular antigen. A drawback of
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Figure 1.6 Overview of bacterial expression of antibody fragments
Schematic representation of the use of bacterial expression systems to produce: - A) single 
chain Fv molecules (scFv); and B) Fab.
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this technique however is that the VH /VL gene combinations created are artificial and not 
all may have been expressed in patient serum. This drawback does not apply to monoclonal 
aPL that are derived from immortalised B cells in which the VH /VL gene combination is 
definitely expressed by at least one B cell in the individual from which it was produced.
An alternative to scFv is to express Fab fragments from bacteria, either in soluble form or 
on the surface of a phage particle, as described above. Expression vectors for these 
fragments contain Vh and VL followed 3' by a CH1 sequence and a CL sequence 
respectively, see Figure 1.6 B). Flence the products of expression are the whole light chain 
and half the heavy chain which combine covalently to form Fab (Better et al., 1988). Fab 
are the most appropriate antibody fragments for crystallization studies, particularly if they 
can be produced and purified from large scale bacterial cultures.
Fab and scFv molecules however, are both unsuitable for use in functional assays because 
they lack some or all C region domains. Therefore despite the usefulness of these antibody 
fragments in determining the binding properties of the V region of an antibody they cannot 
be used to investigate how altering these binding properties may affect pathogenicity of 
these antibodies in-vivo. Whole IgG molecules are required for this purpose. Thus it is 
necessary to transfect cultured eukaryotic cells to express whole IgG (Rahman et al., 
2 0 0 2 b).
1.10.2 Eukaryotic expression systems
The expression of whole Ig in mammalian cells may be achieved in a variety of ways which 
give rise to either transient expression of antibody or the selection of stably transfected cell 
lines. In transient expression systems the expression vectors are not preserved in host cells 
for more than a few days, so the total yield of antibody is generally low. This form of 
expression allows rapid screening of large combinations of different Ab and does not 
require the selection of cells for drug resistance markers or long term maintenance of cell 
lines. In contrast, in stable expression systems transfected expression plasmids will be 
incorporated into the genome of a small proportion of the host cells, selected using markers 
such as drug resistance, and be maintained there over many generations. This system allows 
the production of much larger quantities of Ab than with transient expression but is more 
difficult and time consuming to achieve, hence fewer Ab may be expressed.
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To produce whole antibody, expression vectors are created which encode for entire H and L 
chains. The H chain expression vectors contain VH sequence DNA 5' to the appropriate CH 
DNA sequence, thus encoding the entire H chain constant region and hinge region. 
Similarly, in L chain expression vectors VL is cloned 5' to CL. The H and L vectors can 
then be co-transfected into eukaryotic cells and whole fully glycosylated IgG molecules are 
expressed, see Figure 1.7 A). This method makes it easy to carry out chain shuffling 
experiments in which the same H (or L) chain is paired with a range of different partner 
chains. Alternatively, the H and L chain constructs can be combined into a single vector, 
see Figure 1.7 B). An advantage with this method is that a cell does not have to acquire two 
separate plasmids simultaneously and an increased yield of Ig may be obtained although 
chain shuffling is not so readily performed. Lastly, a vector containing only H chain may be 
transfected into hybridoma cells that secrete L chain only, called H chain loss variants 
(HCLV), see Figure 1.7 C).
1.10.3 The use of different expression systems in the further investigation of links 
between sequence, structure and function of anti-DNA antibodies
Therefore the most suitable expression system for analysis of an Ab depends upon the 
precise hypothesis being tested. If the effects of altering the Ab binding site upon its ability 
to bind antigen is being examined, then bacterial expression of antibody fragments as either 
scFv or Fab is appropriate. In particular, the expression of either of these fragments by 
phage display allows large scale chain shuffling experiments to take place investigating the 
relative contributions of the Vh and Vl sequences to antigen binding. Alternatively, if it is 
supposed that an alteration in expressed Ab sequence will affect the functional properties of 
that Ab, then a eukaryotic system must be used to produce large quantities of whole Ig for 
use in an appropriate biological assay.
Various different expression systems have been used to study the relationship between 
sequence, structure and function of murine and human anti-dsDNA Ab. It is instructive to 
consider the results of some of these experiments before considering their suitability for the 
study of aPL.
Bacterial expression systems have been used to produce high affinity anti-DNA Ab by 
repertoire cloning. To investigate whether the random Fl/L chain combinations in the Fab
Ligation into a 
single vector
Transfection o f 
separate vectors 
into eukaryotic 
cells
Transfection o f H 
chain vector into 
cells secreting 
only L chains
Transfection into 
eukaryotic cells
\  ' /
Whole IgG
Figure 1.7 Expression of whole IgG in eukaryotic cells
Schematic representation of the production of whole IgG molecules in eukaryotic cells by 
transfection of: - A) separate heavy and light chain expression vectors; B) a single vector 
containing both heavy and light chain sequences; and C) a heavy chain expression vector 
into cells which secrete only light chains.
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produced represented combinations found in-vivo, one group (Roben et al., 1996) have used 
anti-idiotype antibodies. Idiotypes are antigenic determinants found in the V region of 
antibodies that can be recognised by specific antisera. Few anti-idiotypes identify the gene 
segment used to encode the antibody chain; however antibodies with the same particular 
idiotype should in theory have the same amino acid sequence at the part of the sequence 
that encodes the idiotype. Therefore two antibodies which have the same H chain idiotype 
and the same L chain idiotype are likely to have very similar H and L chain sequences.
Roben et al. (1996) obtained IgG anti-dsDNA Fab from the PBL of two identical twin 
sisters, one of whom had clinically active SLE, by repertoire cloning. One of these Fab, 
AD4-37 derived from the sister with SLE, carried the H chain idiotype B6  and the L chain 
idiotype AJIIa. Using anti-idiotype antibodies in an inhibition ELISA to test the serum of 
the patient from whom AD4-37 was derived, it was found that both of these idiotypes did 
occur on the same circulating anti-DNA antibody in this patient.
In the same experiment, another anti-dsDNA Fab, AD4-18, was derived from PBL of the 
sister with SLE. Both of these Fab, AD4-37 and AD4-18, had high affinity for dsDNA and 
contained accumulations of basic residues in their VhCDR3. The sequence of AD4-37 was 
near germline in both its Vh and Vl regions, whereas AD4-18 contained multiple mutations 
in both. To determine the contributions of the AD4-37 Vh and Vl sequences to DNA 
binding affinity, the library of L chain sequences from each of the twins was ligated into an 
expression plasmid containing the sequence of AD4-37VH. This process enabled the 
production of a library of phages carrying AD4-37VH with many different L chains. 
Analagous experiments were carried out to produce libraries in which AD4-37VL was 
paired with many different H chains. AD4-37VH was able to form anti-dsDNA Fab only in 
combination with some V\ (but not VK) sequences from either sister. Whilst AD4-37VL 
only formed anti-dsDNA Fab with VH sequences from the twin with SLE, and almost all of 
these contained CDR3 sequences identical to that of AD4-37VH. These results suggested 
that the presence of the VH sequence (particularly CDR3) was the dominant factor in 
determining the ability of AD4-37 to bind DNA.
HCLV have been used to study the importance of Arg residues in murine anti-DNA Ab 
3H9 (Radic et al., 1991; Radic et al., 1993). The FI chain of 3H9 contains three somatic
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mutations in CDR2, one of which creates an Arg residue. It also contains an Arg in CDR3, 
which results from N-addition at the VhDh junction. Transfection of an expression vector 
containing the sequence of 3H9Vh into a range of different HCLV showed that it could 
form an anti-DNA binding site in association with several different L chains (Radic et al.,
1991). Mutagenesis of the sequence of 3H9Vh in the expression vector to remove the Arg 
in CDR2 and CDR3 led to a large reduction in affinity for DNA, whereas reversion of the 
other somatic mutations in CDR2 did not do this (Radic et al., 1993). Furthermore, the 
introduction of extra Arg into 3H9Vh at sites where Arg were known to occur in the CDRs 
of other murine anti-DNA Ab led to an increase in affinity for DNA by up to 70-fold. The 
relationship between the number of Arg residues and DNA binding however was not a 
simple one. For example, the introduction of an extra Arg at position 64 of 3H9Vh 
eliminated binding to DNA, probably due to formation of a salt bridge with an adjacent 
aspartic acid residue.
Further experiments have also shown that positively charged residues (such as Arg) in the 
CDRs are not the only factors which influence binding to DNA. A range of Ab produced by 
transfection of mutagenised forms of the Vh sequence of the murine anti-DNA Ab R4A 
into FICLV secreting R4AV l have been studied (Katz et al., 1994). Mutations in R4AVH 
were designed to alter the numbers of charged residues. Although loss of an Arg in CDR3 
was found to reduce binding, there were other positions in the R4AVh where changes that 
increased positive charge led to decreased binding to DNA, or changes that decreased 
positive charge enhanced DNA binding. In fact, the sequence which gave the highest 
binding to DNA had two fewer Arg than the original R4AVh sequence and these Arg had 
been lost from FR3 with no changes in the CDRs at all.
Katz et al. (1994) also took advantage of the fact that they had expressed altered sequences 
as whole Ig molecules by examining the pathogenic effects of these sequence alterations. 
They injected young severe combined immunodeficiency mice intraperitoneally with either 
R4A hybridoma cells or one of the HCLV expressing whole IgG with the altered R4AVH. 
All mice carrying the R4A hybridoma developed proteinuria with glomerular deposition of 
the antibody in the kidneys. The mutant cell line producing IgG with the highest anti- 
dsDNA ability, described above, showed some glomerular deposition but deposited to a 
greater extent in the tubules, although proteinuria still occurred. Therefore the change in
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affinity for dsDNA may also be associated with the acquisition of a novel antigenic cross­
reactivity. In conclusion, these results indicate that changes in the ability to bind dsDNA do 
not necessarily predict changes in the pathogenic properties of an antibody.
Overall the findings from various experiments using different expression systems support 
the importance of basic amino acids at the anti-dsDNA binding site, particularly Arg 
residues in VhCDR3 of anti-DNA Ab. The relationship of these sequence features to 
pathogenicity however is not straight forward, as shown by the experiments of Katz et al. 
(1994). Given that the results of sequence analysis of pathogenic aPL are similar to those of 
pathogenic anti-DNA Ab and demonstrate a clustering of Arg and Lys residues in their 
antigen binding regions (Giles et al., 2003b), the different expression systems described 
above would be ideal to study the relative contribution of these sequence features to antigen 
binding and pathogenicity.
1.10.4 Suitability of different expression systems to study aPL
There have been few studies of the relative importance of heavy and light chain sequence 
motifs in the binding of aPL to PL-I^GPI. Several groups have studied murine aPL 
expressed as scFv. One group found the heavy chain of a pathogenic aPL to be important in 
conferring fi2GPI dependent binding to PL as well as LA activity (Blank et al., 1999b). 
Another group studied the murine anti-DNA antibody 3H9, which has dual specificity for 
PL (Cocca et al., 2001). They found that the introduction of Arg residues into the heavy 
chain of 3H9 variable region at positions known to mediate DNA binding enhanced binding 
to PS-6 2GPI complexes. In contrast, the CL binding activity of different monoclonal 
antibodies A1.72 and A1.84 was found to be solely mediated by the light chain sequence 
(Pereira et al., 1998). The direct relevance of these studies to APS in humans is limited 
however by the use of murine antibodies in the form of scFv, which do not contain any 
constant region sequence, and are therefore not representative of antibodies found in 
patients with APS.
A murine monoclonal anti-phosphorylcholine (PC) antibody 6 G6  was expressed as whole 
IgM molecules secreted from HCLV (Pewzner-Jung et al., 1996). It was demonstrated that 
both the light chain and CDR3 of the heavy chain were necessary for binding to PC. A later 
study expressed a number of human antibodies in the form of Fab produced by E.coli
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(Kumar et al., 2000). These experiments showed that the ability to bind CL was mainly 
dependent on the L chain of some human antibodies, but the H chain of others. These 
studies, however, were primarily directed at investigating the origin and properties of anti- 
DNA Ab. Neither group studied antibodies that were known to be relevant to APS on the 
basis of 8 2 GPI dependent binding to PL or pathogenicity in mouse models. Indeed the first 
report of in-vitro expression of whole human aPL antibodies with these pathogenic 
properties has stemmed from work described in this thesis (Giles et al., 2003a).
1.10.5 Work which needs to be carried out
There remains a need to investigate sequence related binding and pathogenic properties of a 
human aPL that are representative of those antibodies most closely related to disease 
pathogenesis in patients with APS. A monoclonal antibody of this type would need to be 
IgG isotype, bind to known to B2 GPI and be pathogenic in-vivo. Two such antibodies are 
IS4 and CL24 derived from two APS patients (Zhu et al., 1999). Both IS4 and CL24 
possess multiple features likely to make them relevant to the pathogenesis of APS. These 
aPL were derived from a patient with PAPS (IS4) and an SLE/APS patient (CL24). They 
are of IgG isotype, bind with high affinity to anionic PL only in the presence of B2 GPI and 
can bind to B2 GPI alone. Both antibodies have been shown to be thrombogenic in a murine 
in-vivo pinch-induced thrombosis model and to cause EC activation in-vitro (IS4 and 
CL24) and in-vivo (IS4 only) (Pierangeli et al., 2000). The properties of the antibodies IS4 
and CL24 are therefore likely to be relevant to the properties of pathogenic aPL found in 
many APS patients.
Therefore I chose to examine which sequence features in IS4 and CL24 H and L chains 
were important in determining their ability to bind antigen by expressing whole antibodies 
using a mammalian/eukaryotic system. Experiments to produce variant forms of antibodies 
using heavy/light chain exchange, CDR exchange and site directed mutagenesis were also 
carried out and their effects upon antibody binding to phospholipid examined. Although the 
yield from eukaryotic systems is smaller than with bacterial systems, the whole antibody 
produced is capable of bivalent binding to B2GPI (Rahman et al., 2001) and can potentially 
be used in assays of pathogenicity which is a major advantage over antibody fragments 
produced from bacterial expression systems.
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1.11 AIMS OF THIS THESIS
1. To determine and analyse the sequence of the VH and VL regions of two human 
monoclonal IgG anti-B2GPI antibodies (IS4 and CL24) by cloning variable region cDNA 
into pGEM-T Easy Vector for manual sequencing and analysis.
2. To determine the relative contribution of sequence features in the H and L chains of 
IS4 and CL24, expressed as whole IgG molecules in COS-7 cells, in their ability to bind 
CL.
3. To make variant forms of each V region with altered patterns of mutation or basic 
residues by CDR exchange between 2a2 derived light chains and site directed mutagenesis 
of IS4Vh and examine the CL binding properties of these variants.
4. To develop a system for the stable expression of cloned antibody DNA sequences, 
derived from human monoclonal aPL and anti-dsDNA mAb, as whole IgG molecules in 
Chinese hamster ovary (CHO) cells which lack the dihydro folate reductase (dhfr) gene.
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CHAPTER 2 MATERIALS AND METHODS
2.1 Laboratory Reagents
Chemicals, general materials and equipment are listed in appendix B whilst enzymes, 
buffers and solutions are listed in appendix C.
2.2 Plasmids and oligonucleotides
The pGEM-T Easy vector (Promega, Southampton, U.K.) insertion site contains single 
3'dT overhangs on both sides, which are compatible with the single 3'dA base produced by 
the action of Taq polymerase thus allowing rapid cloning of purified PCR products.
Vectors pBCVHCASS4, pG lD l, pGlD106, pGlD210, pKNIOO, pLNlO, pLNlOO were all 
kind gifts from Dr C.A. Kettleborough and Dr T. Jones at AERES Biomedical, Mill Hill, 
London.
The intermediate expression vector pBCVHCASS4 shown in Figure 2.1 is based upon the 
Stratagene phagemid vector pBCSK+ containing a chloramphenicol resistance gene. 
pBCVHCASS4 vector was created from pBCSK+ by insertion of a cassette containing a 
eukaryotic leader sequence together with a number of restriction sites. The leader sequence 
is situated such that it will be in frame with a variable region gene inserted between the Sfi I 
and BamH I sites at position 742 and 811 (see Figure 2.1).
The final expression vectors pG lD l, pGlD106, pGlD210, pKNIOO, pLNlO and pLNlOO 
shown in Figures 2.2 -  2.7, all contain a human cytomegalovirus (HCMV) promoter to 
drive transcription of a recombinant immunoglobulin gene, the SV40 origin of replication 
to give high levels of transient expression in COS-7 cells and an ampicillin resistance gene 
driven by an internal promoter to enable it to be expressed in E.coli. The vectors also 
contain selectable genes (for dihydrofolate reductase or for neomycin resistance) which 
enable them to be selected in a eukaryotic expression system. In pGlD106, pGlD210, 
pKN 100, and pLN 100 vectors the CMV IEI promoter contains a regulatory sequence intron 
A, which has been shown to increase the levels of expression of glycoprotein from vectors 
containing this additional sequence (Chapman et al., 1991). Plasmids pGlDl and pLNlO 
are “old” versions of pGlD210 and pLNlOO respectively which lack intron A.
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f  1 (+) origin
Sfi 1 742
Ig Leader sequence
pBCVHCASS4 
3399 bp
BamHI 811
C hloram phenicol R lac promoter
pUC origin
Figure 2.1 Plasmid map of intermediate expression vector pBCVHCASS4
Abbreviations:- Chloramphenicol R - chloramphenicol resistance gene; Ig Leader 
sequence -  immunoglobulin eukaryotic leader sequence.
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pGlDl and pGlD106 (Figures 2.6 and 2.2 respectively) contain a human cDNA version of 
the gamma-1 constant region (Human CH), 5' to which is a multiple cloning site (MCS) 
allowing the insertion of a variable domain gene immediately followed by a splice donor 
site. The human CH is immediately preceded by a splice acceptor site hence the DNA 
between the V domain and C region is treated like a V::C intron by mammalian cells. The 
Ch is followed by a termination sequence to prevent read through. The promoter driving 
the dihydrofolate reductase {dhfr) gene is crippled so that expression is poor making 
selection by methotrexate amplification during stable transfection possible. pGlD210 
(Figure 2.3) is identical to pGlD106 save for the removal of the V::C intron and the 
replacement of the MCS with a new sequence which also encodes the last few amino acids 
of a heavy chain J region, i.e. GTLVTVSS. VhJh sequences can be cloned into the vector 
directly adjacent to Ch and in frame with it.
The light chain expression vectors pLNlO and pLNlOO (Figures 2.7 and 2.5 respectively) 
both contain a human cDNA version of the k-2 constant region sequence DNA (C>.) whilst 
pKNIOO (Figure 2.4) contains human k constant region sequence cDNA (CK). In all three 
vectors 5' to the constant region cDNA (human C l) is a MCS allowing the insertion of a 
variable domain gene immediately followed by a splice donor site. The constant region 
cDNA is immediately preceded by a splice acceptor site hence the DNA between the V 
domain and C region is treated like a V::C intron by mammalian cells and not represented 
in the expressed light chain peptide. A termination sequence follows the human Cl to 
prevent read through. The bacterial neomycin resistance gene (NeoR) may be used as a 
dominant selectable marker during stable transformation.
Recombinant expression vectors; pGlDl containing human immunoglobulin VH cDNA 
and pLNlO containing human immunoglobulin Vl cDNA were constructed by Dr Anisur 
Rahman, shown in Figures 2.6 - 2.7: and pGlD210 containing human immunoglobulin VH 
cDNA was constructed by Dr Joanna Haley, shown in Figure 2.8.
All oligonucleotide primers were supplied by Genosys, Cambridge, U.K.
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EcoR I 1
AmpR pro
AmpR sigSplice Acceptor 5994 
BamH I 5928 
Hind HI 5880 ' 
Mlu I 5868 N
Human CH AmpR
V::C intron
SV40 originMCS pG!D106
7328 bp
HCMVi promoter
dhfr
SV40 poly A sequence
EcoR I 4297
Figure 2.2 Plasmid map of expression vector pGlD106
Abbreviations: - HCMVi -  improved human cytomegalovirus promoter containing intron 
A; Human CH - cDNA version of the gamma-1 constant region; MCS - multiple cloning 
site; V::C intron - region of plasmid DNA between variable (V) domain insert and constant 
(C) region treated like a V::C intron by mammalian cells; AmpR pro -  promoter for 
ampicillin resistance gene; AmpR sig -  signal sequence for ampicillin resistance gene; 
AmpR - Ampicillin resistance gene; dhfr - dihydrofolate reductase gene.
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Pvu I 621
AmpR pro
AmpR sigXho I 5921
AmpRHuman CH
Hind III 5875
MCS pGlD210
SV40 origin
7268 bp
HCMVi promoter
dhfr
SV40 poly A sequence
EcoR I 4293
Figure 2.3 Plasmid map of expression vector pGlD210
Abbreviations: - HCMVi -  improved human cytomegalovirus promoter containing intron 
A; Human CH - cDNA version of the gamma-1 constant region; MCS - multiple cloning 
site; AmpR pro -  ampicillin internal promoter; AmpR sig -  ampicillin signal sequence; 
AmpR - Ampicillin resistance gene; dhfr - dihydrofolate reductase gene.
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EcoR I 1
Hind III 1584 
BamHI 1614HCMVi promoter
MCS Splice Acceptor 1740pKNIOO
V::C intronNeoR
7694 bp
Human CK
NeoR pro
AmpR pro 
AmpR sig i
AmpR A
SV40 origin
EcoR I 2490
Pvu I 3116
Figure 2.4 Plasmid map of expression vector pKNIOO
Abbreviations: - HCMVi -  improved human cytomegalovirus promoter containing intron 
A; Human CK - cDNA version of the human (allotype Km3) constant region; MCS - 
multiple cloning site; V::C intron - region of plasmid DNA between variable (V) domain 
insert and constant (C) region treated like a V::C intron by mammalian cells; AmpR pro -  
promoter for ampicillin resistance gene; AmpR sig -  signal sequence for ampicillin 
resistance gene; AmpR - ampicillin resistance gene; NeoR pro -  promoter for neomycin 
resistance gene; NeoR -  neomycin resistance gene.
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EcoR  I 1
HCMVi promoter 
pLNlOO MCS
V-C intron7481 bp
NeoR 
^  NeoR pro 
SV40 origin
Human CL
AmpR pro
AmpR sig 
AmpR
Hind HI 1584 
Bam H I 1614 
Splice acceptor 1740
EcoR I 2294
Pvu I 2920
Figure 2.5 Plasmid map of expression vector pLNlOO
Abbreviations: - HCMVi -  improved human cytomegalovirus promoter containing intron 
A; Human CL - cDNA version of the human lambda-2 constant region; MCS - multiple 
cloning site; V::C intron - region of plasmid DNA between variable (V) domain insert and 
constant (C) region treated like a V::C intron by mammalian cells; AmpR pro -  promoter 
for ampicillin resistance gene; AmpR sig -  signal sequence for ampicillin resistance gene; 
AmpR - ampicillin resistance gene; NeoR pro -  promoter for neomycin resistance gene; 
NeoR -  neomycin resistance gene.
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EcoR I 1
SV40 origin
dhfr
33H11VH/PG1D1
6902 bp
AmpR
P v u l 1876
Human CH AmpR sig 
AmpR pro
HCMV promoter f,V::C intron
33H11VH
Splice acceptor 4207
BamH I 4153 \
Splice donor 4147 y 
Leader sequence
EcoR I 2502
Hind III 3729
Figure 2.6 Vector map of recombinant heavy chain expression vector 
33H llV H/pG lD l
This vector containing the Vh region of 33H11 (including a leader sequence from 
pBCVHCASS4) had been previously cloned by Dr A. Rahman.
Abbreviations: - HCMV -  human cytomegalovirus promoter; Human CH - cDNA version 
of the gamma-1 constant region; MCS - multiple cloning site; V::C intron - region of 
plasmid DNA between variable (V) domain insert (33H11 VH) and constant (C) region 
treated like a V::C intron by mammalian cells; AmpR pro -  promoter for ampicillin 
resistance gene; AmpR sig -  signal sequence for ampicillin resistance gene; AmpR - 
Ampicillin resistance gene; dhfr - dihydrofolate reductase gene.
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EcoR 1 1
Hind IH1224 
Acc 651 1402
Splice donor 1624 
BamHI 1630
HCMV promoter
Leader
B3VL'
B3VL/pLN10
7497 bp
Splice acceptor 1756
V::C introi
NeoR Human CL-
NeoR pro AmpR pro 
AmpR sig EcoR 12310
SV40 origin
AmpR
Pvu 12936
Figure 2.7 Vector map of expression vector B 3V l/ p L N 10
The V l region of B3 (including a leader sequence from pBCVHCASS4) had been 
previously cloned by Dr A. Rahman into pLNlO. The vector map of 33H11 VL /pLNlO is 
identical to that shown above but lacks an Acc65 I site in 33H11Vl- UK4Vl is six 
nucleotides smaller than B3Vl in CDR3, hence the features shown above are the same for 
UK4Vi/pLN10 to the Acc65 I site after which the position of all regions and sites is six 
nucleotides less than in B3Vi/pLN10.
Abbreviations: - HCMV -  human cytomegalovirus promoter; Human CL - cDNA version 
of the human lambda-2 constant region; MCS - multiple cloning site; V::C intron - region 
of plasmid DNA between variable (V) domain insert (B3VL) and constant (C) region 
treated like a V::C intron by mammalian cells; AmpR pro -  promoter for ampicillin 
resistance gene; AmpR sig -  signal sequence for ampicillin resistance gene; AmpR - 
ampicillin resistance gene; NeoR pro -  promoter for neomycin resistance gene; NeoR -  
neomycin resistance gene.
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Hind III 5875
AmpRHuman CH
B3VH
Leader
B3VH/pGlD210 SV 40ongm 
7653 bp
HCMVi promoter
SV40 Poly A sequence
EcoR 14293
Figure 2.8 Vector map of recombinant heavy chain expression vector B3Vn/pGlD210
The Vh region of B3 (including a leader sequence from pBCVHCASS4) had previously 
been cloned into pGlD210 by Dr J. Haley.
Abbreviations: - HCMVi -  improved human cytomegalovirus promoter containing intron 
A; Human CH - cDNA version of the gamma-1 constant region; MCS - multiple cloning 
site; AmpR pro -  promoter for ampicillin resistance gene; AmpR sig -  signal sequence for 
ampicillin resistance gene; AmpR - Ampicillin resistance gene; dhfr - dihydrofolate 
reductase gene.
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2.3 Bacterial Strains
Escherichia coli of strain DH5a Invitrogen, Paisley, U.K.
Escherichia coli XL 1-Blue Supercompetent cells Stratagene, California, USA.
2.4 Human monoclonal antibodies
IS4, CL24, B3, 33H11 and UK4 are all human IgG monoclonal antibodies produced from 
lymphocytes of five different patients. IS4 and CL24 were derived from patients with 
PAPS and SLE/APS respectively by EBV transformation of peripheral blood mononuclear 
cells and fusion with the human-mouse heterohybridoma K6H6/B5 cell line (Zhu et al., 
1999). Both IS4 and CL24 bind to CL in the presence of bovine and human p2GPI and to 
human p2GPI alone (Zhu et al., 1999). B3 (Ehrenstein et al., 1994), 33H11 (Winkler et al.,
1992) and UK4 (Menon et al., 1997) were isolated by fusion of PBL from patients with 
cells of the mouse human heteromyeloma line CB-F7. 33H11 is specific for dsDNA, B3 
binds ssDNA, dsDNA and histones (Ehrenstein et al., 1994; Kalsi et al., 1996). UK4 binds 
negatively charged (but not neutral) PL in the absence of p2GPI and does not bind DNA 
(Menon et al., 1997). The hybridoma cell lines of CL24 and IS4 were all produced and 
kindly donated by Dr P.Chen, Department of Medicine, Division of Rheumatology, 
University of California at Los Angeles, Los Angeles, USA and maintained by Dr Jose 
Alves at the Centre for Rheumatology, University College London (U.C.L.), U.K. 33H11 
(Winkler et al., 1992) was a kind gift from Dr Thomas Winkler (Erlangen, Germany). B3 
(Ehrenstein et al., 1994) and UK4 (Menon et al., 1997) were produced by our group at 
U.C.L. in London. The characteristics of the patients are shown in table 2.1 and original 
antibody binding properties of IS4 and CL24 displayed in table 2.2.
2.5 Extraction of total RNA from hybridoma cells
2.5.1 Counting cells using a haemocytometer
Working under sterile conditions 0.2mls of hybridoma cell suspension was placed into a 
sterile bijou and diluted with 0.5mls of 0.4% Trypan blue solution and 0.3mls of Hanks 
Balanced Salt Solution (HBSS) then allowed to stand for five minutes. Trypan blue stains 
only dead (non-viable) cells blue, thus enabling the number of viable (white) cells to be 
counted. With the cover slip in place, enough of the cell suspension was transferred to fill 
both chambers of a sterile haemocytometer.
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Feature Patient 1 Patient 2 K.H. D.H. SLE2
Thrombosis + + + - NS
Pulmonary Emboli - + - - NS
CNS + NS - - NS
Miscarriages - NS - - NS
Migraines NS NS - + NS
Rash - NS + - NS
Arthritis - NS + NS
Serositis NS NS - + NS
Thrombocytopenia NS NS - - NS
Renal Disease - + - + +
ANA + + + + NS
dsDNA - + + + +
Decreased C3 & C4 - + - + +
LA + + - - NS
aCL + + + + NS
Table 2.1 Clinical and serological characteristics of patients from whom monoclonal 
antibodies were derived
IS4 was derived from PBL of a 19 year old patient with PAPS (patient 1). CL24 was 
derived from PBL of a 17 year old SLE/APS patient (patient 2). B3 was derived from 
PBL of a 60 year old patient with SLE (K.H.). UK4 was derived from PBL of a 49 year old 
patient with SLE (D.H.). 33H11 was derived from PBL of a SLE patient (SLE2). NS 
indicates where it was not stated in the relevant journal paper whether the patient from 
whom a mAb was derived, had the particular feature or not.
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IS4 CL24
Immunological reactivity
Antigens
CL/BS H—f~ ++
CL alone - -
CL/HS + +
CL/human B2 GPI ++ ++
Human B2 GPI alone + +
Functional reactivity
LA - +
Table 2.2 Immunological characteristics of IS4 and CL24 monoclonal aPL
Abbreviations: - CL - Cardiolipin; BS - Bovine Serum; HS - Human Serum; LA -  Lupus 
Anticoagulant.
Modified from Table II, Zhu et al. (1999).
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Under the light microscope the number of viable cells in the central 1 mm square and the 
four comer 1mm squares was counted in chamber one and an average obtained. Only cells 
completely inside a square and those touching the right and bottom perimeter of each 
square were counted. The procedure was repeated for chamber two. Each chamber of the 
haemocytometer with cover slip in place represents a total volume of 0.1mm3 . The final 
cell count was taken as an average from the cell count for each chamber. The total numbers 
of cells were calculated using the following formula:-
Cell count (average) x Dilution Factor (5) x 104 x original volume of fluid from which cell 
sample was removed.
The total number of cells recovered was approximately 106to 107.
2.5.2 Isolation of RNA
This was achieved using RNAzol B, which contains phenol and guanidium thiocyanate. A 
suspension of approximately 1 0 6  to 1 0 7 hybridoma cells was centrifuged for 1 0  minutes at 
250g at 4°C. Supernatant was discarded and the cell pellet resuspended in 20 ml PBS then 
centrifuged at 250g at 4°C for five minutes. Supernatant was removed by aspiration and 
200pl of RNAzol per million cells added to the cell pellet, mixed thoroughly and then 
transferred to a sterile 0.5 ml microfuge tube. A 1/10 volume of chloroform was added, 
vortexed for 15 seconds and then the tube was left on ice for 15 minutes. The suspension 
was spun at 13000g in a microcentrifuge for 15 minutes and the upper aqueous layer 
containing RNA transferred to a fresh 0.5 ml microfuge tube. An equal volume of propan- 
2-ol was added and the mixture kept at -20°C for at least one hour (or overnight) to 
precipitate the RNA. Following this a small pellet of RNA was recovered by centrifugation 
at 13000g for 15 minutes and then “washed” by adding 1 ml of 75% ethanol in 0.1% DEPC 
water. In this context “washed” means that the pellet was resuspended in 75% ethanol, then 
reprecipitated by centrifugation at 3300g for 10 minutes. Supernatant was completely 
removed and the pellet was dried at 37°C for approximately 30 minutes. Finally lOpl of 
0.1% DEPC water was added ip which the RNA was fully dissolved by incubation at 65°C 
for 10 minutes before being stored at -80°C.
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2.6 Synthesis of cDNA from hybridoma total RNA
A 1 (4.1 aliquot of stored RNA containing approximately lpg of hybridoma total RNA was 
removed from storage and heated at 65°C for two minutes before being transferred to a 
0.5ml microfuge tube. The following reaction mixture was then added; 2 pl 25mM MgCl2, 
2pl of a mixture of dATP, dCTP, dGTPand dTTP containing each dNTP at a concentration 
of 25mM, lpl random hexamers (0.9 units/ml), 2pl lOxPCR Buffer, 0.5pl (40u/jul) 
ribonuclease inhibitor (RNAsin), 0.5pl (200u/pl) AMV reverse transcriptase and 
autoclaved ddH20 to 2 0 (4,1 .
Each mixture was pulse spun at 13000g in a bench centrifuge and then placed in a 37°C 
bath with the closed lid covered with parafilm for one hour. The products were then used 
immediately as the substrate in a PCR.
2.7 Amplification of Vh and Vl cD N A  by PCR
In this step only cDNA encoding the V region of IS4 and CL24 produced by the hybridoma 
cells from which RNA had been extracted is selectively amplified by specific PCR primers 
(see Table 2.3).The following reaction mixture was added to the 20pl cDNA from section 
2.6; lOpl lOxPCR Buffer, 8 pl 25mM MgCl2, lpl of a mixture of dATP, dCTP, dGTPand 
dTTP containing each dNTP at a concentration of 25mM, lpl forward primer (final 
concentration lpM), lpl reverse primer (final concentration lpM), autoclaved ddH20  to 
80pl and lpl (5u/p.l) Taq Polymerase.
As a negative control no cDNA was added to one reaction mixture. Each mixture was then 
pulse spun and placed into a PCR machine programmed as follows:-
Initial denaturation at 94°C for 5 minutes 
Then 30 cycles as follows: -  
94°C for 1 minute
Annealing temperature for one minute - 65°C for VK primers
55°C for primers
55°C for VH1 and VH3 primers
42°C for VH2, VH5 and VH9 primers
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72°C for one minute
Then a final elongation phase at 72°C for 5 minutes.
The presence of PCR product of the expected length (350 -  400bp) was confirmed by gel 
electrophoresis through a 1 % agarose gel (see section 2 .8 ).
PCR Primers used in this step are shown in table 2.3. The forward primer JL was used to 
amplify IS4 region and binds to the 3' terminus of (Hawkins et al., 1994). 
Amplification of each VH region was achieved using a Cy forward primer that binds to a six 
codon stretch of the gamma constant gene about 20-3Obp from the JHCy junction 
(Stevenson et al., 1993). Similarly the forward primer CK was used to amplify CL24 VK 
(Stevenson et al., 1993).
Primers Sequences
HL 10 5CAGTCTGTGTTGACGCAGCCGCCCTC3'
HL 20 5CAGTCTGCCCTGACTCAGCCTGCCTC3'
HL 30 5' TCCT ATGAGCTGACTC AGCC ACCCTC3'
JL 5ACCTAGGACGGTCAGCTTGGTCCC3'
VK 1 5GACATCCAGATGACCCAGTCTCC3'
VK 2 5GATATTGTGATGACTCAGTCTCC3'
VK 3 5GAAATTGTGTTGACGCAGTCTCC3'
CK 5' CGAG AATTCT AGATC AT C AGAT GGCGGA3'
VH 2 5' C AGGTGC AGCTGGTGG AGTCTGG3'
VH 4 5' AT G A A AC ACCT GT GGTT CTT3'
VH 5 5' GAGGTGC AGCTGCTGC AGTCTG3'
VH 1 5' C AGGTCC AGTTTGTGC AGTCT3'
VH 3 5' G A AGTGG AGTT ATTGG A ATCT3'
Cy 5' C AGGGGG A AG ACCGATGG3'
Table 2.3 PCR primers used to amplify Vh and VL cDNA for initial sequencing
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Back primers HL10, HL20 and HL30 which bind to the first nine codons of genes 
belonging to the V^l, V^2 and V*3 families respectively were used to amplify and identify 
IS4 Vx (Hawkins et al., 1994). To identify CL24 VK the VK1, VK2 and VK3 primers which 
bind to the first eight codons of genes from VK1, VK2 and VK3 families respectively were 
used (Hawkins et al., 1994). Initially the back primers VH2, VH5 and VH9 were employed 
to identify and amplify the VH regions. VH2 and VH5 primers bind specifically to the first 
seven codons of genes from Vh2 and Vh5 families respectively whilst the VH9 primer is 
designed to show homology to the first eight codons of the VH gene segment of families 
VhI, Vh3 and Vh4 (Rahman, 1998). Later the sequences of IS4 and CL24 were provided 
by Dr Chen so primers could be designed which bound specifically to the first seven 
codons of IS4 and CL24 VH. These primers were designated VH3 and VHI respectively.
2.8 Separation of DNA fragments by agarose gel electrophoresis
One litre of TAE buffer was prepared (see appendix C), lOOmls of which were then 
removed and mixed with 1 g of agarose, or low melting point agarose (Invitrogen), to make 
a 1% gel. The solution was heated in a microwave oven until all the agarose had dissolved 
and then allowed to cool until hand hot when 2pl of lOmg/ml ethidium bromide was added. 
Ethidium bromide molecules intercalate between base pairs in the DNA double helix 
rendering it fluorescent when viewed under ultraviolet (UV) light.
The open ends of a gel tray (Bio-Rad) were closed off with tape and the agarose solution 
poured in. Plastic combs were then placed in the gel tray to create wells in the agarose as it 
solidified and any air bubbles were removed. Once the gel had set the comb and tape were 
carefully removed and the gel tray placed in an electrophoresis tank (Bio-Rad) to which the 
remaining 900mls of TAE buffer was added.
To each 12pl of sample to be loaded onto the gel 2pl of loading buffer were added. This 
buffer contains Ficoll which increases the density of the sample, ensuring the DNA in each 
sample sinks evenly into the well. The buffer also colours the sample with a dye (xylene 
cyanole) that moves towards the anode at a predictable rate, allowing progress through the 
gel to be monitored. Between 10 and 40pl of each sample were then added to each well and 
a voltage of 100 Volts applied for one hour.
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The gel was then removed from the electrophoresis tank and examined under UV light. The 
sizes of bands in the gel were estimated by comparison with a standard DNA molecular 
weight marker loaded into another well in the same gel. Photographs of the gel were taken 
using the Genesnap programme (Syngene, Cambridge, UK) and printed onto paper. If the 
DNA had to be recovered from the gel the appropriate band was cut out with a scalpel and 
stored at -20°C.
The concentration of each DNA fragment was estimated by running the product with 
molecular weight markers. The latter contained a known concentration of DNA. Thus 
comparison of the relative brightness of each band produced enabled the estimation of the 
concentration of DNA upon the gel and thus by extrapolation in the total sample.
2.9 Purification of amplified VH and VL cDNA from agarose gels
DNA excised from agarose gels was initially purified by adsorption onto silica particles 
(method A) using the Geneclean II kit (Anachem, Luton, UK) but the QIAquick gel 
extraction (Qiagen, Crawley, West, Sussex, U.K.) kits were later found to increase the yield 
of recombinant DNA (method B).
2.9.1 Method A
Each excised band of DNA was placed in a 1.5ml microfuge tube and its volume 
determined by approximating O.lg of the gel slice to equal lOOpl. Three times the volume 
of sodium iodide (Nal) was added and the agarose melted by incubation in a 55°C water 
bath for five minutes. 5pi of glassmilk were added per 500pl of final volume of solution 
unless the final volume exceeded 1ml in which case 20pl of glassmilk were used. 
Following this the mixture was incubated at room temperature for five minutes with regular 
mixing by vortex every 1-2 minutes. The mixture was then spun at 13000g for 5 seconds 
and the supernatant removed and saved in case all of the DNA did not bind to the 
glassmilk. The pellet was washed three times in 500pl of “New Wash” buffer supplied in 
the kit (see appendix C). Once all of the supernatant from the third wash had been removed 
the pellet was dried under a vacuum for approximately three minutes and resuspended in a 
volume of water equal to the amount of glassmilk used. The suspension was then 
centrifuged at 13000g for one minute and supernatant containing eluted DNA carefully
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removed and placed in a fresh 1.5ml microfuge tube. A second elution was carried out to 
recover a further 10-20% of DNA and saved with the product of the first elution at -20°C.
2.9.2 Method B
An excised band of DNA of up to 0.4 g was placed in a 1.5ml microfuge tube and 1ml of 
buffer QG added. The mixture was then incubated at 55°C for 10 minutes until all agarose 
had dissolved. 700pl of this solution was then added to a spin column placed in a collection 
tube and centrifuged at 13,000g for 10 seconds. Flow through was discarded from the 
collection tube and the procedure repeated until all of the initial mixture had been passed 
through the spin column. A further 500pl of buffer QG was added to each spin column and 
centrifuged at 13,000g for 10 seconds. After discarding the flow through the column was 
washed twice with 500pl of buffer PE and centrifuged as above. Each column was then 
placed into a fresh 1.5ml microfuge tube and dried under a lamp for 5 minutes. Elution of 
DNA from each column was performed by addition of 50pl of solution EB (lOmM Tris- 
HC1 pH 8.5), allowing the column to stand for 1 minute followed by centrifugation as 
above. The product was then stored at -20°C.
2.10 Ligation of amplified cDNA into pGEM-T Easy Vector
Purified PCR products from step 2.9 were then ligated into (50ng) pGEM-T Easy Vector by 
TA cloning at a range of 3:1 to 1:3 insert:vector molar ratios. To 4pl of pGEM-T Easy 
Vector: purified PCR product mix, lpl lOx ligase buffer, 4pl autoclaved water and lpl 
(3u/pl) T4 DNA ligase were added. Samples were incubated overnight at 4°C. The ligation 
product was used to transform competent DH5a cells.
2.11 Production of competent DH5a cells
DH5a cells picked from a discrete colony upon an LB agar plate were grown overnight in 
lOmls of LB medium at 37°C in a shaking incubator (300rpm). The following morning 
lOOpl of this culture were added to 100ml of LB in a sterile flask and returned to the 
shaking incubator for approximately three hours. When swirling clouds of bacteria were 
just visible the culture was removed from the incubator and divided into two 50ml 
centrifuge tubes which were then centrifuged at 1864g for 10 minutes at 4°C. Supernatant 
was discarded from each tube and the pellet resuspended in lOmls of ice cold lOOmM
140
CaCl2.6H20 . Each tube was again centrifuged at 1864g for 10 minutes at 4°C and the 
supernatant discarded. Finally each pellet was resuspended in 2mls of ice-cold lOOmM 
CaCl2.6H20  and this suspension was used for transformations.
2.12 Transformation of competent DH5a cells with recombinant pGEM-T Easy 
Vector
5pi of recombinant plasmid DNA were added to 200pl of competent DH5a cells and left 
on ice for 30 minutes. A heat shock of 42°C for 90 seconds was then applied, following 
which the cells were incubated in 800pl of LB at 37°C for one hour. The cell suspension 
was then centrifuged at 700g for 10 minutes at room temperature; most of the supernatant 
was poured off and the pellet resuspended in the remaining supernatant. This suspension 
was then spread onto an LB agar plate containing 50pg/ml ampicillin, 30pl Xgal (20mg/ml) 
and 30pl IPTG (200mg/ml). After drying on the bench for 15 minutes the plates were then 
incubated at 37°C overnight and finally stored at 4°C.
Only cells that have taken up pGEM-T Easy Vector should produce colonies on the 
ampicillin containing plates because the vector contains a gene conferring resistance to 
ampicillin whilst DH5a cells are sensitive to this antibiotic. Colonies containing both 
pGEM-T Easy Vector and insert will produce white colonies because the insert disrupts the 
p galactosidase gene in pGEM-T Easy Vector. Cells that contain self-ligated vector will 
produce blue colonies, as the p galactosidase gene remains intact and will thus be induced 
by IPTG to digest its substrate X-gal. Growth and differentiation of white colonies from 
blue ones sometimes required several days’ storage at 4°C. After this white colonies were 
picked from the plate into 5ml LB cultures containing 50pg/ml of ampicillin and kept 
overnight in a 37°C shaking incubator. The following day 0.5ml aliquots of the cultures 
produced were mixed with 0.5ml of sterile glycerol and stored at -20°C.
2.13 Small scale extraction of cloned cDNA from E.coli for sequencing
Purification of plasmid DNA from overnight cultures of E.coli in LB medium was carried 
out by alkaline lysis (Bimboim and Doly, 1979), separation into an organic and solvent 
phase and elution of DNA using the Qiagen Miniprep Kit and buffers (see appendix C). A 
bacterial colony was picked from an agar plate and incubated in 5ml of LB containing
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50pg/ml of ampicillin overnight at 37°C. A bacterial pellet was obtained by centrifugation 
at 1864g for 10 minutes at 4°C and dried by inversion. The pellet was resuspended in 250pl 
of buffer PI and transferred to a 0.5ml microfuge tube. Then 250pl of buffer P2 was added 
and the tube inverted six times. Following this 350pl of buffer N3 was added, mixed by 
inversion and then centrifuged for 10 minutes. All subsequent centrifugation steps were 
carried out at 13000g in a microcentrifuge for one minute at room temperature. Supernatant 
from this step was decanted into a QIAprep spin column and centrifuged. DNA bound to 
the QIAprep spin column was washed by adding 0.75ml of Buffer PE and centrifuged. 
Flow through was discarded and the column centrifuged. After placing the QIAprep spin 
column in a clean 1.5ml microfuge tube recombinant DNA was eluted by adding 50pl of 
autoclaved water to the centre of each QIAprep column which was left to stand for one 
minute before being centrifuged. Eluted DNA was then stored at -20°C.
2.14 Restriction enzyme digestion of plasmid DNA
An EcoR I digest confirmed success of the ligation of amplified cDNA into pGEM-T Easy 
Vector, lpg of plasmid DNA (quantified by gel electrophoresis, section 2.8) was incubated
o
with lOu EcoR I and buffer H (described below) at 37 for one hour and the product run 
upon an agarose gel (see section 2.8).
Small scale digests were carried out to characterise the structure of a newly isolated 
plasmid. For the majority of confirmation digests lpg of plasmid DNA and 10 units of 
restriction enzyme were usually incubated in a total volume of 20pl for one hour with the 
appropriate buffer, at the temperature specified by the enzyme manufacturer to achieve full 
digestion. For double digests with enzymes that required incompatible buffering conditions, 
digestion was achieved sequentially with the enzyme requiring the lowest salt concentration 
used first. The solution was then supplemented with additional salts to achieve the correct 
conditions for the second enzyme which was then incubated appropriately. The recipe for a 
typical small scale digest (unless stated otherwise) would be as follows:
Plasmid DNA
ddH 20
Enzyme 
1 Ox Buffer
5 pi (lpg DNA) 
lpl (lOu/pl)
2pl
to 20pl
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2.15 Sequencing and analysis of cloned variable region cDNA
In order for sequencing to be carried out plasmid DNA must first be denatured. Fresh 2M 
NaOH, 2mM EDTA solution was prepared and 1/4 volume added to 45pl of miniprep 
plasmid DNA containing 8-9pg DNA, then left at room temperature for 15 minutes. A 1/10 
volume of 3M sodium acetate (pH 5.2) and 1.5 volumes of 100% ice cold ethanol were 
added and left at -70°C for 30-45 minutes. The solution was then centrifuged at 13000g for 
10 minutes at 4°C and the DNA pellet washed with lOOpl of ice cold 70% ethanol. The 
pellet was dried under a vacuum for 3-5 minutes and resuspended in 10-15pl of 
autoclaved water, then stored at -20°C.
The dideoxynucleotide chain termination method (Sanger et al., 1977) was performed using 
the Sequenase Version2.0 kit (USB). 7pl of denatured template DNA were added to 2pl of 
5xSequenase Buffer and lpl of the appropriate primer at a concentration of lpM. This 
mixture was incubated at room temperature for 15 minutes so the primer could anneal to 
the template DNA. Primers used for sequencing insert in pGEM-T Easy Vector were the T7 
promoter and SP6 which occur on either side of the inserted cDNA. During this incubation 
the termination 0.5ml microfuge tubes were labelled in sets of four with the name of the 
template/primer mix and the letter A, C, G or T on each. Then 2.5pl of a different 
dideoxyNTP (ddNTP, 8pM) was added to each tube. Thus each tube A contained ddATP, 
tube C ddCTP, and so on. Each “termination” tube was then placed in a 49°C water bath.
The following components were then added to the template/primer mix: - 0.7pl 33SdATP, 
lpl Dithiothreitol (DTT), 2pl of a labelling mix containing 1.5pM deaza-dGTP and 1.5pM 
each of dCTP and dTTP and 2pl (13u/pl) Sequenase (DNA Polymerase) diluted 1:7 in 
lOmM Tris HC1, 5mM DTT.
The reaction mixture was then incubated for two minutes at room temperature to enable 
elongation of complementary DNA strands (radiolabelled with 35SdATP) from the primer, 
by DNA Polymerase. Following this 3.3pl of each reaction mixture were added to each of 
the four termination tubes and incubated at 49°C for 5 minutes. The sequencing reaction in 
each tube was then stopped by the addition of a solution containing 95% formamide, 20 
mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanole. The incorporation in each
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termination tube of the respective ddNTP which lacks the terminal 3' hydroxyl group for 
chain extension means that the species of DNA of different lengths in tube A all end in 
ddATP, DNA in tube C ends in ddCTP and so on.
2.15.1 Polyacrylamide gel electrophoresis
Fresh sequencing gel solution (see appendix C) was prepared as above then drawn up into a 
20ml syringe and expelled between two large glass sequencing plates. The plates were 
separated by plastic spacers at each side, two upside down plastic gel combs at the top and 
held together by bulldog clips. Fluid was drawn between the plates by capillary action and 
frequent tapping of the plates at the leading gel edge with a constant supply of fluid at the 
top of the plates ensured an even spread of the gel with no air bubbles. The gel was left for 
one hour to solidify as a thin sheet of polyacrylamide between the plates. Following this the 
plates were placed vertically with the comb facing inwards in an electrophoresis bath 
(Invitrogen) containing 11 of TBE buffer (see appendix C). The combs were then reversed 
so the shark tooth edge pierced the gel creating 48 wells. Samples from sequencing 
reactions were denatured by boiling at 100°C for two minutes and then 3 pi loaded such that 
A, C, G, T tubes from the same reaction were in adjacent wells.
A current was passed through the gel at a power of 42W for approximately 2 hours and 
twenty minutes. The plates were removed and the gel transferred to 3MM chromatography 
paper (Whatman International Ltd, Maidstone, U.K.) then covered in cling-film and dried 
in a vacuum drier for 1-3 hours. Following this the clingfilm was removed. In a dark room 
the gel was placed in an autorad cassette (Bio-Rad) with Kodak (X-OMAT) AR film 
(Amersham Pharmacia Biotech, Bucks, U.K.) and the cassette tightly sealed. Typical 
exposure of the film was for 2-5 days, before developing (Xograph, Bedfordshire, U.K.) 
and reading the sequence of dark bands representing chains of DNA of different length.
2.15.2 Alignment to closest possible germline alleles
Germline genes of origin for each VH and VL chain of IS4 and CL24 were obtained using 
DNAplot software in VBASE, which is a comprehensive sequence directory of all known 
human Ig genes and their alleles (Tomlinson et al., 1996). Nucleotide homology was then 
calculated using the following formula and expressed as a percentage.
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total no. nucleotides in V region -  total no. of mutations in the V region 
total no. nucleotides in V region
Any differences between the germline and expressed antibody sequences were considered 
to be somatic mutations unless they were at sites of junctional diversity or could be shown 
to arise from the PCR primers originally used to clone the antibody cDNA or if they were 
at known sites of allelic polymorphism.
Each somatic mutation was classed as either R or S depending on the effect on amino acid 
sequence. In the rare instances where there were two nucleotide substitutions in one codon, 
the effect of each single mutation upon the amino acid sequence was considered separately 
and correspondingly classed as R or S mutations.
2.15.3 Analysis of distribution of R and S mutations
Statistical analysis of the distribution of R and S mutations was carried out for all Vh and 
V l sequences. The cumulative multinomial method (Lossos et al., 2000) was used to 
calculate the probability that an excess or scarcity of R mutations in the Ig V gene CDRs or 
FRs results from chance alone. Calculations by the multinomial method were made using 
the JAVA applet provided by Lossos et al, at http://www-stat.stanford.edu/immunoglobin.
It has previously been shown from analysis of the known crystal structures of twenty-six 
different antigen-antibody complexes that certain residues within CDRs of the heavy and 
light chains are more likely than others to contact antigens (MacCallum et al., 1996). 
Therefore the amino acid residues most likely to contact antigen were determined according 
to the paper of MacCallum et al. (1996).
2.16 Preparation of cloned Vh and Vl sequences for expression as whole Ig
The stored cDNA of IS4 and CL24 mAbs did not contain splice sites or leader sequences, 
which are required to enable their secretion from mammalian cells. Thus these features had 
to be incorporated by PCR amplification and ligation into an intermediate (pBCVHCASS4) 
then final expression vectors (pLNlOO for V*, pKNIOO for VK and pGlD210 via pGlD106 
for VH), which also contain the appropriate constant region cDNA, necessary to allow the 
production of whole antibody molecules.
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2.16.1 Incorporation of restriction and splice donor sites into stored cDNA by PCR 
amplification
Purified recombinant IS4 and CL24 V region cDNA in pGEM-T Easy vector was obtained 
as described in section 2.13 and then used as a substrate in a PCR reaction. The conditions 
for this reaction were the same as used in section 2.7, except that an annealing temperature 
of 42°C was used with specific primers shown in Table 2.4.
PCR amplification of cloned IS4 and CL24 V region cDNA with specific primers 
incorporates a Sfl I restriction site at the 5' end and a splice donor site followed by a 
BamH I restriction site at the 3' end. The addition of restriction sites allows the cDNA to be 
ligated into subsequent vectors whilst the splice donor site at the 3' end of each V region 
enables a portion of DNA between the V and C regions in the final expression vector to be 
treated as an intron.
The primers were designed so that they overlapped with each VH and VL region followed 
by a spacer of 5-6 nucleotides then SJi I and BamH I restriction sites to be incorporated at 
the 5' and 3' ends of each Vh and Vl region respectively.
Primers Sequences
IS4HBACK
IS4HFOR
CL24HBACK
CL24HFOR
IS4LBACK
IS4LFOR
CL24LBACK
CL24LFOR
5GGCTCGGCCACTGAGGCCCACAGCCAGGTCCAGTTTGTGCAGTCT3'
5'TTGGATCCACTCAC::CTGAGGAGACGATGACCAG3'
5GGCTCGGCCACTGAGGCCCACAGCGAAGTGGAGTTATTGGAATCT3'
5'TTGGATCCACTCAC::CCGAGGAGACGATGACCTG3'
5GGCTCGGCCACTGAGGCCCACAGCCAGTCTGCCCTGACTCAGCCTG3'
5' GTGG ATCC ACTC AC:: CTAGGACGGTC AGCTT3'
5GGCTCGGCCACTGAGGCCCACAGCGAAATTGTGTTGACGCAGTCT3'
5' GTGGATCC ACTC AC: :GTCGTTTG ATCTCC AGCCTGGT3'
Table 2.4 PCR primers used in eukaryotic expression system
Restriction sites are underlined
:: denotes the position of the splice donor site
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The cDNA of IS4 VH was amplified and extended by the following primers. IS4 H back 
primer includes a site for the enzyme Sfi I (GGCCNNNNNGGCC) followed by a spacer of 
six nucleotides and then the first seven codons of IS4 VH. The enzyme site was bounded at 
the 5' end by a five bp “cap” designed to enhance its stability in the PCR product. IS4 H 
forward primer contains a BamH I site (GGATCC) followed by a splice donor site then the 
5' end of the DNA strand complementary to the last six codons of IS4Vh.
The other forward and back primers were designed to include similar elements in the same 
order. IS4L forward and IS4L back primers extend and amplify IS4VL. Names of the 
primers for CL24 are similarly self-explanatory.
2.16.2 Digestion with Sfi I and BamH I
The product of each PCR was confirmed by gel electrophoresis and bands of the 
appropriate size extracted from the gel (by method A, section 2.9) and then digested 
sequentially with Sfi I (NEB) then BamH I (NEB). First a reaction mixture containing - 
19pl of PCR product, 4pl lOx NEB Buffer 2, 2pl (20u/pl) Sfi I and ddFhO to a final volume 
of 40pl was incubated at 50°C for 90 minutes. Then 5.1 pi of NaCl 1M and 2pl (20u/pl) 
BamH I were added and incubated at 37°C for a further hour. Products of the reaction were 
confirmed by gel electrophoresis and bands of approximately 400bp in length containing 
digested V region mAb cDNA were cut out and DNA extracted (by method A, section 2.9). 
The intermediate vector pBCVHCASS4 was digested and purified in exactly the same way.
2.16.3 Cloning into the intermediate vector pBCVHCASS4
Purified V region DNA produced by the preceding methods was then ligated into an 
intermediate expression vector pBCVHCASS4 described in section 2.2 and shown in 
Figure 2.1. Ligation of the purified product of Sfi 1/BamH I digested pBCVHCASS4 (as 
described above) with a PCR amplified V region DNA Sfi VBamH I digested fragment 
places the insert in frame 3' to the leader sequence ensuring it is translated in phase. These 
purified Sfi VBamH I digested PCR products were ligated with three different 
concentrations of Sfi VBamH I digested pBCVHCASS4: - neat, 1 in 5 and a 1 in 10 dilution 
with sterile water. To lOpl of insert/vector mix - 2pl lOx ligase buffer, lpl (3u/pl) T4 DNA 
ligase and autoclaved water to 20pl were added.
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The mixture was incubated at 4°C for 16-20 hours and then used to transform competent 
DH5a E.coli cells as in section 2.12. Paired controls were also set up with each 
concentration of vector and instead of PCR product 5pl of sterile water were added instead. 
An intact plasmid was also transformed as a positive control to check that the cells had 
been made competent. The transformed cells were spread onto LB agar plates containing 
50pg/ml chloramphenicol. A sample of non-transfected bacteria was spread on a separate 
plate as a negative control to show that antibiotic resistance had been conferred only by 
transfection of plasmid. Colonies produced from an overnight incubation at 37°C were then 
grown overnight in 5ml LB containing 50pg/ml chloramphenicol. Glycerol stocks were 
made from these cultures, as in section 2.12.
Plasmid DNA was extracted from these chloramphenicol resistant clones (see section 2.13) 
and 4pg of DNA was digested with 2pl (lOu/pl) Hind III and 2pl (lOu/pl) BamH I, 4pl 
lOx buffer E and ddLEO to a final volume of 40pl. This mixture was incubated at 37°C for 
one hour and the products run upon a gel to check for the presence of a band at 400-45Obp 
confirming incorporation of V region DNA into pBCVHCASS4. This band was then cut 
out, purified (by method A, section 2.9.1) and ligated into the final expression vectors.
2.16.4 Cloning into final expression vectors
The properties of the expression vectors pGlD106, pGlD210, pKNIOO, and pLNlOO are 
described in section 2.2 and allow each VH , VK or sequence cloned into pBCVHCASS4 
to be ligated into a vector containing the appropriate C region DNA. In each of the final 
expression vectors with the exception of pGlD210, the C region DNA contains a splice 
acceptor site at its 5' end and a termination codon at the 3' end. The presence of the splice 
donor site at the 3' end of each V region introduced during the earlier PCR amplification 
ensures that the DNA between the V and C regions is treated as an intron by mammalian 
cells and spliced out of the RNA thereby producing mRNA for translation. Thus the 
expressed peptide will contain only the leader, V and C region sequence.
2.16.5 Transfer of heavy chain variable regions into pGlD210
After the VH regions of both IS4 and CL24 had been successfully ligated into pG ID 106 we 
were informed by the manufacturers of the vector (AERES Biomedical) that intronic DNA
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between the VH and CY regions was not always spliced out by mammalian cells and could 
therefore be present in the whole antibody expressed from COS-7 cells. The effect of this 
expressed intron upon antibody structure and function was unknown. Although no effects 
have been seen in experiments using a variety of cloned antibodies both in our laboratory 
and at AERES Biomedical, a modified version of pGlD106 was created by the 
manufacturers. This new plasmid (pGlD210) lacked the expressed intron but still contained 
the same promoter, ampicillin resistance gene, origin of replication and Cr DNA. Therefore 
Vh fragments of both IS4 and CL24 were transferred from pBCVHCASS4 into pGlD210.
Vector pGlD210 is designed such that the leader -  VhJh sequence can be ligated into it as a 
Hind WVXho I fragment. The Xho I site occurs in the part of the MCS of pGlD210 which 
encodes the final few amino acids of Jh- Therefore any VhJh sequence to be ligated into 
pGlD210 must contain a Xho I site at its 3' end. Alternative sites in Jh include Kpn I and 
BstE II. However, due to somatic mutations in Jh, none of these sites are present in IS4Vh 
or CL24Vh. Therefore Xho I sites were introduced by PCR mutagenesis using specially 
designed primers shown in Table 2.5. Purified recombinant IS4 and CL24VH region cDNA 
in pBCVHCASS4 was obtained as described in section 2.9 and then used as a substrate in a 
PCR reaction. The conditions for this reaction were the same as in section 2.7, but an 
annealing temperature of 55°C was used.
Primers Sequences
IBHFOR
CBHFOR
CIHBACK
5CCACTCACCGCTCGAGACGATGACCAG3' 
5' CC ACTC ACCGCTCGAG ACGATG ACCTG3' 
5GAGCTAAGCTTGCCGCCACCA3'
Table 2.5 PCR primers used to create Hind WUXho I fragment of IS4 and CL24 VH
Hind III (AAGCTT) and Xho I (CTCGAG) restriction sites are underlined.
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Specific forward PCR primers were designed to introduce a silent mutation in the 
nucleotide sequence CTCCTC at the 3' end of the JH region of IS4 and CL24 in 
pBCVHCASS4 leading to the creation of a Xho I site CTCGAG, see Table 2.5. The Xho I 
site was chosen over the other possible restriction sites in the MCS of pGlD210 because it 
required the least change in nucleotide sequence of IS4 and CL24 JH and could be co­
digested with Hind III in buffer B at 37°C for one hour. The primers corresponding to the 
J h  region of IS4 in pBCVH4CASS and CL24 in pBCVH4CASS were named “IBH For” 
and “CBH For” respectively. These forward primers were used in conjunction with a back 
primer “CIH” that identified a sequence common to both fragments because it bound at the 
Hind III region (AAGCTT) of pBCVHCASS4, see Table 2.5.
Products of this PCR step were confirmed by gel electrophoresis (as in section 2.8), the 
appropriate band was purified from the gel (by method B, section 2.9.2) and then co­
digested with Hind III and Xho I (instead of BamH I in section 2.16.3) and cloned into 
pGlD210 (as in section 2.16.4).
2.16.6 Sequencing of inserts in the final expression vectors
The presence and identity of each insert in the recombinant vectors was confirmed by 
further sequence analysis before the DNA was transfected into eukaryotic cells. This 
additional step was required to ensure that no sequence errors had been introduced by PCR 
amplification. Sequencing and polyacrylamide gel electrophoresis were carried out as 
described in methods sections 2.15 and 2.15.1. Primers (shown in Table 2.6) were used 
which bind to the expression vectors pGlD210, pKNIOO and pLNlOO at distances of 30- 
110 base pairs from either end of the insert enabling the full length of the insert to be read.
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Primers Sequences
DONOR 5CAAAGTTCTGCCCTTGG3'
(binds to pLNlOO 80bp 3' of insert)
HCMV1 5' G ACTA AC AGACTGTTCC3'
(binds to pGlD210, pLNlOO and pKNIOO 50bp 5'
of insert)
HUCK 5CTCATCAGATGGCGGGA3'
(binds to pKNIOO 1 lObp 3' of insert)
HUG1 5TTGGAGGAGGGTGCCAG3'
(binds to pGlD210 90bp 3' of insert)
Table 2.6 Primers used in sequencing of inserts in expression vectors 
2.16.7 Site directed PCR mutagenesis
The QuikChange site-directed mutagenesis kit (Stratagene) was found to be a convenient 
method to correct a PCR error causing a Ser to Pro change at codon 14 of IS4VL and 
produce Arg to Ser mutations at various positions in IS4VhCDR3 to assess the effects of 
these mutations on binding to CL.
The basic procedure requires a double stranded DNA vector containing an insert of interest 
and the design of two specific oligonucleotide primers containing the desired mutation. 
The oligonucleotide primers, each complementary to opposite strands of the vector, are 
extended during temperature cycling by PfuTurbo DNA polymerase. This enzyme has a 6- 
fold higher fidelity in DNA synthesis than Taq DNA polymerase hence has a low potential 
for generating further mutations during PCR. Incorporation of the oligonucleotide primers 
generates a mutated plasmid. Following PCR the product is treated with Dpn I, an 
endonuclease specific for methylated DNA produced by DH5a E.coli, which thus digests 
the parental DNA template but not the mutated plasmid. Vector DNA containing the 
desired mutations is then transformed into XL 1-Blue supercompetent cells.
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The mutagenic oligonucleotide primers were designed according to manufacturers 
specifications. Primers were between 25 and 45 bases in length with a melting temperature 
(Tm) greater than or equal to 78°C. The formula used to calculate Tm is shown in Table 2.7 
A) and the specific primers in Table 2.7 B).
Purified plasmid DNA was obtained as described in section 2.13. A series of PCR reactions 
were then set up containing 5ng, lOng, 20, and 50ng concentrations of plasmid DNA with 
the appropriate mutagenic primers, see Table 2.7 B), and reaction solutions provided in the 
QuikChange site-directed mutagenesis kit (Stratagene). 1 pi (5-50ng) of plasmid DNA was 
mixed with 5pl lOx reaction Buffer, lpl of dNTP mix, 5pl forward primer (125ng), 5pl 
reverse primer (125ng), lp l Pfu Turbo DNA Polymerase (2.5 units/pl) and autoclaved 
ddHzO to a final volume of 51 pi.
As a negative control no cDNA was added to one reaction mixture. Each mixture was then 
pulse spun and placed into a PCR machine programmed according to the manufacturers 
instruction with the extension time of each reaction calculated at two minutes per kb of 
plasmid length. Cycling parameters used were as follows: -
Initial denaturation at 95 °C for 30 seconds
Then 12 cycles as follows -  Denaturation - 95°C for 30 seconds
Annealing - 55°C for one minute
Extension - 68°C for 2 minutes per Kb for sample
reactions and 12 minutes for control reaction
The reaction was then held at 4°C until the samples were removed.
Once the PCR step had been carried out the methylated template DNA containing the 
undesired sequence was digested by the addition of lpl (lOu) of Dpn I restriction enzyme 
directly to each amplification reaction. The resultant reaction mixture was mixed gently by 
pipetting up and down several times, after which it was pulse spun in a bench centrifuge 
and incubated at 37°C for one hour.
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A) Tm— 81.5 +  0.41(% G C ) -  675/N - % m ism atch
Where - N is the primer length in bases
Values for %GC and %mismatch are whole numbers
B)
Primer Sequence
1 . 5 ' CCTCCGTGTCTGGGTCTCCTGGACAGTCG3 '
2 . 5 ' CGACT GTCCAGGAGACCCAGACACGGAGG 3 '
3 . 5 ' GCGAGAGGAAGTAGTGACGTTAGTGGAGTTCTTTGGAGGGGCAGTCATGACTAC3 '
4 . 5 ' GTAGTCATGACTGCCCCTCCAAAGAACTCCACTAACGTCACTACTTCCTCTCGC3 '
5. 5 ' CGCGAGAGGAAGTAGTGACGTTCGGG3'
6 . 5 ' CCCGAACGTCACTACTTCCTCTCGCG3'
7 . 5 ' CTGCGCGAGAGGAAGTCGAGACGTTCGG3 '
8 . 5 ' CCGAACGTCTCGACTTCCTCTCGCGCAG3'
9 . 5 ' CGCGAGAGGACGTAGTGACGTTCGGGGAG3 '
1 0 . 5 ' CTCCCCGAACGTCACTACGTCCTCTCGCG3 '
1 1 5 ' GGACGTCGAGACGTTAGTGGAGTTCTTTGGAGG3 '
1 2  . 5  ' CCTCCAAAGAACTCCACTAACGTCTCGACGTCC3 '
1 3 . 5 ' C TTTG G AG G G G C AG TC ATG AC TA CTTTG A C3'
1 4 . 5  ' GTCAAAG TAGTCATGACTGCCCCTCCAAAG3 '
Table 2.7 Properties and sequences of primers used in site directed mutagenesis
A) Formula to calculate melting temperature of mutagenic primers.
B) Mutagenic primers with sites o f point mutation shown in bold. Primers 1 and 2 were 
used to amplify IS4VL and mutate a Pro to Ser residue at codon 14. Primers 3 - 1 4  were 
used to amplify I S 4 V h  and mutate the Arg to Ser residues at the following positions; 
primers 3 and 4 mutated Arg 96, 97, 100 and lOOg to create VHx; primers 5 and 6 mutated 
Arg 96 and 97 to create VHi&ii; primers 7 and 8 mutated Arg 96 to create VHi; primers 9 
and 10 mutated Arg 97 to create Vnii; primers 11 and 12 mutated Arg 100 to create VHiii; 
primers 13 and 14 mutated Arg lOOg to create VHiv.
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A separate 50pl aliquot of XL 1-Blue supercompetent cells was then transformed with lpl 
of the Dpn I treated DNA from each control, sample reaction and transformation control 
plasmid supplied by Stratagene. This method was very similar to that described in section
2.12 with the following exceptions: a heat shock of 42°C was applied for 45 seconds with 
recovery on ice for a further two minutes; and 0.5ml of NZY medium (see appendix D) 
preheated to 42°C was added to each transformation reaction.
Colonies were picked from the sample transformation plates into 5ml LB cultures 
containing 50pg/ml of ampicillin and kept overnight in a 37°C shaking incubator. The 
following day glycerol stocks were made (as in section 2.12) and plasmid DNA purified 
(see section 2.13) and screened for the presence of the desired mutation by sequencing (as 
in section 2.15).
2.16.8 Large scale extraction of DNA for transfection into COS-7 cells
The yield of plasmid DNA from a mini-prep was insufficient for electroporation therefore 
large-scale extraction to produce 100-500pg of DNA per preparation was carried out using 
the Qiagen Plasmid Maxi purification buffers (see appendix C) and protocol. A single 
colony of recombinant DNA in final expression vector was picked from a freshly prepared 
LB/Ampicillin plate to inoculate a starter culture of 5ml LB/Ampicillin medium. This 
culture was incubated for approximately eight hours at 37°C with vigorous shaking at 
approximately 300rpm. One ml of the starter culture was then diluted into 500ml of 
LB/Ampicillin medium and incubated at 37°C for approximately 16 hours overnight with 
vigorous shaking at 300rpm. Following this bacterial cells were harvested by centrifugation 
at 1864g for 15 minutes at 4°C. The supernatant was discarded and the bacterial pellet 
resuspended in lOmls of ice cold buffer PI (for PI - 3 see appendix C). Ten mis of buffer 
P2 was added. After mixing and incubation at room temperature for 5 minutes lOmls of 
chilled buffer P3 was added. The mixture was kept on ice for 20 minutes then centrifuged 
at 20,000g for 30 minutes at 4°C. Supernatant containing plasmid DNA was promptly 
removed and re-centrifuged at 20,000g for 15 minutes at 4°C. A Qiagen tip 500, 
containing a DNA binding resin, was equilibrated by the addition and free gravity flow of 
lOmls Buffer QBT. Supernatant was then applied to the Qiagen tip and allowed to enter and 
bind DNA to the resin by free gravity flow while all other components pass through. The
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DNA was then washed by passing 30 ml of buffer QC through the tip twice and eluted with 
15 ml of buffer QF. To precipitate the DNA 10.5 ml (0.7 volumes) of room temperature 
isopropanol was added to the eluted DNA, mixed and then centrifuged at 1864g for 45 
minutes at 4°C. Supernatant was carefully decanted and the DNA pellet washed with 5 ml 
of room temperature 70% ethanol and centrifuged at 1864g for 15 minutes at 4°C. 
Supernatant was discarded and the pellet dried under a vacuum for 2-5 minutes, then 
redissolved in 1ml of autoclaved water.
The presence and concentration of purified DNA in each sample was confirmed by 
restriction digest (as in section 2.14) and gel electrophoresis with molecular weight markers 
(see section 2.8).
Recombinant DNA was then precipitated. A 2.5 times volume of 100% ice cold ethanol and 
1/10 volume of 3M-sodium acetate was added and left at -70°C for 60 minutes. After this 
the mixture was centrifuged at 13,000g for 10 minutes at 4°C and the pellet washed with 
lml of ice-cold 70% ethanol before further centrifugation as above for 5 minutes. 
Precipitated DNA was then dried under a vacuum and the pellet resuspended under sterile 
conditions, in an appropriate volume of autoclaved water to give a final concentration of 
2pg/ml and stored at -20°C.
2.17 Expression of cloned Vh and Vl sequences as whole antibodies
2.17.1 Tissue culture
All tissue culture preparation was carried out in a sterile tissue culture hood. Any buffers, 
solutions and materials required were kept in the tissue culture laboratory and solely used 
for this work. Plastic ware was supplied by Nunc, VWR International, Leicester, U.K. For 
growth media and solutions for maintenance of eukaryotic cell lines see appendix D.
2.17.2 Eukaryotic cell lines
COS-7 cells and CHOdhfr cells were kind gifts from Alison Levy, AERES Biomedical, 
Mill Hill, London, U.K. The COS-7 cells were originally derived from American Type 
Culture Collection, Ref No. CRL 1651.
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CHOdhfr cells used are from the cell line DXB11 originally derived from CHO-K1 in 
1978 by Professor Lawrence Chasin (Professor of Biological Sciences, Columbia 
University, USA). These CHO-K1 cells were obtained from Ted Puck and Fa-ten Kao at 
the Eleanor Roosevelt Cancer Institute in Denver, Colorado, USA in 1970. One dhfr allele 
was deleted in DXB11 and the other allele carries a mis-sense mutation resulting in a single 
amino acid substitution (Urlaub and Chasin, 1980).
2.17.3 Transient expression in COS-7 cells
COS-7 cells are immortal monkey kidney cells, which express the T antigen of the human 
polyoma virus SV40 constitutively. The T antigen binds to the SV40 origin to stimulate 
replication. Plasmids used in this study all contain the SV40 origin (which is not otherwise 
present in COS-7 cells) hence will be replicated actively in COS-7 cells and achieve a high 
copy number. This expression system is thus ideal for achieving efficient transient 
expression of heavy and light chains.
2.17.4 Maintenance of COS-7 cells in tissue culture
A master cell bank of COS-7 cells frozen at as low a passage number as possible to 
enhance the efficiency of transfection was stored in liquid nitrogen. Aliquots of these cells 
were frozen in growth medium 1 (see appendix D) containing 10% DMSO which is 
cryoprotective during freezing but toxic to the cells once they have thawed. Thus as soon as 
the cell aliquot was thawed it was immediately added to 10ml prewarmed growth medium 1 
and spun at 250g for 10 minutes at room temperature. Medium was then discarded and the 
cell pellet resuspended in 10ml growth medium 1 and transferred to an 80cm2 flask 
containing a further 10ml of the same medium.
COS-7 cells were maintained in a continuous culture by changing the growth medium 
every 3-4 days. All solutions and media to be used were initially placed in a 37°C water 
bath for 10 minutes. The 80cm2 or 175cm2 tissue culture flask containing COS-7 cells was 
removed from the incubator. Old medium was removed by aspiration and the remaining 
cells adherent to the floor of the flask washed by adding lOmls sterile HBSS to remove any 
remaining fetal calf serum. HBSS was then removed and 3mls of 10% Trypsin/Versene 
(T/V) solution added. The flask was shaken gently to allow T/V to fully cover the floor of 
the flask. T/V was then left in contact with the cells for two minutes in a 37°C incubator to
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release all cells adherent to the floor of the flask. At the end of this time the flask was 
tapped and viewed under the microscope to make sure at least 80% of the cells had become 
detached. lOmls of growth medium 1 were then added to the flask and gently shaken to 
inactivate the T/V solution. This mixture was then split from an 80cm2 to a 175cm2 flask or 
from one 175cm2 to three new 175cm2flasks and growth medium 1 added to a final volume 
of 20ml for an 80cm2 flask or 25ml for a 175cm2 flask. The flasks were then placed 
horizontally in a 37°C incubator in which the concentration of C 02 was 5% and checked 
daily to assess growth.
To create a cell bank, cells of a low passage number growing in an exponential phase were 
trypsinised as above then spun at 250g for 10 minutes at room temperature. Following a 
cell count (carried out as in section 2.5.1) the cells were resuspended in the appropriate 
volume of growth medium 1 containing 10% DMSO, to give a concentration of 1 x 107 
cells/ml. 1.5ml aliquots were then put in cryovials, immediately placed at -80°C overnight 
and then transferred to liquid nitrogen.
2.17.5 Transfection of recombinant expression vector into COS-7 cells
One 175cm2 flask was prepared as described above with the exception that the final split 
was between two rather than three large flasks, for each Vh/Vl combination to be tested. 
The following day the cells in each flask were washed with HBSS and trypsinised as 
described above. Ten mis of warm medium 1 were added to each flask and the entire 
contents then transferred to a sterile 50ml centrifugation tube. The cells were then 
centrifuged at 250g for five minutes at room temperature. The supernatant was discarded 
and the pellet of COS-7 cells resuspended in 20-50 mis of autoclaved PBS according to the 
size of the cell pellet. A cell count was performed upon a 200pl aliquot of the suspension to 
estimate the number of cells present (see section 2.5.1). The remainder of the suspension 
was again centrifuged at 250g for 10 minutes at room temperature. Supernatant was 
carefully removed by aspiration and the cell pellet resuspended in the appropriate volume 
of PBS to give a final concentration of 1 x 107 cells per ml.
lOpg of thawed recombinant vector containing the heavy chain to be tested plus lOpg of 
vector containing the light chain to be combined with this heavy chain were added to a
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disposable electroporation cuvette. 700pl of the COS-7 cell suspension was also added and 
the cuvette placed in a Gene Pulser II electroporator (Biorad). A pulse of charge at 1.9kV 
and 25 pF was applied and repeated for each experimental transfection to be performed. A 
negative control cuvette containing COS-7 cells only and no DNA was prepared and 
subjected to an electroporation pulse in exactly the same way.
The COS-7 cells were allowed to recover at room temperature for 10 minutes. The contents 
of each cuvette were then transferred to a separate 10cm tissue culture dish containing 8ml 
of medium 2 (see appendix D) warmed to 37°C. Incubation of the dish in 5% CO2 at 37°C 
for 72 hours then took place before harvesting the COS-7 cell supernatant for analysis. At 
the end of the incubation period the medium from each dish was carefully transferred by 
pipette into a sterile 15ml centrifuge tube. The tubes were centrifuged at 800g at room 
temperature for five minutes to remove cell debris. Supernatant was then removed from 
each tube and treated with 6u of DNase I after which the sample was incubated for one 
hour at 37°C. EDTA to a final concentration of 15mM was then added to inactivate the 
enzyme plus 5pl of 1M sodium azide solution. The DNase I was added to digest any free 
DNA in solution that may interfere with subsequent testing for anti-DNA activity in an 
ELISA as demonstrated previously (Rahman et al., 1998). Sodium azide solution prevented 
colonisation by microorganisms. Supernatant was stored at 4°C for testing by ELISA.
A fresh 8ml aliquot of warmed growth medium 2 was added to the COS-7 cells in each 
10cm tissue culture dish and incubated at 37°C in 5% C 0 2 before harvesting the COS-7 cell 
supernatant for analysis after a further 72 hours as explained above.
Growth medium 2 contains y-globulin free fetal bovine serum. Thus any IgG detected in the 
supernatant after the 72 hour incubation is very likely to be the result of IgG production 
from COS-7 cells due to transfected Ig genes. An alternative post elctroporation medium 3 
(see appendix D) containing a serum replacement Ultroser Cj (which lacks (32GPI) instead 
of y-globulin free fetal bovine serum was used when the antibodies produced were to be 
tested in a modified (hence (32GPI free) CL ELISA. The negative control of COS-7 cells 
containing no DNA was included to confirm that no IgG production occurs without 
transfected IgG genes.
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2.17.6 Concentration of COS-7 cell supernatant
Centricon YM-30 (Millipore) devices were used to concentrate antibody within the COS-7 
cell supernatant. Concentration was performed as per the manufacturer’s instructions. Two 
mis of supernatant was added to each sample reservoir coupled with its filtrate vial and 
centrifuged at 2000g at room temperature for 30 minutes. Further supernatant was then 
added to the sample reservoir and subsequent centrifugation steps performed for 40-50 
minutes. This process was repeated until all but the final one ml of supernatant had passed 
through the membrane of the sample reservoir. A retentate vial was then placed over the 
sample reservoir the unit inverted and centrifuged at 5000g for 2 minutes to transfer 
concentrated antibody from the membrane into the remaining supernatant. Concentrated 
samples were then stored at 4°C.
2.17.7 Heat shock and Phospholipase C treatment of COS-7 cell supernatant
In some cases a comparison was made between properties of the supernatant before and 
after a heat shock at 56°C or digestion with Phospholipase C (PLC). After centrifuging to 
remove cell debris, the COS-7 cell supernatant was divided equally into two aliquots one of 
which was treated with PLC and the other by heat shock as performed by Cabiedes and 
colleagues (Cabiedes et al., 1998).
One aliquot of the supernatant was further divided in half and 1 Ou of PLC were added to 
each half. The optimum conditions for PLC are incubation at 37°C in pH 7.3 for one hour. 
The pH of the supernatant ranged from 7.35 - 7.45 hence the incubation time was extended 
to two hours. In one half (called “inactivated PLC”) the enzyme was inactivated 
immediately by adding EDTA to a final concentration of 15mM prior to incubation at 37°C 
for 120 minutes. In the other half (the “active PLC”) the enzyme remained active during the 
incubation period before the EDTA was added. Hence the only difference between the two 
aliquots was that digestion of phospholipids occurred in one but not the other
The other aliquot of the supernatant was also divided into two halves only one of which 
was subjected to a heat shock at 56°C for 30 minutes. All of the supernatant treated with 
PLC or +/- heat shock were treated with 1M sodium azide and stored at 4°C.
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2.18 Detection and characterisation of whole IgG molecules in COS-7 supernatants by 
ELISA
2.18.1 Detection of whole IgG molecules in COS-7 supernatants by ELISA
In all of the different ELISAs performed the 96 well plates were supplied by Nunc, VWR 
International, Leicester, U.K. and OD measured by the Genios plate reader (Tecan, 
Reading, U.K.). Each plate was marked vertically to divide it into two halves. The 36 wells 
at the edge of the plate were not used and henceforth all descriptions of the plate refer to the 
inner 60 wells only. All ELISA reagents and buffers are listed in appendix C.
Goat anti-human IgG (Fc fragment specific) was dissolved in bicarbonate (BIC) buffer to 
give a working solution of 400ng/ml. 50pl of this solution were added to each well of a 
maxisorp plate in the left (test) half of the plate. 50pl of BIC buffer alone was added to the 
wells in the right (control) half of the plate. Each plate was then covered and incubated 
overnight at 4°C. After this the plates were washed three times with PBS/0.1% Tween and 
lOOpl of PBS containing 2% BSA were added to each well to block non-specific binding of 
Ig to the plastic. The plates were incubated for one hour at 37°C and then washed three 
times with PBS/0.1% Tween.
In order to dilute COS-7 cell supernatant in SEC buffer serially, such that for each well in 
the test half of the plate there was a well in the control half containing the same supernatant 
at the same dilution the following procedure was performed. 50pl of SEC buffer was added 
to each well in both halves of the plate except the top wells. lOOpl of neat COS-7 cell 
supernatant was added to the top well and diluted down the column such that each well 
contained supernatant at half the concentration of the well above. Human IgG^ of known 
concentration (lOOng/ml or lOng/ml) was loaded and diluted in the same way upon each 
plate to allow the construction of a standard curve relating optical density (OD) to Ig 
concentration. The plates were incubated for one hour at 37°C and then washed three times 
with PBS/0.1% Tween. Goat anti-human X or k  alkaline phosphatase conjugate (depending 
on the light chain to be detected) was diluted 1 in 2500 with SEC buffer and 50pl added to 
each well.
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After further one-hour incubation at 37°C the plates were washed three times with 
PBS/0.1 % Tween and once with bicarbonate buffer. One tablet of p-Nitrophenyl phosphate 
was dissolved per 5mls of bicarbonate buffer and supplemented with lOpl of 2mM MgCl2. 
50 pi of this substrate solution was added to each well. The plates were then incubated at 
37°C till development of a yellow colour, which took one hour. The results were read as 
OD at 405nm. For each dilution of supernatant the result was calculated as the difference 
between the OD in the test well and the control well. Thus only conjugate bound directly to 
IgG in that supernatant, which had been captured by goat anti-human Fc on the plate would 
contribute directly to the result.
2.18.2 Detection of aCL in COS-7 supernatants by standard ELISA
Wells in the test half of a polysorp ELISA plate were coated with 50pl of cardiolipin 
(diluted to 50pg/ml in ethanol) and 50 pi of ethanol alone were added to wells in the control 
half. The plates were incubated uncovered overnight at 4°C. Each plate was then washed 
three times with PBS and lOOpl of PBS containing 10% FCS (Invitrogen) were added to 
each well to block non-specific binding of Ig to the plastic. After incubation at 37°C for one 
hour plates were washed three times with PBS.
Each concentrated COS-7 supernatant to be tested was serially diluted in PBS containing 
10% FCS. An identical concentration of supernatant was loaded into a well in the test half 
and a corresponding well in the control half of the plate. Serum containing polyclonal 
antibodies known to bind CL was loaded as a positive control to each plate. The total 
volume in each well was 50pl. Plates were then incubated for 90 minutes at 37°C after 
which they were washed three times with PBS. Goat anti-human IgG alkaline phosphatase 
conjugate was diluted 1000 fold in PBS containing 10% FCS and 50pl of this solution 
added to each well. After one hour at 37°C the plate was washed four times with PBS and 
once with BIC buffer. Addition of substrate and incubation were carried out as in section
2.18.1 with additional OD measurements taken at 30 minutes.
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2.18.3 Detection of aCL antibodies in COS-7 supernatants by modified ELISA
The standard CL ELISA was modified to remove (32GPI from the assay by replacing 10% 
FCS in each relevant step with 10% BSA when testing antibody combinations produced in 
post electroporation medium 3 (see appendix D).
2.18.4 Detection of anti-f32GPI antibodies in COS-7 supernatants by ELISA
A maxisorp ELISA plate was coated with 50pl of p2GPI (diluted to lOpg/ml in PBS) on 
wells in the test half and 50pl of PBS alone on the control half. Plates were covered and 
incubated overnight at 4°C. Following that each plate was washed three times with PBS. In 
order to block non-specific binding 50pl of 0.25% gelatin/PBS was added to each well. 
After incubation at 37°C for one hour plates were washed three times with PBS.
Antibody samples were serially diluted in 0.1% BSA/PBS and then loaded upon each half 
of the plate, as well as a positive control of serum containing polyclonal anti-p2GPI 
antibodies leaving a final volume in each well of 50jul. Plates were then incubated for two 
hours at 37°C after which they were washed three times with PBS. Goat anti-human IgG 
alkaline phosphatase conjugate was diluted 1000 fold in PBS containing 0.1% BSA/PBS 
and 50pl of this solution added to each well. A final incubation for one hour at 37°C was 
performed and the plate washed four times with PBS and once with bicarbonate buffer. 
Addition of substrate and incubation were carried out as in section 2.18.1 with additional 
OD measurements taken at 30 minutes.
2.18.5 Detection of anti-dsDNA antibodies in COS-7 supernatants by ELISA
The test half of a maxisorp ELISA plate was coated with 50pl per well of purified calf 
thymus dsDNA (diluted to lOpg/ml in PBS) and 50pl per well of PBS alone on the control 
half. Purified dsDNA used in this ELISA was a kind gift from Arti Sharma. The plates 
were covered and incubated overnight at 4°C. Each plate was then washed three times with 
PBS and non-specific binding of Ig to the plastic was blocked by the addition of 150pl of 
PBS containing 2% casein to each well. After one hour at 37°C the blocking agent was 
tipped out and each plate blotted upside down on tissue paper.
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Samples of concentrated COS-7 supernatant to be tested were serially diluted in PBS/0.1% 
Tween and identical concentrations of supernatant added to each half of the plate. A human 
mAb (RH-14) known to bind dsDNA was loaded as a positive control to each plate and 
titrated from 1:400 to 1:32400 by three fold dilutions down the column. The total volume 
remaining in each well was 50pl. Plates were then incubated for one hour at 37°C after 
which they were washed six times with PBS/0.1% Tween. 50pl of goat anti-human IgG 
alkaline phosphatase conjugate (diluted 1000 fold in PBS/0.1% Tween) were then added to 
each well. After one hour at 37°C the plate was washed six times with PBS/0.1% Tween 
and twice with BIC buffer. Addition of substrate and incubation were carried out as in 
section 2.18.1 with additional OD measurements taken at 30 minutes.
2.19 Generation of 2a2 V gene family hybrids
Once the initial Vh/Vl chain exchange experiments had been performed hybrid (CDR 
exchanged) light chains were created from B3Vl; UK4Vl ; and IS4VL. Hybrid light chains 
were composed of the sequence of one Vl up to position 106 (including FR1 and CDR1) 
and the sequence of another Vl from position 106 onwards (see Figure 2.9).
The hybrids were produced by digesting the recombinant pLNlOO (or pLNlO) expression 
vectors containing each Vl with the enzymes Acc65 I and Pvu I. Acc65 I cuts all the Vl 
sequences studied at position 106 and does not cut anywhere else in the vector. Pvu I cuts 
the vector at a unique site approximately 1.5Kb from the Acc65 I site and does not cut any 
of the VL segments. Thus a Acc65 VPvu I digest gives two fragments of approximately 
5.9Kb and 1.5Kb. The 1.5Kb fragment contains the sequence of VL from position 106 
onwards while the 5.9Kb fragment contains the rest of VL. By ligating the 5.9Kb fragment 
from one VL expression vector to the 1.5Kb fragment from another, the required hybrid VL 
were made.
Two hybrid light chains one of which contained CDR1 of B3 joined with the CDR2 and 3 
of UK4 (named BU) and another containing CDR 1 of UK4 and CDR 2 and 3 of B3 (called 
UB) had already been created by Dr Joanna Haley.
163
IS4 VH
IS4V l 
UK4 VL 
B3 VL
IUVL 
IB Vl 
U I V l  
U B V l  
B U V l  
BI VL
B3 V H
IS4 VL
UK4 VL 
B3 VL
U B V l
BU VL
Figure 2.9 Generation of 2a2 V gene family hybrids
Schematic representation of the generation o f hybrid (CDR exchanged) light chains from 
B3Vl; UK4Vl; and IS4Vl. Hybrid light chains were composed of the sequence of one V l  
up to position 106 (including FR1 and CDR1) and the sequence of another V l from 
position 106 onwards.
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I created four more hybrids: - IB containing CDR1 of IS4 joined with CDR2 and 3 of B3; 
IU containing CDR1 of IS4 joined with CDR2 and 3 of UK4; BI containing CDR1 of B3 
joined with CDR2 and 3 of IS4; and UI containing CDR1 of UK4 joined with CDR2 and 3 
of UK4.
8|ig of purified plasmid DNA of IS4VL/pLN100, B3VL/pLN10 and UK4VL/pLN10 was 
obtained as described in section 2.13, and digested with 2pl (lOu/pI) Acc65 I and 2pl 
(8u/pl) Pvu I, lOx Buffer D and ddFUO to a final volume of 250pl. This mixture was 
incubated at 37°C for 18 hours and the products run upon a gel to check for the presence of 
two bands of appropriate size, the smaller of which contains CDR2 and 3 of each VL plus 
the Jl and part of the parent plasmid and a larger band containing CDR1 of each VL and the 
remaining portion of parent plasmid. The bands were then cut out, purified and ligated (as 
described in method B section 2.9, and section 2.10).
2.19.1 Confirmation digest of 2a2 Vl hybrids
In order to confirm the identity of VL hybrids (IB, IU, BI and UI) generated, suitable 
restriction sites were chosen which would distinguish the hybrids form the “parent’' 
plasmids (IS4Vi/pLN100, B3Vl/p LN10 and UK4VL/pLN10) and from each other. The 
restriction sites which gave the most suitable fragment sizes were Aat II and Ava I. In some 
instances these restriction enzymes were combined with either Hind III or BamW I to give 
easily distinguishable fragments. In each case lpg of plasmid DNA was digested with 
either:- 5u Aat II in l Ox buffer J; lOu Ava I and lOu Hind III in l Ox buffer B; or 5u Aat II 
and lOu BamW I in lOx buffer J plus ddTCO to 20pl, as in section 2.14.
2.20 Production of Supervectors
The expression vectors pGlD210, pLNlO and pLNlOO could also be used in a stable 
expression system. The heavy chain expression vector pGlD210 contains the dhfr gene 
whilst the light chain expression vectors pLNlO and pLNlOO contain the neomycin 
resistance gene (neo). Therefore in CWOdhff (selective) growth medium that contains no 
ribonucleosides or deoxyribonucleosides but does contain neomycin, only those CHO cells 
with a functional dhfr gene and a functional neo gene would survive. Consequently the 
surviving cells would have the ability to produce IgG heavy chains and light chains. 
Although this system has been shown to work in the past, there was a risk of excess
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production of heavy chain compared to light chain since transfection with dhfr may be 
comparatively more productive than transfection with neo.
Therefore the two vectors were combined to produce “supervectors”. From the plasmid 
vector pLNlO or pLNlOO, an EcoR I fragment containing the promoter, the X constant 
region gene and the X variable region gene (of the chosen antibody) was transferred into the 
vector pGlD210 containing IS4VH. Three supervectors were produced: SVIS4VH/IS4VL; 
SVIS4Vh/B3V l; and SVIS4Vh/UK 4Vl . The same protocol was used to produce all of the 
supervectors.
2.20.1 EcoR I digest of IS4Vh/pG1D210 and light chain expression vector
The promoter, VL gene and gene were all cut out of pLNlO or pLNlOO by EcoR I 
restriction digest whilst pGlD210 containing IS4VH was linearised in the same way. The 
restriction digests were set up with lOpg of plasmid DNA, 20u EcoRl, lOx buffer H and 
ddH20 to a final volume of 200pl. The mixture was inverted to mix, pulsed and incubated at 
37°C for 45 minutes. The presence of digested DNA was confirmed on a 0.8% agarose gel 
(as in section 2.8) and bands of appropriate size cut out and purified (as in method B 
section 2.9) for subsequent ligation.
2.20.2 Dephosphorylation of the 5' overhangs using calf intestinal alkaline 
phosphatase
The linearised heavy chain expression vector was treated with calf intestinal alkaline 
phosphatase (CIAP) which catalyses the dephosphorylation or hydrolysis of 5'-phosphate 
groups from DNA. Removal of the phosphate groups from both of the 5' termini of the 
linearised heavy chain vector reduces its ability to re-linearise and significantly increases 
the chance of obtaining colonies that contain the heavy chain vector and the insert (light 
chain DNA) following the ligation and transformation of this DNA into E.coli.
In a 1.5ml microfuge tube the following mixture was prepared: 200pl plasmid DNA 
(directly from restriction digest), 40pl lOx CIAP buffer, lpl (lu/pl) CIAP and 159pl sterile 
ddH20. The contents were mixed, pulsed and incubated at 37°C for 30 minutes. The 
mixture was then incubated at 90°C for 10 minutes to inactivate the CIAP. The presence of
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digested DNA was confirmed on a 0.8% agarose gel (as in section 2.8) and bands of 
appropriate size cut out and purified (as in method B section 2.9) for subsequent ligation.
2.20.3 Ligation of EcoR I digested light chain expression vector fragment into 
linearised heavy chain expression vector •
For each supervector, several reaction mixtures were set up containing different ratios of 
the EcoR I digested light chain vector fragment versus linearised recombinant VH 
expression vector to ensure successful ligation. The amount of purified DNA of each EcoR 
I digested vector to be used was estimated by comparing the intensity of the heavy and light 
chain vectors upon a 0.8% agarose gel and choosing the amount of each vector which 
would give a 1:1 and 1:2 ratios of heavydight chain vector. Ligation mixtures were set up 
containing 10-15pl of purified EcoR I digested heavy and light chain vector DNA in the 
above ratios with lOx Ligation buffer, 6u T4 DNA Ligase and sterile ddH20 to 20pl.
Control reactions containing EcoR I digested heavy or light chain vector DNA only were 
also set up to indicate the background re-ligation of the heavy chain vector and to confirm 
that the light chain fragment did not contain uncut parent vector. All reaction mixtures were 
incubated overnight at 14°C and then transformed into competent E.coli cells (see section 
2.12) and the colonies produced screened for the presence of supervector.
2.20.4 Large scale screening of colonies from supervector ligations
In some instances successful ligation could not be achieved after CIAP treatment of the 
heavy chain EcoR I digested fragment and this method was not always performed. 
Therefore large number of colonies had to be screened post ligation, because many 
contained re-ligated pG1D210/IS4Vh without the light chain cassette. This screening is 
easily achieved by the method of osmotic lysis in which 20 - 40 colonies were picked from 
each LB Agar plate from the above ligation and transformation. At least one control colony 
containing parent plasmid only was also picked. Each colony was grown in 1ml of LB 
broth containing Ampicillin at 37°C for 4-6 hours. A lOOpl aliquot was saved from each 
colony and the remaining culture was pelleted in a bench top centrifuge and the supernatant 
removed. 50pl of Osmotic Lysis Solution (10% (w/v) sucrose, 0.25% SDS, 0.08M NaOH) 
were added to the pellets. The tubes were vortexed and placed at 70°C for 10 minutes then
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cooled on ice. 4pl of loading buffer were added and the samples loaded into wells of an 
agarose gel (0.8%) before the gel was submerged in buffer to prevent misloading of the 
viscous mixtures. Electrophoresis (15V for 16-20 hours) enabled plasmid sizes to be 
estimated, relative to empty vector controls. Clones of potentially the right size were 
selected and the remaining lOOpl aliquot of culture was used to inoculate broth for plasmid 
purification.
2.20.5 Confirmation restriction digests of supervectors
Two confirmation digests were performed to confirm the identity of each supervector and 
orientation of the light chain fragment. In each case lgg of plasmid DNA extracted from 
each of the supervector colonies identified by osmotic lysis was digested with either: - 1 Ou 
Hind III, lOu Kpnl, lOx buffer J and ddH20 to 20pl; or 5u Aat II, lOx buffer J and ddH20 to 
20|il (as in section 2.14).
2.21 Stable expression system in Chinese Hamster Ovary (CHOdhfr) cells
2.21.1 Maintenance of CHOdhfr cells prior to electroporation
The CHO cell line (DXB11) used lacks a functional dhfr gene. The enzyme dihydro folate 
reductase is responsible for the intracellular reduction of dihydrofolic acid to 
tetrahydrofolic acid, which is an important co-factor in the synthesis of nucleic acid 
precursors. To survive the CHOdhfr cell line required exogenous hypoxanthine (adenine), 
glycine, proline and thymidine for survival. All of these nutritional requirements were 
provided via non-selective medium.
If however, these CHO dhfr cells were successfully transfected with expression vectors 
(e.g. a supervector) containing a functional dhfr gene the cells would be transformed to a 
dhfr+ phenotype and be able to grow in selective media lacking these exogenous nutrients. 
Consequently CHO dhfr cells were used to provide an expression system in which the 
genes required to produce IgG could be co-transfected with the d/*/rgene.
The CHOdhfr cells were grown in pre-warmed non-selective growth medium A (see 
appendix D) in 175cm2 flasks prior to transfection and split every 3 - 4  days keeping their 
passage number to a minimum prior to transfection. A master cell bank was created and the
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cells were defrosted and frozen down as described in section 2.17.4 using growth medium 
A containing 10% DMSO.
To ensure exponential growth the CHO dhfr cells were trypsinised (with 10% T/V) 24 
hours prior to transfection and divided equally between three 175cm2 flasks containing 
pre-warmed growth medium A. One large flask was required for each supervector to be 
tested. The cells were incubated overnight at 37°C in 5% C 02 The following day the cells 
in each flask were washed, trypsinised, pelleted and resuspended in sufficient autoclaved 
PBS to give a final concentration of 1 x 107 cells per ml.
2.21.2 Transfection of recombinant expression supervector into CHOdhfr cells
A 700pl aliquot of the washed CHOdhfr cell suspension was pipetted into a disposable 
electroporation cuvette to which 20pg of thawed recombinant supervector was added. A 
1.9kV and 25pF capacitance pulse was then delivered to each experimental transfection and 
a control containing CHOdhfr cells only, using a Bio-Rad Gene Pulser® II electroporator. 
The cells were then allowed to recover at room temperature for 10 minutes and the contents 
of each cuvette transferred to a separate 10cm tissue culture dish containing 8ml of pre­
warmed medium A. Each dish was incubated overnight in 5% C 02 at 37°C.
2.21.3 Selection of transfected CHO dhfr cells post electroporation
From this point onwards the cells were maintained in selective growth medium B (see 
appendix D) which lacks ribonucleosides and deoxyribonucleosides and is absent from 
dialysed FCS. Thus only those cells which contain supervector and as a result a functional 
dhfr gene will then be able to grow. Following overnight growth of the transfected 
CHO dhfr cells in non-selective medium A the cells in each 10cm dish were washed with 
lOmls of HBSS, trypsinised and then pelleted at 250g for five minutes at room temperature. 
Cells from each transfection and control were resuspended separately in lOOmls of 
prewarmed selective media B before being divided equally between ten 10cm diameter 
tissue culture dishes.
Incubation of the cells at 37°C in 5% C 02 then took place for 10-14 days changing the 
selective medium B every 3-4 days. After 10-14 days the cells on the no DNA control dish
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were all dead and discrete foci of transfected cells were clearly visible on all the test culture 
dishes. In order to pick these foci they were visualised under a microscope and using a 
sterile pipette tip 200pl of foci plus media was aspirated under direct vision and transferred 
into individual wells of a 24 well tissue culture plate containing 0.5ml of prewarmed 
medium B. A total of 48 foci were picked from each transfection (ten plates). The picked 
cells were then grown in the selective medium B until almost confluent (between 7-14 
days), changing the media every seven days.
Once the cells were almost confluent media was decanted from the individual wells of each 
24 well plate and tested for the presence of whole IgG by ELISA (as described in 
section 2.18.1). Those clones producing the highest levels of antibody were selected for 
expansion in medium B until the cells were growing in 175cm2 flasks.
2.21.4 Assay of antibody production in transfected CHO dhfr cells
Following growth of the selected cells to just below confluent level in selective media in 
175cm2 flasks the cells were washed with 10ml HBSS, trypsinised with T/V and pelleted at 
250g for five minutes at room temperature. Each clone of cells was resuspended in 20ml of 
prewarmed selective medium B and a viable cell count performed (as in section 2.5.1). The 
cells were then pelleted again as above and resuspended in sufficient prewarmed medium B 
to produce a viable cell count of lx l0 6 cells/ml. One ml of this solution was added to a 
10cm diameter tissue culture dish containing 9ml of prewarmed medium B and incubated at 
37°C in 5% CO2 for three days. After this period, media was decanted from each 10cm dish 
and the concentration of intact antibody measured by ELISA (as described in section 
2.18.1). Cells in each 10cm dish were washed with 5ml HBBS, trypsinised (2ml T/V) and 
pelleted at 250g for five minutes at room temperature. Following this the cells were 
resuspended in one ml of prewarmed medium B and a viable cell count was performed as 
above. From the new viable cell count and the antibody concentration in the decanted 
media the level of antibody production was calculated and expressed as ng/106 cells/day.
Cell banks of the clones with the highest antibody production rates were created by 
suspending 1 x 107 cells/ml in medium B containing 10% DMSO and stored in liquid 
nitrogen (as in section 2.17.4) for further selection.
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CHAPTER 3
RESULTS OF SEQUENCE ANALYSIS OF IS4 AND CL24 ANTIBODIES 
3.1 Amplification of Vh and VL cDNA by PCR
Initially I was provided with hybridomas secreting mAb of unknown sequence by Dr Chen. 
Therefore I had to sequence and analyse these mAb myself prior to subsequent expression 
experiments. The VL sequences of IS4VL and CL24Vl were successfully amplified as 
shown in Figure 3.1. IS4V*. belongs to the V*. 2 family as demonstrated in Figure 3.1 A). A 
band of 330 base pairs in length corresponding to IS4 V*. was amplified by HL20 and JL 
primers only. In the same way CL24VK was found to belong to the VK III family, see Figure
3.1 B). I was unable to amplify IS4VH and CL24VH using the VH9 primer. However, I 
amplified these Vh sequences successfully using the VH1 and VH3 primers designed using 
sequences provided by Dr Chen once his group had completed their own sequence analysis 
of IS4 and CL24. The results of VH sequence amplification are shown in Figure 3.2.
3.2 Small scale extraction of cloned cDNA in pGEM-T Easy Vector
Successful ligation of each Vh and VL chain into pGEM-T Easy Vector and subsequent 
cloning into E.coli was confirmed by an EcoR I digest of recombinant DNA extracted from 
overnight cultures of white colonies grown upon ampicillin plates. A successful ligation, 
transformation and digestion yields a 350-400bp insert as well as a band containing 
pGEM-T Easy Vector of 3399bp upon gel electrophoresis shown in Figure 3.3.
3.3 Sequence analysis of IS4 and CL24 in pGEM-T Easy Vector
In Figure 3.4 a representative sequencing gel of IS4Vh and CL24VH cloned into pGEM-T 
Easy Vector is shown reading through CDR2 of each heavy chain. Sequence characteristics 
of IS4 and CL24 Vh and Vl regions are displayed in Table 3.1. The sequences of all four V 
regions are shown in Figures 3.5 -  3.8 and display the positions of the CDRs and FRs 
identified by the Kabat system (Wu and Kabat, 1970) and contact sites as defined by 
MacCallum et #7.(1996). Most of these contact sites are within the CDRs but it is 
important to note that not all CDR residues are contact sites and that some FR residues can 
be contact sites.
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506, 517bp
506, 517bp
13 14 15 16 17
Top lanes in A)
1 & 12 = 1 Kb marker
2 -5  = IS4 cDNA & HL10 primers
6 = no cDNA & HL 10 primers
7 & 8 = IS4 cDNA & HL20 primers
9-11 = no cDNA & HL20 primers
Bottom lanes in A)
13 = 1 Kb marker
14-16 = IS4 cDNA & HL30 primers
17 = no DNA & HL30 primers
B)
506, 517bp
1 2 3 4 5  6 7 8 9  10 11 12
506, 517bp
13 - - - - 18 2021
Top lanes in B)
I & 12 = 1 Kb marker
2 -5  = cDNA & VK1 primers
6 = no cDNA & VK 1 primers
7- 10  = cDNA & VK2 primers
II = no DNA & VK2 primers
Bottom lanes in B)
13 = 1 Kb marker
14-18 = no cDNA & VK3 primers
20-21 = cDNA & VK3 primers
Figure 3.1 PCR amplification of IS4 and CL24 light chain cDNA
A) IS4 cDNA and VjJ-3 family light chain PCR primers. A 330bp band of cDNA 
consistent with IS4Vl is seen only in lanes 7 and 8 with the HL20 (V^2 family) primers. B) 
CL24 cDNA and VKl-3 family light chain PCR primers. A 324bp band of cDNA consistent 
with CL24Vl is seen only in lanes 21 and 22 with the VK3 (VK3 family) primers.
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Lanes in A)
1 = 1 Kb marker
2-7 = IS4 cDNA & VH1 primers
8 = no cDNA & VH1 primers
Lanes in B)
1 = 1 Kb marker
2-7 =CL24 cDNA & VH3 primers
8 = no DNA & VH3 primers
Figure 3.2 PCR amplification of IS4 and CL24 heavy chain cDNA
A) IS4 cDNA and primers specifically designed to amplify IS4VH. Bands of cDNA 400bp 
in size consistent with IS4Vh are seen in lanes 2 - 7  with the VH1 (VhI family) primers. B) 
CL24 cDNA and primers specifically designed to amplify CL24VH. Bands of cDNA 389bp 
in size consistent with CL24Vh are seen in lanes 2 - 7  VH3 (Vh3 family) primers.
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3000bp
506,
517bp-
4 5 6 7 8 9 10 11 12 13
= 1Kb marker
= EcoR I digested IS4VL/pGEM-T Easy Vector 
= EcoR I digested IS4VH/pGEM-T Easy Vector 
= EcoR I digested CL24Vl/pGEM-T Easy Vector 
= EcoR I digested CL24Vn/pGEM-T Easy Vector
1 2 3
Lanes
1
2 - 5
6 - 9
1 0 - 1 1
12- 13
Figure 3.3 EcoR I digest of IS4 and CL24 heavy and light chain variable regions in 
pGEM-T Easy vector
In lanes 2 - 1 3  the larger fragments are identical and contain the 3399bp EcoR I digested 
pGEM-T Easy Vector. The smaller band contain variable region DNA of: - 336bp for 
IS4Vl  in lanes 2 - 5 ;  390bp for IS4VH in lanes 6 - 9 ;  330bp for CL24Vl in lanes 10 -  11; 
and 369bp for CL24Vh in lanes 12-13.
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IS4VH/pGEM-T CL24VH/pGEM-T 
Easy Vector Easy Vector
„ A ________    Ar  r >
A C G T A C G  T
Figure 3.4 Sequence gel of IS4 and CL24 heavy chain variable regions cloned into 
pGEM-T Easy Vector
This figure shows samples of the sequences of IS4VH and CL24VH as read from manual 
sequencing gels. Sequences can be read downward from the top of the gel, from position 
145 to 225 for IS4VH (compare Fig 3.6) and position 123 to 203 for CL24VH (compare Fig 
3.8). The beginning of CDR2 is shown with an arrow in each sequence.
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The sequences of IS4VL and CL24Vl and sequence analysis of IS4 and CL24 VH and VL 
regions shown in this thesis constitute original work. The Vh sequences of these mAb 
however, were derived using primers designed based upon sequences provided by Dr 
Chens group.
3.4 Sequence analysis of IS4
3.4.1 The light chain
The V region of IS4VL shares 93.3% nucleotide and 83.4% amino acid homology with the 
2a2 germline gene, Figure 3.5. The sequence of the first 26 nucleotides is determined by the 
PCR primer rather than the sequence of cDNA itself. Therefore any differences between the 
germline gene and IS4Vl in this region could not be considered true somatic mutations. 
Hence the initial 26 nucleotides encoded by the PCR primer HL20 were not included in the 
calculations of nucleotide homology or significance of distribution of R/S mutations.
The 2a2 gene contains no known sites of allelic polymorphism (VBASE) hence any 
differences between the two sequences are likely to be due to somatic mutation. Within 
IS4Vl there are a total of 20 nucleotide changes compared to 2a2. In the CDRs there are 12 
R mutations (five of which occur in CDR3) and only two S mutations. The FRs contain six 
R mutations and no S mutations. This distribution of R/S mutations is suggestive of antigen 
drive and confirmed by the significant Pm values (see Table 3.1) of 0.0389 in the FRs 
(where a lack of R mutations is significant) and 0.0006 in the CDRs (indicating a 
significant clustering of R mutations). Interestingly in CDR3, a serine (Ser) residue is 
replaced by an Asn although this is not a contact residue. There are no other somatic 
mutations to Arg, Asn or Lys in any contact region and no overall change in charge of the 
CDRs.
The J region aligns with JL3b the final 24 nucleotides of which are determined by the JL 
PCR primer.
3.4.2 The heavy chain
The closest alignment of IS4VH is with the V I-03 germline gene as shown in Figure 3.6. 
Homology is 92.5% at the nucleotide level and 86.7% at the amino acid level.
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Antibody Family V Gene Nucleotide
homology
VD Vj No.
R
No.
S
Pm
IS4 VL Vx2 2a2 93.3% - JL3b FR 6 0 0.0389
CDR 12 2 0.0006
IS4 VH VH1 V I-03 92.5% NM JH4b FR 10 4 0.1187
CDR 6 2 0.1441
CL24 VL VkIII A l l 90.9% - JK2 FR 8 6 0.0291
CDR 10 0 0.0206
CL24 VH Vh3 V3-23 84% D6-19 JH4b FR 15 18 0.0195
CDR 8 6 0.2554
Table 3.1 Sequence Features of IS4 and CL24
Abbreviations:- NM -  No Match; FR -  Framework Region; CDR -  Complementarity 
Determining Region; R -  Replacement mutation; S -  Silent mutation; No. -  number of R 
or S mutations in CDR/FR; Pm -  p value from multinomial method of Lossos et al. (2000) 
that represents the probability that the observed distribution of R and S mutations could 
have arisen by chance alone i.e. without antigen driven selection.
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FR1 CDR1
Q S A L T Q P A S V  S G S P G Q S  I T  I S C T G T > A  
2a2 CAG TCT GCC CTG ACT CAG CCT GCC TCC GTG TCT GGG TCT CCT GGA CAG TCG ATC ACC ATC TCC TGC ACT GGA ACC 
IS4 ....................................................................... G- -
FR2
S S D V>I G G>S Y N Y>S V S W Y Q Q>H H>L P G K A P K L M>I I
2a2 AGC AGT GAC GTT GGT GGT TAT AAC TAT GTC TCC TGG TAC CAA CAG CAC CCA GGC AAA GCC CCC AAA CTC ATG ATT
IS4 ......................A - - . . .  TC- - - - - - -  -C- - - -  - -  - - - - - .................. C - T .................................................................... A - - -
CDR2 FR3
Y E>D V S N>S R P S  G V S N R  F S  G S  K S  G N>F T A S L
2a2 TAT GAG GTC AGT AAT CGG CCC TCA GGG GTT TCT AAT CGC TTC TCT GGC TCC AAG TCT GGC AAC ACG GCC TCC CTG
IS4 —  - - - .. ...................................................................................................................................................... TT.......
CDR3
T I S G L Q A>P E D E A D Y Y C S>C S Y T S>T S>I S>N T L>W
2a2 ACC ATC TCT GGG CTC CAG GCT GAG GAC GAG GCT GAT TAT TAC TGC AGC TCA TAT ACA AGC AGC AGC ACT CTG 
IS4 .............................................. C ......................................................................... T - - --- -er-T- -A - . . .  TCS-
V F G G G T K L T V L G  
JL3b GTG TTC GGC GGA GGG ACC AAG CTG ACC GTC CTA GGT 
IS4 ..................................................................................................
Figure 3.5 Sequence of IS4V*. compared to 2a2 and JL3b germline genes
The positions of CDRs and FRs are as defined by Wu and Kabat (1970). Regions encoded by PCR primers are underlined and contact residues as 
predicted by MacCallum et al. (1996) are highlighted.
The first 21 nucleotides of the V region are encoded by a PCR primer specifically designed 
to amplify IS4VH, hence this region was included in the homology calculations. None of 
the differences observed between IS4VH and V I-03 occur at a site of known 
polymorphism. Fourteen nucleotide differences occur between the two sequences in the 
FRs leading to 10 R mutations and four S mutations. Six R mutations and only two S 
mutations occur in CDR 1 and 2. The distribution of somatic mutation found is not very 
suggestive of antigen driven selection and the non significant Pm values for both the FR 
and CDR confirm this, see Table 3.1. These calculations however, do not include CDR3 
which could not be matched to a germline gene and also contributes to the antigen binding 
site. IS4VhCDR3 contains five Arg residues which may have arisen as a result of antigen 
drive.
Again there was no overall effect upon charge by the somatic mutations. The H2 contact 
region however contains three Asn and one Lys residue which are all germline encoded and 
does not contain any acidic residues. In the H3 contact region there are four Arg and two 
acidic residues.
No match could be made for the D region. The reason for this is that the DNAPLOT 
software used very stringent criteria for aligning Ab sequences to germline D segments, 
described in section 1.7.7.2. The J region aligns with JH4b.
3.5 Sequence analysis of CL24
3.5.1 The light chain
In CL24Vk, shown in Figure 3.7, the initial 23 nucleotides are encoded by the VK3 primer 
used in PCR amplification. Therefore the first 23 nucleotides were not included in 
calculations of homology. Hence CL24 VK shares 90.9% nucleotide and 84.1% amino acid 
homology with the germline gene A27. There are no known sites of allelic polymorphism 
in A27 thus all differences seen between the two sequences can be ascribed to somatic 
mutation. In the CDRs there are ten R mutations (of which seven occur in CDR1) and no S 
mutations at all. This pattenj is very suggestive of antigen drive with a Pm of 0.0206. The 
FR has eight R mutations and six S mutations also with a significant Pm of 0.0291.
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FR1
Q V Q L>F V Q  S G A E  V K K P  G A S  V K V S C K A S > F  
Vl-03 CAG GTC CAG CTT GTG CAG TCT GGG GCT GAG GTG AAG AAG CCT GGG GCC TCA GTG AAG GTT TCC TGC AAG GCT TCT 
IS4 ....................... T ............................. .....................................................................................................A ............................................ T-
CDR1 FR2
G Y T>S F T S Y A>F M>L H W V R Q A P G Q  R>G L>P E W M G
Vl-03 GGA TAC ACC TTC ACT AGC TAT GCT ATG CAT TGG GTG CGC CAG GCC CCC GGA CAA AGG CTT GAG TGG ATG GGA 
IS4 .................G ............ - - t  - - -  TT- T-A ......................................................................... G- - -C ...................................
CDR2 FR3
W I N A>S G N G N T K Y S Q  K>N F Q G R V T>S I T R D T
Vl-03 TGG ATC AAC TCG GGC AAT GGT AAC ACA AAA TAT TCA CAG AAG TTC CAG GGC AGA GTC ACC ATT ACC AGG GAC ACA
IS4 * ■* - *•  T* «■■ ■ ■ -  . Hi M - m  m . ;» m m  -  -  C - - - - - - - - C - -  -  -  -  -  -  -  -     -  -  -  T “ ~ -  -  -  -  -  -  -  -  A -  -  -  -  -  -
S A S T>V A>V Y M E L S S L R>G S E  D T  A V Y Y  C A R
Vl-03 TCC GCG AGC ACA GCC TAC ATG GAG CTG AGC AGC CTG AGA TCT GAA GAC ACG GCT GTG TAT TAC TGT GCG AGA 
IS4 .....................  GT- - T .......................................T ................ G.................................................................................C - - - - - -
CDR3
G R R D V  R G  V L W R  G R  H D
IS4 GGA CGT CGA GAC GTT CGG GGA GTT CTT TGG AGG GGC AGA CAT GAC
Y F D Y>F W G Q G T  L V T > I V S  S 
JH4b TAC TTT GAC TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA 
IS4 ......................... T................................................................. T..........................
Figure 3.6 Sequence of IS4 V h compared to Vl-03 and W b
For footnote see figure 3.5.
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An increase in the number of basic residues is found in CDR1 with a serine replaced by an 
Arg in codon 28 and in codon 31 which is a site of antigen contact. A Tyrosine is mutated 
to Asn in codon 32. Overall, however, the net charge is unchanged because of two 
mutations where a glycine is replaced with Asp at codon 50 in CDR2 and a Ser mutated to 
another Asp at codon 93 in CDR3 which are both sites of antigen contact.
The J region aligns to the JK2 gene with one S mutation and one R mutation of a Lys to 
Arg.
3.5.2 The heavy chain
Figure 3.8 demonstrates the sequence of CL24VH to have 84% nucleotide and 76.5% amino 
acid homology with V3-23 germline gene. The 47 nucleotide differences found do not 
occur at sites of known allelic polymorphism and are not due to the PCR primers used. 
CDRs 1 and 2 contain eight R mutations and six S mutations a pattern that is not suggestive 
of antigen drive with a non significant Pm value of 0.2554. The FRs contain 15 R 
mutations and 18 S mutations and have a significant Pm of 0.0195. Somatic mutations lead 
to the formation of basic residues at sites of antigen contact in H2 and H3 and no acidic 
residues in any of the CDRs.
The D region could be matched to D6-19 germline gene and the nucleotide differences give 
rise to four R and three S mutations in this region. JH4b encodes the JH region with four 
nucleotide differences leading to two R mutations and two S mutations.
3.6 Modelling of three-dimensional structures
To ascertain whether arginines residues hypothesised to be important in binding to CL are 
in fact surface exposed and hence available to bind antigen, modeling studies were carried 
out by Dr Sylvia Nagl, shown in Figure 3.9. The three-dimensional structures of CL24Vl 
and IS4Vl were modeled using SWISS-MODEL (Guex and Peitsch, 1997) and the 
coordinates of B3VL as a template (Kalsi et al., 1996; Rahman et al., 2001). IS4VH was 
modeled using B3 and lVGE.pdb (chain H) as templates. Molecular graphics were 
generated in WebLab Viewer.
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FR1 CDR1
E I V L T Q S P G T L  S>Y L S P G E>D R A T L S C R A  
A27 GAA ATT GTG TTG ACG CAG TCT CCA GGC ACC CTG TCT TTG TCT CCA GGG GAA AGA GCC ACC CTC TCC TGC AGG GCC 
CL24 ............................................................................... A- C.................... T ...................................... G .......................
FR2
S Q S>R V S>G S>R S>T Y>N L>V A W Y Q Q K P>F G Q A P R L L I Y
A27 AGT CAG AGT GTT AGC AGC AGC TAC TTA GCC TGG TAC CAG CAG AAA CCT GGC CAG GCT CCC AGG CTC CTC ATC TAT 
CL24 .................... A - - -  G*- - -G -CGr A—‘G-- - - -  - - -  - - T .................... GTT................................................ ........................
CDR2 FR3
G>D A S  S R A T G I  P D R F  S G S  G S  G T  D F T L  T>I 
A27 GGT GCA TCC AGC AGG GCC ACT GGC ATC CCA GAC AGG TTC AGT GGC AGT GGG TCT GGG ACA GAC TTC ACT CTC ACC 
CL24 -A- ....................................  T-
CDR3
I S R L>M E P E D F  A V>I Y Y C Q  Q Y G S>D S P
A27 ATC AGC AGA CTG GAG CCT GAA GAT TTT GCA GTG TAT TAC TGT CAG CAG TAT GGT AGC TCA CCG
CL24........ ................. A.......................C  A -A  C - - -  - - -  - -  —  GA..............
Y T F G Q G T K>R L E I K 
Jk2 TAC ACT TTT GGC CAG GGG ACC AAG CTG GAG ATC AAA 
CL24 —  - - C ............................................G...................................
Figure 3.7 Sequence of CL24 VL compared to A27 and JK2
For footnote see figure 3.5.
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FR1
E V Q>E L L E S G G G L V  Q P G G S L R L S C A A S  
V3-23 GAG GTG CAG CTC TTG GAG TCT GGG GGA GGC TTG GTA CAG CCT GGG GGG TCC CTG AGA CTC TCC TGT GCA GCC TCT 
CL24 - -A —  G - - T -A  A — ..................................... G  G ............................................................................................
CDR1 FR2 CDR2
G F T>S F>L S>A S Y>H A M  S W V R Q A>R P G K G  L E W V > I S  A>S
V3-23 GGA TTC ACC TTT AGC AGC TAT GCC ATG AGC TGG GTC CGC CAG GCT CCA GGG AAG GGG CTG GAG TGG GTC TCA GCT 
CL24 ................T-- - -AGC- - - -  C - - ...................... ................... T - - A C G  C - - A ..................... A - - -  - - -  A AG-
FR3
I S>T G>I S>R G G S T>I Y Y A D S V K G R F T I S R D N S
V3-23 ATT AGT GGT AGT GGT GGT AGC ACA TAC TAC GCA GAC TCC GTG AAG GGC CGG TTC ACC ATC TCC AGA GAC AAT TCC 
CL24 . . .  -C* AtC C - - - - -  - - T ATT - - T .............................T .............................C .......................................................C - - -
K>R N T>I L Y L Q>E M N S>N L R A E D T A V>L Y Y>H C A K>R
V3-23 AAG AAC ACG CTG TAT CTG CAA ATG AAC AGC CTG AGA GCC GAG GAC ACG GCC GTA TAT TAC TGT GCG AAA 
CL24 -G- - - T - T C  - - A  G ........................A - T ------- G .......................................... T ............ C ........................-G-
CDR3
R G I> S A V A>I G>R S
D6-19 AGG GGT ATA GCA GTG GCT GGT ACC
CL24 . . . . .  CNGT - - - - - -  AT- A- A f  - -
Y>H F D Y W G Q G T L>Q V T>I V S S
JH4b TAC TTT GAC TAC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA 
CL24 C ...........................................................................A..............T........................G
Figure 3.8 Sequence of CL24 Vh compared to V3-23, D6-19 and Jn4b
For footnote see figure 3.5.
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The models show that multiple surface exposed Arg residues are prominent features of 
IS4Vh and CL24V l. CL24V l has two surface exposed Arg residues (positions 28 and 31) 
in CDR1, which have both been produced as a result of somatic mutation, see Figure 3.9 
A). There are germline encoded Arg residues at position 54 in CDR2 and position 61 in 
FR3, see Figure 3.9 A). In contrast, IS4VL has only one surface exposed germline encoded 
Arg residue, at position 54, see Figure 3.9 B). In the Arg rich CDR3 of IS4VH. four out of 
five Arg residues (at positions 96, 97, 100 and lOOg) are predicted by the model to be 
surface exposed and therefore potentially important in binding to CL, shown in Figures 3.9 
C) and D).
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A) Ar§ 61
7 Arg 54
Arg 31
Arg 28
B)
C) D)
Figure 3.9 Modelling studies of CL24Vl , IS4VL and IS4VH
A) Model of the light chain of CL24 is shown in secondary structure mode. B) A model of 
the light chain of IS4 in secondary structure mode. C) Spacefill model of the heavy chain 
of IS4. The labelled arginines (Arg) in the large CDR3 loop region of IS4VH are predicted 
to importantly contribute to CL-binding specificity. D) The heavy chain of IS4 in 
secondary structure mode. In all models Arg residues predicted to be exposed are shown in 
dark blue {spacefill mode); CDR1 in light and heavy chains is depicted in yellow, CDR2 in 
orange and CDR3 in red.
Arg 96 
Arg 97
ArglOOg
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3.7 Discussion of results
When studying monoclonal antibodies such as IS4 and CL24 derived from different 
patients, uncertainty arises as to whether such antibodies are truly representative of 
pathogenic antibodies found in other patients with APS. Thus it is important to consider to 
what extent the sequences of these two antibodies are in agreement with what has been 
previously discovered about human aPL. In particular: - the pattern of gene usage; degree 
of somatic mutation; evidence of antigen drive; and existence of any sequence motifs likely 
to be important in binding to CL/P2 GPI must all be considered in IS4 and CL24.
3.7.1 Pattern of gene usage
Previous analyses have shown that the aPL most likely to be representative of those 
developing in patients with APS are those in which the Vh and Vl sequence are encoded by 
commonly rearranged genes (Giles et al., 2003a). The light chains of IS4 and CL24 both 
utilise some of the most commonly expressed Vl genes, 2a2 and A27 respectively, (Cox et 
al., 1994; Ignatovich et al., 1997; Brezinschek et al., 1998). The Jl gene usage of both 
antibodies JL3b for IS4 and JK2 for CL24 conforms to the known usage of these genes in 
peripheral lymphocytes where Jl2 or Jl 3 and JK2, JK3 and JK4 genes are most commonly 
expressed (Domer et al., 1999; de Wildt et al., 2000).
CL24Vh utilises one of the most commonly rearranged genes V3-23 (Brezinschek et al., 
1997; de Wildt et al., 2000). IS4VH, however, is encoded by the germline gene Vl-03, 
which is not amongst those genes most commonly expressed in healthy individuals and 
patients with SLE (Cox et al., 1994; Brezinschek et al., 1997; Ignatovich et al., 1997; de 
Wildt et al., 2000). Furthermore, in a systematic analysis of all published aPL sequences, 
Vl-03 was not found to encode any of 36 published human IgM or IgG monoclonal aPL 
(Giles et al., 2003b).
IS4VhCDR3 could not be matched to any known DH gene through VBASE and this may be 
because this region of the antibody is in fact highly mutated hence it cannot be matched to 
any known germline genes. The D segment of CL24Vh uses the D6 family, D6-19 gene 
thus differing from the most commonly expressed D2 and D3 families (Brezinschek et al., 
1997; Corbett et al., 1997; de Wildt et al., 2000). Both aPL however use the JH4b gene
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which is one of the most commonly rearranged JH genes in peripheral B cells (de Wildt et 
al., 2000).
Therefore the pattern of gene usage in CL24 and IS4VL is that which would be expected 
from the intrinsic bias of the recombination mechanism. Genes that are commonly 
rearranged by that mechanism are also commonly used to encode both IgM and IgG aPL. 
The gene usage of IS4VH however, is unusual and it seems unlikely that the germline 
sequence of this gene is predisposed to formation of a CL binding site. Therefore unless the 
entire CL binding ability of IS4 is conferred by the light chain there must another 
distinguishing feature of this aPL heavy chain, such as somatic mutations and/or certain 
sequence motifs in VhCDR3.
3.7.2 Degree of somatic mutation
The V regions of both antibodies demonstrate a high degree of somatic mutation. The 
greatest numbers of somatic mutations were found in CL24 particularly in the heavy chain 
and a similar pattern was found in IS4. IS4VH is highly mutated with only 92.5% homology 
to the germline gene. However, many of these mutations are R in FRs or S mutations in 
CDRs, with the result that statistical analysis of the pattern of mutations does not suggest 
that they have been selected by antigen. Although this analysis cannot exclude the 
possibility that an individual mutation in IS4Vh CDR1 or 2 could be playing a role in 
binding to CL, there are only four R mutations in these CDRs of which only one is a 
mutation to Asn with no mutations to Arg or Lys.
3.7.3 Evidence of antigen drive
Statistical analysis of CL24 using the multinomial method of Lossos et al. (2000) reached 
levels of significance in both the heavy and light chain sequence. In IS4 only the VL 
sequence reached levels of significance. The multinomial analysis only examines the VH 
region up to the end of FR3 and does not include CDR3 of each heavy chain. Therefore 
although a non significant p value was obtained for IS4Vh, the CDR3 of this heavy chain 
may have arisen as a result, of antigen drive. CDR3 has been shown to be important in 
conferring binding of anti-dsDNA antibodies to dsDNA in previous studies (Li et al., 2000) 
and the same may well hold true for pathogenic aPL which share some similarities with the 
former antibodies (Rahman et al., 1996).
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3.7.4 Evidence of any sequence motifs likely to be important in binding to CL/p2GPI
Overall the heavy chain CDRs of both IS4 and CL24 display an accumulation of 
predominantly Arg and Asn residues compared to acidic residues greater than that seen in 
the light chains. The numerous Arg residues found in IS4VHCDR3, which far outnumber 
any acidic residues, may also be conferring a strong affinity for antigen (Figure 3.6). 
CL24Vh demonstrates a greater number of somatic mutations in all CDRs leading to the 
formation of Arg residues in CDR2 and 3 (Figure 3.8).
IS4VhCDR3 is long (15 amino acids) with a very high content of five Arg residues. It 
seems likely that the length and Arg content of this CDR3 arise from N addition and 
somatic mutation and that selection by antigen has acted to promote expansion of the clone 
containing these Arg residues. Models in Figures 3.9 C) and D) support this hypothesis 
because four of the five Arg residues in CDR3 are surface exposed and could therefore be 
important in contributing to CL-binding specificity.
The model of CL24Vl in Figure 3.9 A) clearly shows that the two Arg residues created by 
somatic mutation in CDR1 (at position 28 and 31) are surface exposed. In contrast, IS4VL 
shown in Figure 3.9 B) has no somatic mutations to Arg at all but does contain a germline 
encoded Arg at position 54 which is also present in CL24Vl.
3.7.5 Conclusion
In conclusion IS4 and CL24 are highly mutated human IgG aPL. Both chains of CL24 and 
IS4Vl utilise commonly expressed VH and VL genes and are thus representative of other 
pathogenic aPL. The heavy chain of IS4VH, however, does not utilise a commonly 
expressed gene but does contain a long Arg rich CDR3 which could not be matched to 
germline gene. On the whole the heavy chains carry more somatic mutations than the light 
chains, but the distribution of R and S mutations in the latter is more suggestive of antigen 
driven clonal expansion as measured by a statistical method. A greater number of Arg, Asn 
or Lys residues some of which are somatically mutated, are found in the CDRs of the heavy 
chains compared to the light chains. Both somatic mutations and Arg residues are likely to 
be important in determining the ability of IS4 and CL24 to bind PL/p2GPI. Flence the 
purpose of subsequent experiments was to examine which features of which chains were 
the most important.
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CHAPTER 4
RELATIVE IMPORTANCE OF DIFFERENT HUMAN aPL DERIVED HEAVY 
AND LIGHT CHAINS IN THE BINDING OF aPL TO CARDIOLIPIN 
4.1 PCR amplification of IS4 and CL24
The first step in this process was to PCR amplify cloned V region DNA of IS4 and CL24 
with specific primers to add a SJi I restriction site at the 5' end and a splice donor site 
followed by a BamH I restriction site at the 3' end. Successful PCR products were 
confirmed by gel electrophoresis. Figure 4.1 demonstrates a band of approximately 350 
base pairs for each VL region and approximately 400 base pairs for each VH region 
compared to a negative control in which no DNA was added to the PCR mixture to confirm 
that non-specific amplification did not occur.
4.2 Cloning into the intermediate vector pBCVHCASS4
Purified IS4 and CL24 PCR products from the previous step were then Sfi VBamW I 
digested and ligated into pBCVHCASS4, which had been digested by the same enzymes. 
Successful ligation was confirmed by dual digestion with Hind \WIBamW I. Figure 4.2 
shows an agarose gel of Hind WVBamW I digested recombinant plasmid DNA in which the 
upper band of DNA contains pBCVHCASS4 3446bp in size and the lower bands show 
inserts of the appropriate size in A) of 463bp for IS4 Vh and 442bp for CL24 VH and in B) 
of 406bp for both IS4 V l and CL24 Vl.
4.3 Cloning into the final expression vectors
Hind III/BamH I digested insert was purified and ligated into pLNlOO, pKNIOO for the 
light chains and pGlD106 for the both heavy chains. The presence of insert was confirmed 
by a Hind WVBamWl digest of the recombinant plasmids. In Figure 4.3 A) lanes 2 - 1 1  two 
separate bands of DNA are visible, the larger containing pGlD106 (7328bp) and the 
smaller CL24VH (442bp). A similar pattern is seen in Figure 4.3 B), with lanes 2 - 6  
containing pLNlOO (745lbp) and IS4 VL (406bp) and lanes 7 - 8  containing pKNIOO 
(7664bp) and CL24 VL (406bp). IS4VH was not successfully cloned into pGlD106.
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A) 1 2 3 4 5 6 7 8 9 10 11 12 13
506,
517bp
B)
506,
517bp
1 2 3 4 5
Lanes in A)
= 1 Kb marker
2 - 3  = IS4 cDNA PCR amplified with IS4HF and HB primers
4 - 5  = no cDNA PCR amplified with IS4HF and HB primers
6 - 7  = IS4 cDNA PCR amplified with IS4LF and LB primers 
8 - 9  = no cDNA PCR amplified with IS4LF and LB primers
10 -11=  CL24 cDNA PCR amplified with CL24HF and HB primers 
12-13 = no cDNA PCR amplified with CL24HF and HB primers
Lanes in B)
1 = 1 Kb marker
2 - 3  = CL24 cDNA PCR amplified with CL24LF and LB primers
4 - 5  = no cDNA PCR amplified with CL24LF and LB primers
Figure 4.1 PCR amplification of IS4 and CL24 V region cDNA to incorporate S/l I, 
BamH I restriction sites and a splice donor site
A) The following PCR products are visible; - 410bp DNA fragment containing IS4VH (in 
lanes 2 and 3); a 354bp DNA fragment containing IS4VL (in lanes 6 and 7); and a 389bp 
DNA fragment containing CL24VH (in lanes 10 and 11). A control reaction with each set of 
PCR primers and no cDNA did not yield a product. B) A 353bp DNA fragment containing 
CL24Vl is present in lanes 2 and 3 with no product when the same PCR reaction and 
primers were used with no cDNA.
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7Lanes in A)
1 -2 = BamH l/Hind III digested IS4VH/pBCVHCASS4
3 = BamH l/Hind III digested CL24VH/pBCVHCASS4
4 = 1 Kb marker, 3054bp (upper) and 506, 517bp (lower) bands arrowed
B)
Lanes in B)
1 = 1 Kb marker, 3054bp (upper) and 506, 517bp
(lower) bands arrowed
2 & 3 = BamH l/Hind III digested IS4VL/pBCVHCASS4
4 & 5 = BamH l/Hind III digested CL24VL/pBCVHCASS4
Figure 4.2 BamH l/H ind  III digest of IS4 and CL24 heavy and light chains in 
pBCVHCASS4
A) A 463bp fragment of DNA is seen in lanes 1 and 2 containing IS4VH and a 442bp 
fragment in lane 3 containing CL24VH, the larger fragments in lanes 1 -  3 are 3446bp 
long containing the remainder of pBCVHCASS4.
B) The BamH l/Hind III digested fragments of DNA are: - 406bp containing IS4VL in 
lanes 2 and 3; and 406bp containing CL24 VL in lanes 4 and 5. The larger fragments in 
lanes 2 -  5 are 3446bp long containing the remainder of pBCVHCASS4.
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3054bp
1 2 3 4 5 6 7 8 9  10 11
Lanes in A)
1 = 1 Kb marker
2-11= CL24VH/pGlD106
Lanes in B)
1 = 1Kb marker
2-6 = IS4Vl/PLN100
7-8 = CL24 V L/pKN 100
3054bp 
506,517bp
Figure 4.3 Cloning into expression vectors pGlD106, pLNlOO and pKNIOO
In the above figures each lane represents plasmid derived from a different colony on 
LB Agar plates. A) Hind III/BamH I digest of CL24 VH/pGlD106 in lanes 2 - 1 1  reveals 
a larger band of DNA containing pGlD106 (7328bp) and the smaller CL24VH (442bp).
B) A Hind III/BamH I digest of: - IS4VL/pLN100 (lanes 2 - 6 )  reveals two bands of 
DNA one containing pLNlOO (7451 bp) and the other IS4 Vl (406bp); and 
CL24VL/pKN 100 in lanes 7 - 8  gives a large band of DNA containing pKNIOO 
(7664bp) and a smaller CL24 V l (406bp) band.
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4.4 Transfer of heavy chain variable regions into pG!D210
Both heavy chains were transferred from pBCVHCASS4 into pGlDZlO for reasons given 
in section 2.16.5. The first step was to introduce a Xho 1 site into the JH region o f both 
heavy chains at codon 111 -  113, which was achieved by PCR, the products o f which are 
shown in Figure 4.4. These PCR products were then purified and dual digested with Hind  
III and Xho I. These bands were then purified and the amount o f  DNA quantified by gel 
electrophoresis, shown in Figure 4.5 A) before cloning different insert:vector ratios into 
pG lD 210. Success o f  the ligation was determined by screening recombinant DNA 
recovered from bacterial colonies post ligation by Hind I I I  /Xho  I digest for the presence of 
IS4Vh and CL24 Vh, see Figure 4.5 B).
4.5 Sequencing of inserts in the final expression vectors
Further sequence analysis o f each insert in the appropriate recombinant vectors was 
performed. The light chain o f CL24 and both heavy chains were identical to those 
characterised in section 3.4 and 3.5. An example o f a sequencing gel containing both 
IS4Vh and CL24VH that have been PCR amplified and ligated into pG l 1)210 N shown in 
Figure 4.6 and the beginning o f  CDR2 highlighted. A PCR error however, had occurred in 
IS4V l leading to a replacement mutation in FR1 o f Ser to Pro at codon 14. 1 o rectify this 
PCR error, site directed mutagenesis o f IS4VL was performed as described in section 2.16.7 
with the primers shown in Table 2.7 B). Comparative sequencing gels o f IS4VL before and 
after the m utagenesis are shown in Figure 4.7 A) and B) respectively.
4.6 Expression of whole IgG antibodies in COS-7 supernatants
To study the relative contribution o f sequence features in the heavy and light chains of 1S4 
and CL24 to their ability to bind CL, each heavy chain was expressed with a range o f 
different light chains. Conversely, each light chain was expressed with a range o f different 
heavy chains. A total o f  four heavy chains and five light chains were studied the sequence 
characteristics o f  which are summarized in Table 4.1. The patients from whom these mAbs 
were isolated have previously been described in section 2.4.
193
3054bn
1 2 3 4 5 6 7 8 9 10 11 12 13
Lanes 1 = 1Kb marker
2-3, 5-6 = CL24VH with CHB primers
4 and 7 = No DNA with CHB primers
8-9, 11-12 = IS4Vh with IHB primers
10 and 13 = No DNA with IHB primers
Figure 4.4 Introduction of Xho I restriction site into IS4VH and CL24VH
PCR amplification of CL24VH (442bp in lanes 2, 3, 5 and 6) and IS4VH (463bp in lanes 8, 
9, 11 and 12).
A)
7126bp
506, 517bp
Lanes in A) 1
2 - 3
4 - 5
6 - 7
1 2  3 4  5
= 1 Kb marker
= Purified Hind WVXho I digested CL24VH 
= Purified Hind WVXho I digested IS4VH 
= Purified Hind WVXho I digested pGlD210
B)
5OObp—
1 8 9 10 11 12 13 14
Lanes in B)
2 3 4 5 6 /
I and 14 =1 OObp ladder
2 - 4 & 8 - 1 0  = Hind WVXho I digested CL24VH/pGlD210 
5 - 7  = Hind WVXho I digested IS4VH/pG 1D210
II = Hind WVXho I digested CL24VH/pGEM-T Easy vector
12 = Hind WVXho I digested I S 4 V h/ p G E M -T  Easy vector
13 = Uncut pGlD210
Figure 4.5 Ligation of H indlll/X ho  I digested heavy chains into pGlD210
A) Confirmation gel of purified Hind WVXho I digested CL24VH (442bp in lanes 2 -3), 
IS4Vh (463bp in lanes 4 - 5 )  and pGlD210 (7222bp in lanes 6 -7) DNA used in subsequent 
ligations. B) Screening colonies (lanes 1 - 1 0 )  post ligation of Hind WVXho I digested 
IS4Vh and CL24VH into Hind WVXho I digested pGlD210. Heavy chain inserts of CL24VH 
(442bp) are visible in lanes 2, 4, 8, 9 and 10 whilst IS4VH (463bp) is visible in lanes 5 and 
7. Recombinant pGEM-T Easy vector containing CL24VH and IS4VH was Hind WVXho I 
digested and run for comparison in lanes 11 and 12.
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IS4VH/pGl D210 CL24 Vh/PG1 D210
-» . . *mm
Figure 4.6 Sequence gel of IS4 and CL24 heavy chain variable regions cloned into 
PG1D210
This figure shows samples of the sequences of IS4VH and CL24VH as read from manual 
sequencing gels. Sequences can be read downward from the top of the gel, from position 
145 to 237 for IS4VH (compare Fig 3.6) and position 123 to 216 for CL24VH (compare Fig 
3.8). The beginning of CDR2 is shown with an arrow in each sequence.
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C) FR1
Codon 10 20
Germline 2a2 GTG TCT GGG TCT CCT GGA CAG TCG ATC ACC
Sequencing gel A) ---- --------------C— ------------------------------------------
Sequencing gel B) ---- --------------T— ----------------------------------- -------
Figure 4.7 Sequence gels of IS4Vl/p LN1 00 before and after site directed mutagenesis
Manual sequencing gels of IS4VL/pLN100 containing a PCR error before, shown in A) and 
after site directed mutagenesis, shown in B). Sequences can be read upwards from the 
bottom of the gel, from position 28 to 49. A) The Taq polymerase induced serine to proline 
replacement mutation at codon 14 is boxed off. B) The same region of IS4VL is shown post 
site directed mutagenesis to revert the proline back to the germline encoded serine residue 
(shown in the box). C) The relevant sequence of IS4Vl is shown for comparison.
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4.7 Sequences of light chains expressed
Amino acid sequences of IS4VL, UK4VL, B3VL and 33H11VL and germline gene 2a2, are 
shown in Figure 4.8 A). CL24VLand germline gene A27 are displayed in Figure 4.8 B). All 
of these light chains with the exception of 33H11VL contain numerous somatic mutations. 
Previous statistical analysis has shown that the observed pattern of R mutations in the 
CDRs of these sequences (except 33H11) is consistent with antigen driven selection 
(Winkler et al., 1992; Ehrenstein et al., 1994; Menon et al., 1997; Rahman et al., 1998; 
Chukwuocha et al., 2002; Rahman et al., 2002).
The Vl sequences of IS4, B3, 33H11 and UK-4 are all encoded by the germline V*. gene 
2a2, but differ in their patterns of somatic mutation. In each of these light chains, some 
mutations create new Arg or Asn residues; see Figure 4.8 A). In CDR3 of IS4VL a Ser 
residue is replaced by Asn. B3Vl contains adjacent Arg residues in CDR1, which have 
been produced by somatic mutations. The CDR3 of 33H11Vl contains two Arg residues, 
one of which is created by somatic mutation whilst the other is formed by the junction 
between 2a2 and J*,2. UK4 has a single somatic mutation to Arg in CDR3. In CDR1 of 
CL24Vl there are two Arg residues created by somatic mutation.
4.8 Sequences of heavy chains expressed
The amino acid sequences of each Vh chain and corresponding germline gene are displayed 
in Figure 4.8 C). The heavy chains all contain numerous somatic mutations. CL24 CDR2 
and CDR3 each contain a codon somatically mutated to Arg. B3Vh has a single somatic 
mutation to Arg in CDR2. The CDR2 of IS4 VH contains an Asn residue created by somatic 
mutation. Statistical analysis has shown that the pattern of R mutations in these antibodies 
is suggestive of antigen driven selection, with the exception of IS4VH. However IS4VH 
contains five Arg residues in CDR3 as described in section 3.4.2.
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mAb Origin VH
Gene
Nucleotide 
Homology (%)
vL
Family/Gene
Nucleotide 
Homology (%)
Binding
CL24 SAPS V3-23 84 VkIII/A27 90.9 p2GPI /CL
IS4 PAPS V I-03 92.5 V„2/2a2 93.3 p2GPI /CL
UK4 SLE V3-74 95 V^2/2a2 94 CL
B3 SLE V3-23 94 Vx2/2a2 93 dsDNA, CL
33H11 SLE V3-07 95 Vj,2/2a2 99.4 dsDNA
Table 4.1 Sequence characteristics of monoclonal antibodies expressed in COS-7 cell 
supernatant
IS4 & CL24 kindly donated by Dr P. Chen (University of California at Los Angeles), UK4 
- produced by Dr S. Menon (University College London), B3 - produced by Dr M. 
Ehrenstein (University College London), 33H11 - produced by Dr T. Winkler, Erlangen, 
Germany.
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A) Lambda chains
FRl CDR1 FR2 CDR2 FR3 CDR3
1 20 24 27 34 35 40 50 60 70 80 89 100
I | I l a b c  | I I I I I I I I
2a2 QSALTQPASVSG.SPGQSITISC TGTSSDVGGYNYVS WYQQHPGKAPKLMIY EVSNRPS GVSNRFSGSKSGNTASLTISGLQAEDEADYYC SSYTSSST VVFGGGTKLTVLG
IS4 -----------.--------- --A-- I-S--S----- HL 1-- D— S ---------- F---------P------- C TIN- W------------
UK4 -----------.---------- SN-- S---- --- L-- E----L—  DAIK-----------E--------------- G--- ---- NR.. -F----------
33.H11-----------.------------- 1----  L---- D--T--- -------------------------------  R--- R------------
B) Kappa chains
FRl CDR1 FR2 CDR2 FR3 CDR3 JK
31
I a
A27 EIVLTQSPGTLSLSPGERATLSC RASQSVSSS..YLA WYQQKPGQAPRLLIY GASSRAT GIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSP YTFGQGTKLEIK 
CL24 --------- Y--- D-----  R-GRT..NV------ F-------- D-------  1-- M----- 1---  D--  R---
C) Heavy chains
FRl CDR1 FR2 CDR2 FR3 CDR3 JH
30 31 36 40 50 60 70 82 90 100 101
I I I I I I I I abc | I I
1-03 QVQLVQSGAEVKKPGASVKVSCKASGYTFT SYAMH WVRQAPGQRLEWMG WINSGNGNTKYSQKFQG RVTITRDTSASTAYMELSSLRSEDTAVYYCAR YFDYWGQGTLVTVSS
IS4  F F--S-- --FL--------GP--- ------------ N-- --S-------- VV------ G---------- GRRDVRGVLWRGRHD---F------ 1--
3-23 EVQLLESGGGLVQPGGSLRLSCAASGFTFS SYAMS WVRQAPGKGLEWVS AISGSGGSTYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK YFDYWGQGTLVTVSS
CL24 --E----------------------SLA -H------ R------ 1- S-TIR 1---------------- R-I E— N------ L-H— R RGSAVIRS H-------Q-I--
B3  V---------------- T---- T T--- ------------- T R-S-G— Q -  L----------S-------------------PNVGSGW S —  S L-T--
3-07 EVQLVESGGGLVQPGGSLRLSCAASGFTFS SYWMS WVRQAPGKGLEWVA NIKQDGSEKYYVDSVKG RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR YFDYWGQGTLVTVSS
33.H11-------------------------1-- NF--T------------ --N-G--KRS------- -------- V---------------------LV -C-----------
Figure 4.8 Sequence alignments of expressed Vl and Vh regions
Sequences have been aligned using DNAplot VBASE (Tomlinson et al., 1996). A) Sequences of expressed VA regions compared to 2a2. B) Sequences of 
expressed Vk regions compared to A27. C) Sequences of expressed Vh regions compared to 1-03 (IS4), 3-23 (CL24 and B3) and 3-07 (33H11). Only the Dh 
region of CL24 could be matched to a germline gene (D6-19) using DNAplot and somatic mutations in this region are underlined.
The amino acids are numbered according to Kabat. Dots have been inserted to facilitate the alignment. A dash indicates homology with the corresponding germline sequence. 
Abbreviations:- FR -  Framework region; CDR -  Complementarity determining region.
4.9 Detection of whole IgG molecules in COS-7 supernatants by ELISA
Each of the four heavy chains was paired with each of the five light chains so that a total of 
20 heavy/light chain combinations were expressed in COS-7 cells. At least two expression 
experiments were carried out for each combination. IgG was obtained in the supernatant for 
19 of the 20 combinations. The exception was 33H11 Vh/CL24Vl , from which no IgG was 
obtained despite repeated attempts. It is possible that the structure of this heavy chain is 
such that it cannot form a stable antibody with a k  chain, or that the patterns of somatic 
mutations in these two chains lead to three-dimensional structures that are sterically 
incompatible.
The concentration of IgG in each COS-7 cell supernatant is shown in Table 4.2. In each 
case the negative control sample in which COS-7 cells were electroporated without any 
plasmid DNA contained no detectable IgG. Consistently high yields were obtained with the 
B3Vh/IS4Vl and B3Vh/CL24Vl combinations compared to the other antibody 
combinations. The phenomenon of variable expression with different VH and VL constructs 
is well documented both in this antibody expression system and others (Rahman et al., 
1998; Rahman et al., 2001) although the reason for its occurrence is not clear.
4.10 Results of aCL ELISA
For each heavy/light chain combination which bound CL, the linear portion of the binding 
curve for absorbance against antibody concentration was determined empirically by 
dilution of antibody over a wide range of concentrations. Similar patterns of binding were 
obtained with each antibody combination from repeated expression experiments hence 
representative results from two separate experiments are shown in Figure 4.9 A) and B).
Only five combinations showed any binding to CL. These were IS4VH/B3VL, 
IS4Vh/CL24Vl, IS4Vh/IS4Vl , IS4Vh/33H1 1Vl and B3VH/B3VL. Despite being tested 
over a wide range of antibody concentrations, none of the other combinations showed any 
binding to CL at all.
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Heavy chain Light chain IgG Concentration (ng/ml) CL Binding DNA Binding
CL24 CL24 69.5-310 - -
CL24 B3 260 - 475 - -
CL24 UK4 88 - 360 - -
CL24 IS4 430- 1190 - -
CL24 33H11 32 -33.5 - -
B3 B3 3.5 -5 + +++
B3 33H11 2-10 - ++
B3 UK4 42.5 - 540 - -
B3 IS4 1120-6040 - -
B3 CL24 2200 - 4920 - -
IS4 IS4 119.5-420 + -
IS4 B3 4 -4 0 +++ -
IS4 CL24 104-120 ++ -
IS4 UK4 250 - 675 - -
IS4 33HII 27 - 235 + -
33H11 33H11 8-17.5 - -
33H11 IS4 24-73.5 - -
33H11 B3 2 6-74 - -
33H11 UK4 17-63.5 - -
No DNA No DNA 0 - -
Table 4.2 Range of IgG concentrations produced in ng/ml and binding characteristics 
of each heavy/light chain construct during the expression experiments
Abbreviations: - CL -  cardiolipin. “+” represents binding of the IgG heavy/light chain 
combination to the antigen whilst represents no binding.
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Figure 4.9 A) Results of aCL ELISA
The graphs show binding of IgG in COS-7 cell supernatants containing each heavy light chain combination to cardiolipin.
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Figure 4.9 B) Results of aCL ELISA
For footnote see Figure 4.9 A).
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IS4Vh binds CL in combination with four of the five light chains tested, but these light 
chains do not bind CL in combination with the other heavy chains tested (with the single 
exception of B3VH/B3VL). This finding suggests that the heavy chain plays a dominant role 
in binding of IS4 to CL. The differences between the abilities of these four combinations to 
bind to CL must arise from the differences between their light chains. The wild type 
combination IS4Vh/IS4Vl  did not show the strongest binding to CL. The ability of IS4 to 
bind this antigen was increased considerably by changing the light chain to B3V l or 
CL24Vl , and increased less markedly by changing the light chain to 33H11VL.
Despite being tested at a range of concentrations between 5.6 and 168 times higher than 
those which gave maximal CL binding for the other combinations containing IS4VH, 
IS4Vh/UK4Vl showed no binding to CL.
The combination B3Vh/B3Vl has previously been shown to bind CL by Kumar et al. 
(Kumar et al., 2000) after expression of Fab from bacteria. This result was confirmed in the 
current experiment by expression from COS-7 cells.
4.11 Results of modified anti-cardiolipin ELISA
In order to try and demonstrate that aPL binding to CL was serum dependent and required a 
cofactor, such as P2 GPI, a modified serum free assay was performed upon supernatant 
harvested from COS-7 cells grown in the absence of serum. The five Vh/Vl combinations 
listed above which bound CL in the standard CL ELISA were tested and bound just as 
strongly in the modified assay as in the original assay, see Figure 4.10.
4.12 Results of anti^G PI ELISA
At the concentrations tested, none of these Vh/Vl combinations could be shown to bind 
human P2 GPI convincingly. A positive control of human serum, from a patient with PAPS 
bound well in the anti-p2 GPI ELISA, see Figure 4.11.
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Figure 4.10 Modified aCL ELISA
Cardiolipin binding of IgG in COS-7 cell supernatants containing wild-type heavy chains expressed with wild-type light chain 
constructs in a modified CL ELISA in which 10% bovine serum albumin was used in place of 10% fetal calf serum.
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Figure 4.11 Anti-p2Glycoprotein I ELISA
Patient serum was used as positive control in the anti-p2Glycoprotein I ELISA, as this gave predictable results in each assay. The 
values on the X axis display doubling dilutions of neat serum from 100%, in 0.1% bovine serum albumin (BSA)/phosphate buffered 
saline (PBS).
4.13 Results of anti-DNA ELISA
Each of the Vh/Vl combinations was also examined for binding to dsDNA and consistent 
patterns of binding were found from successive expression experiments. For each 
combination, representative results are shown from two separate experiments in Figure 4.12 
A) and B).
Only two combinations bound to dsDNA. These were B3Vh/B3Vl and B3Vh/33H1 1Vl . 
Both of these heavy/light chain pairs produced very small amounts of whole IgG 
(combined range of 2-10ng/ml, see Table 4.2) yet clearly bound dsDNA. B3VH/B3VL 
bound dsDNA more strongly than did B3VH/33FI11 Vl.
4.14 Modelling of three-dimensional structures
In addition to the modelling studies described in chapter 3.6, B3V l was also modeled by Dr 
Sylvia Nagl and is shown in Figure 4.13 alongside IS4Vh, IS4Vl and CL24Vl. The 
combinations IS4Vh/B3V l and IS4Vh/CL24Vl displayed the strongest binding to CL 
(shown in Figure 4.9), whilst the wild-type combination IS4Vh/IS4V l was much weaker at 
binding CL.
The models show that multiple surface exposed Arg residues are prominent features of the 
chains that confer particularly high ability to bind CL. In B3V l there are four surface 
exposed Arg residues, three of which have arisen due to somatic mutation, at positions 27 
and 27a in CDR1 and position 96 in CDR3, as shown in Figures 4.13 A) and B). The Arg 
residue at position 54 in CDR2 is germline encoded. CL24Vl has two surface exposed 
somatically mutated Arg residues in CDR1 and germline encoded Arg residues in CDR2 
and FR3, see Figure 4.13 C), whilst IS4Vl has only one surface exposed germline encoded 
Arg residue in CDR2 (Figure 4.13 D). In the Arg rich CDR3 of IS4VH, four out of five Arg 
residues are predicted by the model to be surface exposed and therefore potentially 
important in binding to cardiolipin, shown in Figures 4.13 E) and 4.13 F).
208
£cir, 
©
d
o
0.6
0.4
0.2
100001 10 100 1000
Whole IgG concentration ng/ml
Figure 4.12 A) Results of anti-dsDNA ELISA
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Results of anti-dsDNA ELISA
in COS-7 cell supernatants containing each heavy light chain combination to dsDNA.
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Figure 4.13 Modelling studies of B3VL, CL24Vl , IS4VL and IS4VH
B3VLin A) spacefill mode and B) secondary structure mode. C) CL24Vl in secondary 
structure mode. D) IS4Vl in secondary structure mode. IS4Vh in E) spacefill mode 
and F) in secondary structure mode. For abbreviations and colour code see Figure 3.9.
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4.15 Discussion of results
The results in this section show that the heavy chain of the human aPL IS4 is dominant in 
conferring the ability to bind CL and the identity of the light chain is important in fine 
tuning the strength of that binding. Each of the heavy and light chains that enhanced CL 
binding contained a number of surface exposed Arg residues most of which are likely to 
have arisen as a result of antigen drive.
These experiments report the use of an in-vitro eukaryotic expression system to produce 
whole human IgG aPL. Of the two wild-type combinations expressed, IS4VH/IS4VL could 
be shown to bind CL, whereas CL24Vh/CL24Vl could not be shown to bind CL. These 
results are consistent with the original published data (Zhu et al., 1999). These authors 
tested affinity purified monoclonal aPL (secreted by hybridoma cells) at much higher 
concentrations than those I was able to obtain by expression in COS-7 cells. They found 
that IS4 bound more strongly to CL than CL24. Twice as much CL24 (2pg/ml) as IS4 
(lpg/ml) was required to obtain similar binding to CL in ELISA. The amounts of 
CL24Vh/CL24Vl produced by the COS-7 cells (69.5-3 lOng/ml) in these experiments were 
six times lower than the levels of CL24 originally tested (Zhu et al., 1999). The lack of 
binding of the expressed CL24Vh/CL24Vl in the aCL ELISA is therefore likely to be due 
to the low concentration of antibody tested.
The great advantage of this transient expression system is that it allows rapid testing of 
large numbers of heavy/light chain combinations. The results of these experiments allow 
inferences to be made about the importance of particular sequence motifs in binding to 
DNA and CL. Because IS4VH utilises an unusual germline gene (VI-03) in which the 
pattern of somatic mutations are not suggestive of antigen drive, these properties are 
unlikely to account for its dominant role in binding to CL. The most likely contributor to 
the CL-binding specificity of IS4VH is its highly mutated CDR3 region which contains five 
Arg residues, four of which are surface exposed, see Figure 4.13 E) and F) and could 
therefore be important in contributing to CL-binding specificity. It seems likely that the 
selecting antigen was CL or a complex containing CL, since the presence of IS4VH tends to 
confer the ability to bind this antigen.
2 1 2
Although the IS4VH sequence plays a dominant role in conferring the ability to bind CL, 
the nature of the light chain paired with it affects the strength of binding. The B3Vl and 
CL24Vl sequences are much more favorable for binding of CL than IS4VL. A striking 
similarity between the sequences of B3VL and CL24Vl is that both have two Arg residues 
created by somatic mutation in CDR1. In contrast, IS4VL has no somatic mutations to Arg. 
The modelling studies in Figures 4.13 (A-C) clearly show that the somatically mutated Arg 
residues in CDR1 of B3Vl and CL24VLare surface exposed. These somatic mutations may 
confer an additional ability to bind to CL above that conferred by the germline encoded 
Arg at position 54 which is present in all three of those light chains.
I was unable to demonstrate binding of either IS4VH/IS4VL or CL24Vh/CL24Vl  produced 
from COS-7 cells to feGPI. Both these antibodies were originally described as weak 
binders to human B2 GPI, requiring testing at concentrations of 10 to 20pg/ml of purified 
antibody, in order to demonstrate any binding on ELISA (Zhu et al., 1999). It is therefore 
unsurprising that it was not possible to detect binding to B2GPI using the much smaller 
amounts of antibody (119.5-420ng/ml of IS4VH/IS4VL and 69.5-3 lOng/ml of 
CL24Vh/CL24Vl) obtained using this expression system.
An indirect method of demonstrating that these antibodies bound 132GPI would have been to 
show that their binding to CL could be abolished in the absence of serum. I was unable to 
demonstrate this by growing the COS-7 cells in serum free media post electroporation and 
subsequent testing in a modified and serum, hence B2 GPI free CL ELISA. The most likely 
reason for this is that B2 GPI was adsorbed onto the surface of the COS-7 cells during their 
growth in medium containing serum, prior to transfection, and that this J32GPI was released 
into the supernatant after some of these cells were killed during electroporation. Possible 
measures to resolve this problem would be to grow the cells in serum free medium 
throughout, or to affinity purify the antibodies from the supernatant before testing. Affinity 
purification is not feasible with the small amounts of antibody produced from COS-7 cells. 
However, these measures became unnecessary following successful demonstration of direct 
binding of the antibodies to B2 GPI at the higher concentrations expressed in chapter five.
Low levels of expression would explain the lack of binding seen with 33H1 1Vh/33H1 I V l 
in the anti-dsDNA ELISA. Much smaller amounts of antibody were produced by this
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expression system (8-17.5ng/ml) compared to that produced by hybridoma cells (3- 
35pg/ml) in the original experiments which characterized binding to dsDNA (Winkler et 
al., 1991). These results were consistent with those obtained in previous studies of 
expression of this combination in COS-7 cells (Rahman et al., 1998; Rahman et al., 2001) 
and as Fab from bacteria (Kumar et al., 2000).
I studied binding of the expressed antibodies both to CL and to dsDNA. The links between 
antibodies binding to these two antigens are a source of some interest. Anti-dsDNA 
antibodies and aPL share a number of sequence characteristics and some show dual 
specificity for both antigens (Kumar et al., 2000; Cocca et al., 2001). It has been shown 
that a murine anti-PC antibody can lose specificity for phospholipid and become an anti- 
DNA antibody as the result of a single point mutation in VHCDR3 (Diamond and Scharff, 
1984).
Furthermore, it seems increasingly likely that both aPL and anti-dsDNA antibodies may 
arise due to an immune response directed against debris from apoptotic cells. Cocca et al. 
(2001) showed that a particular pattern of mutations to arginine in VH of the murine 
antibody 3H9 could enhance binding to PL, dsDNA and to blebs derived from apoptotic 
cells. Conversely, Pewzner-Yung et al. (1996) showed that some sequence features in the 
Vh sequences of murine antibodies derived from the same germline gene, Vh 11, enhanced 
affinity for DNA whereas different features favoured binding to PC.
Some of the human heavy and light chains that I expressed were derived from aPL whereas 
others were derived from anti-DNA. By studying the properties of various combinations of 
these chains, I aimed to distinguish sequence features important in binding to DNA from 
those important in binding to PL.
Previous experiments have shown that Arg at position 27a in B3 Vl CDR1 plays an 
important role in binding to dsDNA (Rahman et al., 2001). This may be an example of an 
Arg residue which, like those described by Cocca et al. (2001), can enhance binding to both 
DNA and PL. In contrast, the Arg residue in CDR3 (Arg92) of 33H11 Vl, which enhances 
binding to DNA (Rahman et al., 2001), does not seem to enhance binding to CL as much as
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the CDR1 Arg residues in B3VL and CL24Vl . The combination IS4Vh/33H1 1VL did not 
bind CL as well as either IS4VH/B3VL or IS4Vh/CL24Vl
The presence of UK4VL appears to be inhibitory because it was the only light chain which 
did not bind CL in combination with IS4VH. Previously a computer model has shown that 
the inhibitory effect of UK4VL upon dsDNA binding is likely to be due to a large blocking 
Arg group at position 94 (Arg94) of UK4Vl CDR3 (Rahman et al., 2001). It is possible that 
the inhibitory effect of UK4VL upon binding to CL observed in this study is due to the 
same Arg94 residue.
The Arg-rich CDR3 sequence of IS4VH does not confer the ability to bind dsDNA. This 
heavy chain did not bind DNA in combination with any of the five light chains tested, 
despite the fact that two of them (B3VL and 33H11VL) are derived from anti-DNA 
antibodies and can bind DNA when expressed with B3VH in this system.
The COS-7 cell expression system has previously been used to express B3Vh in 
combination with light chains derived from four different monoclonal antibodies, including 
B3 itself (Rahman et al., 1998; Rahman et al., 2001). Although whole IgG molecules were 
obtained from each combination, only two combinations bound dsDNA in ELISA. The new 
combinations B3Vh /IS4Vl and B3Vh /CL4Vl  do not bind dsDNA either. These results 
support the contention that the presence of an appropriate light chain is crucial in enabling 
antibodies containing B3Vh to bind DNA (Rahman et al., 2001) and (Kumar et al., 2000). 
Computer modelling studies suggested that Arg27a in B3Vl CDR1 and Arg 92 in 33H11VL 
CDR3 form important interactions with the dsDNA molecule (Rahman et al., 2001). It is 
clear that the exact positions occupied by these Arg residues are important since UKVl and 
CL24Vl  will not bind dsDNA in combination with any heavy chain tested, despite 
containing Arg in CDR3 and CDR1 respectively.
In summary, I have described the expression of whole human aPL molecules from cloned 
cDNA in-vitro. I have used this system to demonstrate the importance of Arg residues in 
both heavy and light chains in binding to CL or dsDNA. Whereas Arg residues at some 
sites (e.g. position 27a of B3 Vl CDR1) may play a role in binding to both these antigens, 
there are other positions at which Arg enhances binding to one antigen or the other, but not
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both. For example, the multiple Arg residues in IS4VHCDR3 enhance binding to CL but not 
dsDNA. Finally, some Arg residues, such as Arg 94 in UK4V l, seem to inhibit binding to 
both antigens. The presence and exact location of Arg residues in the CDRs play a major 
role in binding to CL, which is different to the role played by these residues in creating the 
DNA binding site.
Therefore the next step was to use the transient expression system to further characterise 
the role of specific Arg residues in both heavy and light chains of these whole human aPL. 
This work was performed by swapping CDRs between 2a2 gene encoded light chains (IS4, 
UK4 and B3) and pairing the variant chains with IS4VH and B3VH. Thus the overall 
structure of each chain is retained but the pattern of mutations is altered. As a result of such 
CDR exchange one may investigate whether the Arg residues in B3V l CDR1 lead to an 
enhanced binding to CL when combined with IS4VL CDR2 and 3 and whether the 
suggested blocking effect of the Arg in UK4 CDR3 is dominant. In addition site directed 
mutagenesis of specific Arg codons at sites of antigen contact, e.g. in IS4VH CDR3, to 
germline residues were performed to assess the contribution of individual Arg residues to 
CL binding.
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CHAPTER 5
SOMATIC MUTATIONS TO ARGININE RESIDUES AFFECT THE BINDING OF 
HUMAN MONOCLONAL ANTIBODIES TO CARDIOLIPIN
5.1 Generation of hybrid light chains
Hybrids were made from three parental light chains: - B3VL; UK4VL; and IS4VL. The 
hybrids were named by combining the names of the two parent antibodies such that the first 
letter represented the antibody from which the CDR1 was derived and the last letter 
represented the antibody from which both the CDR2 and 3 were derived. Thus, hybrid IB 
contains CDR1 from IS4 and CDR2 and 3 from B3 whereas hybrid BI contains the reverse 
combination (CDR1 from B3 and CDR2 and 3 from IS4). All three light chains are 
encoded by the 2a2 gene and differ only in their pattern of somatic mutation. The restriction 
fragments produced by Acc65 I and Pvu I digest of expression plasmids containing these 
V l  sequences are shown in Table 5.1 and Figure 5.1.
Light chain donating CDR1 
(parent plasmid & fragment size 
after Acc65 VPvu I digest)
Light chain donating CDR2 & CDR3 
(parent plasmid & fragment size after 
Acc65 IJPvu I digest)
Hybrid 
(overall size)
IS4 (pLNlOO, 6323bp) B3 (pLNlO, 1534bp) IB (7857bp)
IS4 (pLNlOO, 6323bp) UK4 (pLNlO, 1528bp) IU (7851bp)
B3 (pLNlO, 5963bp) IS4 (pLNlOO, 1534bp) BI (7497bp)
UK4 (pLNlO, 5963bp) IS4 (pLNlOO, 1534bp) UI (7497bp)
Table 5.1 Components of each hybrid 
5.2 Confirmation digest of 2a2 Vl hybrids
To confirm the production of the required hybrid, I took advantage of the fact that the 
patterns of internal Ava I and Aat II sites difer between the three parental light chains as 
shown in Figure 5.2. Thus, for example, the hybrids IB and BI can be distinguished from 
both parental sequences because IB contains no Aat II sites whereas BI contains two Aat II 
sites.
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Lanes
1 = 1 Kb marker
2=Acc65 1/Pvu I digested IS4VL/pLN100
3 = Acc65 11 Pvu I digested UK4VL/pLN10
4 =Acc65 11 Pvu I digested B3Vl/p LN10
1 2  3 4
Figure 5.1 Acc65 l/Pvu I digest for creation of 2a2 hybrid light chains
Acc 65 I/Pvu I digest of IS4Vl/pLN100 (1534bp and 6323bp) in lane 2; UK4Vl/pLN10 
(1528bp and 5963bp) in lane 3; and B3Vl/p LN10 (1534bp and 5963bp) in lane 4. The 
smaller fragment in lanes 2 - 4  contains CDR2 and CDR3 of each light chain variable 
region whilst CDR1 remains in the larger fragment.
6108bp—
1636bp—
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Acc65 I restriction site
\
IS4 V L
UK4 VL 
B 3V l
IU V L 
IB V l 
UI VL
u b v l
BU VL. 
B IV l
= Aat II restriction site 
= Ava I restriction site
Figure 5.2 Altered patterns of Aat II and Ava I restriction sites in 2a2 VL hybrids
Schematic representation of Aat II and Ava I restriction sites in hybrid (CDR exchanged) 
light chains compared to the native light chains from which they were derived, B3Vl; 
UK4Vl; and IS4VL. An Aat II site occurs at position 158 in IS4VL CDR2 and position 78 
in B3Vl CDR1. UK4Vl contains an Ava I site at position 115 in FR2. All native and hybrid 
light chains contain Acc65 Isite at position 106.
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Figure 5.3 Construction of IBV^pLNlOO hybrid
For legend see following page.
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Figure 5.3 Construction of IBVl/pLNIOO hybrid
A) Plasmid map of IS4Vl/pLN100 with the region removed by a Acc65 I/Pvu I digest
indicated; IS4VL is shown in green and the human CL region in red.
S)Acc65 l/Pvu I digested fragment from B3VL/pLN10 is shown with the region containing 
CDR2 and CDR3 of B3Vl shaded pink, the introns shaded brown and the human constant 
region in red.
C) Final plasmid map of IBVl/pLNIOO.
IUVl/pLNIOO was constructed in the same way and is almost identical to IBVl/pLNIOO 
except that the variable region fragment containing CDR2 and CDR3 was donated from 
UK4Vl and is six base pairs shorter than that of B3Vl, hence altering the overall plasmid
size. For a full list of plasmid abbreviations see Figure 2.5.
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E coR Il
Ava 16255
Aat n  689 
Aat n  742 
Aat II 825
Aat I I 1011
Hind III 1224
Aat I I 1374
Acc 651 1402
HCMV i promoter
Leader
B3VL
IS4VL 
V-C intron
BIVL/pLNlO 
7497 bpNeoR
Human CL region
NeoR pro 
^  SV40 origin
AmpR pro 
AmpR sig
EcoRI 2310
Aat II 2385
AmpR
ColEI origin
Aat II 1446
Splice donor 1624 
BamHI 1630 
Splice acceptor 1636 
Aval 1857
Pvu I 2936
Figure 5.4 Plasmid map of BIVL/pLNlO hybrid
Plasmid map of BIVi/pLNlO with the region containing B3VLCDR1 shown in pink and 
IS4Vl CDR 2 and CDR3 shown in green, the intron is shaded brown and the human 
constant region red. The construction of UIVi/pLNlOO is similar to BIVi/pLN100 except 
that the fragment containing B3VlCDR1 is replaced by UK4Vl and the overall size of the 
plasmid is the same. For a full list of plasmid abbreviations see Figure 2.7.
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There are five Ava I and five Aat II sites in the expression vectors pLNlOO and pLNlO. 
Figure 5.3 shows the vector map of hybrid IB and its construction whilst a final vector map 
of a hybrid with a pLNlO backbone is shown in Figure 5.4. In each of these hybrid vector 
maps the relevant restriction sites are shown and the distinguishing Aat II sites in the VL 
regions highlighted in red.
In some instances Aat II and Ava I were combined with either Hind III or Bam HI in 
restriction digests to give fragments which were easily distinguishable on an agarose gel. 
Results of restriction digests of are shown in Figures 5.5 to 5.8. The Aat II digest alone 
clearly distinguishes IB and IU hybrids from the parent plasmid IS4Vl/pLN100 in Figure 
5.5. Double digestion with Ava HHind III identifies IB from IU, in Figure 5.6 because Ava I 
is present in IU but has been removed in IB. Double digestion was carried out rather than 
digestion with Ava I alone, in order to create fragments of easily distinguishable lengths.
The Aat WIBamW I dual digest distinguishes BI from B3Vi/pLN10, see Figure 5.7 and the 
Ava VHind III digest shown in Figure 5.8 distinguishes UI from UK4VL/pLN10.
5.3 Site directed mutagenesis of IS4Vh
Six mutant forms of IS4Vh were created by site directed mutagenesis and plasmid DNA of 
the appropriate size was confirmed, post transformation, by a Hind III/Xho I digest. This 
plasmid DNA was then sent for sequencing (MWG-Biotech) which confirmed the presence 
of the desired point mutations in each heavy chain.
5.4 Heat shock and Phospholipase C treatment of COS-7 cell supernatants
During electroporation approximately 80% of the cells die, releasing their contents 
(including DNA and PL) into the supernatant. Anti-dsDNA antibodies produced by this 
expression system have been shown to bind to DNA in the supernatant. Treatment of these 
COS-7 cell supernatants containing DNA binding antibodies with DNase I prior to their 
testing in a whole IgG ELISA led to a relative increase in the amount of antibody detected 
in the whole IgG assay and was essential in order to detect these antibodies in an anti-DNA 
ELISA (Rahman et al., 1998). The DNase I was considered to have broken down mAb- 
DNA immune complexes in the supernatant leaving the IgG molecules free to be detected 
in the supernatants.
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4361bp
2322bp
500bp
1 2 3 4 5 6 7 8 9 10 11 12 1
3 = Aat II digested IS4VL/pLN100
4 = Aat II digested B3 VL/pLN 10
5 = Aat II digested UK4VL/pLN 10
6 -9  = Aat II digested IBVl/pLN 100
10 - 13 = Aat II digested IU V l/p LNIOO
Figure 5.5 Confirmation Aat II digest of IB and IU hybrid light chains
The hybrids IBVi7pLN100 (lanes 6 - 9 )  and IU V l/ p LNIOO (lanes 10 -  13) are clearly 
different from the parental vectors. They differ from IS4Vi/pLN100 (lane 3) and 
B3Vi7pLN10 (lane 4) due to loss of the internal Aat II site. They differ from 
UK4Vi7pLN10 (lane 5) due to a different pattern of Aat II sites in the expression vectors 
pLNlO and pLNlOO.
Lanes
1 = Lambda DNA I Hind III marker
2 = lOObp marker
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500bp
1 2 3 4 5 6 7 8 9 10 11 12 13
Lanes
1 = Lambda DNA/Hind III marker
2 = lOObp marker
3 = Hind Ul/Ava I digested IS4VL/pLN 100
4 = Hind III I Ava I digested B3 VL/pLN 10
5 = Hind III I Ava I digested UK4 Vl/pLN 10
6 -9  = Hind III I Ava I digested IB V^pLN 100
10-13 = Hind III /Ava I digested IUVi7pLN 100
Figure 5.6 Confirmation Hind III!Ava I digest of IB and IU hybrid light chains
The hybrids IBVL/pLN100 (in lanes 6 - 9 )  and IUVL/pLN100 (lanes 10 -  13) are easily 
distinguished from each other due to the presence of an internal Ava I site in IUVL but not 
IBVl .
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Lanes:
1 = Lambda UN AJHind III marker
2 = 1 OObp marker
3 = Aat WIBamU I digested IS4VL/pLN 100
4 = Aat WIBamU I digested B3VL/pLN 10
5 = Aat WIBamU I digested UK4VL/pLN 10
6 - 1 2  = Aat WIBamU I digested BIVL/pLN 10
13- 19  = Aat WIBamU I digested UIVL/pLN 10
20 = uncut B3 VL/pLN 10
Figure 5.7 Screening Aat WIBamU I digest of BI and UI hybrid light chain ligations
In the above figure each lane represents plasmid derived from a different colony on 
LBAgar plates. The expected pattern on restriction digest with Aat WJBamU I of the hybrids 
is seen only in lanes indicated by an arrow; 10 and 12 for BIVi7pLN 100; and lane 18 for 
UIVi/pLNlOO. These differences are seen because the hybrid BIVl/pLN 100 has an 
additional internal Aat II site compared to the parent plasmids B3Vl/pLN 10 (lane 4) and 
IS4Vl/p LN100 (lane 3) and UIVl/pLN 100 has gained an internal Aat II site compared to 
UK4Vl/p LN10.
t
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Lanes:
1 = Lambda DNA I Hind III marker
2 = lOObp marker
3 = Hind IIII Ava I digested IS4Vl/pLN 100
4 = Hind IIMAva I digested B3Vi/pLN 10
5 = Hind WMAva I digested U K 4 V l/ p L N  10
6 - 1 2  = Hind III I Ava I digested colonies from BIVl/pLN 100 ligations 
12 - 19 = Hind WMAva I digested colonies from U I V l/ p L N  10 ligations
20 = Uncut B3Vi7pLN10
Figure 5.8 Screening Hind WHAva I digest of BI and UI hybrid light chain ligations
In the above figure each lane represents plasmid derived from a different colony on 
LBAgar plates. The pattern on restriction digest with Hind WMAva I with the hybrids 
B I V l/ p L N 1 0 0  (successful ligation in lanes 6  -  12) and UIVUpLNlOO (successful ligation 
in lane 18 only) will be indistinguishable from that of B3Vi/pLN10 (lane 4) because none 
of these plasmids contain an internal Ava I site, but will clearly differ from U K 4 V l/ p L N 1 0  
(lane 5) because this plasmid does contain an internal Ava I site.
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Hence a possible explanation for the observed variation in the yield of whole IgG from the 
transient expression system could be that certain heavy/light chain combinations which 
bind PL form immune complexes with PL released from dying cells thus rendering them 
undetectable in ELISA.
Two methods, heat shock and treatment with PLC were tried to see if a relative increase in 
whole IgG concentration or enhanced binding to CL could be revealed in the COS-7 cell 
supernatant. Three heavy/light chain combinations were examined; IS4VH/IS4VL because 
of its weak CL binding; IS4Vh/B3 Vl because this gave the strongest pattern of CL binding; 
and B3Vh/IS4Vl to see if any CL binding could be revealed from this non-binder. Samples 
of each of these three COS-7 cell supernatants were divided into two identical aliquots 
which were treated with heat shock or PLC. Figure 5.9 displays the graphs of whole IgG 
concentration of these heavy/light chain combinations remaining identical both pre and post 
heat shock and treatment with PLC. The effects of these treatments upon CL binding are 
shown in Figure 5.10 and there is clearly no difference with the IS4Vh/IS4Vl and 
B3Vh/IS4Vl combinations. The CL binding of IS4Vh/B3Vl however was reduced by 
approximately a third when treated with heat shock or PLC (both the active and inactive 
aliquots). Therefore there was no evidence that immune complex formation is masking 
detection of aPL from any of these combinations.
5.5 Comparison of three and six day harvest from COS-7 cell supernatant
In the transient expression experiments described in chapter 3, the supernatants of the 
transfected cells were collected after 72 hours (when fresh medium was applied) and 144 
hours of incubation in 5% CO2  at 37°C. The reason for this dual harvest was that previously 
this same expression system has been shown to continue to express whole IgG for at least 
six days post electroporation (Haley, 2003).
To investigate whether COS-7 cells transfected with the heavy/light chain combinations 
described in this thesis continue to express IgG for longer than three days the concentration 
of expressed IgG was measured from the three and six day harvest separately for 
comparison. Each harvest was treated identically by treatment with DNase I and sodium 
azide before the concentration of IgG was determined by ELISA (as in section 2.18.1).
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Figure 5.9 Effects of heat shock and Phospholipase C upon IgG concentration of three 
heavy/light chain combinations
Each graph shows OD (405nm) on the y axis against serial dilutions of a standard (human 
IgGx, 100% concentration = lOOng/ml) and four heavy/light chain combinations upon an 
ELISA plate. Concentration of IgG in the latter is estimated by comparison with the 
standard. Abbreviations: - NHS -  no heat shock; HS -  heat shock; PLC -  Phospholipase C.
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Figure 5.10 Effects of heat shock and phospholipase C upon cardiolipin binding of three heavy/light chain combinations
Each column represents an average OD (+/- Standard Deviation) taken from the six different aliquots of each antibody. 
Abbreviations: - NHS -  no heat shock; HS -  heat shock; PLC -  phospholipase C.
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Table 5.2 shows that of the 12 heavy/light chain combinations tested five did not produce 
any further IgG at all after three days, and four combinations produced less than lOng/ml in 
the same period. Only three combinations continued to produce an appreciable amount of 
IgG at the six day harvest produce. Thus when harvesting expressed IgG from heavy/light 
chain combinations containing point mutations in either chain, supernatants were collected 
after three days and the cells were then discarded.
ANTIBODY CONCENTRATION ng/ml
Heavy chain Light chain 3/7 harvest 6/7 harvest
IS4 IS4 22 6
IS4 B3 10 0
IS4 UK4 10 0
IS4 IB 16 4
IS4 IU 30 6
IS4 BU 20 0
IS4 UB 20 0
B3 IS4 45 36
B3 UK4 10 0
B3 IB 75 32
B3 IU 110 40
B3 BU 39 <3.125
No DNA No DNA 0 0
Table 5.2 IgG concentrations in COS-7 cell supernatant from three and six day 
harvests
5.6 Sequences of light chains expressed
Amino acid sequences of the six hybrid light chains and two point mutations of B3VL are 
compared with wild-type IS4VL, UK4VL, B3VL and germline gene 2a2, in Figure 5.11 A). 
Sequence characteristics of the wild-type VL have been discussed previously (chapter 3.4 
and 3.5) and all of the mutants and hybrids are derived from one or more of these light 
chains.
The mutant form of B3VL shown in Figure 5.11 was generated by Dr A. Rahman and 
cloned into expression vectors by Dr J. Haley (Rahman et al., 2001). This mutant (named
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B3 VLa) contains an Arg residue at position 27a in CDR1 reverted to Ser, the amino acid 
found at this position in the germline gene 2 a2 .
Figure 5.11 also shows the amino acid sequences of the Vl CDR hybrids in which each 
newly formed chain construct contains CDR1 of one antibody with CDR2 and CDR3 of a 
different antibody.
5.7 Expression of whole IgG molecules in COS-7 cells
Each of the 10 light chains shown in Figure 5.11 A) was paired with B3Vh and IS4VH. 
Each of the six mutant forms of IS4Vh, see Figure 5.11 B) and legend to Table 2.7 (page 
153), was paired with IS4V l and B3Vl. A total of 32 heavy/light chain combinations were 
expressed in COS-7 cells. At least two expression experiments were carried out for each 
combination. IgG was obtained in the supernatant for all of the combinations. The 
concentrations of IgG in COS-7 cell supernatants from each of the 32 heavy/light chain 
combinations are shown in Table 5.3. In each case the negative control sample, in which 
COS-7 cells were electroporated without any plasmid DNA, contained no detectable IgG. 
Consistently high yields were obtained with the B3Vh/BIV l, B3Vh/UIVl and IS4Vh/UIV l 
combinations compared to the other antibody combinations.
5.8 Results of aCL ELISA
For each heavy/light chain combination, which bound CL, the linear portion of the binding 
curve for absorbance against antibody concentration was determined empirically by 
dilution of antibody over a range of concentrations. Similar patterns of binding were 
obtained with each antibody combination from repeated expression experiments and 
representative results from two experiments (A and B) are shown for Figures 5.12 to 5.16. 
A heavy/light chain combination was not considered to bind CL if its binding curve gave an 
absorbance of less than 0.1 (at 405nm) for all concentrations tested in the aCL ELISA.
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A) Lambda chains
FRl CDR1 FR2 CDR2 FR3 CDR3 Jx
1 20 24 27 34 35 40 50 60 70 80 89 100
I I I I  abc I I I  I I | | | |
2a2 QSALTQPASVSG.SPGQSITISC TGTSSDVGGYNYVS WYQQHPGKAPKLMIY EVSNRPS GVSNRFSGSKSGNTASLTISGLQAEDEADYYC SSYTSSST WFGGGTKLTVLG
IS4 ---------- .-------- — A I-S— S—  HL 1—  D— S ---------- F-------- P------ C TIN- W-----------
UK 4  .---- --SN--S-------L---E--- L—  DAIK ------- E-------------- G  NR.. -F---------
B3 ---------- .----------- RR---F— --------------  H----- T-- A---S----------------  S-TTR------------
B3a ---------- .----------- R----F— --------------  H----- T-- A---S----------------  S-TTR------------
IB ---------- .-------- — A I-S— S----------------  H----- T--A---S----------------- --S-TTR-----------
IU ---------- .-------- — A I-S— S—  L E L—  DAIK -------- E-------------- G  NR.. -F---------
UI  .-----  SN-S-------HL------ 1—  D— S ---------- F-------- P------ C TIN- W-----------
UB ---------- .----------- SN-S------------------  H----- T--A---S----------------  S-TTR------------
BI    RR -F—  HL-1—  D— S ---------- F-------- P------ C TIN- W-----------
BU ----------- .— *----------  RR-F—  L E-------- L—  DAIK -------- E---------------- G— —  NR.. -F----------
B) H eavy chains
FRl
IS4
CDRl FR2 
30 31 36 40
CDR2
50
FR3 CDR3
60 70 82
I abc
90 100  101
1-03 QVQLVQSGAEVKKPGASVKVSCKASGYTFT SYAMH WVRQAPGQRLEWMG WINSGNGNTKYSQKFQG RVTITRDTSASTAYMELSSLRSEDTAVYYCAR
-FL-
YFDYWGQGTLVTVSS 
GRRDVRGVLWRGRHD  F----- I--
3-23 EVQLLESGGGLVQPGGSLRLSCAASGFTFS SYAMS WVRQAPGKGLEWVS AISGSGGSTYYADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK 
B3  V--------------- T----T T---------------- T--R-S----G--Q---L-----S------------------- PNVGSGW
YFDYWGQGTLVTVSS 
S —  S---- L-T-
Figure 5.11 Sequence alignm ent o f  expressed V L and V H regions
Sequences were aligned using D N A plot V BA SE  (Tom linson et al., 1996). A ) Sequences o f  expressed regions compared to 2a2. B) Sequences o f  expressed  
Vh regions compared to 1-03 (IS4), 3-23 (B 3). The Dh regions could not be matched to germ line genes. Arginine residues altered by site directed m utagenesis 
to serine residues in IS4Vh CDR3 are underlined. The amino acids are numbered according to Kabat. Dots have been inserted to facilitate the alignment. A  
dash indicates hom ology with the corresponding germline sequence. Abbreviations:- FR -  Framework region; CDR -  Complementarity determining region.
Heavy chain Light chain IgG Concentration (ng/ml) CL Binding
IS4 IS4 24-368 +
IS4 IB 22-140 +
IS4 IU 70-194 -
IS4 B3 5-14 ++
IS4 Bl 50-60 ++
1S4 BU 5-60 -
IS4 UK4 11-22 -
IS4 Ul 50-480 +
IS4 UB 9-50 -
B3 IS4 71-192 -
B3 IB 41-96 -
B3 IU 89-376 -
B3 B3 6 +
B3 Bl 120-608 -
B3 BU 40-68 -
B3 UK4 8-28 -
B3 Ul 60-480 -
B3 UB 2-20 -
IS4 B3a 48-60 ++
B3 B3a 2.5-4 -
IS4VHi IS4 50-56 -
IS4VHii IS4 65-70 -
IS4VHiii IS4 48-90 -
IS4VHiv IS4 48-90 -
IS4Vhx IS4 78-94 -
IS4VHi&ii IS4 74-80 -
IS4VHi B3 24-54 ++
IS4VHii B3 30 ++
IS4VHiii B3 30-34 +
IS4VHiv B3 28-30 +
IS4Vhx B3 32-34 -
IS4Vni&ii B3 32-47 ++
Table 5.3 Range of IgG concentrations in ng/ml produced by expression of the 
heavy/light chain combinations and a summary of their ability to bind CL
For a description of B3a and IS4Vh mutants see section 5.6 and legend to Table 2.7, page 
153, respectively.
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5.9 The importance of arginine residues in IS4VH
As shown in chapter four, the presence of the heavy chain of IS4 plays a dominant role in 
binding to CL (Giles et al., 2003). IS4VH binds CL in combination with five of the nine 
light chains tested (Figures 5.12 A and B). These were B3VL, BIVL, IS4VL, IBVL and 
UIVl, but only one of these light chains (B3VL) binds CL in combination with B3VH 
(Figures 5.13 A and B). Despite being tested over a wide range of antibody concentrations, 
none of the other combinations showed any binding to CL at all.
To identify the features of IS4Vh that show enhanced binding to CL, I focused on the 
combination IS4Vh/B3Vl. This combination shows high binding to CL. This binding could 
be altered by the replacement of some or all of the four surface-exposed Arg in IS4VH 
CDR3 to Ser, as shown in Figures 5.14 A) and B). Substitution of all four Arg with Ser 
residues (IS4Vhx) abolished CL binding completely. This effect seems likely to be due 
entirely to the changes at positions 100 and lOOg. This is supported by the fact that heavy 
chain combinations containing Arg to Ser mutations at these positions (IS4VHiii and 
IS4VHiv) displayed reduced binding to CL as shown by the downward shift of the curve 
compared to the wild-type IS4Vh/B3V l combination. In contrast, there were no reductions 
in CL binding for the heavy chains containing Arg to Ser mutations at position 96 (IS4VHi), 
position 97 (IS4Vnii) or both (IS4VHi&ii).
235
OD
 
at 
40
5n
m
0.1 1 10 100 1000
Concentration IgG ng/ml
m —  IS4VH&IS4VL 
IS4VH&IBVL 
■x— IS4VH&IUVL 
x —IS4VH&B3VL 
IS4VH&BIVL 
IS4VH&BUVL 
h— IS4VH&UK4VL 
—  IS4VH&UBVL 
IS4VH&UIVL
Figure 5.12 A) Effect of CDR exchange in the light chains
Cardiolipin binding of IgG in COS-7 cell supernatants containing wild-type IS4VH expressed with wild-type or hybrid light chains
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Figure 5.12 B) Effect of CDR exchange in the light chains
For legend see Figure 5.12 A).
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Figure 5.13 A) Effect of CDR exchange in the light chains
Cardiolipin binding of IgG in COS-7 cell supernatants containing wild-type B3Vh expressed with wild-type or hybrid light chains
B3VH&B3VL
B3VH&IS4VL
B3VH&UK4VL
B3VH&BIVL
B3VH&BUVL
B3VH&IBVL
B3VH&IUVL
B3VH&UIVL
B3VH&UBVL
Concentration IgG ng/ml
Figure 5.13B) Effect of CDR exchange in the light chains
For legend see Figure 5.13 A).
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Figure 5.14 A) Effect of Arg to Ser point mutations in IS4VHCDR3
Cardiolipin binding of IgG in COS-7 cell supernatants containing wild type or mutant forms of IS4 heavy chain expressed with wild type B3 
or IS4 light chains. The IS4VH mutants VHi, VHii, VHiii and VHiv contain single Arg to Ser point mutations at positions 96, 97, 100 and 
lOOg respectively; whilst VHi&ii contains Arg to Ser at positions 96 and 97; and VHx has an Arg to Ser mutation at all four positions.
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Figure 5.14 B) Effect of Arg to Ser point mutations in IS4VHCDR3
For legend see Figure 5.14 A).
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5.10 The importance of arginine residues in the light chain CDRs
Five light chains bound CL in conjunction with IS4VH; see Figures 5.12 A) and B). The 
strongest binding was seen with light chains containing B3VLCDR1, namely B3VL and 
BIVl , in combination with IS4VH. In contrast, light chains IB and UB, containing CDR2 
and CDR3 from B3, showed weak and no binding to CL respectively in combination with 
IS4Vh. To test the hypothesis that the arginine at position 27a in B3VLCDR1 is responsible 
for the favourable effect of this CDR on binding to CL, I expressed combinations of IS4VH 
and B3Vh with B3VLa, in which Arg 27a has been mutated to Ser. As shown in Figures 
5.15 A) and B), there was a significant decrease in CL binding of B3Vn/B3VLa compared 
with B3Vh/B3Vl- Although the combination IS4VH/B3VLa binds CL less strongly than 
IS4Vh/B3Vl, reduction in binding is not as great as that seen when these light chains are 
combined with B3VH. This observation is consistent with the idea that IS4VH plays a 
dominant role in binding to CL.
Despite being tested at a range of concentrations up to 75 times higher than those which 
gave maximal CL binding for the other combinations containing IS4VH none of the light 
chains containing UK4Vl CDR2 and 3 (UK4 wild type, IU and BU) showed any binding to 
CL.
5.11 Results of anti-dsDNA ELISA
Figures 5.16 A) and B) shows anti-DNA binding of combinations of IS4VH or B3Vh with 
each of the wild type or hybrid light chains. Only the combination B3Vh/B3Vl showed 
significantly more binding than any other combination. Anti-dsDNA ELISAs were not 
performed upon the Vh/Vl combinations containing point mutations in their heavy or light 
chains, since IS4Vh does not confer the ability to bind DNA and the effects of light chain 
mutations in B3VL have already been well established (Rahman et al., 2001).
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Figure 5.15 A) Effect of point mutation Arg 27a to Ser in B3 VLCDR1
Comparison of cardiolipin binding of IgG in COS-7 cell supernatants containing wild-type heavy chains expressed with B3 VL or B3 VLa.
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Figure 5.15 B) Effect of point mutation Arg 27a to Ser in B3 VlCDRI
Comparison of cardiolipin binding of IgG in COS-7 cell supernatants containing wild-type heavy chains expressed with B3VL or 
B3VLa. The B3 Vh/B3V l combination did not produce any IgG on this occasion therefore is not shown.
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Figure 5.16 A) Results of anti-dsDNA ELISA
The graph shows binding of IgG in COS-7 cell supernatants containing each heavy light chain combination to dsDNA.
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5.12 Discussion of results
Based on the results of sequence analysis, modelling studies (see chapters 3 and 4) and 
heavy/light chain exchange experiments (in chapter 4) I postulated that surface exposed 
Arg residues in IS4VH and B3VL may be important for CL binding. The results described in 
this chapter complement my earlier findings and support my hypothesis as well as showing 
that it is not just the presence but the precise location of Arg residues in the CDRs that is 
important in determining ability to bind CL.
The importance of Arg residues at specific positions in the VH and Vl sequences of anti- 
DNA antibodies has been examined by many groups by expressing the antibodies in-vitro, 
and then altering the sequence of the expressed Ig by chain swapping or mutagenesis. In 
general, these studies have shown that altering the numbers of Arg residues in the CDRs of 
these antibodies can lead to significant alterations in binding to DNA. Arg in VHCDR3 
often play a particularly important role in binding to this antigen (Radic et al., 1991; 
Mockridge et al., 1996; Pewzner-Jung et al., 1996; Li et al., 2000; Rahman et al., 2001). 
Recently it was shown that the affinity of human phage derived anti-dsDNA Fabs from a 
lupus patient correlated with the presence of somatically mutated Arg residues in CDR1 
and CDR2 of the heavy chains (Behrendt et al., 2003).
Previous studies of the contribution of aPL heavy or light chains to CL binding have 
yielded conflicting results. Different groups have reported important contributions from the 
heavy chain (Blank et al., 1999; Cocca et al., 2001), the light chain (Pereira et al., 1998), or 
both (Pewzner-Jung et al., 1996; Kumar et al., 2000). In one of these studies the role of Arg 
residues was examined in a murine antibody (3H9) with dual specificity for PL and DNA. 
The introduction of Arg residues into the heavy chain V region at positions known to 
mediate DNA binding enhanced binding to PS-B2 GPI complexes and to apoptotic cell 
debris, which may be an important physiological source of both these antigens (Cocca et 
al., 2002).
These data shows that combinations of IS4Vh with light chains containing CDR1 of B3 (B3 
wild type and Bl) produced the strongest binding to CL. This CDR contains two surface 
exposed Arg residues at positions 27 and 27a. Previous modelling studies have suggested 
that the binding of B3VH/B3VL to dsDNA is stabilised by the interaction of dsDNA with
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Arg 27a in CDR1 and Arg 54 in CDR2 of the light chain (Kalsi et al., 1996). Expression 
and mutagenesis studies from our group confirmed that mutation of Arg27a to Ser led to a 
reduction in binding to DNA (Rahman et al., 2001). In this paper the same change has been 
shown to reduce binding to CL, supporting the conclusion of Cocca et al. (Cocca et al., 
2001) that Arg at particular positions can enhance binding to both DNA and CL.
The presence of UK4VL CDR 2 and 3 in any light chain blocked binding to CL, even when 
combined with B3VLCDR1 (light chain BU). UK4VLCDR1, however, does not block 
binding. Our group has previously shown that the presence of UK4VLCDR2 and 3 blocks 
binding to DNA and histones but not to the Ro antigen (Rahman et a l , 2001; Haley et al., 
2003). Modelling studies have shown that an Arg at position 94 in CDR3 of UK4VL 
hinders DNA binding sterically. A similar effect may be occurring with regards to the 
binding ofUK4VLto CL.
The effect of point mutations of specific Arg residues in CDR3 of IS4VH upon CL binding 
is shown in Figures 5.14 A) and B). The low binding of IS4Vh/IS4Vl was abolished by 
inclusion of any one of these mutations. This is not the case, however, when these mutants 
are expressed with B3Vl- In this case the Arg residues at 100 and lOOg confer a greater 
effect on CL binding compared to the Arg residues at positions 96 and 97. Substitutions of 
all four of these IS4Vh CDR3 Arg residues were sufficient to completely abolish all 
binding to CL.
These data confirm that the effect of Arg residues on binding to CL is highly dependent on 
the positions that they occupy in the sequence. The precise location of Arg residues has 
been shown to be important in the binding of both murine and human anti-dsDNA to DNA 
in numerous studies (Radio et al., 1993; Radic and Weigert, 1994; Rahman et al., 2001). 
Interestingly, Krishnan et al. (Krishnan et al., 1996; Krishnan and Marion, 1998) have 
demonstrated a strong correlation between specificity for dsDNA and the relative position 
of Arg residues in VhCDR3. They reported that the frequency of Arg expression among 
murine anti-dsDNA binding Abs was highest at position 100 and postulate that the 
importance of this residue in binding to dsDNA lies in its position at the centre of the 
VhCDR3 loop in the structure of the antigen combining site (Krishnan et al., 1996).
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Assuming that this loop would be projected outward from the antigen-combining site, an 
Arg at position 100 would be located at the apex of the VHCDR3 loop.
In summary, I have demonstrated the relative importance of certain surface exposed Arg 
residues at critical positions within the light chain CDR1 and heavy chain CDR3 of 
different human mAbs in conferring the ability to bind CL in a direct ELISA. It is now 
important to test the effects of sequence changes involving these amino acids on pathogenic 
functions of these aPL, by expressing the altered antibodies in larger quantities from stably 
transfected (CHO) cells. More accurate information about changes in affinity of variant 
forms of aPL for binding to CL or P2 GPI could be obtained by testing larger quantities of 
purified antibodies in assays such as SPR or inhibition ELISA. Pathogenic properties of 
these variant forms of aPL could then be tested both in in-vivo and in-vitro models of the 
APS.
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CHAPTER 6
STABLE EXPRESSION OF WHOLE IgG FROM CLONED ANTIBODY cDNA IN 
CHOdhff  CELLS
6.1 EcoR I digest of pGlD210 containing IS4Vh and light chain expression vector
The constituent parts (and EcoR I fragment size) of each supervector are shown in Table 
6.1. The results of an EcoR I digest are shown in Figure 6.1. Bands of the appropriate size 
(see Table 6.1) were cut out and purified (as in chapter 2.8) for subsequent ligation.
HEAVY CHAIN 
(EcoR I fragment size)
LIGHT CHAIN
(Parent plasmid, EcoR I
fragment size)
SUPERVECTOR 
(Overall size)
IS4 (7674) IS4 (pLNlOO, 2670) SVIS4Vh/IS4Vl (10344)
IS4 (7674) B3 (pLNlO, 2310) SVIS4VH/B3VL (9984)
IS4 (7674) UK4 (pLNl0,2304) SVIS4VH/UK4VL (9978)
Table 6.1 Components of each supervector
6.2 Large scale screening of colonies from supervector ligations
The rapid screening of large numbers of colonies was possible using the osmotic lysis 
technique described in section 2.20.4. In Figure 6.2 A), 18 colonies (lanes 2-19) from two 
LB/Agar/Amp plates containing different insert:vector ratios of IS4Vh and UK4VL and two 
colonies (lanes 1 and 20) containing re-ligated vector only in the absence of insert, have 
been screened. The only positive clone in this instance occurred in lane 10 where a “step” is 
clearly visible indicating an increase in size of the plasmid due to the successful ligation of 
UK4Vl into IS4Vn/pGlD210. Figure 6.2 B) shows the result from screening of 18 colonies 
from a single LB/Agar/Amp plate containing IS4Vh (vector) and IS4Vl (insert) and two 
control colonies (lanes 1 and 20) containing vector only. In this case there were four 
positive clones in lanes 4, 10, 11 and 19. These clones of potentially the right size were 
selected and the remaining 100pl aliquot of culture was used to inoculate broth for 
purification and further characterization of the plasmids.
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Lanes
1 = 1Kb marker
2 = Uncut IS4VH/pGlD210
3 = EcoR I digested IS4VH/pGlD210
4 = EcoR I digested UK4Vl/p LN10
5 = EcoR I digested IS4Vl/p LN100
6 = EcoR I digested B3Vl/p LN10
Figure 6.1 Preparation of EcoR I fragments for creation of supervectors
EcoR I digest of: - IS4VH/pGlD210 (7674bp) in lane 3; U K 4 V l/p L N 1 0  (5187bp and 
2304bp) in lane 4; IS4Vl/pLN100 (5187bp and 2670bp) in lane 5; and B3VL/pLN10 
(5187bp and 2310bp) in lane 6. Uncut IS4VH/pGlD210 is shown for comparison in lane 2. 
The smaller fragments in lanes 4 - 6  contain the light chain variable region.
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A)
Chromosomal DNA
IS4VH/pGlD210
Chromosomal DNA
JS4VH/pGlD210
10 15 20
Figure 6.2 Large scale screening of supervectors
A) Colonies from a ligation of an EcoR I cassette containing UK4VL into EcoR I digested 
IS4Vn/pGlD210 which is 7674bp long. In lane 10 (arrowed) the presence of a supervector 
is suggested by the presence of a larger band of DNA which should be 9978bp long for 
SVIS4Vh/UK4Vl .
B) Similarly colonies from a ligation of an EcoR I cassette containing IS4Vl into EcoR I 
digested IS4VH/pGlD210. Lanes 1 and 20 contain the transformation control of uncut 
IS4VH/pGlD210 which is 7674bp long. In lanes 4, 10, 11 and 19 (arrowed) the presence of 
a supervector is suggested by the presence of a larger band of DNA which should be 
10344bp long for SVIS4VH/IS4VL.
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6.3 Confirmation restriction digests of supervectors
6.3.1 Hind \l\IA cc651 digests
Figure 6.3 shows the vector map of supervector SVIS4Vh/IS4Vl  and its construction. Each 
supervector contains two Hind III restriction sites one of which is present in pGlD210 and 
the other is conferred by the parent plasmid of the light chain insert. The precise location of 
the Hind III site differs slightly between each supervector, see Figures 6.3 and 6.4. The 
Acc65 I site however is unique to each light chain V region at position 106 and not present 
anywhere else in either of the parent plasmids or heavy chain V region, see Figure 6.3. 
Hence the Hind III and Acc65 I restriction sites were ideal to confirm both the presence and 
orientation of each light chain insert.
Figure 6.4 A) shows a Hind HVAcc65 I dual digest of SVIS4Vh/B3Vl in lanes 2 - 9 ,  
compared to SVIS4Vh/B3Vl single cut with Hind ID in lane 10 and DNA markers in lanes 
1 and 11. The expected pattern of three bands with Hind WVAcc65 I is clearly seen in lanes 
3 - 8  with fragments of DNA 7316, 2490 and 178 nucleotides in length. This pattern also 
confirms the orientation of the light chain insert as reading in the same direction as the Vh 
insert because the fragment sizes would be 7000, 2806 and 178 if the insert was in the 
reverse orientation. The single Hind m  cut SVIS4Vh/B3 V l was run as a control because it 
yields two fragments 7316 and 2668 nucleotides in length and a step is clearly visible 
distinguishing the 2490 fragment of SVIS4Vh/B3Vl (lanes 3 - 8 )  and the 2668 fragment in 
lane 11, when the samples (seen in 6.4 A) were run overnight at 10 Volts, see 6.4 B).
A similar pattern is seen in Figure 6.4 C) which displays the Hind III/Acc65 I dual digest of 
SVIS4Vh/UK4Vl in lanes 3 —7 and SVIS4Vh/IS4Vl in lanes 8 - 1 1  compared to 
SVIS4Vh/B3Vl single cut with Hind ID in lane 12 and DNA markers in lanes 1 and 2. The 
fragment sizes seen of these two supervectors are those expected with the light chain inserts 
in the correct orientation and are 7316, 2484 and 178 for SVIS4Vh/UK4Vl; and 7676, 
2490 and 178 for SVIS4Vh/IS4Vl. If the inserts were in the reverse orientation then sizes 
of 6994, 2806 and 178 for SVIS4Vh/UK4Vl  and 7100, 3166 and 178 for SVIS4Vh/IS4Vl  
would have been obtained. A step is once again visible between the 2668 fragment in lane 
12 and all of the middle fragments in lanes 3 - 1 1  and 13, which are smaller in size hence 
confirming their correct orientation.
253
AmpRprc^
AmpR sig
Human CH
SV40 origin
HCMVi promoter
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Figure 6.3 Construction of supervectors
For legend see over
254
Figure 6.3 Construction of supervectors
A) Plasmid map of IS4Vh/pG1D210 with the EcoR I insertion site indicated; IS4VH is 
shown in green and the human Cl region in red.
B) The EcoR I digestion fragment removed from IS4Vl/pLN100 is shown containing 
IS4Vl  shaded green, the intron shaded brown and the human constant region in red.
C) Final plasmid map of IS4Vh&IS4Vl/pG1D210.
The other two supervectors IS4Vh&B3Vl/pG1D210 and IS4Vh&UK4Vl/pG1D210 were 
constructed in the same way using the appropriate EcoR I digested light chain fragments 
from B3Vi/pLN10 and UK4Vi/pLN10 leading to slight variations in the overall plasmid 
size. For a full list of plasmid abbreviations see Figures 2.3 and 2.7.
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2322bp
2 0 3 6bp
1 2 3 4 5 6 7 8 9  10 11 1 2 3 4 5 6 7 8 9  10 11
Lanes in A) and B)
I = 1Kb marker
2 - 9  = Hind \\MAcc65 I digested SVIS4VH/B3VL
10 = Hind III digested SVIS4VH/B3VL
II = Lambda DNA I Hind III marker
Lanes in C)
1 = Lambda DNA/Hind III marker
2 = 1Kb marker 
3-7 = Hind \\MAcc65 I digested
SVIS4Vh/UK4Vl 
8-11= Hind III/Acc65 I digested 
SVIS4Vh/IS4Vl
12 = Hind III digested
SVIS4Vh/B3Vl
13 = Hind\WAcc65 I digested 
1 2 3 4 5 6 7 8 9 10 11 12 13 SVIS4VH/B3VL
Figure 6.4 Confirmation Hind \WIAcc651 digest of supervectors
A) The expected pattern from a Hind m /Acc65 I digest of SVIS4Vh/B3 VL is seen in lanes 
3 to 8 with bands of DNA 178bp, 2490bp and 7316bp in size. The Hind HI digested 
SVIS4Vh/B3Vl was run in lane 10 it yields a band of DNA 2668bp in length and serves as 
a marker for the 2490bp fragment of DNA seen in lanes 3 to 8.
B) The gel displayed in A) was run overnight at 10 Volts. A step is clearly visible between 
the 2668bp band in lane 10 and the 2490bp bands of DNA in lanes 3 to 9.
C) The expected patterns from a Hind III!Acc65 I  digest are: - 178bp, 2484bp and 7316bp 
for SVIS4Vh/UK4Vl , seen in lanes 3 to 7; and 178bp, 2490bp and 7676bp for 
SVTS4Vh/IS4Vl, seen in lanes 8 to 11. Once again the middle bands of DNA for 
SVIS4Vh/UK4Vl (2484) and S\TS4Vh/IS4Vl (2490) are clearly smaller than the 2668bp 
band in Hind III digested SYIS4VH/B3VL in lane 12.
2322bp
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6.3.2 Aat II digests
The identity of each supervector was further confirmed by an Aat II digest. This restriction 
site is present in two Vl regions, nucleotide position 78 in the CDR1 of B3VL and position 
158 in the CDR2 of IS4VL. Aat II is not however, present in UK4 VL. The supervectors 
also contain five Aat II sites in pGlD210 and four from the pLNlO and pLNlOO fragments 
shown in Figure 6.3. The expected fragment sizes and corresponding gels are shown in 
Figure 6.5.
6.4 Detection of whole IgG molecules
6.4.1 Transient expression of whole IgG molecules in COS-7 cells
In the stable expression system it takes 3 - 4  weeks before it can be determined whether the 
transfected CHOdhjr cells are able to express whole IgG molecules. Thus prior to 
transfection into CHO dhjr cells SVIS4VH/IS4VL, SVIS4VH/B3VL and SVIS4VH/UK4VL 
were transfected into the transient expression system. Only SVIS4VH/UK4VL produced 
much larger amounts of whole IgG compared to the range of values previously obtained 
from transfections with the single chain vectors, shown in Table 6.2. CL binding of each 
supervector is shown in Figure 6.6. Interestingly SVIS4Vh/IS4Vl binds CL better than 
IS4Vh/IS4Vl produced by single chain vectors and SVIS4Vh/UK4Vl clearly binds CL at 
the higher concentrations produced from the supervector.
ANTIBODY Concentration IgG ng/ml produced in COS-7 cells from:
Supervector Separate heavy and light chain
IS4Vh and IS4VL 82 2 4 - 4 2 0
IS4Vh and B3VL 8 4 - 4 0
IS4Vh and UK4VL 880 11 - 540
Table 6.2 Concentration of IgG produced by supervectors compared to separate 
heavy/light chain combinations in COS-7 cells
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1 2  3 4 5 6 7 8
Lanes
1 = 1Kb marker
2 & 3 = Aat II digested SVIS4VH/UK4VL 
4 & 5 = Aat II digested SVIS4VH/IS4VL
6 = Aat II digested SVIS4VH/B3VL
7 = Uncut SVIS4Vh/B3Vl
8 = Lambda DNA/Hind III marker
Figure 6.5 Aat II digest of supervectors
The expected patterns from an Aat II digest were obtained as follows: - for 
SVIS4Vh/UK4Vl of 53bp, 83bp, 186bp, 1440bp, 1481 bp, 1501bp, and 4912bp in lanes 2 
and 3; for SVIS4VH/IS4VL of 53bp, 83bp, 186bp, 101 lbp, 1332bp, 148lbp, 1501bp, and 
4375bp in lanes 4 and 5; and for SVIS4VH/B3VL of 53bp, 83bp, 186bp, 363bp, 1083bp, 
148lbp, 150lbp, and 4912bp in lane 6.
5 0 9 0 b p
1 6 3 6 b p
1 0 1 8 b p
5 0 6 ,
5 1 7 b p
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— IS4VH//B3 VL 
———IS4VH/UK4VL 
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Concentration IgG ng/ml
Figure 6.6 Comparison of the cardiolipin binding of three antibodies produced by transfection of separate heavy and light 
chain plasmids and supervectors in COS-7 cells detected by ELISA
The cardiolipin binding of IgG in COS-7 cell supernatants containing the supervectors SVIS4VH/IS4VL, SVIS4Vh/B3Vl and 
SVIS4Vh/UK4Vl is compared with the cardiolipin binding of the same whole antibodies produced by transfection of separate heavy 
and light chains.
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6.4.2 Stable expression of whole IgG molecules in CYLOdhfr cells
Three stable cell lines were produced from a single round of selection in growth medium B 
lacking ribo and deoxyribonucleosides (see appendix D). The amount of IgG produced was 
determined as described in chapter 2.18.1 from which the IgG production rate was 
determined for a number of clones of each supervector. The production rates of the highest 
producers are shown in Table 6.3.
SUPERVECTOR IgG Production rate (ng/106 cells/day)
SVIS4Vh/IS4Vl 7
SVIS4Vh/B3Vl 6
SVIS4Vh/UK4Vl 100
Table 6.3 IgG production rates of stable cell lines
6.5 Results of aCL ELISA
The CL binding of each of the IS4Ve/2a2-derived Vl IgG products expressed from 
CHOdhfr cells is shown in Figure 6.7.
6.6 Results of anti-(32GPI ELISA
The IS4VH/2a2-derived Vl IgG supervector combinations derived from a single round of 
selection of CHO dhfr cells described above, were grown in selective growth media 
containing 1x10'8M concentrations of methotrexate (MTX) by Nancy Lambrianides. 
Increased amounts of each supervector were produced: SVIS4Vh/IS4Vl - 144 ng/106 
cells/day; SVIS4VH/B3VL - 40 ng/106 cells/day; SVIS4VH/UK4VL - 160 ng/106 cells/day. 
The binding of each of the supervectors to P2 GPI was tested by me and is shown in Figure 
6 .8 .
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Figure 6.7 Cardiolipin binding of whole IgG produced from CHO dhfr cells detected 
by ELISA
The cardiolipin binding of IgG produced in CHOdhfr cell supernatants containing the 
highest producers from each of the three supervector cell lines is shown.
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Figure 6.8 P2 GPI binding of whole IgG produced from CHO dhfr cells detected by 
ELISA
The P2GPI binding of IgG produced in supernatants from CHOdhfr cells following 
amplification with methotrexate and selection of those lines secreting the highest amount of 
IgG.
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6.7 Discussion of results
In this final results chapter I describe the successful development of a stable expression 
system to produce whole human recombinant aPL IgGl molecules from cloned PCR 
products encoding aPL antibody sequences. Furthermore, when larger amounts of IgG were 
produced by Nancy Lambrianides using MTX amplification, binding to P2 GPI was clearly 
demonstrated (see Figure 6.8), thus replicating the observations of the original authors (Zhu 
et al., 1999). This system has the potential to produce significant amounts of antibody 
whose sequence-related functional properties can be studied both in in-vitro and in-vivo 
assays.
The total yield of IgGl varied between 6 and 100 ng per 106 cells per day depending on the 
heavy/light chain combination expressed. The yield of these antibodies was increased by 
further selection of the stable cell lines in selective growth media containing MTX by up to 
20 fold in the case of SVIS4Vh/IS4Vl. This process of MTX amplification selects those 
clones of cells with a higher dhfr copy number and consequently a higher copy number of 
IgG cDNA flanking the dhfr gene. MTX is a competitive inhibitor of the intracellular 
activity of the dhfr enzyme and MTX resistance is proportional to the amount of dhfr 
activity and the degree of amplification of the dhfr gene. In resistant cells where 
amplification has occurred there is sufficient free enzyme to generate intracellular 
tetrahydrofolate required for cell biosynthesis.
The yield of antibody produced by MTX amplification is still very low when compared to 
the amounts produced by hybridoma cell lines. However, larger yields could possibly be 
obtained with these cell lines by transferring them into larger scale in-vitro culture systems. 
In fact, a stable cell line of human anti-dsDNA antibodies (B3) produced by Dr J. Haley has 
been tested in a hollow fibre system by a company (Chemicon) in collaboration with our 
group and they have produced milligram quantities of purified antibody by this method. 
With such large amounts of purified antibody, not only could these antibodies be studied 
in-vivo, but more accurate information about changes in affinity for CL and P2 GPI could be 
obtained in assays such as SPR or inhibition ELISA.
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The CL binding properties of the three IgG heavy/light chain combinations after 
transfection of supervectors into COS-7 cells are similar but not identical to those seen with 
the same whole IgGl produced after transfection of single chain vectors into COS-7 cells. 
SVIS4Vh/B3Vl and SVIS4Vh/IS4Vl displayed stronger CL binding compared to the 
equivalent aPL from separate heavy and light chain vectors over similar concentration 
ranges, see Figure 6.6. In particular SVIS4VH/IS4VL has a more consistent CL binding 
pattern when produced from both COS-7 and CHO dhfr cells.
Heavy/light chain imbalance issues: - a possible explanation for differences in binding 
properties of antibody derived from transfection of supervectors and separate heavy/light 
chain vectors arises from the possibility of imbalance in expression of heavy and light 
chains. A theoretical risk exists, of an imbalance in the production of heavy or light chains 
when COS-7 cells are co-transfected with two expression vectors. This inequity may occur 
if more cells take up only one vector rather than both vectors together; or if one of the 
heavy/light chain genes is expressed at a lower level compared to the other. If such an 
imbalance in the expression of heavy or light chains were to occur it could affect the 
binding abilities of the expressed IgGl, since heavy chain fusion proteins (each containing 
a VH domain and a B domain of staphylococcal protein A) have been shown to bind 
dsDNA in the absence of any light chain (Lecerf et al., 1998). Therefore it might be argued 
that the difference in binding seen with the whole IgGl produced by supervectors 
compared to separate expression vectors in COS-7 cells arises as a result of an excess of 
either free heavy or light chains produced from separate vectors.
There is also a potential risk of an imbalance in heavy/light chain expression with the 
supervectors due to their design. The construction of the supervectors involves a light chain 
expression cassette (containirig the HCMV promoter, the X constant region gene and the X 
variable region gene of chosen autoantibody) being transferred into the heavy chain 
expression vector directly upstream from the HCMV promoter, see Figure 6.3. As a result 
the light chain and heavy chain are being expressed in sequence. When two promoters in 
sequence are used to express two genes in this way the second gene may be expressed at a 
lower level than the first. Therefore it is possible that the heavy chain in the supervectors 
will be expressed at lower levels than the light chain.
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There are a number of reasons why I do not think that the results I have described in this 
thesis are due to heavy or light chain over expression from either separate expression 
vectors or supervectors. Firstly, in a number of experiments carried out at AERES 
biomedical and in our laboratoiy by Dr Joanna Haley (Haley, 2003) have not shown 
adverse effects of heavy/light chain imbalance using this expression system to produce 
various different antibodies. Secondly, it is clear that the binding properties of the products 
expressed by the COS-7 cells and CHO cells in my experiments depended on both the 
heavy and light chain expressed, which would not be the case if over expression of either 
chain were the dominant factor. For example IS4Vh has very different binding properties in 
combination with each of the five light chains paired with it in chapter four, ranging from 
no binding (IS4Vh/UK4VL) to very strong binding (IS4VH/B3VL).
The demonstration of binding to P2 GPI in the absence of CL described in this chapter and 
shown in Figure 6.8, confirms the observations of Zhu et a l (1999) who found that IS4 
secreted by hybridoma cells bound P2 GPI more weakly than it bound CL. The fact that IS4 
binds P2 GPI is further evidence of the relevance of the study of a single monoclonal aPL 
(IS4) to try and advance our understanding of the pathogenesis of the APS. Since P2 GPI is 
recognised as an important cofactor for pathogenic aPL the demonstration that IS4 binds 
this clinically relevant antigen lends further support to the argument that this aPL is typical 
of pathogenic aPL found in other patients with APS.
There are very few published reports of the production of functional aPL from bacterial or 
eukaryotic expression systems using cloned DNA sequences, discussed in chapter 1. Only 
one report describes a stable expression system to produce a murine monoclonal anti-PC 
antibody (6G6) as whole IgM molecules secreted from HCLV (Pewzner-Jung et al., 1996). 
No group has ever reported in-vitro stable expression of whole human aPL antibodies with 
these pathogenic properties.
Therefore the stable expression of IS4 and variants reported here is to my knowledge, the 
first report of stable expression of human aPL and the future challenge will be to produce 
sufficient quantities of these whole Ig molecules so that the pathogenic properties of 
sequence alterations can be determined.
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CHAPTER 7
OVERVIEW AND IDEAS FOR FUTURE WORK
Work described in this thesis demonstrates the importance of Arg residues in the binding of 
both human heavy and light chain combinations to CL, with the heavy chain of IS4 
dominant in conferring the ability to bind CL and the nature of the light chain paired with 
IS4Vh determining the strength of binding to CL. It is therefore now important to examine 
the functional properties of the variants of IS4, because it does not necessarily follow that 
an alteration in sequence affecting CL binding will lead to an alteration in function. 
Experiments to produce mutagenised forms of the VH of a murine monoclonal anti-dsDNA 
antibody (including alterations of arginine residues) have shown that sequence alterations 
which enhanced binding to dsDNA did not always enhance the antibodies’ capacity to 
cause glomerulonephritis when administered to mice (Katz et al., 1994). Similarly, 
sequence analysis of a range of aPL tested in the in-vivo models of microcirculation by 
Pierangeli et al. (2000) revealed that there is no simple relationship between pathogenicity 
and strength of binding to CL. Two of the antibodies tested (IS1 and IS2), contained 
identical Vh and their light chains differed from each other by only five amino acids 
(Chukwuocha et al., 2002). IS IV l contained slightly more mutations than IS2Vl which 
improved its reactivity for antigen but abrogated its thrombogenic activity (Zhu et al., 
1999; Pierangeli et al., 2000).
To investigate the hypothesis that Arg residues in human monoclonal aPL are important in 
determining both their binding and pathogenic properties a larger yield of a number of 
heavy/light chain combinations derived from the pathogenic human monoclonal IgG aPL, 
IS4 would need to be produced. These combinations would have to differ from each other 
in sequence at specific points where Arg residues appear to contribute to binding to PL. 
Milligram quantities of purified antibody could be produced by the transfer of different 
heavy/light chain combinations from stably transfected CHO dhfr cell lines into larger scale 
in-vitro culture systems, such as the hollow fibre system used by Chemicon, described in 
section 6.7. Affinity constants for the binding of the antibodies to B2 GPI, could then be 
obtained from inhibition ELISA and SPR assay, a more accurate technique than ELISA for
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measuring small changes in antibody binding affinity. More importantly the properties of 
these expressed affinity purified aPL could then be tested in assays of biological function.
The heavy/light chain combinations that I would select for stable expression of 
supervectors, so that larger quantities can be purified, would be the three already made: - 
IS4Vh with IS4Vl  (i.e. wild-type IS4 antibody) IS4Vh/B3Vl, IS4Vh/UK4Vl ; and other 
combinations containing B3Vl or IS4Vl with different variants of IS4VH, each designed to 
lose particular Arg from CDR3. IS4VL, UK4VL and B3VL are all encoded by the same 
germline gene (2a2) hence share 93% homology and differ only in their pattern of somatic 
mutations many of which are Arg residues. Using these combinations, I would be able to 
determine the effects of Arg residues at particular positions in VH and Vl upon binding to 
CL and P2 GPI as well their functional effects in two biological assays.
Currently one of the best animal models in which to demonstrate a thrombogenic effect of 
human aPL is the in-vivo model of microcirculation developed by Pierangeli et al. (2000). 
IS4 has consistently been shown to be highly thrombogenic and to enhance endothelial 
activation in these in-vivo models (Pierangeli et al. (2000) and (2001)). I am developing a 
collaboration with Professor Pierangeli to spend time in her laboratory in order to test the 
effects of my expressed wild-type and variant IS4 molecules upon thrombus formation and 
leucocyte adhesion in-vivo. Furthermore Professor Pierangeli has the facilities to study the 
effects of aPL upon vascular EC activation in-vitro by examining the expression of 
adhesion molecules with murine monoclonal antibodies against endothelial (E)-Selectin, 
ICAM-1 and VCAM-1 (Pierangeli et al., 2000).
The effects of IS4 on vascular function have also been studied in organ chamber 
experiments at UCL (by Dr J. Alves, personal communication). Isolation of a blood vessel 
with IS4 leads to inducible nitric oxide synthase (iNOS) production in the vessel wall 
which results in hyporeactivity to vasoconstrictors such as phenylephrine, which can be 
reversed by nitro-L-arginine methyl ester and 1400W (non-selective and iNOS selective 
inhibitors respectively). The effects are abolished by pre-isolation with a 100 fold excess of 
cardiolipin. NO causes hyporeactivity but protects against thrombosis. A lack of NO is 
likely to occur after the original increase, due to suppression of eNOS as a result of the
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iNOS activity. The eNOS activity remains low after the iNOS burst ends, leading to a 
period of low NO which could lead to platelet activation, and thus to thrombosis.
It would be fascinating to examine the effects of incubation of blood vessels with wild type 
IS4 compared with the variant forms of IS4 described above upon NO production. If 
alterations in the heavy or light chain of IS4 altered its effects on NO production, the 
experiment could be repeated to determine whether the alteration is abolished by pre­
incubation with cardiolipin or 62GPI. If so, it would imply that the effect is mediated via 
changes in the antigen/antibody interaction.
Thus this future research would help to elucidate the precise role of Arg residues in the 
binding of aPL to their target antigen but also provide greater understanding of how 
manipulation of aPL binding sites may affect the function of these antibodies and their 
effects upon endothelium leading to thrombosis and AS. In the future this knowledge could 
lead to the development of a more targeted therapy designed to block the aPL-l^GPI-PL 
interaction thus providing a safer, more effective treatment for APS patients than is 
currently available.
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APENDICES
APPENDIX A ONE LETTER CODE FOR AMINO ACIDS
ONE LETTER CODE AMINO ACID
A Alanine
C Cysteine
D Aspartic Acid
E Glutamic Acid
F Phenylalanine
G Glycine
H Histidine
I Isoleucine
K Lysine
L Leucine
M Methionine
N Asparagine
P Proline
Q Glutamine
R Arginine
S Serine
T Threonine
V Valine
W Tryptophan
Y Tyrosine
APPENDIX B CHEMICALS, MATERIALS AND EQUIPMENT
1) Chemicals
All chemicals used in this project were supplied by BDH, Lutterworth, Leicestershire, 
UK, with the following exceptions:- 
SdATP Amersham Pharmacia, Buckinghamshire, UK
RNAzol B Biogenesis, Poole, Dorset, UK
Absolute Alcohol & Propan-2-ol Hayman Ltd, Witham, Essex, UK 
Dimethyl Sulfoxide # D5879, Sigma, Poole, UK
Trypan Blue Solution (0.4%) # T8154, Sigma, Poole, UK
Hanks Balanced Salt Solution (HBSS) Invitrogen, Paisley, U.K.
Diethyl pyrocarbonate (DEPC) Solution Sigma, Poole, UK
5-bromo-4-chloro-3-indolyl-P-D-galactopyranoside in dimethylformamide (Xgal) and 
Isopropyl -  p -  thiogalactopyranoside (IPTG) - Insight Biotechnology Ltd, Wembley, 
U.K.
All solid chemicals were dissolved in ddH20, adjusted to the correct pH with 0.1M 
HCL, glacial acetic acid or 0.1M NaOH and autoclaved or filter sterilised unless 
otherwise stated. NaOH was not autoclaved. Ethidium bromide was stored in the dark.
2) General materials and equipment
15ml and 50ml Sterile tubes # 91015T, Helena Biosciences, Sunderland, U.K.
Bijou tubes # 39740, Bibby Sterilin Ltd, Staffordshire, U.K.
Sterilin tubes #30593, Bibby Sterilin Ltd.
1.5ml and 0.5ml microfuge tubes Anachem, Luton, Bedfordshire, U.K.
Centrifuges Sorvall Biofuge Pico (and refrigerated version), Sorvall RT-7 Plus 
and RC26 Plus, Kendro Laboratory Products Ltd, Herts, U.K.
PCR Machine • Eppendorf Mastercycler, Hamburg, Germany
Gene Pulser II Electroporator Bio-Rad Laboratories Ltd, Herts, U.K.
Gene Pulser II Cuvettes 0.4cm # 165-2088, Bio-Rad Laboratories Ltd
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APPENDIX C ENZYMES, BUFFERS AND SOLUTIONS
Enzymes
All restriction enzymes, DNA modifying enzymes, RNAse inhibitor and buffers were 
supplied by Promega, Southampton, U.K. with the following exceptions:- 
SJi I and BamH I New England BioLabs (NEB), Herts, UK
DNA Polymerase (Sequenase version 2.0 ) USB Corporation, Cleveland, USA 
Rnase-free Dnasel #776785, Roche, Lewes, East Sussex, U.K.
PfuTurbo DNA Polymerase Stratagene, California, U.S.A.
Phospholipase C # P4039, Sigma, Poole, U.K.
All enzymes and reaction buffers were stored at -20°C.
Reaction buffers
a.) PCR Buffer 1 Ox (Promega) 50mM KC1, 1 OmM Tris-HCl (pH 9.0 at 25°C)
1.5mM MgCl2, 0.1% Triton®X-100
b.) Ligase Buffer lOx (Promega) 300mM Tris-HCl (pH 7.8), lOOmM MgCl2
lOOmMDTT, 1 OmM ATP
c.) IX NEBuffer for BamHI(NEB) 150mM NaCl, lOmM Tris-HCl (pH 7.9 at 25°C)
lOmM MgCl2, ImM DTT
d.) IX NEBuffer 2 for Sy?l(NEB) 50mM NaCl, lOmM Tris-HCl (pH 7.9 at 25°C)
lOmM MgCl2, ImM DTT
e.) Buffers A, B, D, E, H and J for restriction digests (Promega)
f.) Sequenase 5x reaction buffer (USB)
h.) 1 Ox PfuTurbo DNA Polymerase reaction buffer (Stratagene, California, U.S.A.) 
lOOmMKCl, lOOmM (NH^SCU, 200mM Tris-HCl (pH 8.8), 20mM M gS04, 1% Triton 
X-100, 1 mg/ml nuclease free bovine serum albumin
General buffers and solutions
Phosphate buffered saline (PBS) pH 7.4. One PBS tablet (Invitrogen) was added per 
500ml of sterile water. To make PBS/0.1% Tween, 1ml “Tween 20” detergent was 
added to 11 PBS
Tris-EDTA (TE) buffer, pH7.5 lOmM Tris-HCL (pH7.5), ImM EDTA
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Specific buffers and solutions
a) Agarose gel electrophoresis
1 x Tris Acetate EDTA 40mM Tris base, 20mM glacial acetic acid,
(TAE buffer) 1 mM EDTA (pH 8)
DNA markers 1Kb DNA MW marker (Invitrogen.)
LambdaJHind III DNA MW marker (Promega) 
Loading Buffer 0.25% (w/v) xylene cyanole,
1.5% (w/v) Ficoll 400 (Pharmacia, Biotech, Uppsala, 
Sweden) in ddH20 stored at room temperature
b) Purification of amplified VH and Vl cDNA from agarose gels
New Wash buffer 14ml of concentrated NaCl, Tris and EDTA ( #1001-402) 
solution, 280ml ddH20 and 310ml 100% Ethanol
c) DNA extraction from bacterial cultures
Buffer PI (Resuspension Buffer) 50mM Tris-Cl, pH 8.0, lOmM EDTA
lOOpg/ml Rnase A 
200mM NaOH, 1% SDS 
Buffer N3 (Neutralisation Buffer) 3.OmM potassium acetate, pH 5.5
75OmM NaCl, 50mM MOPS, pH 7.0 
15% isopropanol, 0.15% Triton®X-100
Buffer P2 (Lysis Buffer)
i 
Buffer QBT (Equilibriation Buffer)
Buffer QC (Wash Buffer)
Buffer QF (Elution Buffer)
1.0M NaCl, 5OmM MOPS, pH 7.0 
15% isopropanol
1.25M NaCl, 50mM MOPS, pH 7.0 
15% isopropanol
d) Polyacrylamide gel electrophoresis
Tris Borate EDTA (TBE) buffer 45mM Tris borate, ImM EDTA (pH 8.0) 
Sequencing gel 60ml polyacrylamide gel solution (Amresco, Ohio, USA),
300pi 10% (w/v) ammonium persulphate solution,
30pl N, N, N ', N ' tetramethylethylenediamine (Sigma)
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e) ELISA Reagents and buffers
Bovine serum albumin (BSA) # A7030, Sigma.
Goat anti-human IgG (Fc fragment specific) # 18885, Sigma.
Cardiolipin # C l649, Sigma.
B2-Glycoprotein I # B2G1-0001, Haematologic Technologies Inc, U.S.A.
Purified human IgGx. # 15029, Sigma.
Goat anti-human X alkaline phosphatase conjugate # A2094, Sigma.
Goat anti-human k  alkaline phosphatase conjugate # A3813, Sigma.
Goat anti-human IgGy alkaline phosphatase conjugate # A3150, Sigma,
p nitrophenyl phosphate tablets # 104-105, Sigma.
Sample, enzyme and conjugate (SEC) buffer
lOOmM Tris-HCl (pH 7), lOOmM NaCl, 0.02% Tween 20 and 0.2% BSA. 
Bicarbonate (BIC) buffer
0.5M sodium bicarbonate and 0.05M sodium dihydrogencarbonate.
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APPENDIX D ANTIBIOTICS AND GROWTH MEDIA
Bacterial growth media
Media were made in ddF^O and sterilised by autoclaving at 121°C for 15 minutes at 
151b/inch2.
Luria-Bertani (LB) medium 1% (w/v) Bacto-tryptone (Duchefa, The Netherlands)
1% (w/v) NaCl, 0.5% (w/v) Bacto-yeast extract 
(Duchefa). Adjusted to pH 7.0 using 5M NaOH
Agar plates were prepared from this by the addition of 1.5% (w/v) agar (Duchefa)
NZY Medium 1% (w/v) NZ Amine (Sigma), 5% (w/v) Bacto-yeast
extract (Duchefa), 5% NaCl plus filter sterilised 1.25%
1M MgCb, 1.25% 1M MgS0 4  and 1% 2M Glucose prior
to use.
Where antibiotics were added to media and LB agar plates final concentrations of 
50pg/ml ampicillin or 50pg/ml chloramphenicol were added. Stock solutions of 
ampicillin at 50mg/ml in sterile water and chloramphenicol at 34mg/ml in ethanol were 
kept at -20°C in light-tight containers.
Growth media and solutions for maintenance of eukaryotic cell lines
COS-7 growth medium 1 (Pre-Electroporation)
Dulbecco's Modified Eagle Medium (DMEM) (41966-029, Invitrogen, Paisley, U.K.)
containing 10% (v/v) Foetal calf serum (FCS) (10099-133, Invitrogen), 580pg/ml L-
glutamine (25030-024, Invitrogen), 10000 Units/ml penicillin / lOmg/ml streptomycin 
(15140-122, Invitrogen).
COS-7 growth medium 2 (Post-Electroporation)
As for medium 1 except FCS was replaced by Ultra low IgG FCS (#16250-078, 
Invitrogen).
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COS-7 growth medium 3 (Post-Electroporation)
As for medium 1 except FCS was replaced by 2% (v/v) Ultroser G serum replacement 
(#15950-017, Invitrogen),
CHOdhfr' (Non-selective) growth medium A
MEM a-Medium (a-MEM) with ribonucleosides and deoxyribonucleosides (#32571- 
028, Invitrogen) containing 10% (v/v) FCS (#10099-133, Invitrogen), 5000 Units/ml 
penicillin / 5mg/ml streptomycin.
CHOdhjr (Selective) growth medium B
MEM a-Medium (a-MEM) without ribonucleosides and deoxyribonucleosides 
(#32571-029, Invitrogen) containing 10% (v/v) Dialysed FCS (#FH 30079, Hyclone), 
5000 Units/ml penicillin / 5mg/ml streptomycin.
Hanks' Balanced Salt Solution, without magnesium and calcium (HBSS) (#14175-053, 
Invitrogen).
10% Trypsin (#25090028, Invitrogen) in Versene (#15040033, Invitrogen)
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APPENDIX E MAIN PUBLICATIONS ARISING FROM WORK
DESCRIBED IN THIS THESIS
Relative importance of different human aPL derived heavy and light chains in the 
binding of aPL to cardiolipin. LGiles, J.Haley, S.Nagl, D.Latchman, P.Chen, 
R.Chukwuocha, D.Isenbergand A.Rahman. Molecular Immunology (2003) 40, 49-60.
A systematic analysis of sequences of human antiphospholipid antibodies (aPL) and 
anti-p2Glycoprotein I antibodies reveals the importance of somatic mutations and 
certain sequence motifs. LGiles, J.Haley, S.Nagl, D.Isenberg, D.Latchman and 
A.Rahman. Seminars in Arthritis and Rheumatism (2003) 32, 246-65.
How do antiphospholipid antibodies bind phospholipid? I.Giles. D.Isenberg, 
D.Latchman and A.Rahman. Arthritis and Rheumatism (2003) 48, 2111-21.
Systematic analysis of sequences of anti-DNA antibodies -  relevance to theories of 
origin and pathogenicity. A.Rahman, I.Giles, J.Haley and D.Isenberg. Lupus (2002) 11, 
807-823.
Somatic mutations to Arginine residues affect the binding of human monoclonal 
antibodies to DNA, Histones and SmD. J.Haley, L.Mason, S.Nagl, I.Giles. D.Latchman, 
D.Isenberg, and A.Rahman. (2003) Molecular Immunology (2003) 40, 745-758.
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